{"00573277e6be50669016f770bc28ec2da0639a8f": [["We identified a nurse who was asymptomatic for SARS-CoV infection, worked in the SARS ward since the disease outbreak, and used full infection control procedures as recommended by the World Health Organization (WHO).", [["SARS-CoV infection", "DISEASE", 47, 65], ["SARS", "DISEASE", 81, 85], ["infection", "DISEASE", 133, 142], ["SARS-CoV", "SPECIES", 47, 55], ["asymptomatic", "PROBLEM", 30, 42], ["SARS", "PROBLEM", 47, 51], ["CoV infection", "PROBLEM", 52, 65], ["the disease outbreak", "PROBLEM", 97, 117], ["full infection control procedures", "TREATMENT", 128, 161], ["infection", "OBSERVATION", 56, 65]]], ["The nurse performed procedures, including nasopharyngeal aspiration, handling of fecal matter, and oral feeding of SARS patients.", [["nasopharyngeal", "ANATOMY", 42, 56], ["fecal matter", "ANATOMY", 81, 93], ["oral", "ANATOMY", 99, 103], ["SARS", "DISEASE", 115, 119], ["nasopharyngeal", "ORGAN", 42, 56], ["fecal", "ORGANISM_SUBDIVISION", 81, 86], ["oral", "ORGANISM_SUBDIVISION", 99, 103], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["procedures", "TREATMENT", 20, 30], ["nasopharyngeal aspiration", "PROBLEM", 42, 67], ["fecal matter", "TREATMENT", 81, 93], ["oral feeding of SARS patients", "TREATMENT", 99, 128], ["nasopharyngeal", "ANATOMY", 42, 56], ["aspiration", "OBSERVATION", 57, 67], ["fecal matter", "ANATOMY", 81, 93]]], ["SARS developed in six colleagues who worked in the same ward.", [["SARS", "DISEASE", 0, 4]]], ["She had unprotected exposure to a colleague who contracted SARS and required hospitalization.", [["SARS", "DISEASE", 59, 63]]], ["Serologic testing for SARS-CoV antibody was performed in the microbiology laboratory of Princess Margaret Hospital on week 8 of the nurse's SARS ward duty.", [["SARS", "DISEASE", 140, 144], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 22, 30], ["SARS-CoV antibody", "PROTEIN", 22, 39], ["SARS-CoV", "SPECIES", 22, 30], ["Serologic testing", "TEST", 0, 17], ["SARS", "PROBLEM", 22, 26], ["CoV antibody", "TEST", 27, 39]]], ["The result of the test was positive by enzyme-linked immunosorbent assay.", [["the test", "TEST", 14, 22], ["enzyme", "TEST", 39, 45], ["immunosorbent assay", "TEST", 53, 72]]], ["The test was repeated by the Government Virus Unit of the Department of Health, one of the reference laboratories in Hong Kong.", [["The test", "TEST", 0, 8]]], ["The second test also showed a positive result with an antibody titer of 400 by immunofluorescence assay (normal: <25).", [["The second test", "TEST", 0, 15], ["an antibody titer", "TEST", 51, 68], ["immunofluorescence assay", "TEST", 79, 103]]], ["We performed another serologic test on week 10 of her SARS ward duty; the result was again positive.", [["SARS", "DISEASE", 54, 58], ["another serologic test", "TEST", 13, 35]]], ["She did not report any symptoms typical of SARS, such as fever, chills, rigors, malaise, myalgia, cough, dyspnea, and diarrhea (1,3) during and after her SARS ward duty.", [["SARS", "DISEASE", 43, 47], ["fever", "DISEASE", 57, 62], ["chills", "DISEASE", 64, 70], ["rigors", "DISEASE", 72, 78], ["myalgia", "DISEASE", 89, 96], ["cough", "DISEASE", 98, 103], ["dyspnea", "DISEASE", 105, 112], ["diarrhea", "DISEASE", 118, 126], ["SARS", "DISEASE", 154, 158], ["any symptoms", "PROBLEM", 19, 31], ["SARS", "PROBLEM", 43, 47], ["fever", "PROBLEM", 57, 62], ["chills", "PROBLEM", 64, 70], ["rigors", "PROBLEM", 72, 78], ["malaise", "PROBLEM", 80, 87], ["myalgia", "PROBLEM", 89, 96], ["cough", "PROBLEM", 98, 103], ["dyspnea", "PROBLEM", 105, 112], ["diarrhea", "PROBLEM", 118, 126], ["SARS", "OBSERVATION", 43, 47], ["myalgia", "OBSERVATION", 89, 96], ["cough", "OBSERVATION", 98, 103], ["diarrhea", "OBSERVATION", 118, 126]]], ["She did have a mild, short-term headache, which she has had periodically for many years.", [["headache", "DISEASE", 32, 40], ["a mild, short-term headache", "PROBLEM", 13, 40], ["mild", "OBSERVATION_MODIFIER", 15, 19], ["short-term", "OBSERVATION_MODIFIER", 21, 31], ["headache", "OBSERVATION", 32, 40]]], ["She did not record any rise in body temperature >37\u00b0C and had a leukocyte count of 5.9 x 10 9 /L and a lymphocyte count of 1.6 x 10 9 /L. Results of liver and renal function tests were all normal.", [["body", "ANATOMY", 31, 35], ["leukocyte", "ANATOMY", 64, 73], ["lymphocyte", "ANATOMY", 103, 113], ["liver", "ANATOMY", 149, 154], ["renal", "ANATOMY", 159, 164], ["body", "ORGANISM_SUBDIVISION", 31, 35], ["leukocyte", "CELL", 64, 73], ["lymphocyte", "CELL", 103, 113], ["liver", "ORGAN", 149, 154], ["renal", "ORGAN", 159, 164], ["body temperature", "TEST", 31, 47], ["a leukocyte count", "TEST", 62, 79], ["a lymphocyte count", "TEST", 101, 119], ["liver and renal function tests", "TEST", 149, 179], ["leukocyte", "ANATOMY", 64, 73], ["liver", "ANATOMY", 149, 154], ["renal", "ANATOMY", 159, 164], ["normal", "OBSERVATION", 189, 195]]], ["Reverse transcription-polymerase chain reaction results for SARS-CoV in stool, urine, throat, and nasal swabs collected during weeks 10 and 14 of her SARS ward duty were all negative.", [["stool", "ANATOMY", 72, 77], ["urine", "ANATOMY", 79, 84], ["throat", "ANATOMY", 86, 92], ["nasal swabs", "ANATOMY", 98, 109], ["SARS", "DISEASE", 150, 154], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 60, 68], ["stool", "ORGANISM_SUBSTANCE", 72, 77], ["urine", "ORGANISM_SUBSTANCE", 79, 84], ["throat", "ORGANISM_SUBDIVISION", 86, 92], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 98, 109], ["SARS-CoV", "SPECIES", 60, 68], ["polymerase chain reaction", "TEST", 22, 47], ["SARS", "PROBLEM", 60, 64], ["CoV in stool, urine, throat, and nasal swabs", "TEST", 65, 109], ["her SARS ward duty", "TEST", 146, 164], ["throat", "ANATOMY", 86, 92], ["nasal", "ANATOMY", 98, 103]]], ["No abnormal radiologic change was identified in the lungs.", [["lungs", "ANATOMY", 52, 57], ["lungs", "ORGAN", 52, 57], ["abnormal radiologic change", "PROBLEM", 3, 29], ["abnormal", "OBSERVATION_MODIFIER", 3, 11], ["radiologic", "OBSERVATION", 12, 22], ["lungs", "ANATOMY", 52, 57]]], ["None of her family members contracted SARS, and all showed a negative result in the serologic testing for SARS-CoV.", [["SARS", "DISEASE", 38, 42], ["SARS", "DISEASE", 106, 110], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 106, 114], ["SARS-CoV", "SPECIES", 106, 114], ["the serologic testing", "TEST", 80, 101], ["SARS", "PROBLEM", 106, 110], ["CoV", "PROBLEM", 111, 114]]]], "3691c1e9130028008093d3d62e16a43883631cae": [["inTRODUCTiOnHeterologous neutralizing serums or antiserums consist of neutralizing antibodies produced mainly in horses or sheep and have been effectively used for more than a century.", [["serums", "ORGANISM_SUBSTANCE", 38, 44], ["horses", "ORGANISM", 113, 119], ["sheep", "ORGANISM", 123, 128], ["neutralizing antibodies", "PROTEIN", 70, 93], ["horses", "SPECIES", 113, 119], ["sheep", "SPECIES", 123, 128], ["horses", "SPECIES", 113, 119], ["sheep", "SPECIES", 123, 128], ["inTRODUCTiOnHeterologous neutralizing serums", "TEST", 0, 44], ["antiserums", "PROBLEM", 48, 58], ["neutralizing antibodies", "PROBLEM", 70, 93]]], ["Antiserums were born in the golden age of microbiology when, in 1890, von Behering and Kitasato showed that the serum of a diphtheria-infected animal confers immunity against the same disease on naive animals (1, 2) .", [["serum", "ANATOMY", 112, 117], ["diphtheria-infected", "DISEASE", 123, 142], ["serum", "ORGANISM_SUBSTANCE", 112, 117], ["diphtheria", "ORGANISM", 123, 133], ["animal", "ORGANISM", 143, 149], ["the serum", "TEST", 108, 117], ["a diphtheria", "PROBLEM", 121, 133]]], ["Four years later, antiserum was used in humans.", [["antiserum", "ORGANISM_SUBSTANCE", 18, 27], ["humans", "ORGANISM", 40, 46], ["humans", "SPECIES", 40, 46], ["humans", "SPECIES", 40, 46], ["antiserum", "TREATMENT", 18, 27]]], ["From that point, this method has always been demonstrated to be highly effective in the treatment of both infection and envenoming.", [["infection", "DISEASE", 106, 115], ["envenoming", "DISEASE", 120, 130], ["both infection", "PROBLEM", 101, 115], ["envenoming", "PROBLEM", 120, 130], ["both", "OBSERVATION_MODIFIER", 101, 105], ["infection", "OBSERVATION", 106, 115]]], ["However, antiserums did not have good outcomes with respect to safety in their initial applications, causing many life-threatening side reactions (3) .", [["many life-threatening side reactions", "PROBLEM", 109, 145]]], ["Currently, in many applications, heterologous serums have been replaced by other drugs, such as antibiotics or homologous serums.", [["serums", "ANATOMY", 122, 128], ["serums", "ORGANISM_SUBSTANCE", 46, 52], ["serums", "ORGANISM_SUBSTANCE", 122, 128], ["heterologous serums", "PROBLEM", 33, 52], ["other drugs", "TREATMENT", 75, 86], ["antibiotics", "TREATMENT", 96, 107], ["homologous serums", "TREATMENT", 111, 128]]], ["However, in the case of envenoming from snakebites, scorpions and arachnids, antiserums remain the only effective treatment (4).", [["envenoming", "DISEASE", 24, 34], ["snakebites", "DISEASE", 40, 50], ["envenoming", "PROBLEM", 24, 34], ["snakebites", "PROBLEM", 40, 50], ["scorpions", "TREATMENT", 52, 61], ["arachnids", "TREATMENT", 66, 75], ["antiserums", "TREATMENT", 77, 87], ["envenoming", "OBSERVATION", 24, 34]]], ["In recent applications, antiserums have demonstrated a good safety profile, with <15% of patients having mild adverse reactions and <1% having severe reactions (4-6).", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["mild adverse reactions", "PROBLEM", 105, 127], ["severe reactions", "PROBLEM", 143, 159], ["mild", "OBSERVATION_MODIFIER", 105, 109]]], ["The only weakness antiserums have is that, like most biological products, the induced reactivity in patients generates antibodies against the antiserum (7).", [["patients", "ORGANISM", 100, 108], ["antibodies", "PROTEIN", 119, 129], ["patients", "SPECIES", 100, 108], ["weakness antiserums", "PROBLEM", 9, 28], ["the induced reactivity", "PROBLEM", 74, 96], ["weakness", "OBSERVATION", 9, 17]]], ["This weakness causes the effectiveness and safety to be compromised in successive treatments, or, in other words, heterologous serums can only be used once.HETEROLOGOUS SERUMS AS AnTiMiCROBiALSIn the first decades of the twentieth century, before the advent of antibiotics, heterologous serums were the best treatment choice against infectious diseases (8, 9) .", [["infectious diseases", "DISEASE", 333, 352], ["serums", "ORGANISM_SUBSTANCE", 127, 133], ["serums", "ORGANISM_SUBSTANCE", 287, 293], ["This weakness", "PROBLEM", 0, 13], ["successive treatments", "TREATMENT", 71, 92], ["heterologous serums", "PROBLEM", 114, 133], ["antibiotics", "TREATMENT", 261, 272], ["heterologous serums", "PROBLEM", 274, 293], ["infectious diseases", "PROBLEM", 333, 352]]], ["Many diseases were treated with heterologous serum with high effectiveness but with variable safety.", [["serum", "ANATOMY", 45, 50], ["serum", "ORGANISM_SUBSTANCE", 45, 50], ["Many diseases", "PROBLEM", 0, 13], ["heterologous serum", "TEST", 32, 50], ["diseases", "OBSERVATION", 5, 13]]], ["For example, in 1904, a Neisseria meningitidis epidemic in New York City was controlled with a heterologous specific serum, decreasing the mortality by one-third (10) .HETEROLOGOUS SERUMS AS AnTiMiCROBiALSLater in the twentieth century, antiserums began to be displaced by drugs with better safety profiles, antibiotics, and vaccination.", [["serum", "ANATOMY", 117, 122], ["Neisseria meningitidis epidemic", "DISEASE", 24, 55], ["Neisseria meningitidis", "ORGANISM", 24, 46], ["serum", "ORGANISM_SUBSTANCE", 117, 122], ["Neisseria meningitidis", "SPECIES", 24, 46], ["Neisseria meningitidis", "SPECIES", 24, 46], ["a Neisseria meningitidis epidemic", "PROBLEM", 22, 55], ["antibiotics", "TREATMENT", 308, 319], ["vaccination", "TREATMENT", 325, 336], ["Neisseria", "OBSERVATION_MODIFIER", 24, 33], ["meningitidis", "OBSERVATION", 34, 46], ["New", "OBSERVATION_MODIFIER", 59, 62]]], ["However, for the treatment of envenomation, tetanus, diphtheria, and rabies, antiserums have seen continued successful use.", [["envenomation", "DISEASE", 30, 42], ["tetanus", "DISEASE", 44, 51], ["diphtheria", "DISEASE", 53, 63], ["rabies", "DISEASE", 69, 75], ["rabies", "ORGANISM", 69, 75], ["rabies", "SPECIES", 69, 75], ["envenomation", "PROBLEM", 30, 42], ["tetanus", "PROBLEM", 44, 51], ["diphtheria", "PROBLEM", 53, 63], ["rabies", "PROBLEM", 69, 75], ["envenomation", "OBSERVATION", 30, 42]]], ["Currently, the treatment for tetanus and diphtheria has been changed from antiserums to homologous serums obtained from healthy human donors, but in many countries, antiserums remain the only option for such treatment.", [["serums", "ANATOMY", 99, 105], ["tetanus", "DISEASE", 29, 36], ["diphtheria", "DISEASE", 41, 51], ["serums", "ORGANISM_SUBSTANCE", 99, 105], ["human", "ORGANISM", 128, 133], ["antiserums", "SIMPLE_CHEMICAL", 165, 175], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 128, 133], ["the treatment", "TREATMENT", 11, 24], ["tetanus", "PROBLEM", 29, 36], ["diphtheria", "PROBLEM", 41, 51], ["homologous serums", "TEST", 88, 105], ["antiserums", "TREATMENT", 165, 175], ["such treatment", "TREATMENT", 203, 217]]], ["In the case of snakebite and other envenomations, the antiserum is the only effective treatment.FROM nOW OnWARDFor many emerging diseases, such as the Ebola virus, the risk-benefit equation for the use of antiserum appears to be highly tilted toward benefit.", [["snakebite", "DISEASE", 15, 24], ["Ebola virus", "DISEASE", 151, 162], ["antiserum", "ORGANISM_SUBSTANCE", 54, 63], ["Ebola virus", "ORGANISM", 151, 162], ["antiserum", "ORGANISM_SUBSTANCE", 205, 214], ["Ebola virus", "SPECIES", 151, 162], ["Ebola virus", "SPECIES", 151, 162], ["snakebite", "PROBLEM", 15, 24], ["other envenomations", "PROBLEM", 29, 48], ["the antiserum", "TREATMENT", 50, 63], ["effective treatment", "TREATMENT", 76, 95], ["many emerging diseases", "PROBLEM", 115, 137], ["the Ebola virus", "PROBLEM", 147, 162], ["antiserum", "TREATMENT", 205, 214], ["diseases", "OBSERVATION", 129, 137]]], ["Additionally, it is necessary to use the antiserum only once because surviving patients demonstrate immunity after first contact.", [["antiserum", "ORGANISM_SUBSTANCE", 41, 50], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["the antiserum", "TREATMENT", 37, 50]]], ["Another benefit is the low production cost, which makes this type of drug affordable for most countries (6, 11, 12) .", [["the low production cost", "PROBLEM", 19, 42], ["low production", "OBSERVATION_MODIFIER", 23, 37]]], ["Unfortunately, while vaccination, monoclonal and homologous antibodies became the most popular solutions, antiserums had less success.", [["monoclonal and homologous antibodies", "PROTEIN", 34, 70], ["vaccination", "TREATMENT", 21, 32], ["monoclonal and homologous antibodies", "TREATMENT", 34, 70]]], ["Against many emerging diseases and future threats, however, antiserums could have a chance.", [["many emerging diseases", "PROBLEM", 8, 30], ["diseases", "OBSERVATION", 22, 30]]], ["Dixit and coworkers (6) are proposed antiserum as a possible solution to avian influenza, MERS-CoV, and viral hemorrhagic fevers.", [["influenza", "DISEASE", 79, 88], ["MERS-CoV", "DISEASE", 90, 98], ["viral hemorrhagic fevers", "DISEASE", 104, 128], ["antiserum", "ORGANISM_SUBSTANCE", 37, 46], ["MERS-CoV", "ORGANISM", 90, 98], ["MERS-CoV", "SPECIES", 90, 98], ["influenza", "PROBLEM", 79, 88], ["CoV", "PROBLEM", 95, 98], ["viral hemorrhagic fevers", "PROBLEM", 104, 128], ["viral", "OBSERVATION_MODIFIER", 104, 109], ["hemorrhagic", "OBSERVATION_MODIFIER", 110, 121], ["fevers", "OBSERVATION", 122, 128]]], ["Heterologous serum also has the advantage that it can be made using recombinant proteins, which avoids the risk of manipulating the infective pathogen during the production stage.COnCLUSiOnAntiserums are an old drug with more than a century of use.", [["serum", "ANATOMY", 13, 18], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["COnCLUSiOnAntiserums", "SIMPLE_CHEMICAL", 179, 199], ["recombinant proteins", "PROTEIN", 68, 88], ["Heterologous serum", "TEST", 0, 18], ["recombinant proteins", "TREATMENT", 68, 88], ["the infective pathogen", "PROBLEM", 128, 150], ["infective", "OBSERVATION_MODIFIER", 132, 141], ["pathogen", "OBSERVATION", 142, 150]]], ["Perhaps for this, most pharmaceutical companies and scientist consider this type of drug as obsolete and opt for the new generation of antibodies (monoclonal, humanized).COnCLUSiOnHowever, antiserums still have some advantages to monoclonal antibodies, such as shorter product development time, and above all reduced costs in development and production.", [["antibodies", "PROTEIN", 135, 145], ["monoclonal", "PROTEIN", 147, 157], ["monoclonal antibodies", "PROTEIN", 230, 251], ["the new generation of antibodies", "PROBLEM", 113, 145], ["COnCLUSiOnHowever", "TEST", 170, 187], ["monoclonal antibodies", "TEST", 230, 251], ["reduced", "OBSERVATION_MODIFIER", 309, 316], ["costs", "OBSERVATION", 317, 322]]], ["In summary, antiserums can be a good option for the treatment of emerging infectious diseases when other drugs are unavailable.AUTHOR COnTRiBUTiOnSThe author confirms being the sole contributor of this work and approved it for publication.", [["infectious diseases", "DISEASE", 74, 93], ["the treatment", "TREATMENT", 48, 61], ["emerging infectious diseases", "PROBLEM", 65, 93], ["infectious", "OBSERVATION", 74, 84]]]], "PMC6306240": [["IntroductionOnchocerciasis, caused by the parasitic filarial nematode Onchocerca volvulus, remains a significant source of morbidity throughout sub-Saharan Africa [1].", [["IntroductionOnchocerciasis", "CHEMICAL", 0, 26], ["Onchocerca volvulus", "DISEASE", 70, 89], ["filarial nematode", "ORGANISM", 52, 69], ["Onchocerca volvulus", "ORGANISM", 70, 89], ["Onchocerca volvulus", "SPECIES", 70, 89], ["Onchocerca volvulus", "SPECIES", 70, 89], ["IntroductionOnchocerciasis", "PROBLEM", 0, 26], ["the parasitic filarial nematode Onchocerca volvulus", "PROBLEM", 38, 89], ["morbidity", "PROBLEM", 123, 132], ["parasitic", "OBSERVATION_MODIFIER", 42, 51], ["filarial nematode", "OBSERVATION", 52, 69], ["Onchocerca volvulus", "OBSERVATION", 70, 89], ["significant", "OBSERVATION_MODIFIER", 101, 112], ["morbidity", "OBSERVATION", 123, 132]]], ["O. volvulus infection is commonly diagnosed through the presence of microfilariae in skin snips, but skin samples can be further analyzed by qPCR for enhanced sensitivity [2].", [["microfilariae", "ANATOMY", 68, 81], ["skin snips", "ANATOMY", 85, 95], ["skin samples", "ANATOMY", 101, 113], ["O. volvulus infection", "DISEASE", 0, 21], ["O. volvulus", "ORGANISM", 0, 11], ["microfilariae", "ORGANISM", 68, 81], ["skin", "ORGAN", 85, 89], ["snips", "ORGANISM_SUBSTANCE", 90, 95], ["skin samples", "CANCER", 101, 113], ["O. volvulus", "SPECIES", 0, 11], ["O. volvulus", "SPECIES", 0, 11], ["volvulus infection", "PROBLEM", 3, 21], ["microfilariae in skin snips", "PROBLEM", 68, 95], ["skin samples", "TEST", 101, 113], ["volvulus", "OBSERVATION_MODIFIER", 3, 11], ["infection", "OBSERVATION", 12, 21], ["microfilariae", "OBSERVATION", 68, 81], ["skin", "ANATOMY", 85, 89], ["skin", "ANATOMY", 101, 105]]], ["Antibody tests (e.g. Ov16 [3,4]) are available but do not have the ability to differentiate between past and present infections which is problematic in areas where the infection is endemic [5].", [["infections", "DISEASE", 117, 127], ["infection", "DISEASE", 168, 177], ["Antibody tests", "TEST", 0, 14], ["Ov16", "TEST", 21, 25], ["present infections", "PROBLEM", 109, 127], ["the infection", "PROBLEM", 164, 177], ["infections", "OBSERVATION", 117, 127], ["infection", "OBSERVATION", 168, 177]]], ["Recently, a limited number of biomarkers have been identified in the urine that can distinguish between O. volvulus-infected and non-infected individuals [6\u20138].IntroductionA significant obstacle for studying the biology of O. volvulus and for the development of new therapeutics and diagnostics has been the absence of small animal models.", [["urine", "ANATOMY", 69, 74], ["O. volvulus-infected", "DISEASE", 104, 124], ["O. volvulus", "DISEASE", 223, 234], ["urine", "ORGANISM_SUBSTANCE", 69, 74], ["O. volvulus", "ORGANISM", 104, 115], ["O. volvulus", "ORGANISM", 223, 234], ["O. volvulus", "SPECIES", 104, 115], ["O. volvulus", "SPECIES", 223, 234], ["O. volvulus", "SPECIES", 104, 115], ["O. volvulus", "SPECIES", 223, 234], ["the urine", "TEST", 65, 74], ["O. volvulus", "PROBLEM", 104, 115], ["volvulus", "PROBLEM", 226, 234], ["small animal models", "PROBLEM", 319, 338], ["volvulus", "OBSERVATION", 107, 115], ["infected", "OBSERVATION_MODIFIER", 116, 124], ["volvulus", "OBSERVATION", 226, 234], ["new", "OBSERVATION_MODIFIER", 262, 265]]], ["The only susceptible animal hosts for O. volvulus are chimpanzees [9,10] and mangabey monkeys [11].", [["O. volvulus", "DISEASE", 38, 49], ["O. volvulus", "ORGANISM", 38, 49], ["chimpanzees", "ORGANISM", 54, 65], ["O. volvulus", "SPECIES", 38, 49], ["mangabey monkeys", "SPECIES", 77, 93], ["O. volvulus", "SPECIES", 38, 49], ["O. volvulus", "PROBLEM", 38, 49], ["chimpanzees", "TEST", 54, 65], ["volvulus", "OBSERVATION", 41, 49]]], ["Chimpanzees infected with O. volvulus had patent infections that lasted between 6 to 9 years with adult-worm bundles located in deep tissues with microfilariae in skin snips being detected 12\u201318 months post infection [12,13].", [["bundles", "ANATOMY", 109, 116], ["tissues", "ANATOMY", 133, 140], ["microfilariae", "ANATOMY", 146, 159], ["skin snips", "ANATOMY", 163, 173], ["Chimpanzees infected with O. volvulus", "DISEASE", 0, 37], ["patent infections", "DISEASE", 42, 59], ["infection", "DISEASE", 207, 216], ["O. volvulus", "ORGANISM", 26, 37], ["deep tissues", "TISSUE", 128, 140], ["microfilariae", "ORGANISM_SUBSTANCE", 146, 159], ["skin", "ORGAN", 163, 167], ["O. volvulus", "SPECIES", 26, 37], ["O. volvulus", "SPECIES", 26, 37], ["O. volvulus", "PROBLEM", 26, 37], ["patent infections", "PROBLEM", 42, 59], ["worm bundles", "PROBLEM", 104, 116], ["microfilariae in skin snips", "PROBLEM", 146, 173], ["infection", "PROBLEM", 207, 216], ["volvulus", "OBSERVATION", 29, 37], ["patent", "OBSERVATION_MODIFIER", 42, 48], ["infections", "OBSERVATION", 49, 59], ["deep tissues", "ANATOMY", 128, 140], ["microfilariae", "OBSERVATION", 146, 159], ["skin", "ANATOMY", 163, 167], ["infection", "OBSERVATION", 207, 216]]], ["While immunologically intact mice are resistant to infection with the infective larvae (L3) of O. volvulus [14], adult worms within nodules have been successfully transplanted into SCID mice (NOD.CB17-Prkdcscid/J) with the worms surviving greater than 20 weeks [15].", [["worms", "ANATOMY", 119, 124], ["nodules", "ANATOMY", 132, 139], ["infection", "DISEASE", 51, 60], ["O. volvulus", "DISEASE", 95, 106], ["mice", "ORGANISM", 29, 33], ["O. volvulus", "ORGANISM", 95, 106], ["adult worms", "ORGANISM", 113, 124], ["nodules", "CANCER", 132, 139], ["SCID mice", "ORGANISM", 181, 190], ["CB17", "GENE_OR_GENE_PRODUCT", 196, 200], ["CB17", "PROTEIN", 196, 200], ["Prkdcscid", "PROTEIN", 201, 210], ["mice", "SPECIES", 29, 33], ["O. volvulus", "SPECIES", 95, 106], ["worms", "SPECIES", 119, 124], ["mice", "SPECIES", 186, 190], ["worms", "SPECIES", 223, 228], ["mice", "SPECIES", 29, 33], ["O. volvulus", "SPECIES", 95, 106], ["mice", "SPECIES", 186, 190], ["infection", "PROBLEM", 51, 60], ["the infective larvae", "PROBLEM", 66, 86], ["O. volvulus", "PROBLEM", 95, 106], ["adult worms within nodules", "PROBLEM", 113, 139], ["CB17", "TEST", 196, 200], ["infection", "OBSERVATION", 51, 60], ["infective", "OBSERVATION_MODIFIER", 70, 79], ["L3", "ANATOMY", 88, 90], ["volvulus", "OBSERVATION", 98, 106], ["nodules", "OBSERVATION", 132, 139]]], ["This observation was confirmed by the successful transplantation of adult Onchocerca ochengi into SCID mice [16].", [["Onchocerca ochengi", "ORGANISM", 74, 92], ["SCID mice", "ORGANISM", 98, 107], ["Onchocerca ochengi", "SPECIES", 74, 92], ["mice", "SPECIES", 103, 107], ["Onchocerca ochengi", "SPECIES", 74, 92], ["mice", "SPECIES", 103, 107], ["the successful transplantation", "TREATMENT", 34, 64]]], ["As an alternative approach, O. volvulus L3 were implanted in primates and rodents within diffusion chambers that consist of a Lucite ring enclosed with permeable membranes, allowing for migration of cells and other humoral factors into the diffusion chamber with simultaneous containment of the parasites.", [["membranes", "ANATOMY", 162, 171], ["cells", "ANATOMY", 199, 204], ["O. volvulus L3", "ORGANISM", 28, 42], ["primates", "ORGANISM", 61, 69], ["membranes", "CELLULAR_COMPONENT", 162, 171], ["cells", "CELL", 199, 204], ["humoral factors", "PROTEIN", 215, 230], ["O. volvulus", "SPECIES", 28, 39], ["O. volvulus", "SPECIES", 28, 39], ["an alternative approach", "TREATMENT", 3, 26], ["volvulus L3", "PROBLEM", 31, 42], ["diffusion chambers", "TEST", 89, 107], ["a Lucite ring", "TREATMENT", 124, 137], ["permeable membranes", "TREATMENT", 152, 171], ["migration of cells", "TREATMENT", 186, 204], ["other humoral factors", "TREATMENT", 209, 230], ["volvulus", "OBSERVATION", 31, 39], ["L3", "ANATOMY", 40, 42], ["permeable membranes", "OBSERVATION", 152, 171], ["diffusion chamber", "OBSERVATION", 240, 257], ["simultaneous", "OBSERVATION_MODIFIER", 263, 275], ["containment", "OBSERVATION_MODIFIER", 276, 287], ["parasites", "OBSERVATION", 295, 304]]], ["O. volvulus in diffusion chambers implanted in multiple species of rodents and primates showed limited growth of larvae in all host species [17].IntroductionSeveral strategies have been employed to overcome murine resistance to infection with various human pathogens.", [["infection", "DISEASE", 228, 237], ["O. volvulus", "ORGANISM", 0, 11], ["primates", "ORGANISM", 79, 87], ["murine", "ORGANISM", 207, 213], ["human", "ORGANISM", 251, 256], ["O. volvulus", "SPECIES", 0, 11], ["murine", "SPECIES", 207, 213], ["human", "SPECIES", 251, 256], ["O. volvulus", "SPECIES", 0, 11], ["human", "SPECIES", 251, 256], ["volvulus in diffusion chambers", "PROBLEM", 3, 33], ["limited growth of larvae", "PROBLEM", 95, 119], ["IntroductionSeveral strategies", "TREATMENT", 145, 175], ["murine resistance to infection", "PROBLEM", 207, 237], ["various human pathogens", "PROBLEM", 243, 266], ["volvulus", "OBSERVATION", 3, 11], ["infection", "OBSERVATION", 228, 237]]], ["The Collaborative Cross (CC) is a large group of inbred mouse strains that were developed to address many of the different shortcomings found within the existing experimental mouse populations, including small numbers of homozygous strains, limited genetic diversity, and non-ideal population structures.", [["CC", "CHEMICAL", 25, 27], ["mouse", "ORGANISM", 56, 61], ["mouse", "ORGANISM", 175, 180], ["mouse", "SPECIES", 56, 61], ["mouse", "SPECIES", 175, 180], ["mouse", "SPECIES", 56, 61], ["mouse", "SPECIES", 175, 180], ["inbred mouse strains", "PROBLEM", 49, 69], ["the different shortcomings", "PROBLEM", 109, 135], ["homozygous strains", "PROBLEM", 221, 239], ["large", "OBSERVATION_MODIFIER", 34, 39], ["experimental mouse populations", "OBSERVATION", 162, 192], ["small", "OBSERVATION_MODIFIER", 204, 209], ["numbers", "OBSERVATION_MODIFIER", 210, 217], ["homozygous strains", "OBSERVATION", 221, 239], ["diversity", "OBSERVATION_MODIFIER", 257, 266], ["non-ideal population", "OBSERVATION", 272, 292]]], ["Based on the hypothesis that there is a genetic basis for mouse susceptibility and resistance to infection, novel strains of CC mice have been identified that are susceptible to specific bacteria, viruses, and parasites of humans [18\u201323].IntroductionAs an alternative approach to overcome murine resistance to infection, mice have been developed with greatly diminished immune responses.", [["infection", "DISEASE", 97, 106], ["CC", "CHEMICAL", 125, 127], ["infection", "DISEASE", 310, 319], ["mouse", "ORGANISM", 58, 63], ["CC mice", "ORGANISM", 125, 132], ["humans", "ORGANISM", 223, 229], ["murine", "ORGANISM", 289, 295], ["mice", "ORGANISM", 321, 325], ["mouse", "SPECIES", 58, 63], ["mice", "SPECIES", 128, 132], ["humans", "SPECIES", 223, 229], ["murine", "SPECIES", 289, 295], ["mice", "SPECIES", 321, 325], ["mouse", "SPECIES", 58, 63], ["mice", "SPECIES", 128, 132], ["humans", "SPECIES", 223, 229], ["mice", "SPECIES", 321, 325], ["mouse susceptibility", "PROBLEM", 58, 78], ["infection", "PROBLEM", 97, 106], ["novel strains of CC mice", "PROBLEM", 108, 132], ["specific bacteria", "PROBLEM", 178, 195], ["viruses", "PROBLEM", 197, 204], ["an alternative approach", "TREATMENT", 253, 276], ["murine resistance to infection", "PROBLEM", 289, 319], ["greatly diminished immune responses", "PROBLEM", 351, 386], ["infection", "OBSERVATION", 97, 106], ["infection", "OBSERVATION", 310, 319]]], ["SCID mice were shown to be susceptible to infection with Brugia malayi while immunocompetent mice were resistant to the infection [24].", [["infection", "DISEASE", 42, 51], ["Brugia malayi", "DISEASE", 57, 70], ["infection", "DISEASE", 120, 129], ["SCID mice", "ORGANISM", 0, 9], ["Brugia malayi", "ORGANISM", 57, 70], ["mice", "ORGANISM", 93, 97], ["mice", "SPECIES", 5, 9], ["Brugia malayi", "SPECIES", 57, 70], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 5, 9], ["Brugia malayi", "SPECIES", 57, 70], ["mice", "SPECIES", 93, 97], ["infection", "PROBLEM", 42, 51], ["Brugia malayi", "PROBLEM", 57, 70], ["immunocompetent mice", "PROBLEM", 77, 97], ["the infection", "PROBLEM", 116, 129], ["infection", "OBSERVATION", 42, 51]]], ["NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice are a highly immune-compromised strain of mice that have profound defects in the adaptive and innate immune responses [25].", [["NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)", "GENE_OR_GENE_PRODUCT", 0, 37], ["mice", "ORGANISM", 85, 89], ["NOD.Cg", "PROTEIN", 0, 6], ["PrkdcscidIl2rgtm1Wjl", "PROTEIN", 7, 27], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 85, 89], ["NOD.Cg", "TEST", 0, 6], ["profound defects", "PROBLEM", 100, 116], ["profound", "OBSERVATION_MODIFIER", 100, 108], ["defects", "OBSERVATION", 109, 116]]], ["The most notable defects include those in: 1) macrophages, dendritic cells and in the complement cascade [26\u201328]; 2) maturation of T and B cells [29]; 3) NK cells; 4) signaling of 6 different cytokines [30] and 5) the presence of eosinophils in the peripheral circulation and in tissue [31].", [["macrophages", "ANATOMY", 46, 57], ["dendritic cells", "ANATOMY", 59, 74], ["T", "ANATOMY", 131, 132], ["B cells", "ANATOMY", 137, 144], ["NK cells", "ANATOMY", 154, 162], ["eosinophils", "ANATOMY", 230, 241], ["peripheral circulation", "ANATOMY", 249, 271], ["tissue", "ANATOMY", 279, 285], ["macrophages", "CELL", 46, 57], ["dendritic cells", "CELL", 59, 74], ["T", "CELL", 131, 132], ["B cells", "CELL", 137, 144], ["NK cells", "CELL", 154, 162], ["eosinophils", "CELL", 230, 241], ["peripheral circulation", "MULTI-TISSUE_STRUCTURE", 249, 271], ["tissue", "TISSUE", 279, 285], ["macrophages", "CELL_TYPE", 46, 57], ["dendritic cells", "CELL_TYPE", 59, 74], ["T and B cells", "CELL_TYPE", 131, 144], ["NK cells", "CELL_TYPE", 154, 162], ["cytokines", "PROTEIN", 192, 201], ["eosinophils", "CELL_TYPE", 230, 241], ["The most notable defects", "PROBLEM", 0, 24], ["dendritic cells", "PROBLEM", 59, 74], ["the complement cascade", "TEST", 82, 104], ["maturation of T and B cells", "TEST", 117, 144], ["NK cells", "TEST", 154, 162], ["signaling", "TEST", 167, 176], ["different cytokines", "TEST", 182, 201], ["eosinophils in the peripheral circulation", "PROBLEM", 230, 271], ["notable", "OBSERVATION_MODIFIER", 9, 16], ["defects", "OBSERVATION", 17, 24], ["macrophages", "ANATOMY", 46, 57], ["dendritic cells", "OBSERVATION", 59, 74], ["eosinophils", "OBSERVATION", 230, 241], ["peripheral", "ANATOMY_MODIFIER", 249, 259], ["circulation", "ANATOMY", 260, 271]]], ["NOD-Rag1tm1MomIL2rgtm1Wjl mice (NRG) are phenotypically similar to NSG mice with disruption in the B and T-Cell production [32].", [["Cell", "ANATOMY", 107, 111], ["NOD", "GENE_OR_GENE_PRODUCT", 0, 3], ["Rag1tm1MomIL2rgtm1Wjl", "GENE_OR_GENE_PRODUCT", 4, 25], ["NRG", "GENE_OR_GENE_PRODUCT", 32, 35], ["NSG mice", "ORGANISM", 67, 75], ["B", "CELL", 99, 100], ["T-Cell", "CELL", 105, 111], ["NOD", "PROTEIN", 0, 3], ["Rag1tm1MomIL2rgtm1Wjl", "PROTEIN", 4, 25], ["NRG", "PROTEIN", 32, 35], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 71, 75], ["disruption", "PROBLEM", 81, 91]]], ["Interestingly, NSG mice can support the complete lifecycle of the human nematode Strongyloides stercoralis, whereas immunologically intact mice cannot [31].IntroductionA third strategy to enhance pathogen survival in mice has been to add human-derived cells required for survival and growth [33].", [["cells", "ANATOMY", 252, 257], ["Strongyloides stercoralis", "DISEASE", 81, 106], ["NSG mice", "ORGANISM", 15, 23], ["human", "ORGANISM", 66, 71], ["nematode", "ORGANISM", 72, 80], ["Strongyloides stercoralis", "ORGANISM", 81, 106], ["mice", "ORGANISM", 139, 143], ["mice", "ORGANISM", 217, 221], ["human", "ORGANISM", 238, 243], ["cells", "CELL", 252, 257], ["human-derived cells", "CELL_TYPE", 238, 257], ["mice", "SPECIES", 19, 23], ["human", "SPECIES", 66, 71], ["Strongyloides stercoralis", "SPECIES", 81, 106], ["mice", "SPECIES", 139, 143], ["mice", "SPECIES", 217, 221], ["human", "SPECIES", 238, 243], ["mice", "SPECIES", 19, 23], ["human", "SPECIES", 66, 71], ["Strongyloides stercoralis", "SPECIES", 81, 106], ["mice", "SPECIES", 139, 143], ["mice", "SPECIES", 217, 221], ["human", "SPECIES", 238, 243], ["the human nematode", "TREATMENT", 62, 80], ["Strongyloides stercoralis", "PROBLEM", 81, 106], ["IntroductionA third strategy", "TREATMENT", 156, 184], ["human-derived cells", "TREATMENT", 238, 257]]], ["NSG mice have the unique ability to support several different xenografts including human hematopoietic stem cells (CD34+ stem cells) that allow for the development of an immature partially-functional human immune system [25,27,30,34].", [["xenografts", "ANATOMY", 62, 72], ["hematopoietic stem cells", "ANATOMY", 89, 113], ["CD34+ stem cells", "ANATOMY", 115, 131], ["NSG mice", "ORGANISM", 0, 8], ["xenografts", "CANCER", 62, 72], ["human", "ORGANISM", 83, 88], ["hematopoietic stem cells", "CELL", 89, 113], ["CD34+ stem cells", "CELL", 115, 131], ["human", "ORGANISM", 200, 205], ["human hematopoietic stem cells", "CELL_TYPE", 83, 113], ["CD34+ stem cells", "CELL_TYPE", 115, 131], ["mice", "SPECIES", 4, 8], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 200, 205], ["mice", "SPECIES", 4, 8], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 200, 205], ["several different xenografts", "TREATMENT", 44, 72], ["human hematopoietic stem cells", "TREATMENT", 83, 113], ["hematopoietic stem cells", "OBSERVATION", 89, 113], ["stem cells", "OBSERVATION", 121, 131], ["immature", "OBSERVATION", 170, 178]]], ["NOD.Cg-PrkdcscidIl2rgtm1Wjl Tg (CMV-IL3, CSF2, KITLG)1Eav/MloySzJ (SGM) mice have an additional three human genes IL3, CSF2, and KITLG under the CMV promoter to enhance the overall microenvironment for the development of human xenografts.", [["xenografts", "ANATOMY", 227, 237], ["NOD.Cg-PrkdcscidIl2rgtm1Wjl Tg", "GENE_OR_GENE_PRODUCT", 0, 30], ["CMV", "ORGANISM", 32, 35], ["-IL3, CSF2, KITLG)1Eav/MloySzJ (SGM)", "GENE_OR_GENE_PRODUCT", 35, 71], ["human", "ORGANISM", 102, 107], ["IL3", "GENE_OR_GENE_PRODUCT", 114, 117], ["CSF2", "GENE_OR_GENE_PRODUCT", 119, 123], ["KITLG", "GENE_OR_GENE_PRODUCT", 129, 134], ["CMV", "ORGANISM", 145, 148], ["human", "ORGANISM", 221, 226], ["xenografts", "CANCER", 227, 237], ["NOD.Cg", "PROTEIN", 0, 6], ["PrkdcscidIl2rgtm1Wjl Tg", "PROTEIN", 7, 30], ["IL3", "PROTEIN", 36, 39], ["SGM", "PROTEIN", 67, 70], ["human genes", "DNA", 102, 113], ["IL3", "DNA", 114, 117], ["CSF2", "DNA", 119, 123], ["KITLG", "DNA", 129, 134], ["CMV promoter", "DNA", 145, 157], ["mice", "SPECIES", 72, 76], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 221, 226], ["mice", "SPECIES", 72, 76], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 221, 226], ["NOD.Cg", "TEST", 0, 6], ["PrkdcscidIl2rgtm1Wjl", "TEST", 7, 27], ["Tg", "TEST", 28, 30], ["CMV", "TEST", 32, 35], ["IL3", "TEST", 36, 39], ["CSF2", "TEST", 41, 45], ["KITLG", "TEST", 47, 52], ["CSF2", "TEST", 119, 123], ["KITLG", "TREATMENT", 129, 134], ["the CMV promoter", "TREATMENT", 141, 157], ["human xenografts", "TREATMENT", 221, 237]]], ["This results in increased numbers of CD33+ myeloid cells, B-cells, T-cells, and hematopoietic stem cells [35].", [["CD33+ myeloid cells", "ANATOMY", 37, 56], ["B-cells", "ANATOMY", 58, 65], ["T-cells", "ANATOMY", 67, 74], ["hematopoietic stem cells", "ANATOMY", 80, 104], ["CD33", "GENE_OR_GENE_PRODUCT", 37, 41], ["myeloid cells", "CELL", 43, 56], ["B-cells", "CELL", 58, 65], ["T-cells", "CELL", 67, 74], ["hematopoietic stem cells", "CELL", 80, 104], ["CD33", "PROTEIN", 37, 41], ["myeloid cells", "CELL_TYPE", 43, 56], ["B-cells", "CELL_TYPE", 58, 65], ["T-cells", "CELL_TYPE", 67, 74], ["hematopoietic stem cells", "CELL_TYPE", 80, 104], ["CD33", "TEST", 37, 41], ["myeloid cells", "PROBLEM", 43, 56], ["hematopoietic stem cells", "TEST", 80, 104], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["myeloid cells", "OBSERVATION", 43, 56], ["hematopoietic stem cells", "OBSERVATION", 80, 104]]], ["Humanized BLT mice are NSG mice that received a xenograft of human CD34+ stem cells and a transplant of human fetal thymus and liver implanted under the kidney capsule, which results in the formation of a \u201chuman immune organ\u201d [36].IntroductionControl and potential elimination of onchocerciasis has been significantly impeded by the limited number of available drugs and the development of resistance to those therapies [37,38].", [["xenograft", "ANATOMY", 48, 57], ["CD34+ stem cells", "ANATOMY", 67, 83], ["fetal thymus", "ANATOMY", 110, 122], ["liver", "ANATOMY", 127, 132], ["kidney capsule", "ANATOMY", 153, 167], ["organ", "ANATOMY", 219, 224], ["onchocerciasis", "DISEASE", 280, 294], ["BLT mice", "ORGANISM", 10, 18], ["NSG mice", "ORGANISM", 23, 31], ["xenograft", "CANCER", 48, 57], ["human", "ORGANISM", 61, 66], ["CD34", "GENE_OR_GENE_PRODUCT", 67, 71], ["stem cells", "CELL", 73, 83], ["human", "ORGANISM", 104, 109], ["fetal thymus", "MULTI-TISSUE_STRUCTURE", 110, 122], ["liver", "ORGAN", 127, 132], ["kidney capsule", "MULTI-TISSUE_STRUCTURE", 153, 167], ["human", "ORGANISM", 206, 211], ["organ", "ORGAN", 219, 224], ["human CD34+ stem cells", "CELL_TYPE", 61, 83], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 27, 31], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 206, 211], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 27, 31], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 206, 211], ["Humanized BLT mice", "TREATMENT", 0, 18], ["a xenograft of human CD34+ stem cells", "TREATMENT", 46, 83], ["a transplant of human fetal thymus", "TREATMENT", 88, 122], ["the kidney capsule", "TREATMENT", 149, 167], ["IntroductionControl", "TREATMENT", 231, 250], ["onchocerciasis", "PROBLEM", 280, 294], ["available drugs", "TREATMENT", 351, 366], ["those therapies", "TREATMENT", 404, 419], ["stem cells", "OBSERVATION", 73, 83], ["thymus", "ANATOMY", 116, 122], ["liver", "ANATOMY", 127, 132], ["implanted", "OBSERVATION", 133, 142], ["kidney", "ANATOMY", 153, 159], ["onchocerciasis", "OBSERVATION", 280, 294]]], ["In addition, biomarkers to assess the infection status of treated individuals or macrofilaricidal activity are sorely lacking [6\u20138].", [["infection", "DISEASE", 38, 47], ["biomarkers", "TEST", 13, 23], ["the infection", "PROBLEM", 34, 47], ["treated individuals", "PROBLEM", 58, 77], ["macrofilaricidal activity", "PROBLEM", 81, 106], ["infection", "OBSERVATION", 38, 47]]], ["One of the critical barriers blocking drug and biomarker development has been the absence of suitable small animal hosts for experimentation.", [["the critical barriers blocking drug", "TREATMENT", 7, 42]]], ["Hence, this study was focused on the development of a small animal model that would support the growth and maturation of O. volvulus and could serve to identify parasite specific biomarkers.", [["O. volvulus", "DISEASE", 121, 132], ["O. volvulus", "ORGANISM", 121, 132], ["O. volvulus", "SPECIES", 121, 132], ["O. volvulus", "SPECIES", 121, 132], ["this study", "TEST", 7, 17], ["a small animal model", "TREATMENT", 52, 72], ["the growth", "PROBLEM", 92, 102], ["O. volvulus", "PROBLEM", 121, 132], ["parasite specific biomarkers", "TEST", 161, 189], ["small", "OBSERVATION_MODIFIER", 54, 59], ["volvulus", "OBSERVATION", 124, 132]]], ["To this end we tested multiple genetically defined mouse strains and xenografted (with human cells) immunodeficient mice to identify those microenvironments suitable for O. volvulus development.", [["strains", "ANATOMY", 57, 64], ["xenografted", "ANATOMY", 69, 80], ["cells", "ANATOMY", 93, 98], ["O. volvulus", "DISEASE", 170, 181], ["mouse", "ORGANISM", 51, 56], ["xenografted", "CANCER", 69, 80], ["human", "ORGANISM", 87, 92], ["cells", "CELL", 93, 98], ["immunodeficient mice", "ORGANISM", 100, 120], ["human cells", "CELL_TYPE", 87, 98], ["mouse", "SPECIES", 51, 56], ["human", "SPECIES", 87, 92], ["mice", "SPECIES", 116, 120], ["mouse", "SPECIES", 51, 56], ["human", "SPECIES", 87, 92], ["mice", "SPECIES", 116, 120], ["O. volvulus", "SPECIES", 170, 181], ["multiple genetically defined mouse strains", "PROBLEM", 22, 64], ["xenografted (with human cells) immunodeficient mice", "TREATMENT", 69, 120], ["O. volvulus development", "PROBLEM", 170, 193], ["mouse strains", "OBSERVATION", 51, 64], ["volvulus", "OBSERVATION", 173, 181]]], ["In so doing, we were able to develop convenient and tractable murine models that support the development of O. volvulus L3 into advanced larval stages.", [["murine", "ORGANISM", 62, 68], ["murine", "SPECIES", 62, 68], ["O. volvulus", "SPECIES", 108, 119], ["O. volvulus", "SPECIES", 108, 119], ["tractable murine models", "PROBLEM", 52, 75], ["O. volvulus", "PROBLEM", 108, 119], ["volvulus", "OBSERVATION", 111, 119], ["L3", "ANATOMY", 120, 122]]], ["Moreover, we were able to use these O. volvulus-infected animals to identify parasite-derived biomarkers measurable in both urine and serum.Ethics statement ::: Materials and methodsThe parasite material was collected during the years 1994\u20131999 in the research facility at the Tropical Medicine Research Station, Kumba, Cameroon.", [["urine", "ANATOMY", 124, 129], ["serum", "ANATOMY", 134, 139], ["O. volvulus", "ORGANISM", 36, 47], ["animals", "ORGANISM", 57, 64], ["urine", "ORGANISM_SUBSTANCE", 124, 129], ["serum", "ORGANISM_SUBSTANCE", 134, 139], ["O. volvulus", "SPECIES", 36, 47], ["O. volvulus", "SPECIES", 36, 47], ["volvulus", "PROBLEM", 39, 47], ["infected animals", "PROBLEM", 48, 64], ["parasite", "TEST", 77, 85], ["derived biomarkers", "TEST", 86, 104], ["urine and serum", "TEST", 124, 139], ["The parasite material", "PROBLEM", 182, 203], ["volvulus", "OBSERVATION", 39, 47], ["parasite", "OBSERVATION_MODIFIER", 186, 194]]], ["The procedures used for the production of O. volvulus forest strain third-stage-larvae (L3) were approved by an NIH accredited Institutional Review Board of the Medical Research Council Kumba, Cameroon (Protocol 001).", [["O. volvulus", "ORGANISM", 42, 53], ["O. volvulus", "SPECIES", 42, 53], ["O. volvulus", "SPECIES", 42, 53], ["The procedures", "TREATMENT", 0, 14], ["O. volvulus", "PROBLEM", 42, 53], ["L3", "ANATOMY", 88, 90]]], ["The protocol was reviewed and approved annually.", [["The protocol", "TREATMENT", 0, 12]]], ["L3 were collected from black flies (Simulium damnosum) that were fed on consenting infected donors.", [["Simulium damnosum", "ORGANISM", 36, 53], ["donors", "ORGANISM", 92, 98], ["Simulium damnosum", "SPECIES", 36, 53], ["black flies", "SPECIES", 23, 34], ["Simulium damnosum", "SPECIES", 36, 53]]], ["After seven days the flies were dissected and the developed L3 were collected, cleaned and cryopreserved.", [["flies", "ORGANISM", 21, 26], ["L3", "ANATOMY", 60, 62]]], ["The cryopreserved L3 were shipped to the New York Blood Center in liquid nitrogen and upon arrival in New York were stored in liquid nitrogen.", [["nitrogen", "CHEMICAL", 73, 81], ["nitrogen", "CHEMICAL", 133, 141], ["The cryopreserved L3", "TREATMENT", 0, 20], ["liquid nitrogen", "TREATMENT", 66, 81], ["liquid nitrogen", "TREATMENT", 126, 141], ["L3", "ANATOMY", 18, 20], ["liquid nitrogen", "OBSERVATION", 66, 81]]], ["All protocols using the L3 cryopreserved samples in this study were approved by the New York Blood Center's IRB (Protocol 321 and Protocol 603\u201309).", [["samples", "ANATOMY", 41, 48], ["All protocols", "TREATMENT", 0, 13], ["the L3 cryopreserved samples", "TREATMENT", 20, 48], ["this study", "TEST", 52, 62], ["L3", "ANATOMY", 24, 26]]], ["All L3 samples were anonymized.Ethics statement ::: Materials and methodsAll experimental procedures in mice were performed in compliance with the ethical and regulatory standards set by the NIH for animal experimentation.", [["L3 samples", "ANATOMY", 4, 14], ["L3 samples", "CANCER", 4, 14], ["mice", "ORGANISM", 104, 108], ["mice", "SPECIES", 104, 108], ["mice", "SPECIES", 104, 108], ["All L3 samples", "TEST", 0, 14], ["All experimental procedures", "TREATMENT", 73, 100], ["L3", "ANATOMY", 4, 6]]], ["The animal care and use protocol adhered to the \u201cGuide for the Care and Use of Laboratory Animals\u201d published by the National Research Council, USA.Parasites and infection of mice ::: Materials and methodsCryopreserved L3 were prepared as previously described [39\u201341].", [["infection", "DISEASE", 161, 170], ["Parasites", "CELL", 147, 156], ["mice", "ORGANISM", 174, 178], ["mice", "SPECIES", 174, 178], ["mice", "SPECIES", 174, 178], ["Parasites", "PROBLEM", 147, 156], ["methodsCryopreserved L3", "TREATMENT", 197, 220], ["infection", "OBSERVATION", 161, 170], ["L3", "ANATOMY", 218, 220]]], ["Briefly, black flies (Simulium damnosum) were fed on consenting donors infected with O. volvulus, and after 7 days the developed L3 were collected from dissected flies, cleaned, and cryopreserved in dimethyl sulfoxide and sucrose using Biocool II computerized freezing equipment (FTS Systems Inc., Stone Ridge, NY) [42].Parasites and infection of mice ::: Materials and methodsCryopreserved L3 were removed from liquid nitrogen storage and placed on dry ice for 15 minutes followed immediately by a 37\u00b0 water bath.", [["O. volvulus", "DISEASE", 85, 96], ["dimethyl sulfoxide", "CHEMICAL", 199, 217], ["sucrose", "CHEMICAL", 222, 229], ["Biocool II", "CHEMICAL", 236, 246], ["infection", "DISEASE", 334, 343], ["dimethyl sulfoxide", "CHEMICAL", 199, 217], ["sucrose", "CHEMICAL", 222, 229], ["nitrogen", "CHEMICAL", 419, 427], ["black flies", "ORGANISM", 9, 20], ["Simulium damnosum", "ORGANISM", 22, 39], ["donors", "ORGANISM", 64, 70], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 199, 217], ["sucrose", "SIMPLE_CHEMICAL", 222, 229], ["Parasites", "CELL", 320, 329], ["mice", "ORGANISM", 347, 351], ["Simulium damnosum", "SPECIES", 22, 39], ["O. volvulus", "SPECIES", 85, 96], ["mice", "SPECIES", 347, 351], ["black flies", "SPECIES", 9, 20], ["Simulium damnosum", "SPECIES", 22, 39], ["O. volvulus", "SPECIES", 85, 96], ["mice", "SPECIES", 347, 351], ["black flies (Simulium damnosum", "PROBLEM", 9, 39], ["O. volvulus", "PROBLEM", 85, 96], ["L3", "PROBLEM", 129, 131], ["dimethyl sulfoxide", "TREATMENT", 199, 217], ["sucrose", "TREATMENT", 222, 229], ["Biocool II computerized freezing equipment", "TREATMENT", 236, 278], ["Parasites", "PROBLEM", 320, 329], ["methodsCryopreserved L3", "TREATMENT", 370, 393], ["liquid nitrogen storage", "TREATMENT", 412, 435], ["dry ice", "TREATMENT", 450, 457], ["volvulus", "OBSERVATION", 88, 96], ["L3", "ANATOMY", 129, 131], ["Stone", "OBSERVATION", 298, 303], ["infection", "OBSERVATION", 334, 343], ["L3", "ANATOMY", 391, 393]]], ["The L3 were then washed 5 times in a 1:1 mixture of NCTC-135 and Iscove\u2019s modified Dulbecco\u2019s medium (Sigma, St. Louis MO) supplemented with 100 U penicillin, 100 \u03bcg streptomycin (Corning, Tewksbury MA) 100 \u03bcg gentamicin and 30 \u03bcg chloramphenicol per ml (Sigma).", [["NCTC-135", "CHEMICAL", 52, 60], ["penicillin", "CHEMICAL", 147, 157], ["streptomycin", "CHEMICAL", 166, 178], ["gentamicin", "CHEMICAL", 210, 220], ["chloramphenicol", "CHEMICAL", 231, 246], ["penicillin", "CHEMICAL", 147, 157], ["streptomycin", "CHEMICAL", 166, 178], ["gentamicin", "CHEMICAL", 210, 220], ["chloramphenicol", "CHEMICAL", 231, 246], ["NCTC-135", "SIMPLE_CHEMICAL", 52, 60], ["St. Louis MO", "ORGANISM", 109, 121], ["penicillin", "SIMPLE_CHEMICAL", 147, 157], ["streptomycin", "SIMPLE_CHEMICAL", 166, 178], ["gentamicin", "SIMPLE_CHEMICAL", 210, 220], ["chloramphenicol", "SIMPLE_CHEMICAL", 231, 246], ["NCTC-135", "SPECIES", 52, 60], ["a 1:1 mixture of NCTC", "TREATMENT", 35, 56], ["100 U penicillin", "TREATMENT", 141, 157], ["streptomycin", "TREATMENT", 166, 178], ["Tewksbury MA)", "TREATMENT", 189, 202], ["gentamicin", "TREATMENT", 210, 220], ["L3", "ANATOMY", 4, 6]]], ["L3 isolated from different collection days were tested first for viability in diffusion chambers implanted in BALB/ByJ for 21 days, as previously described [17].", [["BALB/ByJ", "CELL", 110, 118], ["L3", "DNA", 0, 2], ["viability in diffusion chambers", "TREATMENT", 65, 96], ["different", "OBSERVATION_MODIFIER", 17, 26], ["collection", "OBSERVATION", 27, 37]]], ["Batches of L3 with viabilities greater than 50% at 21 days post implantation were used in these studies.", [["viabilities", "TEST", 19, 30], ["implantation", "TREATMENT", 64, 76], ["these studies", "TEST", 90, 103], ["L3", "ANATOMY", 11, 13], ["viabilities", "OBSERVATION_MODIFIER", 19, 30], ["greater", "OBSERVATION_MODIFIER", 31, 38]]], ["One hundred worms (except where noted) were then counted and loaded into 1 ml tuberculin syringes with 21 g needle for subcutaneous injection of the larvae into the nape of the neck.Mice ::: Materials and methodsAll mice were housed in micro-isolator boxes in a pathogen-free room at the Laboratory Animal Science Facility at Thomas Jefferson University (Philadelphia, PA).", [["worms", "ANATOMY", 12, 17], ["subcutaneous", "ANATOMY", 119, 131], ["larvae", "ANATOMY", 149, 155], ["nape", "ANATOMY", 165, 169], ["neck", "ANATOMY", 177, 181], ["worms", "ORGANISM", 12, 17], ["nape", "ORGANISM_SUBDIVISION", 165, 169], ["neck", "ORGAN", 177, 181], ["Mice", "ORGANISM", 182, 186], ["mice", "ORGANISM", 216, 220], ["worms", "SPECIES", 12, 17], ["Mice", "SPECIES", 182, 186], ["mice", "SPECIES", 216, 220], ["mice", "SPECIES", 216, 220], ["1 ml tuberculin syringes", "TREATMENT", 73, 97], ["21 g needle", "TREATMENT", 103, 114], ["subcutaneous injection of the larvae", "TREATMENT", 119, 155], ["nape", "ANATOMY_MODIFIER", 165, 169], ["neck", "ANATOMY", 177, 181]]], ["Collaborative Cross (CC) mouse strains, Cast/EIJ, IL16680 (CC055/TauUnc), AU8052 (CC052/GeniUnc), AU8049 (CC038/GeniUnc) and OR13067 (CC003/Unc), were purchased and imported from the Systems Genetics Core Facility of University of North Carolina (UNC-Chapel Hill).", [["mouse", "ORGANISM", 25, 30], ["Cast/EIJ", "ORGANISM", 40, 48], ["mouse", "SPECIES", 25, 30], ["mouse", "SPECIES", 25, 30], ["Cast/EIJ", "TEST", 40, 48], ["GeniUnc", "TEST", 88, 95], ["GeniUnc", "TEST", 112, 119]]], ["Information about the CC strains can be found on the UNC Systems Genetics website at http://csbio.unc.edu/CCstatus/index.py.", [["CC", "CHEMICAL", 22, 24], ["the CC strains", "PROBLEM", 18, 32]]], ["The mice were kept under temperature, humidity and light cycle-controlled conditions and fed autoclavable rodent chow and given water ad libitum.Mice ::: Materials and methodsNOD-scid IL2Rgnull (NSG), NOD-Rag1nullIL2rgnull (NRG), and NOD-scid IL2Rgnull-3/GM/SF (SGM) mice were obtained from The Jackson Laboratories (Bar Harbor, ME).", [["mice", "ORGANISM", 4, 8], ["Mice", "ORGANISM", 145, 149], ["NOD-Rag1nullIL2rgnull", "GENE_OR_GENE_PRODUCT", 201, 222], ["NRG", "GENE_OR_GENE_PRODUCT", 224, 227], ["SGM", "GENE_OR_GENE_PRODUCT", 262, 265], ["mice", "ORGANISM", 267, 271], ["NOD", "PROTEIN", 175, 178], ["scid IL2Rgnull", "PROTEIN", 179, 193], ["NOD", "PROTEIN", 201, 204], ["Rag1nullIL2rgnull", "PROTEIN", 205, 222], ["NRG", "PROTEIN", 224, 227], ["NOD", "PROTEIN", 234, 237], ["mice", "SPECIES", 4, 8], ["rodent", "SPECIES", 106, 112], ["Mice", "SPECIES", 145, 149], ["mice", "SPECIES", 267, 271], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 267, 271], ["humidity", "TREATMENT", 38, 46], ["light cycle-controlled conditions", "TREATMENT", 51, 84], ["Materials", "TEST", 154, 163], ["methodsNOD", "TEST", 168, 178], ["NOD", "TEST", 201, 204], ["NOD", "TEST", 234, 237], ["IL2Rgnull", "TEST", 243, 252]]], ["An NSG, NRG, and SGM mouse breeding colony was maintained in the Laboratory Animal Science Facility, at Thomas Jefferson University with breeding trios given acidified water and low fat 5K52 animal chow (LabDiet, St. Louis, MO).Injection of cells for single cell xenografts ::: Materials and methodsThe following human cell types were individually transferred into NSG mice: (1) human keratinocytes (HaCat) (ATCC, Manassas, VA), (2) bovine embryo skeletal muscle cells (BESM) [43], (3) lymphatic endothelial cells (LEC) (PromoCell, Heidelberg, Germany), and (4) human skeletal smooth muscle cells (HuSkMc) (Cell Application, San Diego, CA).", [["colony", "ANATOMY", 36, 42], ["cells", "ANATOMY", 241, 246], ["cell xenografts", "ANATOMY", 258, 273], ["cell", "ANATOMY", 319, 323], ["keratinocytes", "ANATOMY", 385, 398], ["HaCat", "ANATOMY", 400, 405], ["ATCC", "ANATOMY", 408, 412], ["Manassas", "ANATOMY", 414, 422], ["VA", "ANATOMY", 424, 426], ["embryo skeletal muscle cells", "ANATOMY", 440, 468], ["BESM", "ANATOMY", 470, 474], ["lymphatic endothelial cells", "ANATOMY", 486, 513], ["LEC", "ANATOMY", 515, 518], ["PromoCell", "ANATOMY", 521, 530], ["skeletal smooth muscle cells", "ANATOMY", 568, 596], ["HuSkMc", "ANATOMY", 598, 604], ["Cell", "ANATOMY", 607, 611], ["NRG", "GENE_OR_GENE_PRODUCT", 8, 11], ["mouse", "ORGANISM", 21, 26], ["cells", "CELL", 241, 246], ["single cell xenografts", "CANCER", 251, 273], ["human", "ORGANISM", 313, 318], ["cell", "CELL", 319, 323], ["NSG mice", "ORGANISM", 365, 373], ["human", "ORGANISM", 379, 384], ["keratinocytes", "CELL", 385, 398], ["HaCat", "CELL", 400, 405], ["ATCC", "CELL", 408, 412], ["VA", "CELL", 424, 426], ["bovine", "ORGANISM", 433, 439], ["embryo skeletal muscle cells", "CELL", 440, 468], ["BESM", "CELL", 470, 474], ["lymphatic endothelial cells", "CELL", 486, 513], ["LEC", "CELL", 515, 518], ["human", "ORGANISM", 562, 567], ["skeletal smooth muscle cells", "CELL", 568, 596], ["HuSkMc", "CELL", 598, 604], ["Cell", "CELL", 607, 611], ["NRG", "PROTEIN", 8, 11], ["human keratinocytes", "CELL_TYPE", 379, 398], ["HaCat", "CELL_LINE", 400, 405], ["bovine embryo skeletal muscle cells", "CELL_TYPE", 433, 468], ["BESM", "CELL_TYPE", 470, 474], ["lymphatic endothelial cells", "CELL_TYPE", 486, 513], ["LEC", "CELL_TYPE", 515, 518], ["human skeletal smooth muscle cells", "CELL_TYPE", 562, 596], ["mouse", "SPECIES", 21, 26], ["human", "SPECIES", 313, 318], ["mice", "SPECIES", 369, 373], ["human", "SPECIES", 379, 384], ["bovine", "SPECIES", 433, 439], ["human", "SPECIES", 562, 567], ["mouse", "SPECIES", 21, 26], ["human", "SPECIES", 313, 318], ["mice", "SPECIES", 369, 373], ["human", "SPECIES", 379, 384], ["ATCC", "SPECIES", 408, 412], ["Manassas", "SPECIES", 414, 422], ["bovine", "SPECIES", 433, 439], ["human", "SPECIES", 562, 567], ["acidified water", "TREATMENT", 158, 173], ["human keratinocytes (HaCat) (ATCC, Manassas, VA), (2) bovine embryo skeletal muscle cells", "PROBLEM", 379, 468], ["lymphatic endothelial cells", "PROBLEM", 486, 513], ["human skeletal smooth muscle cells", "PROBLEM", 562, 596], ["skeletal muscle", "ANATOMY", 447, 462], ["lymphatic endothelial", "ANATOMY", 486, 507], ["skeletal", "ANATOMY", 568, 576], ["smooth muscle", "ANATOMY", 577, 590]]], ["HaCat and BESM were maintained in Dulbecco\u2019s Modification of Eagle\u2019s Medium (DMEM) (Corning, Manassas, VA) supplemented with 100 U penicillin, 100 \u03bcg streptomycin (Corning), 200 nM L-glutamine (Corning) and 10% fetal bovine serum (FBS) (Gemini BioProducts, West Scaramento, CA).", [["fetal bovine serum", "ANATOMY", 211, 229], ["FBS", "ANATOMY", 231, 234], ["penicillin", "CHEMICAL", 131, 141], ["streptomycin", "CHEMICAL", 150, 162], ["L-glutamine", "CHEMICAL", 181, 192], ["penicillin", "CHEMICAL", 131, 141], ["streptomycin", "CHEMICAL", 150, 162], ["L-glutamine", "CHEMICAL", 181, 192], ["HaCat", "SIMPLE_CHEMICAL", 0, 5], ["penicillin", "SIMPLE_CHEMICAL", 131, 141], ["streptomycin", "SIMPLE_CHEMICAL", 150, 162], ["L-glutamine", "SIMPLE_CHEMICAL", 181, 192], ["bovine", "ORGANISM", 217, 223], ["serum", "ORGANISM_SUBSTANCE", 224, 229], ["FBS", "ORGANISM_SUBSTANCE", 231, 234], ["bovine", "SPECIES", 217, 223], ["bovine", "SPECIES", 217, 223], ["100 U penicillin", "TREATMENT", 125, 141], ["10% fetal bovine serum (FBS) (Gemini BioProducts", "TREATMENT", 207, 255]]], ["LEC were maintained in EGM-2MV media (Lonza, Walkersville, MD), and HuSkMc were maintained in Skeletal Muscle Growth Medium (Cell Applications Inc, San Diego, CA) following manufacturer\u2019s recommendations.Injection of cells for single cell xenografts ::: Materials and methodsIn the initial experiments, mice were injected with 5\u00d7106 BESM, HaCaT, LEC, or HuSkMc cells subcutaneously weekly throughout the experiment.", [["LEC", "ANATOMY", 0, 3], ["Cell", "ANATOMY", 125, 129], ["cells", "ANATOMY", 217, 222], ["cell xenografts", "ANATOMY", 234, 249], ["HaCaT", "ANATOMY", 339, 344], ["LEC", "ANATOMY", 346, 349], ["HuSkMc cells", "ANATOMY", 354, 366], ["LEC", "CELL", 0, 3], ["Cell", "CELL", 125, 129], ["cells", "CELL", 217, 222], ["single cell xenografts", "CANCER", 227, 249], ["mice", "ORGANISM", 303, 307], ["HaCaT", "CELL", 339, 344], ["LEC", "CELL", 346, 349], ["HuSkMc cells", "CELL", 354, 366], ["HaCaT", "CELL_LINE", 339, 344], ["LEC", "CELL_LINE", 346, 349], ["HuSkMc cells", "CELL_LINE", 354, 366], ["mice", "SPECIES", 303, 307], ["mice", "SPECIES", 303, 307], ["LEC", "TEST", 0, 3], ["EGM", "TEST", 23, 26], ["HaCaT, LEC", "TREATMENT", 339, 349], ["HuSkMc cells", "TREATMENT", 354, 366], ["Skeletal Muscle", "ANATOMY", 94, 109]]], ["The frequency of injection was subsequently determined by in vivo imaging experiments.", [["injection", "TREATMENT", 17, 26]]], ["Genes encoding green fluorescent protein (GFP) and luciferase were inserted into HuSkMc cells using lentiviral vectors following the manufacturer\u2019s recommendations (Cell Biolabs, Inc, San Diego, CA).", [["HuSkMc cells", "ANATOMY", 81, 93], ["Cell", "ANATOMY", 165, 169], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 15, 40], ["GFP", "GENE_OR_GENE_PRODUCT", 42, 45], ["luciferase", "GENE_OR_GENE_PRODUCT", 51, 61], ["HuSkMc cells", "CELL", 81, 93], ["lentiviral", "ORGANISM", 100, 110], ["green fluorescent protein", "PROTEIN", 15, 40], ["GFP", "PROTEIN", 42, 45], ["luciferase", "PROTEIN", 51, 61], ["HuSkMc cells", "CELL_LINE", 81, 93], ["Genes encoding green fluorescent protein (GFP", "PROBLEM", 0, 45], ["luciferase", "TEST", 51, 61], ["lentiviral vectors", "TREATMENT", 100, 118]]], ["Cells expressing GFP were isolated using the GFP marker by fluorescence-activated cell sorting using a BD FACS Aria (BD Biosciences, Franklin Lakes, NJ).", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 82, 86], ["Cells", "CELL", 0, 5], ["GFP", "GENE_OR_GENE_PRODUCT", 17, 20], ["GFP", "GENE_OR_GENE_PRODUCT", 45, 48], ["cell", "CELL", 82, 86], ["GFP", "PROTEIN", 17, 20], ["the GFP marker", "TEST", 41, 55]]], ["The isolated cells were grown in HuSkMc media as described above and 5\u00d7106 cells were injected subcutaneously into NSG mice.", [["cells", "ANATOMY", 13, 18], ["5\u00d7106 cells", "ANATOMY", 69, 80], ["subcutaneously", "ANATOMY", 95, 109], ["cells", "CELL", 13, 18], ["5\u00d7106 cells", "CELL", 69, 80], ["NSG mice", "ORGANISM", 115, 123], ["5\u00d7106 cells", "CELL_LINE", 69, 80], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 119, 123], ["The isolated cells", "PROBLEM", 0, 18], ["isolated cells", "OBSERVATION", 4, 18], ["grown", "OBSERVATION_MODIFIER", 24, 29], ["HuSkMc media", "OBSERVATION", 33, 45]]], ["Mice were injected with VivoGlo (Promega, Madison, WI) and imaged following manufacturer\u2019s recommendations on an IVIS Lumina XR (Promega).Humanized mice with multiple human cell types ::: Materials and methodsTwo approaches were used to create humanized mice containing multiple human-cell types [25,36].", [["cell", "ANATOMY", 173, 177], ["cell", "ANATOMY", 285, 289], ["Mice", "ORGANISM", 0, 4], ["mice", "ORGANISM", 148, 152], ["human", "ORGANISM", 167, 172], ["cell", "CELL", 173, 177], ["mice", "ORGANISM", 254, 258], ["human", "ORGANISM", 279, 284], ["cell", "CELL", 285, 289], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 148, 152], ["human", "SPECIES", 167, 172], ["mice", "SPECIES", 254, 258], ["human", "SPECIES", 279, 284], ["mice", "SPECIES", 148, 152], ["human", "SPECIES", 167, 172], ["mice", "SPECIES", 254, 258], ["human", "SPECIES", 279, 284], ["VivoGlo", "TREATMENT", 24, 31], ["an IVIS Lumina XR", "TREATMENT", 110, 127], ["Materials", "TREATMENT", 188, 197], ["methodsTwo approaches", "TREATMENT", 202, 223], ["humanized mice containing multiple human-cell types", "TREATMENT", 244, 295]]], ["Human umbilical cord blood was obtained through collaboration with Thomas Jefferson University Hospital Department of Obstetrics and Gynecology from full term natural deliveries.", [["umbilical cord blood", "ANATOMY", 6, 26], ["Human", "ORGANISM", 0, 5], ["cord blood", "ORGANISM_SUBSTANCE", 16, 26], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human umbilical cord blood", "TEST", 0, 26], ["umbilical cord", "ANATOMY", 6, 20]]], ["CD34+ stem cells were isolated from cord blood using magnetic assisted cell sorting (MACS) and cryopreserved until use.", [["CD34+ stem cells", "ANATOMY", 0, 16], ["cord blood", "ANATOMY", 36, 46], ["cell", "ANATOMY", 71, 75], ["CD34", "GENE_OR_GENE_PRODUCT", 0, 4], ["cord blood", "ORGANISM_SUBSTANCE", 36, 46], ["cell", "CELL", 71, 75], ["CD34", "PROTEIN", 0, 4], ["stem cells", "CELL_TYPE", 6, 16], ["MACS", "CELL_TYPE", 85, 89], ["CD34", "TEST", 0, 4], ["stem cells", "TEST", 6, 16], ["cord blood", "TEST", 36, 46], ["magnetic assisted cell sorting", "TREATMENT", 53, 83], ["stem cells", "OBSERVATION", 6, 16]]], ["SGM, NRG and NSG mice were humanized with CD34+ umbilical cord derived stem cells by intrahepatic injection of 5x105 CD34+ stem cells into 48-hour old pups that were irradiated with 1.5 gray.", [["CD34+ umbilical cord derived stem cells", "ANATOMY", 42, 81], ["intrahepatic", "ANATOMY", 85, 97], ["5x105 CD34+ stem cells", "ANATOMY", 111, 133], ["NRG", "GENE_OR_GENE_PRODUCT", 5, 8], ["NSG mice", "ORGANISM", 13, 21], ["CD34", "GENE_OR_GENE_PRODUCT", 42, 46], ["cord derived stem cells", "CELL", 58, 81], ["CD34", "GENE_OR_GENE_PRODUCT", 117, 121], ["stem cells", "CELL", 123, 133], ["pups", "ORGANISM", 151, 155], ["NRG", "PROTEIN", 5, 8], ["CD34", "PROTEIN", 42, 46], ["umbilical cord derived stem cells", "CELL_TYPE", 48, 81], ["5x105 CD34+ stem cells", "CELL_LINE", 111, 133], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["stem cells", "TEST", 123, 133], ["umbilical cord", "ANATOMY", 48, 62], ["stem cells", "OBSERVATION", 71, 81], ["intrahepatic", "ANATOMY", 85, 97], ["stem cells", "OBSERVATION", 123, 133]]], ["Six weeks following injection of the stem cells, peripheral blood from the mice was screened for the presence of human cells and mice with counts greater than 600 human CD45+ hematopoietic cells per \u03bcl of whole blood were used for experimentation, following previously published protocols [31].Humanized mice with multiple human cell types ::: Materials and methodsBLT mice were purchased from The Jackson Laboratories or were prepared following previously established protocols [27].", [["stem cells", "ANATOMY", 37, 47], ["peripheral blood", "ANATOMY", 49, 65], ["cells", "ANATOMY", 119, 124], ["CD45+ hematopoietic cells", "ANATOMY", 169, 194], ["\u03bcl", "ANATOMY", 199, 201], ["whole blood", "ANATOMY", 205, 216], ["cell", "ANATOMY", 329, 333], ["stem cells", "CELL", 37, 47], ["peripheral blood", "ORGANISM_SUBSTANCE", 49, 65], ["mice", "ORGANISM", 75, 79], ["human", "ORGANISM", 113, 118], ["cells", "CELL", 119, 124], ["mice", "ORGANISM", 129, 133], ["human", "ORGANISM", 163, 168], ["CD45", "GENE_OR_GENE_PRODUCT", 169, 173], ["hematopoietic cells", "CELL", 175, 194], ["blood", "ORGANISM_SUBSTANCE", 211, 216], ["mice", "ORGANISM", 304, 308], ["human", "ORGANISM", 323, 328], ["cell", "CELL", 329, 333], ["mice", "ORGANISM", 369, 373], ["stem cells", "CELL_TYPE", 37, 47], ["human cells", "CELL_TYPE", 113, 124], ["CD45", "PROTEIN", 169, 173], ["hematopoietic cells", "CELL_TYPE", 175, 194], ["mice", "SPECIES", 75, 79], ["human", "SPECIES", 113, 118], ["mice", "SPECIES", 129, 133], ["human", "SPECIES", 163, 168], ["mice", "SPECIES", 304, 308], ["human", "SPECIES", 323, 328], ["mice", "SPECIES", 369, 373], ["mice", "SPECIES", 75, 79], ["human", "SPECIES", 113, 118], ["mice", "SPECIES", 129, 133], ["human", "SPECIES", 163, 168], ["mice", "SPECIES", 304, 308], ["human", "SPECIES", 323, 328], ["mice", "SPECIES", 369, 373], ["the stem cells", "TREATMENT", 33, 47], ["peripheral blood", "TEST", 49, 65], ["human cells", "TREATMENT", 113, 124], ["counts", "TEST", 139, 145], ["hematopoietic cells", "TEST", 175, 194], ["whole blood", "TEST", 205, 216], ["methodsBLT mice", "TREATMENT", 358, 373], ["stem cells", "OBSERVATION", 37, 47], ["hematopoietic cells", "OBSERVATION", 175, 194]]], ["Briefly, NSG mice (4- to 6-week old) were implanted with 1 mm3 sections of fetal thymus and liver (Advanced Biomedical Resources, Alameda, CA) under the kidney capsule.", [["sections", "ANATOMY", 63, 71], ["fetal thymus", "ANATOMY", 75, 87], ["liver", "ANATOMY", 92, 97], ["kidney capsule", "ANATOMY", 153, 167], ["NSG mice", "ORGANISM", 9, 17], ["fetal thymus", "MULTI-TISSUE_STRUCTURE", 75, 87], ["liver", "ORGAN", 92, 97], ["kidney capsule", "CANCER", 153, 167], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["Advanced Biomedical Resources", "TREATMENT", 99, 128], ["the kidney capsule", "TREATMENT", 149, 167], ["fetal thymus", "ANATOMY", 75, 87], ["liver", "ANATOMY", 92, 97], ["kidney", "ANATOMY", 153, 159], ["capsule", "ANATOMY_MODIFIER", 160, 167]]], ["Two weeks post-implantation the mice were treated with busulfan (Sigma) (20 mg/kg IP) and were injected retro-orbitally with 5x105 CD34+ stem cells, isolated from the donor fetal liver using MACS, (Miltenyi Biotec Inc. Auburn, CA).", [["5x105 CD34+ stem cells", "ANATOMY", 125, 147], ["fetal liver", "ANATOMY", 173, 184], ["busulfan", "CHEMICAL", 55, 63], ["busulfan", "CHEMICAL", 55, 63], ["mice", "ORGANISM", 32, 36], ["busulfan", "SIMPLE_CHEMICAL", 55, 63], ["Sigma", "SIMPLE_CHEMICAL", 65, 70], ["CD34", "GENE_OR_GENE_PRODUCT", 131, 135], ["stem cells", "CELL", 137, 147], ["fetal", "MULTI-TISSUE_STRUCTURE", 173, 178], ["liver", "ORGAN", 179, 184], ["CD34", "PROTEIN", 131, 135], ["stem cells", "CELL_TYPE", 137, 147], ["MACS", "CELL_TYPE", 191, 195], ["Miltenyi Biotec", "PROTEIN", 198, 213], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 32, 36], ["busulfan (Sigma)", "TREATMENT", 55, 71], ["stem cells", "OBSERVATION", 137, 147], ["fetal", "ANATOMY_MODIFIER", 173, 178], ["liver", "ANATOMY", 179, 184]]], ["Eight weeks following the stem cell xenograft the peripheral blood from the BLT mice was screened for the presence of human cells.", [["stem cell xenograft", "ANATOMY", 26, 45], ["peripheral blood", "ANATOMY", 50, 66], ["cells", "ANATOMY", 124, 129], ["stem cell xenograft", "CANCER", 26, 45], ["peripheral blood", "ORGANISM_SUBSTANCE", 50, 66], ["BLT", "ORGANISM", 76, 79], ["mice", "ORGANISM", 80, 84], ["human", "ORGANISM", 118, 123], ["cells", "CELL", 124, 129], ["human cells", "CELL_TYPE", 118, 129], ["mice", "SPECIES", 80, 84], ["human", "SPECIES", 118, 123], ["mice", "SPECIES", 80, 84], ["human", "SPECIES", 118, 123], ["the stem cell xenograft", "TREATMENT", 22, 45], ["the BLT mice", "TEST", 72, 84], ["human cells", "PROBLEM", 118, 129], ["stem cell xenograft", "OBSERVATION", 26, 45], ["peripheral", "ANATOMY_MODIFIER", 50, 60], ["blood", "ANATOMY", 61, 66], ["human cells", "OBSERVATION", 118, 129]]], ["BLT mice were screened and selected using the same protocol described above for the CD34+ cord blood mice.qPCR screening of tissues for the presence of O. volvulus parasites ::: Materials and methodsPCR screening for O. volvulus DNA was performed on all the infected mouse tissues to identify the presence of current or past O. volvulus larvae in that location.", [["CD34+ cord blood", "ANATOMY", 84, 100], ["tissues", "ANATOMY", 124, 131], ["tissues", "ANATOMY", 273, 280], ["O. volvulus parasites", "DISEASE", 152, 173], ["BLT mice", "ORGANISM", 0, 8], ["CD34", "GENE_OR_GENE_PRODUCT", 84, 88], ["mice", "ORGANISM", 101, 105], ["tissues", "TISSUE", 124, 131], ["O. volvulus", "ORGANISM", 152, 163], ["volvulus", "ORGANISM", 220, 228], ["DNA", "CELLULAR_COMPONENT", 229, 232], ["mouse", "ORGANISM", 267, 272], ["tissues", "TISSUE", 273, 280], ["CD34", "PROTEIN", 84, 88], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 101, 105], ["O. volvulus", "SPECIES", 152, 163], ["O. volvulus", "SPECIES", 217, 228], ["mouse", "SPECIES", 267, 272], ["O. volvulus", "SPECIES", 325, 336], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 101, 105], ["O. volvulus", "SPECIES", 152, 163], ["O. volvulus", "SPECIES", 217, 228], ["mouse", "SPECIES", 267, 272], ["O. volvulus", "SPECIES", 325, 336], ["the same protocol", "TEST", 42, 59], ["the CD34", "TEST", 80, 88], ["cord blood mice", "TEST", 90, 105], ["methodsPCR screening", "TEST", 192, 212], ["O. volvulus DNA", "PROBLEM", 217, 232], ["past O. volvulus larvae", "PROBLEM", 320, 343], ["cord", "ANATOMY", 90, 94], ["volvulus", "OBSERVATION", 155, 163], ["volvulus", "OBSERVATION", 328, 336]]], ["Mice were anesthetized and exsanguinated, and the internal organs were removed, and the skin was removed from the muscle.", [["internal organs", "ANATOMY", 50, 65], ["skin", "ANATOMY", 88, 92], ["muscle", "ANATOMY", 114, 120], ["Mice", "ORGANISM", 0, 4], ["organs", "ORGAN", 59, 65], ["skin", "ORGAN", 88, 92], ["muscle", "ORGAN", 114, 120], ["Mice", "SPECIES", 0, 4], ["Mice", "SPECIES", 0, 4], ["internal organs", "ANATOMY", 50, 65], ["removed", "OBSERVATION", 71, 78], ["skin", "ANATOMY", 88, 92], ["removed", "OBSERVATION", 97, 104], ["muscle", "ANATOMY", 114, 120]]], ["The muscle and skin were then divided into 100 different sections and individually frozen in 1.7 ml Eppendorf tubes.", [["muscle", "ANATOMY", 4, 10], ["skin", "ANATOMY", 15, 19], ["sections", "ANATOMY", 57, 65], ["muscle", "ORGAN", 4, 10], ["skin", "ORGAN", 15, 19], ["1.7 ml Eppendorf tubes", "TREATMENT", 93, 115], ["muscle", "ANATOMY", 4, 10], ["skin", "ANATOMY", 15, 19]]], ["DNA was extracted from the tissue sections using the Promega genomic DNA kit A1125 following the manufacturer\u2019s directions.", [["tissue sections", "ANATOMY", 27, 42], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 27, 42], ["DNA", "CELLULAR_COMPONENT", 69, 72], ["Promega genomic DNA", "DNA", 53, 72], ["DNA", "PROBLEM", 0, 3], ["the Promega genomic DNA kit", "TREATMENT", 49, 76]]], ["Realtime PCR was performed using custom Taqman probes (Integrated DNA Technologies, Coralville, IA) against the Ov-150 [44\u201346] repeats and an ABI OneStep-Plus (ThermoFisher).Necropsy and morphological analysis ::: Materials and methodsMice were necropsied following previously established protocols for the isolation of filarial worms from tissues [47,48].", [["worms", "ANATOMY", 329, 334], ["tissues", "ANATOMY", 340, 347], ["filarial worms", "DISEASE", 320, 334], ["DNA", "CELLULAR_COMPONENT", 66, 69], ["Mice", "ORGANISM", 235, 239], ["filarial", "ORGANISM", 320, 328], ["worms", "DEVELOPING_ANATOMICAL_STRUCTURE", 329, 334], ["tissues", "TISSUE", 340, 347], ["Taqman probes", "DNA", 40, 53], ["Ov-150 [44\u201346] repeats", "DNA", 112, 134], ["ABI OneStep", "DNA", 142, 153], ["ThermoFisher", "DNA", 160, 172], ["Mice", "SPECIES", 235, 239], ["worms", "SPECIES", 329, 334], ["Realtime PCR", "TEST", 0, 12], ["an ABI OneStep", "TEST", 139, 153], ["previously established protocols", "TREATMENT", 266, 298], ["filarial worms", "PROBLEM", 320, 334], ["filarial worms", "OBSERVATION", 320, 334]]], ["Briefly, mice were anesthetized using isoflurane gas and exsanguinated.", [["isoflurane", "CHEMICAL", 38, 48], ["isoflurane", "CHEMICAL", 38, 48], ["mice", "ORGANISM", 9, 13], ["isoflurane", "SIMPLE_CHEMICAL", 38, 48], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 9, 13], ["isoflurane gas", "TREATMENT", 38, 52]]], ["The head was removed from the body of the mouse and discarded.", [["head", "ANATOMY", 4, 8], ["body", "ANATOMY", 30, 34], ["head", "ORGAN", 4, 8], ["body", "ORGANISM_SUBDIVISION", 30, 34], ["mouse", "ORGANISM", 42, 47], ["mouse", "SPECIES", 42, 47], ["mouse", "SPECIES", 42, 47], ["head", "ANATOMY", 4, 8], ["removed", "OBSERVATION", 13, 20]]], ["The remaining internal organs and skin were removed from the muscles, and the muscle was divided into upper and lower sections at the bottom of the rib cage.", [["internal organs", "ANATOMY", 14, 29], ["skin", "ANATOMY", 34, 38], ["muscles", "ANATOMY", 61, 68], ["muscle", "ANATOMY", 78, 84], ["lower sections", "ANATOMY", 112, 126], ["organs", "ORGAN", 23, 29], ["skin", "ORGAN", 34, 38], ["muscles", "ORGAN", 61, 68], ["muscle", "ORGAN", 78, 84], ["upper", "ORGANISM_SUBDIVISION", 102, 107], ["lower sections", "MULTI-TISSUE_STRUCTURE", 112, 126], ["rib cage", "MULTI-TISSUE_STRUCTURE", 148, 156], ["internal", "ANATOMY_MODIFIER", 14, 22], ["organs", "ANATOMY", 23, 29], ["skin", "ANATOMY", 34, 38], ["removed", "OBSERVATION", 44, 51], ["muscles", "ANATOMY", 61, 68], ["muscle", "ANATOMY", 78, 84], ["upper", "ANATOMY_MODIFIER", 102, 107], ["lower sections", "ANATOMY_MODIFIER", 112, 126], ["bottom", "ANATOMY_MODIFIER", 134, 140], ["rib", "ANATOMY", 148, 151], ["cage", "ANATOMY_MODIFIER", 152, 156]]], ["All portions of the mouse (muscle, skin, and all internal organs with the exception of the head) were soaked overnight in RPMI containing 10% FBS and with 100 U penicillin, 100 \u03bcg streptomycin (Corning), and emerging parasites were then collected and enumerated.", [["muscle", "ANATOMY", 27, 33], ["skin", "ANATOMY", 35, 39], ["organs", "ANATOMY", 58, 64], ["head", "ANATOMY", 91, 95], ["FBS", "ANATOMY", 142, 145], ["penicillin", "CHEMICAL", 161, 171], ["streptomycin", "CHEMICAL", 180, 192], ["penicillin", "CHEMICAL", 161, 171], ["streptomycin", "CHEMICAL", 180, 192], ["mouse", "ORGANISM", 20, 25], ["muscle", "ORGAN", 27, 33], ["skin", "ORGAN", 35, 39], ["organs", "ORGAN", 58, 64], ["head", "ORGANISM_SUBDIVISION", 91, 95], ["FBS", "ORGANISM_SUBSTANCE", 142, 145], ["penicillin", "SIMPLE_CHEMICAL", 161, 171], ["streptomycin", "SIMPLE_CHEMICAL", 180, 192], ["mouse", "SPECIES", 20, 25], ["mouse", "SPECIES", 20, 25], ["RPMI", "TREATMENT", 122, 126], ["10% FBS", "TREATMENT", 138, 145], ["100 U penicillin", "TREATMENT", 155, 171], ["streptomycin", "TREATMENT", 180, 192], ["emerging parasites", "PROBLEM", 208, 226], ["muscle", "ANATOMY", 27, 33], ["skin", "ANATOMY", 35, 39], ["head", "ANATOMY", 91, 95]]], ["Infected mice were evaluated using two criteria: 1) percent established, measured the proportion of mice in a group of infected animals from which live parasites were recovered; and 2) the geometric mean number of live worms recovered per mouse within the group.Necropsy and morphological analysis ::: Materials and methodsRecovered worms were placed in boiling fixative consisting of 95% ethanol (Deacon Labs, King of Prussia, PA) and 5% glycerol (Fisher, Fair Lawn, NJ).", [["ethanol", "CHEMICAL", 389, 396], ["glycerol", "CHEMICAL", 439, 447], ["ethanol", "CHEMICAL", 389, 396], ["glycerol", "CHEMICAL", 439, 447], ["mice", "ORGANISM", 9, 13], ["mice", "ORGANISM", 100, 104], ["mouse", "ORGANISM", 239, 244], ["worms", "ORGANISM", 333, 338], ["ethanol", "SIMPLE_CHEMICAL", 389, 396], ["glycerol", "SIMPLE_CHEMICAL", 439, 447], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 100, 104], ["worms", "SPECIES", 219, 224], ["mouse", "SPECIES", 239, 244], ["worms", "SPECIES", 333, 338], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 100, 104], ["mouse", "SPECIES", 239, 244], ["boiling fixative", "TREATMENT", 354, 370], ["Prussia", "TREATMENT", 419, 426], ["infected", "OBSERVATION", 119, 127]]], ["After allowing the alcohol to evaporate, glycerol was added, and the worms were transferred to glycerin jelly (gelatin 10 g, ddH2O 60.0 ml, glycerine 70.0 ml, Phenol 1.0 ml).", [["alcohol", "CHEMICAL", 19, 26], ["glycerol", "CHEMICAL", 41, 49], ["glycerin jelly", "CHEMICAL", 95, 109], ["glycerine", "CHEMICAL", 140, 149], ["Phenol", "CHEMICAL", 159, 165], ["alcohol", "CHEMICAL", 19, 26], ["glycerol", "CHEMICAL", 41, 49], ["glycerin", "CHEMICAL", 95, 103], ["glycerine", "CHEMICAL", 140, 149], ["Phenol", "CHEMICAL", 159, 165], ["alcohol", "SIMPLE_CHEMICAL", 19, 26], ["glycerol", "SIMPLE_CHEMICAL", 41, 49], ["glycerine", "SIMPLE_CHEMICAL", 140, 149], ["worms", "SPECIES", 69, 74], ["glycerol", "TREATMENT", 41, 49], ["glycerin jelly", "TREATMENT", 95, 109], ["gelatin", "TREATMENT", 111, 118], ["ddH2O", "TREATMENT", 125, 130], ["glycerine", "TREATMENT", 140, 149], ["Phenol", "TREATMENT", 159, 165]]], ["Fixed worms were measured using an Olympus SZX16 dissecting scope connected to a DP26 camera (Olympus, Center Valley, PA).", [["worms", "SPECIES", 6, 11], ["Fixed worms", "PROBLEM", 0, 11], ["an Olympus SZX16 dissecting scope", "TREATMENT", 32, 65], ["a DP26 camera", "TREATMENT", 79, 92]]], ["CellSens Dimensions software (Olympus) was used to measure the length of the recovered worms.Serum and urine proteomics ::: Materials and methodsSerum and urine were collected and frozen as terminal procedures during necropsy.", [["worms", "ANATOMY", 87, 92], ["Serum", "ANATOMY", 93, 98], ["urine", "ANATOMY", 103, 108], ["urine", "ANATOMY", 155, 160], ["Serum", "ORGANISM_SUBSTANCE", 93, 98], ["urine", "ORGANISM_SUBSTANCE", 103, 108], ["urine", "ORGANISM_SUBSTANCE", 155, 160], ["worms", "SPECIES", 87, 92], ["Serum and urine proteomics", "TEST", 93, 119], ["methodsSerum and urine", "TEST", 138, 160], ["terminal procedures", "TREATMENT", 190, 209], ["necropsy", "TREATMENT", 217, 225], ["length", "OBSERVATION_MODIFIER", 63, 69], ["recovered worms", "OBSERVATION", 77, 92]]], ["Serum was thawed on ice and 25 \u03bcL removed for processing from each mouse.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["mouse", "ORGANISM", 67, 72], ["mouse", "SPECIES", 67, 72], ["mouse", "SPECIES", 67, 72], ["Serum", "TEST", 0, 5], ["ice", "TREATMENT", 20, 23]]], ["Sera from 4 mice from each group/strain were pooled for maximizing the protein identifications.", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["mice", "ORGANISM", 12, 16], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 12, 16], ["Sera", "TEST", 0, 4], ["the protein identifications", "TEST", 67, 94]]], ["Abundant proteins were depleted using an affinity chromatography (MARS-Ms-3, Agilent) according to the manufacturer\u2019s directions.", [["Abundant proteins", "PROBLEM", 0, 17], ["an affinity chromatography", "TEST", 38, 64], ["MARS-Ms", "TEST", 66, 73]]], ["Urine was thawed on ice, centrifuged and then filtered through a 0.22 \u03bcM filter (Corning).", [["Urine", "ANATOMY", 0, 5], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["Urine", "TEST", 0, 5], ["ice", "TREATMENT", 20, 23], ["a 0.22 \u03bcM filter", "TREATMENT", 63, 79]]], ["Serum and urine samples were prepared for mass spectrometry by digestion using the filter-assisted sample preparation (FASP) method [49].", [["Serum", "ANATOMY", 0, 5], ["urine samples", "ANATOMY", 10, 23], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["urine samples", "ORGANISM_SUBSTANCE", 10, 23], ["Serum and urine samples", "TEST", 0, 23], ["mass spectrometry", "PROBLEM", 42, 59], ["the filter-assisted sample preparation", "TREATMENT", 79, 117]]], ["Briefly, the samples brought to 1% sodium deoxycholate (SDC), 50 mM Tris-HCl, pH 7.6, 3 mM dithiothreitol, sonicated briefly, and incubated in a Thermo-Mixer at 90o C, 1,000 RPM for 20 min.", [["samples", "ANATOMY", 13, 20], ["sodium deoxycholate", "CHEMICAL", 35, 54], ["SDC", "CHEMICAL", 56, 59], ["Tris-HCl", "CHEMICAL", 68, 76], ["dithiothreitol", "CHEMICAL", 91, 105], ["sodium deoxycholate", "CHEMICAL", 35, 54], ["Tris-HCl", "CHEMICAL", 68, 76], ["dithiothreitol", "CHEMICAL", 91, 105], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 35, 54], ["SDC", "SIMPLE_CHEMICAL", 56, 59], ["Tris-HCl", "SIMPLE_CHEMICAL", 68, 76], ["dithiothreitol", "SIMPLE_CHEMICAL", 91, 105], ["1% sodium deoxycholate", "TREATMENT", 32, 54], ["pH", "TEST", 78, 80], ["3 mM dithiothreitol", "TREATMENT", 86, 105]]], ["Samples were centrifuged to clarify and the supernatant was transferred to a passivated 30 kD MWCO device (Millipore, Merck KGaA, Darmstadt, Germany) and centrifuged at 13,000g for 30 min.", [["Samples", "ANATOMY", 0, 7], ["supernatant", "ANATOMY", 44, 55], ["Samples", "TEST", 0, 7], ["a passivated 30 kD MWCO device", "TREATMENT", 75, 105]]], ["The remaining sample was buffer exchanged with 1% SDC, 100 mM Tris-HCl, pH 7.6, then alkylated with 15 mM iodoacetamide.", [["sample", "ANATOMY", 14, 20], ["Tris-HCl", "CHEMICAL", 62, 70], ["iodoacetamide", "CHEMICAL", 106, 119], ["Tris-HCl", "CHEMICAL", 62, 70], ["iodoacetamide", "CHEMICAL", 106, 119], ["SDC", "SIMPLE_CHEMICAL", 50, 53], ["Tris-HCl", "SIMPLE_CHEMICAL", 62, 70], ["iodoacetamide", "SIMPLE_CHEMICAL", 106, 119], ["pH", "TEST", 72, 74], ["15 mM iodoacetamide", "TREATMENT", 100, 119]]], ["The SDC concentration was reduced to 0.1%.", [["SDC", "SIMPLE_CHEMICAL", 4, 7], ["The SDC concentration", "TREATMENT", 0, 21]]], ["Samples were digested using trypsin at an enzyme to substrate ratio of 1:100, overnight, at 37o C in a thermo-mixer at 1,000 RPM.", [["Samples", "ANATOMY", 0, 7], ["trypsin", "GENE_OR_GENE_PRODUCT", 28, 35], ["trypsin", "PROTEIN", 28, 35], ["Samples", "TEST", 0, 7], ["trypsin", "TREATMENT", 28, 35], ["an enzyme", "TEST", 39, 48]]], ["Digested peptides were collected by centrifugation and the filter washed with 0.5 NaCl to elute electrostatically bound peptides.", [["NaCl", "CHEMICAL", 82, 86], ["NaCl", "CHEMICAL", 82, 86], ["Digested peptides", "TREATMENT", 0, 17], ["the filter", "TREATMENT", 55, 65], ["0.5 NaCl to elute electrostatically bound peptides", "TREATMENT", 78, 128], ["peptides", "OBSERVATION", 9, 17]]], ["Digested peptides were desalted using reversed phase stop-and-go extraction tips [50].", [["Digested peptides", "TREATMENT", 0, 17], ["reversed phase stop", "TREATMENT", 38, 57], ["extraction tips", "TREATMENT", 65, 80]]], ["Peptides were eluted with 80% acetonitrile, 0.5% formic acid and lyophilized in a SpeedVac (Thermo Savant, Holbrook, NY) to near dryness, approximately 1 h.Liquid chromatography-tandem mass spectrometry ::: Materials and methodsEach digestion mixture was analyzed by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS).", [["acetonitrile", "CHEMICAL", 30, 42], ["formic acid", "CHEMICAL", 49, 60], ["acetonitrile", "CHEMICAL", 30, 42], ["formic acid", "CHEMICAL", 49, 60], ["acetonitrile", "SIMPLE_CHEMICAL", 30, 42], ["formic acid", "SIMPLE_CHEMICAL", 49, 60], ["Peptides", "TEST", 0, 8], ["80% acetonitrile", "TREATMENT", 26, 42], ["formic acid", "TREATMENT", 49, 60], ["near dryness", "PROBLEM", 124, 136], ["methodsEach digestion mixture", "TREATMENT", 221, 250], ["tandem mass spectrometry", "TEST", 312, 336], ["UHPLC", "TEST", 338, 343]]], ["Mobile phase A was 97.5% MilliQ water, 2% acetonitrile, 0.5% formic acid.", [["acetonitrile", "CHEMICAL", 42, 54], ["formic acid", "CHEMICAL", 61, 72], ["acetonitrile", "CHEMICAL", 42, 54], ["formic acid", "CHEMICAL", 61, 72], ["acetonitrile", "SIMPLE_CHEMICAL", 42, 54], ["formic acid", "SIMPLE_CHEMICAL", 61, 72], ["2% acetonitrile", "TREATMENT", 39, 54], ["0.5% formic acid", "TREATMENT", 56, 72]]], ["Mobile phase B was 99.5% acetonitrile, 0.5% formic acid.", [["acetonitrile", "CHEMICAL", 25, 37], ["formic acid", "CHEMICAL", 44, 55], ["acetonitrile", "CHEMICAL", 25, 37], ["formic acid", "CHEMICAL", 44, 55], ["acetonitrile", "SIMPLE_CHEMICAL", 25, 37], ["formic acid", "SIMPLE_CHEMICAL", 44, 55], ["acetonitrile", "TREATMENT", 25, 37]]], ["The 240 min LC gradient ran from 0% B to 35% B over 210 min, then to 80% B for the remaining 30 min.", [["LC gradient", "TEST", 12, 23]]], ["Samples were loaded directly to the column.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["column", "ANATOMY", 36, 42]]], ["The column was 50 cm x 75 um I.D. and packed with 2 \u03bcm C18 media (Thermo Easy Spray PepMap).", [["The column", "TREATMENT", 0, 10], ["2 \u03bcm C18 media (Thermo Easy Spray PepMap", "TREATMENT", 50, 90], ["column", "OBSERVATION_MODIFIER", 4, 10]]], ["The LC was interfaced to a quadrupole-Orbitrap mass spectrometer (Q-Exactive, Thermo Fisher Scientific, Waltham, MA) via nano-electrospray ionization using a source with an integrated column heater (Thermo Easy Spray, Thermo Fisher Scientific, Waltham, MA).", [["nano-electrospray ionization", "TREATMENT", 121, 149], ["an integrated column heater", "TREATMENT", 170, 197], ["Thermo Easy Spray", "TREATMENT", 199, 216], ["LC", "ANATOMY", 4, 6]]], ["The column was heated to 50\u00b0C. An electrospray voltage of 2.2 kV was applied.", [["The column", "TREATMENT", 0, 10], ["An electrospray voltage", "TEST", 31, 54], ["column", "OBSERVATION_MODIFIER", 4, 10]]], ["The mass spectrometer was programmed to acquire, by data-dependent acquisition, tandem mass spectra from the top 10 ions in the full scan from 400\u20131200 m/z.", [["The mass spectrometer", "PROBLEM", 0, 21], ["tandem mass spectra", "PROBLEM", 80, 99], ["the full scan", "TEST", 124, 137], ["mass", "OBSERVATION", 4, 8]]], ["Dynamic exclusion was set to 15 s, singly-charged ions were excluded, isolation width was set to 1.6 Da, full MS resolution to 70,000 and MS/MS resolution to 17,500.", [["Dynamic exclusion", "TEST", 0, 17], ["singly-charged ions", "TREATMENT", 35, 54], ["isolation width", "TEST", 70, 85], ["MS/MS resolution", "PROBLEM", 138, 154]]], ["Normalized collision energy was set to 25, automatic gain control to 2e5, max fill MS to 20 ms, max fill MS/MS to 60 ms and the underfill ratio to 0.1%.Mass spectroscopy data processing and library searching ::: Materials and methodsMass spectrometer RAW data files were converted to mzML format using msconvert [51].", [["MS", "TEST", 108, 110], ["the underfill ratio", "TEST", 124, 143], ["Mass spectroscopy", "TEST", 152, 169]]], ["MGF files were generated from mzML using the Peak Picker HiRes tool, part of the OpenMS framework [52].", [["MGF", "GENE_OR_GENE_PRODUCT", 0, 3], ["MGF", "PROTEIN", 0, 3], ["MGF files", "TEST", 0, 9]]], ["Briefly, all searches required 10 ppm precursor mass tolerance, 0.02 Da fragment mass tolerance, strict tryptic cleavage, up to 2 missed cleavages, fixed modification of cysteine alkylation, variable modification of methionine oxidation and protein-level expectation value scores of 0.0001 or lower.", [["cysteine", "CHEMICAL", 170, 178], ["methionine", "CHEMICAL", 216, 226], ["cysteine", "CHEMICAL", 170, 178], ["methionine", "CHEMICAL", 216, 226], ["cysteine", "AMINO_ACID", 170, 178], ["methionine", "SIMPLE_CHEMICAL", 216, 226], ["Da fragment mass tolerance", "PROBLEM", 69, 95], ["strict tryptic cleavage", "TREATMENT", 97, 120], ["cysteine alkylation", "TREATMENT", 170, 189], ["methionine oxidation", "TREATMENT", 216, 236], ["protein-level expectation value scores", "TEST", 241, 279], ["cysteine alkylation", "OBSERVATION", 170, 189]]], ["Proteome Cluster builds species- and genus-specific protein sequence libraries from the most current UniProtKB distribution [53].", [["Proteome Cluster builds species", "TEST", 0, 31], ["specific protein sequence libraries", "TEST", 43, 78]]], ["MGF files were searched using the most recent protein sequence libraries available from UniProtKB using X!Tandem [54] and OMSSA [55].", [["MGF", "GENE_OR_GENE_PRODUCT", 0, 3], ["MGF", "PROTEIN", 0, 3], ["protein sequence libraries", "DNA", 46, 72]]], ["XML output files were parsed and non-redundant protein sets determined using Proteome Cluster based on previously published rules [56].", [["XML output files", "TEST", 0, 16], ["non-redundant protein sets", "PROBLEM", 33, 59]]], ["MS1-based isotopoic features were detected and peptide peak areas were calculated using the FeatureFinderCentroid tool, part of the OpenMS framework [52].", [["MS1", "PROTEIN", 0, 3], ["MS1", "TEST", 0, 3], ["based isotopoic features", "PROBLEM", 4, 28], ["peptide peak areas", "PROBLEM", 47, 65], ["the FeatureFinderCentroid tool", "TEST", 88, 118]]], ["Proteins were required to have 1 or more unique peptides across the analyzed samples with E-value scores of 0.0001 or less.Statistical analyses ::: Materials and methodsGeometric means (GM) were used as measures of central tendency.", [["samples", "ANATOMY", 77, 84], ["E-value scores", "TEST", 90, 104], ["central tendency", "PROBLEM", 215, 231], ["central tendency", "OBSERVATION", 215, 231]]], ["Data were analyzed for larval growth by multifactorial analysis of variance ANOVA with post-hoc Fisher\u2019s Least Significant Difference (LSD) testing in Systat v.11 (Systat Inc., Evanstown, IL, USA).", [["larval growth", "PROBLEM", 23, 36], ["testing", "TEST", 140, 147], ["Systat", "TEST", 151, 157]]], ["Probability values less than 0.05 were considered statistically significant.", [["Probability values", "TEST", 0, 18]]], ["All experiments were performed a minimum of 2 times.Susceptibility of collaborative cross mice to infection with O. volvulus L3 ::: ResultsTo determine if there was an underlying genetic basis for the resistance of mice to infection with O. volvulus [14], 5 mouse strains having a wide range of genetic diversity from the CC (Cast/EIJ, IL16680, AU8052, AU8049 and OR13067) [57] were screened for their susceptibility to O. volvulus.", [["infection", "DISEASE", 98, 107], ["O. volvulus", "DISEASE", 113, 124], ["infection", "DISEASE", 223, 232], ["O. volvulus", "DISEASE", 238, 249], ["CC", "CHEMICAL", 322, 324], ["OR13067", "CHEMICAL", 364, 371], ["O. volvulus", "DISEASE", 420, 431], ["mice", "ORGANISM", 90, 94], ["mice", "ORGANISM", 215, 219], ["O. volvulus", "ORGANISM", 238, 249], ["mouse", "ORGANISM", 258, 263], ["O. volvulus", "ORGANISM", 420, 431], ["mice", "SPECIES", 90, 94], ["O. volvulus", "SPECIES", 113, 124], ["mice", "SPECIES", 215, 219], ["O. volvulus", "SPECIES", 238, 249], ["mouse", "SPECIES", 258, 263], ["O. volvulus", "SPECIES", 420, 431], ["mice", "SPECIES", 90, 94], ["O. volvulus L3", "SPECIES", 113, 127], ["mice", "SPECIES", 215, 219], ["O. volvulus", "SPECIES", 238, 249], ["mouse", "SPECIES", 258, 263], ["O. volvulus", "SPECIES", 420, 431], ["mice to infection", "PROBLEM", 215, 232], ["O. volvulus", "PROBLEM", 238, 249], ["5 mouse strains", "PROBLEM", 256, 271], ["volvulus", "PROBLEM", 423, 431], ["volvulus", "OBSERVATION", 116, 124], ["volvulus", "OBSERVATION", 423, 431]]], ["Five mice from each of the different strains were infected with 100 O. volvulus L3 and necropsied at 4-weeks post infection.", [["infection", "DISEASE", 114, 123], ["mice", "ORGANISM", 5, 9], ["mice", "SPECIES", 5, 9], ["O. volvulus", "SPECIES", 68, 79], ["mice", "SPECIES", 5, 9], ["O. volvulus L3", "SPECIES", 68, 82], ["the different strains", "PROBLEM", 23, 44], ["volvulus L3", "PROBLEM", 71, 82], ["infection", "PROBLEM", 114, 123], ["volvulus", "OBSERVATION", 71, 79], ["L3", "ANATOMY", 80, 82], ["infection", "OBSERVATION", 114, 123]]], ["None of the 5 strains of CC mice tested was susceptible to infection with O. volvulus L3.Susceptibility of NSG mice to infection with O. volvulus L3 ::: ResultsTo assess the role of the mouse immune system in mediating resistance to O. volvulus, immunodeficient mouse strains were assessed for their susceptibility to infection with O. volvulus.", [["CC", "CHEMICAL", 25, 27], ["infection", "DISEASE", 59, 68], ["O. volvulus", "DISEASE", 74, 85], ["infection", "DISEASE", 119, 128], ["O. volvulus", "DISEASE", 134, 145], ["O. volvulus", "DISEASE", 233, 244], ["infection", "DISEASE", 318, 327], ["O. volvulus", "DISEASE", 333, 344], ["CC mice", "ORGANISM", 25, 32], ["O. volvulus L3", "ORGANISM", 74, 88], ["NSG mice", "ORGANISM", 107, 115], ["mouse", "ORGANISM", 186, 191], ["immune system", "ANATOMICAL_SYSTEM", 192, 205], ["O. volvulus", "ORGANISM", 233, 244], ["mouse", "ORGANISM", 262, 267], ["O. volvulus", "ORGANISM", 333, 344], ["mice", "SPECIES", 28, 32], ["O. volvulus", "SPECIES", 74, 85], ["mice", "SPECIES", 111, 115], ["O. volvulus", "SPECIES", 134, 145], ["mouse", "SPECIES", 186, 191], ["O. volvulus", "SPECIES", 233, 244], ["mouse", "SPECIES", 262, 267], ["O. volvulus", "SPECIES", 333, 344], ["mice", "SPECIES", 28, 32], ["O. volvulus L3", "SPECIES", 74, 88], ["mice", "SPECIES", 111, 115], ["O. volvulus L3", "SPECIES", 134, 148], ["mouse", "SPECIES", 186, 191], ["O. volvulus", "SPECIES", 233, 244], ["mouse", "SPECIES", 262, 267], ["O. volvulus", "SPECIES", 333, 344], ["infection", "PROBLEM", 59, 68], ["O. volvulus L3", "PROBLEM", 74, 88], ["infection", "PROBLEM", 119, 128], ["the mouse immune system", "TREATMENT", 182, 205], ["volvulus", "PROBLEM", 236, 244], ["immunodeficient mouse strains", "PROBLEM", 246, 275], ["their susceptibility to infection", "PROBLEM", 294, 327], ["volvulus", "PROBLEM", 336, 344], ["infection", "OBSERVATION", 59, 68], ["volvulus", "OBSERVATION", 77, 85], ["L3", "ANATOMY", 86, 88], ["infection", "OBSERVATION", 119, 128], ["volvulus", "OBSERVATION", 137, 145], ["volvulus", "OBSERVATION", 236, 244], ["infection", "OBSERVATION", 318, 327], ["volvulus", "OBSERVATION", 336, 344]]], ["In a preliminary set of studies, 250 O. volvulus L3 were injected into 2 NSG mice.", [["NSG mice", "ORGANISM", 73, 81], ["O. volvulus", "SPECIES", 37, 48], ["mice", "SPECIES", 77, 81], ["O. volvulus L3", "SPECIES", 37, 51], ["mice", "SPECIES", 77, 81], ["studies", "TEST", 24, 31], ["volvulus L3", "PROBLEM", 40, 51], ["L3", "ANATOMY", 49, 51]]], ["After 4-weeks the skin and muscle from the mice was divided into 100 anatomically distinct sections and qPCR for O-150 was performed on extracted DNA from each section.", [["skin", "ANATOMY", 18, 22], ["muscle", "ANATOMY", 27, 33], ["sections", "ANATOMY", 91, 99], ["O-150", "CHEMICAL", 113, 118], ["skin", "ORGAN", 18, 22], ["muscle", "ORGAN", 27, 33], ["mice", "ORGANISM", 43, 47], ["O-150", "SIMPLE_CHEMICAL", 113, 118], ["DNA", "CELLULAR_COMPONENT", 146, 149], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["qPCR", "TEST", 104, 108], ["skin", "ANATOMY", 18, 22], ["muscle", "ANATOMY", 27, 33]]], ["Twenty-three of the sections were positive from, spatially widespread regions of the body.", [["sections", "ANATOMY", 20, 28], ["body", "ANATOMY", 85, 89], ["sections", "CANCER", 20, 28], ["body", "ORGANISM_SUBDIVISION", 85, 89], ["the sections", "TEST", 16, 28], ["positive", "OBSERVATION", 34, 42], ["spatially", "OBSERVATION_MODIFIER", 49, 58], ["widespread", "OBSERVATION_MODIFIER", 59, 69], ["body", "ANATOMY", 85, 89]]], ["It was concluded that parasites survived in NSG mice and had the ability to migrate extensively.", [["NSG mice", "ORGANISM", 44, 52], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["parasites", "PROBLEM", 22, 31]]], ["This indicated that all regions of the mice had to be inspected for the presence of parasites following infection.Susceptibility of NSG mice to infection with O. volvulus L3 ::: ResultsNSG mice were infected with 100 O. volvulus L3 and necropsied at 4- and 8-weeks following infection.", [["infection", "DISEASE", 104, 113], ["infection", "DISEASE", 144, 153], ["infection", "DISEASE", 275, 284], ["mice", "ORGANISM", 39, 43], ["NSG mice", "ORGANISM", 132, 140], ["O. volvulus L3", "ORGANISM", 159, 173], ["ResultsNSG mice", "ORGANISM", 178, 193], ["mice", "SPECIES", 39, 43], ["mice", "SPECIES", 136, 140], ["O. volvulus", "SPECIES", 159, 170], ["mice", "SPECIES", 189, 193], ["O. volvulus", "SPECIES", 217, 228], ["mice", "SPECIES", 39, 43], ["mice", "SPECIES", 136, 140], ["O. volvulus L3", "SPECIES", 159, 173], ["mice", "SPECIES", 189, 193], ["O. volvulus L3", "SPECIES", 217, 231], ["parasites", "PROBLEM", 84, 93], ["infection", "PROBLEM", 104, 113], ["infection", "PROBLEM", 144, 153], ["volvulus L3", "PROBLEM", 220, 231], ["infection", "PROBLEM", 275, 284], ["parasites", "OBSERVATION", 84, 93], ["infection", "OBSERVATION", 104, 113], ["infection", "OBSERVATION", 144, 153], ["volvulus", "OBSERVATION", 162, 170], ["L3", "ANATOMY", 171, 173], ["volvulus", "OBSERVATION", 220, 228], ["L3", "ANATOMY", 229, 231], ["infection", "OBSERVATION", 275, 284]]], ["Infected mice had an established infection rate of 63% with a GM worm recovery of 2.0 (range 1 to 4) worms recovered at 4-weeks following infection.", [["infection", "DISEASE", 33, 42], ["GM", "CHEMICAL", 62, 64], ["infection", "DISEASE", 138, 147], ["mice", "ORGANISM", 9, 13], ["mice", "SPECIES", 9, 13], ["worms", "SPECIES", 101, 106], ["mice", "SPECIES", 9, 13], ["infection rate", "TEST", 33, 47], ["a GM worm recovery", "TEST", 60, 78], ["infection", "PROBLEM", 138, 147], ["infection", "OBSERVATION", 33, 42], ["infection", "OBSERVATION", 138, 147]]], ["At 8-weeks, 75% of mice had an established infection, with a GM recovery of 1.4 (range 1 to 3) worms per mouse (Fig 1A).", [["infection", "DISEASE", 43, 52], ["GM", "CHEMICAL", 61, 63], ["mice", "ORGANISM", 19, 23], ["mouse", "ORGANISM", 105, 110], ["mice", "SPECIES", 19, 23], ["worms", "SPECIES", 95, 100], ["mouse", "SPECIES", 105, 110], ["mice", "SPECIES", 19, 23], ["mouse", "SPECIES", 105, 110], ["an established infection", "PROBLEM", 28, 52], ["a GM recovery", "TEST", 59, 72], ["infection", "OBSERVATION", 43, 52]]], ["The recovered worms were measured and found to be significantly increased in size (p<0.0001; Min: 677 \u03bcm, Max 843 \u03bcm, GM: 717 \u03bcm) at 4-weeks compared to L3.", [["worms", "ANATOMY", 14, 19], ["worms", "ORGANISM", 14, 19], ["worms", "SPECIES", 14, 19], ["Max", "TEST", 106, 109], ["GM", "TEST", 118, 120], ["significantly", "OBSERVATION_MODIFIER", 50, 63], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["size", "OBSERVATION_MODIFIER", 77, 81], ["L3", "ANATOMY", 153, 155]]], ["They also significantly increased in size between 4 and 8 weeks (p<0.0001) reaching a maximum of 1,085 \u03bcm (Min: 700 \u03bcm, GM: 1034 \u03bcm) (Fig 2).Susceptibility of NSG mice after receiving single human-cell xenografts ::: ResultsBecause of the species-specific infectivity of O. volvulus (humans and primates), we next examined the ability of nutrients or growth factors from human cells to promote the growth and maturation of the parasite.", [["cell xenografts", "ANATOMY", 197, 212], ["cells", "ANATOMY", 377, 382], ["O. volvulus", "DISEASE", 271, 282], ["NSG mice", "ORGANISM", 159, 167], ["human", "ORGANISM", 191, 196], ["-cell xenografts", "CANCER", 196, 212], ["O. volvulus", "ORGANISM", 271, 282], ["humans", "ORGANISM", 284, 290], ["human", "ORGANISM", 371, 376], ["cells", "CELL", 377, 382], ["growth factors", "PROTEIN", 351, 365], ["human cells", "CELL_TYPE", 371, 382], ["mice", "SPECIES", 163, 167], ["human", "SPECIES", 191, 196], ["O. volvulus", "SPECIES", 271, 282], ["humans", "SPECIES", 284, 290], ["human", "SPECIES", 371, 376], ["mice", "SPECIES", 163, 167], ["human", "SPECIES", 191, 196], ["O. volvulus", "SPECIES", 271, 282], ["humans", "SPECIES", 284, 290], ["human", "SPECIES", 371, 376], ["GM", "TEST", 120, 122], ["Fig", "TEST", 134, 137], ["single human-cell xenografts", "TREATMENT", 184, 212], ["the species", "PROBLEM", 235, 246], ["O. volvulus", "PROBLEM", 271, 282], ["human cells", "TREATMENT", 371, 382], ["significantly", "OBSERVATION_MODIFIER", 10, 23], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["size", "OBSERVATION_MODIFIER", 37, 41], ["volvulus", "OBSERVATION", 274, 282]]], ["Human cells were selected for study based on the anatomical niche they typically inhabit that would parallel the niches of O. volvulus in humans.", [["cells", "ANATOMY", 6, 11], ["O. volvulus", "DISEASE", 123, 134], ["Human", "ORGANISM", 0, 5], ["cells", "CELL", 6, 11], ["O. volvulus", "ORGANISM", 123, 134], ["humans", "ORGANISM", 138, 144], ["Human cells", "CELL_TYPE", 0, 11], ["Human", "SPECIES", 0, 5], ["O. volvulus", "SPECIES", 123, 134], ["humans", "SPECIES", 138, 144], ["Human", "SPECIES", 0, 5], ["O. volvulus", "SPECIES", 123, 134], ["humans", "SPECIES", 138, 144], ["Human cells", "TREATMENT", 0, 11], ["study", "TEST", 30, 35], ["volvulus in humans", "PROBLEM", 126, 144], ["volvulus", "OBSERVATION", 126, 134]]], ["Luciferin labeled HuSkMc cells injected into NSG mice had a life span of approximately one week based on in vivo imaging.", [["HuSkMc cells", "ANATOMY", 18, 30], ["Luciferin", "CHEMICAL", 0, 9], ["Luciferin", "CHEMICAL", 0, 9], ["Luciferin", "SIMPLE_CHEMICAL", 0, 9], ["HuSkMc cells", "CELL", 18, 30], ["NSG mice", "ORGANISM", 45, 53], ["Luciferin labeled HuSkMc cells", "CELL_LINE", 0, 30], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 49, 53], ["Luciferin labeled HuSkMc cells", "TREATMENT", 0, 30], ["vivo imaging", "TEST", 108, 120]]], ["Thus, NSG mice received weekly injections of BESM, LEC, HaCaT, or HuSkMc cells.", [["LEC", "ANATOMY", 51, 54], ["HaCaT", "ANATOMY", 56, 61], ["HuSkMc cells", "ANATOMY", 66, 78], ["NSG mice", "ORGANISM", 6, 14], ["BESM", "CELL", 45, 49], ["LEC", "CELL", 51, 54], ["HaCaT", "CELL", 56, 61], ["HuSkMc cells", "CELL", 66, 78], ["BESM, LEC, HaCaT, or HuSkMc cells", "CELL_LINE", 45, 78], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 10, 14], ["BESM", "TREATMENT", 45, 49], ["HuSkMc cells", "PROBLEM", 66, 78], ["HaCaT", "ANATOMY", 56, 61]]], ["Mice were injected with 100 O. volvulus L3 immediately after the cell inoculations.", [["cell", "ANATOMY", 65, 69], ["Mice", "ORGANISM", 0, 4], ["cell", "CELL", 65, 69], ["Mice", "SPECIES", 0, 4], ["volvulus L3", "PROBLEM", 31, 42], ["the cell inoculations", "TREATMENT", 61, 82], ["volvulus", "OBSERVATION", 31, 39], ["L3", "ANATOMY", 40, 42], ["cell inoculations", "OBSERVATION", 65, 82]]], ["At 4-weeks post-inoculation of the L3, 60% of BESM cell engrafted mice established O. volvulus infection with a GM recovery of 1 worm per mouse with a maximum of 1 worm/mouse recovered (S1 Table).", [["BESM cell", "ANATOMY", 46, 55], ["O. volvulus infection", "DISEASE", 83, 104], ["GM", "CHEMICAL", 112, 114], ["BESM cell", "CELL", 46, 55], ["mice", "ORGANISM", 66, 70], ["O. volvulus", "ORGANISM", 83, 94], ["mouse", "ORGANISM", 138, 143], ["mouse", "ORGANISM", 169, 174], ["mice", "SPECIES", 66, 70], ["O. volvulus", "SPECIES", 83, 94], ["mouse", "SPECIES", 138, 143], ["mouse", "SPECIES", 169, 174], ["mice", "SPECIES", 66, 70], ["O. volvulus", "SPECIES", 83, 94], ["mouse", "SPECIES", 138, 143], ["mouse", "SPECIES", 169, 174], ["BESM cell engrafted mice", "TREATMENT", 46, 70], ["volvulus infection", "PROBLEM", 86, 104], ["L3", "ANATOMY", 35, 37], ["cell engrafted", "OBSERVATION", 51, 65], ["volvulus", "OBSERVATION", 86, 94]]], ["Mice engrafted with LEC had 20% established infection and GM of 4 worms recovered per mouse with a range of 1 to 4 worms per mouse (S1 Table).", [["LEC", "ANATOMY", 20, 23], ["infection", "DISEASE", 44, 53], ["GM", "CHEMICAL", 58, 60], ["Mice", "ORGANISM", 0, 4], ["LEC", "CELL", 20, 23], ["mouse", "ORGANISM", 86, 91], ["mouse", "ORGANISM", 125, 130], ["Mice", "SPECIES", 0, 4], ["worms", "SPECIES", 66, 71], ["mouse", "SPECIES", 86, 91], ["worms", "SPECIES", 115, 120], ["mouse", "SPECIES", 125, 130], ["mouse", "SPECIES", 86, 91], ["mouse", "SPECIES", 125, 130], ["20% established infection", "PROBLEM", 28, 53], ["infection", "OBSERVATION", 44, 53]]], ["HaCaT cell engrafted mice had a 60% established infection and GM recovery 1.7 worms recovered per mouse with between 1 and 2 worms per mouse (S1 Table).", [["HaCaT cell", "ANATOMY", 0, 10], ["infection", "DISEASE", 48, 57], ["GM", "CHEMICAL", 62, 64], ["HaCaT cell", "CELL", 0, 10], ["mice", "ORGANISM", 21, 25], ["mouse", "ORGANISM", 98, 103], ["mouse", "ORGANISM", 135, 140], ["HaCaT cell", "CELL_LINE", 0, 10], ["mice", "SPECIES", 21, 25], ["worms", "SPECIES", 78, 83], ["mouse", "SPECIES", 98, 103], ["worms", "SPECIES", 125, 130], ["mouse", "SPECIES", 135, 140], ["mice", "SPECIES", 21, 25], ["mouse", "SPECIES", 98, 103], ["mouse", "SPECIES", 135, 140], ["a 60% established infection", "PROBLEM", 30, 57], ["cell engrafted", "OBSERVATION", 6, 20], ["infection", "OBSERVATION", 48, 57]]], ["HuSkMc cell engrafted mice had an 81% established O. volvulus infection rate at 4-weeks post-infection and GM recovery 2.4 worms recovered per mouse with between 1 and 8 per mouse.", [["HuSkMc cell", "ANATOMY", 0, 11], ["O. volvulus infection", "DISEASE", 50, 71], ["GM", "CHEMICAL", 107, 109], ["HuSkMc cell", "CELL", 0, 11], ["mice", "ORGANISM", 22, 26], ["O. volvulus", "ORGANISM", 50, 61], ["mouse", "ORGANISM", 143, 148], ["mouse", "ORGANISM", 174, 179], ["mice", "SPECIES", 22, 26], ["O. volvulus", "SPECIES", 50, 61], ["worms", "SPECIES", 123, 128], ["mouse", "SPECIES", 143, 148], ["mouse", "SPECIES", 174, 179], ["mice", "SPECIES", 22, 26], ["O. volvulus", "SPECIES", 50, 61], ["mouse", "SPECIES", 143, 148], ["mouse", "SPECIES", 174, 179], ["volvulus infection rate", "PROBLEM", 53, 76], ["GM recovery", "TEST", 107, 118], ["volvulus", "OBSERVATION_MODIFIER", 53, 61], ["infection", "OBSERVATION", 62, 71]]], ["Based on the enhanced survival of O. volvulus in mice engrafted with HuSkMc cells, extended infections were evaluated.", [["HuSkMc cells", "ANATOMY", 69, 81], ["O. volvulus", "DISEASE", 34, 45], ["infections", "DISEASE", 92, 102], ["O. volvulus", "ORGANISM", 34, 45], ["mice", "ORGANISM", 49, 53], ["HuSkMc cells", "CELL", 69, 81], ["HuSkMc cells", "CELL_LINE", 69, 81], ["O. volvulus", "SPECIES", 34, 45], ["mice", "SPECIES", 49, 53], ["O. volvulus", "SPECIES", 34, 45], ["mice", "SPECIES", 49, 53], ["volvulus", "PROBLEM", 37, 45], ["HuSkMc cells", "PROBLEM", 69, 81], ["extended infections", "PROBLEM", 83, 102], ["volvulus", "OBSERVATION", 37, 45], ["infections", "OBSERVATION", 92, 102]]], ["At 8-weeks post-infection, mice with HuSkMc cells had a 58% established infection rate with a GM parasite recovery of 1.4 with a range of 1 to 3 per mouse.", [["HuSkMc cells", "ANATOMY", 37, 49], ["infection", "DISEASE", 16, 25], ["infection", "DISEASE", 72, 81], ["GM", "CHEMICAL", 94, 96], ["mice", "ORGANISM", 27, 31], ["HuSkMc cells", "CELL", 37, 49], ["mouse", "ORGANISM", 149, 154], ["HuSkMc cells", "CELL_LINE", 37, 49], ["mice", "SPECIES", 27, 31], ["mouse", "SPECIES", 149, 154], ["mice", "SPECIES", 27, 31], ["mouse", "SPECIES", 149, 154], ["post-infection", "PROBLEM", 11, 25], ["HuSkMc cells", "PROBLEM", 37, 49], ["a GM parasite recovery", "TEST", 92, 114], ["infection", "OBSERVATION", 16, 25], ["infection", "OBSERVATION", 72, 81]]], ["At 12-weeks post-infection, 80% of the mice had established infections at recovery with a GM parasite recovery of 1.6 with 1 to 3 per mouse (Fig 1B).", [["infection", "DISEASE", 17, 26], ["infections", "DISEASE", 60, 70], ["GM", "CHEMICAL", 90, 92], ["mice", "ORGANISM", 39, 43], ["mouse", "ORGANISM", 134, 139], ["mice", "SPECIES", 39, 43], ["mouse", "SPECIES", 134, 139], ["mice", "SPECIES", 39, 43], ["mouse", "SPECIES", 134, 139], ["infection", "PROBLEM", 17, 26], ["established infections", "PROBLEM", 48, 70], ["a GM parasite recovery", "TEST", 88, 110], ["infection", "OBSERVATION", 17, 26], ["infections", "OBSERVATION", 60, 70]]], ["At each time point tested the parasites in HuSkMc-engrafted mice demonstrated continued parasite growth.", [["HuSkMc", "GENE_OR_GENE_PRODUCT", 43, 49], ["mice", "ORGANISM", 60, 64], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 60, 64], ["the parasites", "TEST", 26, 39], ["HuSkMc", "TEST", 43, 49], ["continued parasite growth", "PROBLEM", 78, 103], ["parasite growth", "OBSERVATION", 88, 103]]], ["At 4-weeks recovered parasites had GM lengths of 713 \u03bcm (Min: 592 \u03bcm, Max: 788 \u03bcm), at 8-weeks lengths of 751 \u03bcm (Min: 642 \u03bcm, Max: 1,081 \u03bcm), and at 12-weeks the GM length was 1,121 \u03bcm with a maximum length of 2,086 \u03bcm observed (Min: 748 \u03bcm), representing a 4-fold increase in length over L3 (Fig 2).", [["GM", "CHEMICAL", 35, 37], ["GM", "CHEMICAL", 163, 165], ["Max", "TEST", 127, 130], ["the GM length", "TEST", 159, 172], ["a maximum length", "TEST", 191, 207], ["a 4-fold increase in length", "PROBLEM", 257, 284], ["increase", "OBSERVATION_MODIFIER", 266, 274], ["length", "OBSERVATION_MODIFIER", 278, 284]]], ["These growth rates represented significant changes between L3 and 4-week worms (p = 0.0010) and between 8- and 12-week worms (p<0.0001).Susceptibility of NSG mice hosting multiple human cell types ::: ResultsSGM, NRG and NSG (HuNSG) mice humanized with CD34+ umbilical cord derived stem cells were infected with 100 O. volvulus L3.", [["cell", "ANATOMY", 186, 190], ["CD34+ umbilical cord derived stem cells", "ANATOMY", 253, 292], ["NSG mice", "ORGANISM", 154, 162], ["human", "ORGANISM", 180, 185], ["cell", "CELL", 186, 190], ["ResultsSGM", "CELL", 201, 211], ["NRG", "GENE_OR_GENE_PRODUCT", 213, 216], ["NSG (HuNSG)", "ORGANISM", 221, 232], ["mice", "ORGANISM", 233, 237], ["CD34", "GENE_OR_GENE_PRODUCT", 253, 257], ["cord derived stem cells", "CELL", 269, 292], ["ResultsSGM", "PROTEIN", 201, 211], ["NRG", "PROTEIN", 213, 216], ["CD34", "PROTEIN", 253, 257], ["umbilical cord derived stem cells", "CELL_TYPE", 259, 292], ["worms", "SPECIES", 73, 78], ["worms", "SPECIES", 119, 124], ["mice", "SPECIES", 158, 162], ["human", "SPECIES", 180, 185], ["mice", "SPECIES", 233, 237], ["O. volvulus", "SPECIES", 316, 327], ["mice", "SPECIES", 158, 162], ["human", "SPECIES", 180, 185], ["mice", "SPECIES", 233, 237], ["O. volvulus L3", "SPECIES", 316, 330], ["These growth rates", "TEST", 0, 18], ["significant changes between L3 and 4", "PROBLEM", 31, 67], ["ResultsSGM", "TEST", 201, 211], ["NSG (HuNSG)", "TREATMENT", 221, 232], ["CD34+ umbilical cord derived stem cells", "TREATMENT", 253, 292], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["L3", "ANATOMY", 59, 61], ["multiple", "OBSERVATION_MODIFIER", 171, 179], ["human cell", "OBSERVATION", 180, 190], ["umbilical cord", "ANATOMY", 259, 273], ["stem cells", "OBSERVATION", 282, 292], ["L3", "ANATOMY", 328, 330]]], ["Each of these humanized mice had human hematopoietic lineage cells at a concentration greater than 600 cells per \u03bcl of blood.", [["hematopoietic lineage cells", "ANATOMY", 39, 66], ["cells", "ANATOMY", 103, 108], ["blood", "ANATOMY", 119, 124], ["mice", "ORGANISM", 24, 28], ["human", "ORGANISM", 33, 38], ["hematopoietic lineage cells", "CELL", 39, 66], ["cells", "CELL", 103, 108], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["human hematopoietic lineage cells", "CELL_TYPE", 33, 66], ["mice", "SPECIES", 24, 28], ["human", "SPECIES", 33, 38], ["mice", "SPECIES", 24, 28], ["human", "SPECIES", 33, 38], ["human hematopoietic lineage cells", "TREATMENT", 33, 66], ["hematopoietic lineage cells", "OBSERVATION", 39, 66]]], ["While a complete picture of the cell populations in these specific mice was not determined, based upon flow analysis during the screening process all humanized mice had both human B and T-cells present in their blood.", [["cell", "ANATOMY", 32, 36], ["B", "ANATOMY", 180, 181], ["T-cells", "ANATOMY", 186, 193], ["blood", "ANATOMY", 211, 216], ["cell populations", "CELL", 32, 48], ["mice", "ORGANISM", 67, 71], ["mice", "ORGANISM", 160, 164], ["human", "ORGANISM", 174, 179], ["B", "CELL", 180, 181], ["T-cells", "CELL", 186, 193], ["blood", "ORGANISM_SUBSTANCE", 211, 216], ["human B and T-cells", "CELL_TYPE", 174, 193], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 160, 164], ["human", "SPECIES", 174, 179], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 160, 164], ["human", "SPECIES", 174, 179], ["the cell populations", "PROBLEM", 28, 48], ["flow analysis", "TEST", 103, 116], ["the screening process", "TEST", 124, 145], ["cell populations", "OBSERVATION", 32, 48]]], ["At 4-weeks post-infection humanized SGM mice contained a GM of 2.4 (range 1\u20137) worms/mouse, humanized NRG mice had a GM of 1.7 (range 1 to 4) worms/mouse (S1 Table).", [["GM", "CHEMICAL", 57, 59], ["GM", "CHEMICAL", 117, 119], ["SGM", "ORGANISM", 36, 39], ["mice", "ORGANISM", 40, 44], ["mouse", "ORGANISM", 85, 90], ["NRG mice", "ORGANISM", 102, 110], ["mouse", "ORGANISM", 148, 153], ["NRG", "PROTEIN", 102, 105], ["mice", "SPECIES", 40, 44], ["worms", "SPECIES", 79, 84], ["mouse", "SPECIES", 85, 90], ["mice", "SPECIES", 106, 110], ["worms", "SPECIES", 142, 147], ["mouse", "SPECIES", 148, 153], ["mice", "SPECIES", 40, 44], ["mouse", "SPECIES", 85, 90], ["mice", "SPECIES", 106, 110], ["mouse", "SPECIES", 148, 153], ["a GM", "TEST", 55, 59], ["a GM", "TEST", 115, 119]]], ["HuNSG at 4-weeks post-infection had a 69% established infection rate with a GM of 3.4 (range 1\u201314) worms/mouse, and at 8-weeks post infection HuNSG mice had a 46% established infection rate and a GM of 2.6 (range 1\u201318) worms/mouse (Fig 1C).", [["HuNSG", "CHEMICAL", 0, 5], ["infection", "DISEASE", 54, 63], ["GM", "CHEMICAL", 76, 78], ["infection", "DISEASE", 132, 141], ["infection", "DISEASE", 175, 184], ["GM", "CHEMICAL", 196, 198], ["mouse", "ORGANISM", 105, 110], ["mice", "ORGANISM", 148, 152], ["mouse", "ORGANISM", 225, 230], ["worms", "SPECIES", 99, 104], ["mouse", "SPECIES", 105, 110], ["mice", "SPECIES", 148, 152], ["worms", "SPECIES", 219, 224], ["mouse", "SPECIES", 225, 230], ["mouse", "SPECIES", 105, 110], ["mice", "SPECIES", 148, 152], ["mouse", "SPECIES", 225, 230], ["a GM", "TEST", 74, 78], ["infection", "PROBLEM", 132, 141], ["infection rate", "TEST", 175, 189], ["a GM", "TEST", 194, 198], ["infection", "OBSERVATION", 54, 63]]], ["Larval growth in HuNSG mice was comparable to that seen in NSG and in NSG mice engrafted with HuSkMc (Fig 2).", [["NSG", "ANATOMY", 59, 62], ["HuNSG mice", "ORGANISM", 17, 27], ["NSG", "CANCER", 59, 62], ["NSG mice", "ORGANISM", 70, 78], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 74, 78], ["growth", "OBSERVATION_MODIFIER", 7, 13]]], ["A significant increase in length was seen between the L3 and 4-week recovery (p<0.0001, Min: 395 \u03bcm, Max: 886 \u03bcm, GM: 627 \u03bcm), but no significant changes were seen between 4- and 8-weeks (Min: 440 \u03bcm, Max: 886 \u03bcm, GM: 678 \u03bcm) following infection.Susceptibility of NSG mice hosting multiple human cell types ::: ResultsBLT mice humanized with fetal thymus, liver and CD34+ stem cells, which display an enhanced repertoire of the developing human cells [58], were infected with 100 O. volvulus L3 and then necropsied at 4- and 8-weeks post infection.", [["cell", "ANATOMY", 296, 300], ["fetal thymus", "ANATOMY", 342, 354], ["liver", "ANATOMY", 356, 361], ["CD34+ stem cells", "ANATOMY", 366, 382], ["cells", "ANATOMY", 445, 450], ["infection", "DISEASE", 236, 245], ["infection", "DISEASE", 538, 547], ["NSG mice", "ORGANISM", 264, 272], ["human", "ORGANISM", 290, 295], ["cell", "CELL", 296, 300], ["mice", "ORGANISM", 322, 326], ["fetal thymus", "MULTI-TISSUE_STRUCTURE", 342, 354], ["liver", "ORGAN", 356, 361], ["CD34", "GENE_OR_GENE_PRODUCT", 366, 370], ["human", "ORGANISM", 439, 444], ["cells", "CELL", 445, 450], ["liver and CD34+ stem cells", "CELL_TYPE", 356, 382], ["developing human cells", "CELL_TYPE", 428, 450], ["mice", "SPECIES", 268, 272], ["human", "SPECIES", 290, 295], ["mice", "SPECIES", 322, 326], ["human", "SPECIES", 439, 444], ["O. volvulus", "SPECIES", 480, 491], ["mice", "SPECIES", 268, 272], ["human", "SPECIES", 290, 295], ["mice", "SPECIES", 322, 326], ["human", "SPECIES", 439, 444], ["O. volvulus L3", "SPECIES", 480, 494], ["A significant increase in length", "PROBLEM", 0, 32], ["Max", "TEST", 101, 104], ["GM", "TEST", 114, 116], ["significant changes", "PROBLEM", 134, 153], ["GM", "TEST", 214, 216], ["infection", "PROBLEM", 236, 245], ["the developing human cells", "PROBLEM", 424, 450], ["volvulus L3", "PROBLEM", 483, 494], ["infection", "PROBLEM", 538, 547], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["length", "OBSERVATION_MODIFIER", 26, 32], ["L3", "ANATOMY", 54, 56], ["no", "UNCERTAINTY", 131, 133], ["significant", "OBSERVATION_MODIFIER", 134, 145], ["changes", "OBSERVATION", 146, 153], ["infection", "OBSERVATION", 236, 245], ["human cell types", "OBSERVATION", 290, 306], ["thymus", "ANATOMY", 348, 354], ["liver", "ANATOMY", 356, 361], ["CD34", "ANATOMY", 366, 370], ["stem cells", "OBSERVATION", 372, 382], ["human cells", "OBSERVATION", 439, 450], ["volvulus", "OBSERVATION", 483, 491], ["L3", "ANATOMY", 492, 494], ["infection", "OBSERVATION", 538, 547]]], ["At 4-weeks post infection BLT mice had an established infection rate of 77% with a GM of 4.8 (range 2\u201310) worms/mouse.", [["infection", "DISEASE", 16, 25], ["infection", "DISEASE", 54, 63], ["GM", "CHEMICAL", 83, 85], ["BLT", "ORGANISM", 26, 29], ["mice", "ORGANISM", 30, 34], ["mouse", "ORGANISM", 112, 117], ["mice", "SPECIES", 30, 34], ["worms", "SPECIES", 106, 111], ["mouse", "SPECIES", 112, 117], ["mice", "SPECIES", 30, 34], ["mouse", "SPECIES", 112, 117], ["infection", "PROBLEM", 16, 25], ["an established infection rate", "TEST", 39, 68], ["a GM", "TEST", 81, 85], ["infection", "OBSERVATION", 54, 63]]], ["At 8-weeks post infection BLT mice had an established infection rate of 60% with a GM of 2.3 (range 2\u20133) worms/mouse (Fig 1D).", [["infection", "DISEASE", 16, 25], ["infection", "DISEASE", 54, 63], ["GM", "CHEMICAL", 83, 85], ["BLT", "ORGANISM", 26, 29], ["mice", "ORGANISM", 30, 34], ["mouse", "ORGANISM", 111, 116], ["mice", "SPECIES", 30, 34], ["worms", "SPECIES", 105, 110], ["mouse", "SPECIES", 111, 116], ["mice", "SPECIES", 30, 34], ["mouse", "SPECIES", 111, 116], ["infection", "PROBLEM", 16, 25], ["infection rate", "TEST", 54, 68], ["a GM", "TEST", 81, 85], ["infection", "OBSERVATION", 54, 63]]], ["Growth of the parasites was equivalent to that seen in the NSG mice and the other humanized models with the maximum length reaching 1,080 \u03bcm at 4-weeks (Min: 391 \u03bcm, GM: 623 \u03bcm) and 1,448 \u03bcm at 8-weeks (Min: 730 \u03bcm, GM: 949 \u03bcm) (Fig 2).", [["NSG mice", "ORGANISM", 59, 67], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 63, 67], ["the maximum length", "TEST", 104, 122], ["parasites", "OBSERVATION", 14, 23], ["maximum", "OBSERVATION_MODIFIER", 108, 115], ["length", "OBSERVATION_MODIFIER", 116, 122]]], ["The overall growth was significant between the L3 and worms 4-weeks post infection (p<0.0001) and between worms recovered at the 4- and 8-week time points (p<0.0001).Localization of parasites within the murine host ::: ResultsDuring necropsy, mice were sectioned into 4 groupings: upper muscles, lower muscles, skin, and the complete set of internal organs.", [["upper muscles", "ANATOMY", 281, 294], ["lower muscles", "ANATOMY", 296, 309], ["skin", "ANATOMY", 311, 315], ["organs", "ANATOMY", 350, 356], ["infection", "DISEASE", 73, 82], ["worms", "ORGANISM", 106, 111], ["murine", "ORGANISM", 203, 209], ["mice", "ORGANISM", 243, 247], ["upper muscles", "ORGANISM_SUBDIVISION", 281, 294], ["lower muscles", "ORGANISM_SUBDIVISION", 296, 309], ["skin", "ORGAN", 311, 315], ["organs", "ORGAN", 350, 356], ["worms", "SPECIES", 54, 59], ["worms", "SPECIES", 106, 111], ["murine", "SPECIES", 203, 209], ["mice", "SPECIES", 243, 247], ["mice", "SPECIES", 243, 247], ["infection", "PROBLEM", 73, 82], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["growth", "OBSERVATION_MODIFIER", 12, 18], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["L3", "ANATOMY", 47, 49], ["infection", "OBSERVATION", 73, 82], ["parasites", "OBSERVATION", 182, 191], ["upper muscles", "ANATOMY", 281, 294], ["lower muscles", "ANATOMY", 296, 309], ["skin", "ANATOMY", 311, 315], ["internal organs", "ANATOMY", 341, 356]]], ["No nodules were found in any of these tissues upon necropsy.", [["nodules", "ANATOMY", 3, 10], ["tissues", "ANATOMY", 38, 45], ["nodules", "CANCER", 3, 10], ["tissues", "TISSUE", 38, 45], ["nodules", "PROBLEM", 3, 10], ["necropsy", "TEST", 51, 59], ["nodules", "OBSERVATION", 3, 10], ["necropsy", "OBSERVATION", 51, 59]]], ["Worms were recovered from all four of the different tissue groupings with no apparent preference for any region of the animal in all of the mice tested.Morphology ::: ResultsDetailed morphological analyses focused on worms recovered from BLT mice infected for 8-weeks and HuSkMc humanized mice infected for 12-weeks.", [["tissue", "ANATOMY", 52, 58], ["Worms", "CELL", 0, 5], ["tissue", "TISSUE", 52, 58], ["mice", "ORGANISM", 140, 144], ["worms", "ORGANISM", 217, 222], ["BLT mice", "ORGANISM", 238, 246], ["mice", "ORGANISM", 289, 293], ["mice", "SPECIES", 140, 144], ["worms", "SPECIES", 217, 222], ["mice", "SPECIES", 242, 246], ["mice", "SPECIES", 289, 293], ["mice", "SPECIES", 140, 144], ["mice", "SPECIES", 242, 246], ["mice", "SPECIES", 289, 293], ["HuSkMc humanized mice infected", "TREATMENT", 272, 302]]], ["Although there were clear differences in lengths of these worms, their morphological characteristics were similar.", [["worms", "SPECIES", 58, 63], ["clear", "OBSERVATION_MODIFIER", 20, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37], ["lengths", "OBSERVATION_MODIFIER", 41, 48], ["similar", "OBSERVATION_MODIFIER", 106, 113]]], ["No differences in the ratio of males and female worms recovered from the mice was observed, however it was noted that most of the longer worms were females.Morphology ::: ResultsBoth the anterior and posterior ends in both sexes were bluntly rounded and only slightly tapered (Fig 3A, 3B and 3F).", [["anterior", "ANATOMY", 187, 195], ["female worms", "ORGANISM", 41, 53], ["mice", "ORGANISM", 73, 77], ["anterior", "MULTI-TISSUE_STRUCTURE", 187, 195], ["posterior ends", "MULTI-TISSUE_STRUCTURE", 200, 214], ["worms", "SPECIES", 48, 53], ["mice", "SPECIES", 73, 77], ["worms", "SPECIES", 137, 142], ["mice", "SPECIES", 73, 77], ["differences", "OBSERVATION_MODIFIER", 3, 14], ["anterior", "ANATOMY_MODIFIER", 187, 195], ["posterior", "ANATOMY_MODIFIER", 200, 209], ["ends", "ANATOMY_MODIFIER", 210, 214], ["both", "ANATOMY_MODIFIER", 218, 222], ["sexes", "ANATOMY_MODIFIER", 223, 228], ["rounded", "OBSERVATION_MODIFIER", 242, 249], ["slightly", "OBSERVATION_MODIFIER", 259, 267], ["tapered", "OBSERVATION_MODIFIER", 268, 275]]], ["Other than growth in length, the major change from L3 was development of the reproductive systems.", [["the reproductive systems", "PROBLEM", 73, 97], ["growth", "OBSERVATION_MODIFIER", 11, 17], ["length", "OBSERVATION_MODIFIER", 21, 27], ["major", "OBSERVATION_MODIFIER", 33, 38], ["change", "OBSERVATION", 39, 45], ["L3", "ANATOMY", 51, 53]]], ["In the L3, both the female and male systems are rudimentary genital primordia consisting of only several cells.", [["genital primordia", "ANATOMY", 60, 77], ["cells", "ANATOMY", 105, 110], ["genital primordia", "MULTI-TISSUE_STRUCTURE", 60, 77], ["cells", "CELL", 105, 110], ["rudimentary genital primordia", "PROBLEM", 48, 77], ["L3", "ANATOMY", 7, 9], ["both", "ANATOMY_MODIFIER", 11, 15], ["female", "OBSERVATION", 20, 26], ["rudimentary", "OBSERVATION", 48, 59], ["genital primordia", "OBSERVATION", 60, 77], ["several cells", "OBSERVATION", 97, 110]]], ["In the 8-12-week old worms, the female ovejector had formed and had attached to the body wall.", [["body wall", "ANATOMY", 84, 93], ["worms", "ORGANISM", 21, 26], ["body wall", "TISSUE", 84, 93], ["worms", "SPECIES", 21, 26], ["body", "ANATOMY", 84, 88], ["wall", "ANATOMY_MODIFIER", 89, 93]]], ["The ovejector was ovoid in shape, relatively large and filled the body cavity, and had a distinct lumen (Fig 3C and 3D).", [["ovejector", "ANATOMY", 4, 13], ["body cavity", "ANATOMY", 66, 77], ["lumen", "ANATOMY", 98, 103], ["body cavity", "ORGANISM_SUBDIVISION", 66, 77], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 98, 103], ["ovoid in shape", "PROBLEM", 18, 32], ["a distinct lumen (Fig 3C", "TREATMENT", 87, 111], ["ovoid", "OBSERVATION_MODIFIER", 18, 23], ["shape", "OBSERVATION_MODIFIER", 27, 32], ["relatively", "OBSERVATION_MODIFIER", 34, 44], ["large", "OBSERVATION_MODIFIER", 45, 50], ["filled", "OBSERVATION", 55, 61], ["body cavity", "ANATOMY", 66, 77], ["distinct", "OBSERVATION_MODIFIER", 89, 97], ["lumen", "OBSERVATION_MODIFIER", 98, 103]]], ["Rudimentary cellular growth of the reproductive tubes was also evident (Fig 3D).", [["cellular", "ANATOMY", 12, 20], ["cellular", "CELL", 12, 20], ["reproductive tubes", "MULTI-TISSUE_STRUCTURE", 35, 53], ["Rudimentary cellular growth", "PROBLEM", 0, 27], ["the reproductive tubes", "TREATMENT", 31, 53], ["cellular", "OBSERVATION_MODIFIER", 12, 20], ["growth", "OBSERVATION_MODIFIER", 21, 27], ["reproductive tubes", "OBSERVATION", 35, 53]]], ["In males, the testis, located at approximately mid-body, had become elongate in shape and had looped posteriorly to form a classic shepherd\u2019s crook (Fig 3E).", [["testis", "ANATOMY", 14, 20], ["mid-body", "ANATOMY", 47, 55], ["testis", "ORGAN", 14, 20], ["males", "OBSERVATION", 3, 8], ["testis", "ANATOMY", 14, 20], ["elongate", "OBSERVATION_MODIFIER", 68, 76], ["shape", "OBSERVATION_MODIFIER", 80, 85], ["looped", "OBSERVATION_MODIFIER", 94, 100], ["posteriorly", "OBSERVATION_MODIFIER", 101, 112]]], ["In addition, the spicule pads were well developed and demarcated (Fig 3F) but were still oval in shape and had not yet started to take on the shape of the spicules nor was there any evidence of cuticularization.", [["spicule pads", "ANATOMY", 17, 29], ["spicules", "ANATOMY", 155, 163], ["the spicule pads", "TREATMENT", 13, 29], ["cuticularization", "PROBLEM", 194, 210], ["spicule", "OBSERVATION_MODIFIER", 17, 24], ["pads", "OBSERVATION", 25, 29], ["oval", "OBSERVATION_MODIFIER", 89, 93], ["cuticularization", "OBSERVATION", 194, 210]]], ["These observations are consistent with parasite development into advanced fourth stage larvae (L4).Analysis of parasite biomarkers detected in serum and urine from infected mice ::: ResultsGlobal proteomic analyses were performed with serum and urine collected from BLT mice infected for 8-weeks and HuSkMc humanized mice infected for 12-weeks.", [["L4", "ANATOMY", 95, 97], ["serum", "ANATOMY", 143, 148], ["urine", "ANATOMY", 153, 158], ["serum", "ANATOMY", 235, 240], ["urine", "ANATOMY", 245, 250], ["serum", "ORGANISM_SUBSTANCE", 143, 148], ["urine", "ORGANISM_SUBSTANCE", 153, 158], ["mice", "ORGANISM", 173, 177], ["serum", "ORGANISM_SUBSTANCE", 235, 240], ["urine", "ORGANISM_SUBSTANCE", 245, 250], ["BLT", "ORGANISM", 266, 269], ["mice", "ORGANISM", 270, 274], ["mice", "ORGANISM", 317, 321], ["mice", "SPECIES", 173, 177], ["mice", "SPECIES", 270, 274], ["mice", "SPECIES", 317, 321], ["mice", "SPECIES", 173, 177], ["mice", "SPECIES", 270, 274], ["mice", "SPECIES", 317, 321], ["These observations", "TEST", 0, 18], ["advanced fourth stage larvae", "PROBLEM", 65, 93], ["parasite biomarkers", "TEST", 111, 130], ["serum and urine", "TEST", 143, 158], ["ResultsGlobal proteomic analyses", "TEST", 182, 214], ["serum and urine", "TEST", 235, 250], ["HuSkMc humanized mice infected", "TREATMENT", 300, 330], ["consistent with", "UNCERTAINTY", 23, 38], ["parasite", "OBSERVATION", 39, 47], ["advanced", "OBSERVATION_MODIFIER", 65, 73], ["fourth stage", "OBSERVATION_MODIFIER", 74, 86], ["larvae", "OBSERVATION_MODIFIER", 87, 93], ["L4", "ANATOMY", 95, 97]]], ["A total of 7,430 proteins were identified based on the spectral matching to a combined protein database of human, mouse, O. volvulus and its Wolbachia (wOv) endosymbiont.", [["human", "ORGANISM", 107, 112], ["mouse", "ORGANISM", 114, 119], ["O. volvulus", "ORGANISM", 121, 132], ["wOv", "GENE_OR_GENE_PRODUCT", 152, 155], ["7,430 proteins", "PROTEIN", 11, 25], ["human", "SPECIES", 107, 112], ["mouse", "SPECIES", 114, 119], ["O. volvulus", "SPECIES", 121, 132], ["human", "SPECIES", 107, 112], ["mouse", "SPECIES", 114, 119], ["O. volvulus", "SPECIES", 121, 132], ["A total of 7,430 proteins", "TREATMENT", 0, 25], ["volvulus", "PROBLEM", 124, 132], ["volvulus", "OBSERVATION", 124, 132]]], ["Because of the ambiguity in distinguishing certain spectral matches for proteins commonly found in both humans and mice, these proteins were grouped as non-O. volvulus proteins (4,743 in serum, 2,836 in urine, S1 Fig).", [["serum", "ANATOMY", 187, 192], ["urine", "ANATOMY", 203, 208], ["humans", "ORGANISM", 104, 110], ["mice", "ORGANISM", 115, 119], ["non-O. volvulus", "ORGANISM", 152, 167], ["serum", "ORGANISM_SUBSTANCE", 187, 192], ["urine", "ORGANISM_SUBSTANCE", 203, 208], ["non-O. volvulus proteins", "PROTEIN", 152, 176], ["humans", "SPECIES", 104, 110], ["mice", "SPECIES", 115, 119], ["humans", "SPECIES", 104, 110], ["mice", "SPECIES", 115, 119], ["the ambiguity", "PROBLEM", 11, 24], ["proteins", "PROBLEM", 72, 80], ["these proteins", "TEST", 121, 135], ["volvulus proteins", "TEST", 159, 176], ["serum", "TEST", 187, 192], ["urine", "TEST", 203, 208]]], ["The present study, however, focused on only O. volvulus derived proteins as potential parasite-encoded biomarkers of O. volvulus infection.", [["O. volvulus infection", "DISEASE", 117, 138], ["O. volvulus", "ORGANISM", 44, 55], ["O. volvulus", "ORGANISM", 117, 128], ["O. volvulus", "SPECIES", 44, 55], ["O. volvulus", "SPECIES", 117, 128], ["O. volvulus", "SPECIES", 44, 55], ["O. volvulus", "SPECIES", 117, 128], ["The present study", "TEST", 0, 17], ["potential parasite", "PROBLEM", 76, 94], ["volvulus infection", "PROBLEM", 120, 138], ["volvulus", "OBSERVATION", 47, 55], ["volvulus", "OBSERVATION_MODIFIER", 120, 128], ["infection", "OBSERVATION", 129, 138]]], ["Of all the proteins identified, 155 O. volvulus proteins (111 in serum and 44 in the urine) were detected in the infected mice and not in the control mice.", [["serum", "ANATOMY", 65, 70], ["urine", "ANATOMY", 85, 90], ["O. volvulus", "ORGANISM", 36, 47], ["serum", "ORGANISM_SUBSTANCE", 65, 70], ["urine", "ORGANISM_SUBSTANCE", 85, 90], ["mice", "ORGANISM", 122, 126], ["mice", "ORGANISM", 150, 154], ["O. volvulus", "SPECIES", 36, 47], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 150, 154], ["O. volvulus", "SPECIES", 36, 47], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 150, 154], ["all the proteins", "TEST", 3, 19], ["volvulus proteins", "TEST", 39, 56], ["serum", "TEST", 65, 70], ["the urine", "TEST", 81, 90], ["infected", "OBSERVATION", 113, 121]]], ["While there were no proteins that were commonly detected in the serum and urine of the infected mice, the BLT and HuSkMc mice had 5 proteins (OVOC11556, OVOC835, OVOC10244, OVOC4009 and OVOC9087) in common in the serum and 5 (OVOC7220, OVOC4139, OVOC224, OVOC8249 and OVOC9267) in the urine (Fig 4B).", [["serum", "ANATOMY", 64, 69], ["urine", "ANATOMY", 74, 79], ["serum", "ANATOMY", 213, 218], ["urine", "ANATOMY", 285, 290], ["OVOC9267", "CHEMICAL", 268, 276], ["OVOC224", "CHEMICAL", 246, 253], ["OVOC8249", "CHEMICAL", 255, 263], ["OVOC9267", "CHEMICAL", 268, 276], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["urine", "ORGANISM_SUBSTANCE", 74, 79], ["mice", "ORGANISM", 96, 100], ["BLT", "GENE_OR_GENE_PRODUCT", 106, 109], ["HuSkMc mice", "ORGANISM", 114, 125], ["OVOC11556", "GENE_OR_GENE_PRODUCT", 142, 151], ["OVOC835", "GENE_OR_GENE_PRODUCT", 153, 160], ["OVOC10244", "GENE_OR_GENE_PRODUCT", 162, 171], ["OVOC4009", "GENE_OR_GENE_PRODUCT", 173, 181], ["OVOC9087", "GENE_OR_GENE_PRODUCT", 186, 194], ["serum", "ORGANISM_SUBSTANCE", 213, 218], ["OVOC9267", "SIMPLE_CHEMICAL", 268, 276], ["urine", "ORGANISM_SUBSTANCE", 285, 290], ["OVOC9087", "PROTEIN", 186, 194], ["mice", "SPECIES", 96, 100], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 96, 100], ["mice", "SPECIES", 121, 125], ["proteins", "PROBLEM", 20, 28], ["the serum", "TEST", 60, 69], ["the BLT", "TEST", 102, 109], ["OVOC835", "TEST", 153, 160], ["OVOC4009", "TEST", 173, 181], ["OVOC9087", "TEST", 186, 194], ["the serum", "TEST", 209, 218], ["OVOC7220", "TEST", 226, 234], ["OVOC4139", "TEST", 236, 244], ["OVOC224", "TEST", 246, 253], ["OVOC8249", "TEST", 255, 263], ["OVOC9267", "TEST", 268, 276], ["the urine", "TEST", 281, 290], ["no", "UNCERTAINTY", 17, 19]]], ["Almost all the proteins identified have been shown through RNAseq to be transcribed by various stages of the O. volvulus parasite (Fig 4B).DiscussionThe objective of this project was to identify small animal models that would support the development of black-fly derived O. volvulus L3 into advanced mammalian-adapted stages of the parasite.", [["O. volvulus parasite", "ORGANISM", 109, 129], ["Fig 4B", "ORGANISM", 131, 137], ["black-fly", "ORGANISM", 253, 262], ["O. volvulus L3", "ORGANISM", 271, 285], ["O. volvulus", "SPECIES", 109, 120], ["O. volvulus", "SPECIES", 271, 282], ["O. volvulus", "SPECIES", 109, 120], ["black-fly", "SPECIES", 253, 262], ["O. volvulus", "SPECIES", 271, 282], ["RNAseq", "TREATMENT", 59, 65], ["small animal models", "PROBLEM", 195, 214], ["black-fly derived O. volvulus", "PROBLEM", 253, 282], ["the parasite", "PROBLEM", 328, 340], ["volvulus", "OBSERVATION", 112, 120], ["volvulus", "OBSERVATION", 274, 282], ["L3", "ANATOMY", 283, 285], ["parasite", "OBSERVATION", 332, 340]]], ["These small animal models are critically needed for identifying biomarkers released from the early stages of the infection and for screening potential new anthelmintics.", [["infection", "DISEASE", 113, 122], ["the infection", "PROBLEM", 109, 122], ["new anthelmintics", "TREATMENT", 151, 168], ["small", "OBSERVATION_MODIFIER", 6, 11], ["early stages", "OBSERVATION_MODIFIER", 93, 105], ["infection", "OBSERVATION", 113, 122]]], ["Published findings on the susceptibility of mice to infection with the L3 of O. volvulus suggest that mice are resistant to infection when the larvae were injected subcutaneously [14].", [["subcutaneously", "ANATOMY", 164, 178], ["infection", "DISEASE", 52, 61], ["O. volvulus", "DISEASE", 77, 88], ["infection", "DISEASE", 124, 133], ["mice", "ORGANISM", 44, 48], ["O. volvulus", "ORGANISM", 77, 88], ["mice", "ORGANISM", 102, 106], ["larvae", "ORGANISM", 143, 149], ["mice", "SPECIES", 44, 48], ["O. volvulus", "SPECIES", 77, 88], ["mice", "SPECIES", 102, 106], ["mice", "SPECIES", 44, 48], ["O. volvulus", "SPECIES", 77, 88], ["mice", "SPECIES", 102, 106], ["infection", "PROBLEM", 52, 61], ["O. volvulus", "PROBLEM", 77, 88], ["infection", "PROBLEM", 124, 133], ["the larvae", "TREATMENT", 139, 149], ["infection", "OBSERVATION", 52, 61], ["L3", "ANATOMY", 71, 73], ["volvulus", "OBSERVATION", 80, 88], ["infection", "OBSERVATION", 124, 133]]], ["However, O. volvulus L3 have been shown to survive and develop in mice when implanted within diffusion chambers at rates comparable to those seen in susceptible primates [17].DiscussionGenetic traits can play a significant role in the susceptibility of animals to infection as has been clearly demonstrated by the diversity of susceptibility of different mouse strains to infection with Litomosoides sigmodontis [59].", [["infection", "DISEASE", 264, 273], ["infection", "DISEASE", 372, 381], ["O. volvulus L3", "ORGANISM", 9, 23], ["mice", "ORGANISM", 66, 70], ["primates", "ORGANISM", 161, 169], ["mouse", "ORGANISM", 355, 360], ["Litomosoides sigmodontis", "ORGANISM", 387, 411], ["O. volvulus", "SPECIES", 9, 20], ["mice", "SPECIES", 66, 70], ["mouse", "SPECIES", 355, 360], ["Litomosoides sigmodontis", "SPECIES", 387, 411], ["O. volvulus", "SPECIES", 9, 20], ["mice", "SPECIES", 66, 70], ["mouse", "SPECIES", 355, 360], ["Litomosoides sigmodontis", "SPECIES", 387, 411], ["infection", "PROBLEM", 264, 273], ["different mouse strains to infection", "PROBLEM", 345, 381], ["Litomosoides sigmodontis", "PROBLEM", 387, 411], ["volvulus", "OBSERVATION", 12, 20], ["L3", "ANATOMY", 21, 23], ["infection", "OBSERVATION", 264, 273]]], ["The CC mouse project was developed to produce an extremely diverse set of inbred animals that could be used for mapping different genetic traits [57].", [["CC", "CHEMICAL", 4, 6], ["mouse", "ORGANISM", 7, 12], ["mouse", "SPECIES", 7, 12], ["mouse", "SPECIES", 7, 12]]], ["Five different CC mouse strains, selected based on their diverse genetic backgrounds, were tested for susceptibility to O. volvulus and were completely resistant to the infection.", [["CC", "CHEMICAL", 15, 17], ["O. volvulus", "DISEASE", 120, 131], ["infection", "DISEASE", 169, 178], ["mouse", "ORGANISM", 18, 23], ["O. volvulus", "ORGANISM", 120, 131], ["CC mouse strains", "CELL_LINE", 15, 31], ["mouse", "SPECIES", 18, 23], ["O. volvulus", "SPECIES", 120, 131], ["mouse", "SPECIES", 18, 23], ["O. volvulus", "SPECIES", 120, 131], ["Five different CC mouse strains", "PROBLEM", 0, 31], ["susceptibility", "PROBLEM", 102, 116], ["O. volvulus", "PROBLEM", 120, 131], ["the infection", "PROBLEM", 165, 178], ["mouse strains", "OBSERVATION", 18, 31], ["volvulus", "OBSERVATION", 123, 131], ["infection", "OBSERVATION", 169, 178]]], ["This observation suggests that either mice are missing some integral factors required for parasite growth or the immune responses in mice are effective at eliminating the infection.", [["infection", "DISEASE", 171, 180], ["mice", "ORGANISM", 38, 42], ["mice", "ORGANISM", 133, 137], ["integral factors", "PROTEIN", 60, 76], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 133, 137], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 133, 137], ["This observation", "TEST", 0, 16], ["some integral factors", "PROBLEM", 55, 76], ["parasite growth", "PROBLEM", 90, 105], ["the infection", "PROBLEM", 167, 180], ["infection", "OBSERVATION", 171, 180]]], ["The question remains as to why parasites are recovered live from diffusion chambers implanted in mice but not when injected into the tissues.", [["tissues", "ANATOMY", 133, 140], ["mice", "ORGANISM", 97, 101], ["tissues", "TISSUE", 133, 140], ["mice", "SPECIES", 97, 101], ["mice", "SPECIES", 97, 101], ["parasites", "PROBLEM", 31, 40], ["diffusion chambers", "TREATMENT", 65, 83], ["tissues", "ANATOMY", 133, 140]]], ["There are several possible explanations including: (1) the diffusion chamber acts as a barrier from the immune response creating an immune privileged site, (2) the larvae within the diffusion chamber are blocked from migrating through the tissue releasing excretory and secretory products and thereby eliciting an immune reaction, or (3) the diffusion chamber attracts host components to the parasite microenvironment that are beneficial for parasite development.DiscussionTo test the hypothesis that mouse-intrinsic immune responses control O. volvulus infections, NSG mice that lack both functional innate and adaptive immune systems were infected with O. volvulus L3.", [["site", "ANATOMY", 150, 154], ["tissue", "ANATOMY", 239, 245], ["excretory", "ANATOMY", 256, 265], ["O. volvulus infections", "DISEASE", 542, 564], ["tissue", "TISSUE", 239, 245], ["mouse", "ORGANISM", 501, 506], ["O. volvulus", "ORGANISM", 542, 553], ["NSG mice", "ORGANISM", 566, 574], ["O. volvulus L3", "ORGANISM", 655, 669], ["mouse", "SPECIES", 501, 506], ["O. volvulus", "SPECIES", 542, 553], ["mice", "SPECIES", 570, 574], ["O. volvulus", "SPECIES", 655, 666], ["mouse", "SPECIES", 501, 506], ["O. volvulus", "SPECIES", 542, 553], ["mice", "SPECIES", 570, 574], ["O. volvulus L3", "SPECIES", 655, 669], ["the diffusion chamber acts", "PROBLEM", 55, 81], ["an immune reaction", "PROBLEM", 311, 329], ["the diffusion chamber", "PROBLEM", 338, 359], ["parasite development", "PROBLEM", 442, 462], ["volvulus infections", "PROBLEM", 545, 564], ["adaptive immune systems", "PROBLEM", 612, 635], ["volvulus L3", "PROBLEM", 658, 669], ["diffusion chamber", "OBSERVATION", 182, 199], ["immune reaction", "OBSERVATION", 314, 329], ["volvulus", "OBSERVATION", 658, 666], ["L3", "ANATOMY", 667, 669]]], ["Advanced stages of the parasites were consistently recovered from the infected NSG mice, and parasites survived and developed over the 8-week time course into advanced L4.", [["L4", "ANATOMY", 168, 170], ["NSG mice", "ORGANISM", 79, 87], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 83, 87], ["the parasites", "PROBLEM", 19, 32], ["parasites", "PROBLEM", 93, 102], ["parasites", "OBSERVATION", 23, 32], ["infected", "OBSERVATION_MODIFIER", 70, 78], ["L4", "ANATOMY", 168, 170]]], ["These findings demonstrate that the mouse immune response was capable of controlling infection with O. volvulus, with elements of the mouse immune response eliminating the infection in immunologically intact mice.", [["infection", "DISEASE", 85, 94], ["O. volvulus", "DISEASE", 100, 111], ["infection", "DISEASE", 172, 181], ["mouse", "ORGANISM", 36, 41], ["O. volvulus", "ORGANISM", 100, 111], ["mouse", "ORGANISM", 134, 139], ["mice", "ORGANISM", 208, 212], ["mouse", "SPECIES", 36, 41], ["O. volvulus", "SPECIES", 100, 111], ["mouse", "SPECIES", 134, 139], ["mice", "SPECIES", 208, 212], ["mouse", "SPECIES", 36, 41], ["O. volvulus", "SPECIES", 100, 111], ["mouse", "SPECIES", 134, 139], ["mice", "SPECIES", 208, 212], ["controlling infection", "PROBLEM", 73, 94], ["O. volvulus", "PROBLEM", 100, 111], ["the mouse immune response", "PROBLEM", 130, 155], ["the infection", "PROBLEM", 168, 181], ["infection", "OBSERVATION", 85, 94], ["volvulus", "OBSERVATION", 103, 111], ["infection", "OBSERVATION", 172, 181]]], ["Many mechanisms have been described for innate immune control of nematode infections in mice [39,60\u201367] all or some of which may be effective against O. volvulus.", [["nematode infections", "DISEASE", 65, 84], ["O. volvulus", "DISEASE", 150, 161], ["nematode", "ORGANISM", 65, 73], ["mice", "ORGANISM", 88, 92], ["O. volvulus", "ORGANISM", 150, 161], ["mice", "SPECIES", 88, 92], ["O. volvulus", "SPECIES", 150, 161], ["mice", "SPECIES", 88, 92], ["O. volvulus", "SPECIES", 150, 161], ["nematode infections", "PROBLEM", 65, 84], ["volvulus", "PROBLEM", 153, 161], ["may be", "UNCERTAINTY", 125, 131], ["volvulus", "OBSERVATION", 153, 161]]], ["Interestingly, tissues and cells in NSG mice provide required factors for parasite development and based on PCR analyses, the larvae actively migrated far from the infection site.DiscussionThe present study did not identify the point at which O. volvulus ceased surviving and developing in NSG mice.", [["tissues", "ANATOMY", 15, 22], ["cells", "ANATOMY", 27, 32], ["infection", "DISEASE", 164, 173], ["O. volvulus", "DISEASE", 243, 254], ["tissues", "TISSUE", 15, 22], ["cells", "CELL", 27, 32], ["NSG mice", "ORGANISM", 36, 44], ["NSG mice", "ORGANISM", 290, 298], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 294, 298], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 294, 298], ["parasite development", "PROBLEM", 74, 94], ["PCR analyses", "TEST", 108, 120], ["the larvae", "TREATMENT", 122, 132], ["the infection site", "PROBLEM", 160, 178], ["The present study", "TEST", 189, 206], ["volvulus", "PROBLEM", 246, 254], ["infection", "OBSERVATION", 164, 173], ["volvulus", "OBSERVATION", 246, 254]]], ["Studies with the human parasite S. stercoralis have demonstrated that the entire parasite life cycle will develop in NSG mice within 4-weeks [31].", [["human", "ORGANISM", 17, 22], ["parasite S. stercoralis", "ORGANISM", 23, 46], ["NSG mice", "ORGANISM", 117, 125], ["human", "SPECIES", 17, 22], ["S. stercoralis", "SPECIES", 32, 46], ["mice", "SPECIES", 121, 125], ["human", "SPECIES", 17, 22], ["S. stercoralis", "SPECIES", 32, 46], ["mice", "SPECIES", 121, 125], ["Studies", "TEST", 0, 7], ["the human parasite S. stercoralis", "PROBLEM", 13, 46]]], ["Given the significant difference in time that it takes for O. volvulus adults to develop (12\u201315 months in chimpanzees [9,10]) and their size as mature adults (females are 50 cm [68]) it is unlikely that the entire O. volvulus life cycle, including mating and development of microfilariae, will occur in NSG mice.DiscussionIn vitro studies on the development of filarial worms including O. volvulus [69,70] and Brugia malayi [71] have demonstrated that host cells are needed in the culture wells to optimize parasite growth and development.", [["microfilariae", "ANATOMY", 274, 287], ["cells", "ANATOMY", 457, 462], ["filarial worms", "DISEASE", 361, 375], ["O. volvulus", "DISEASE", 386, 397], ["O. volvulus", "ORGANISM", 59, 70], ["O. volvulus", "ORGANISM", 214, 225], ["microfilariae", "ORGANISM", 274, 287], ["NSG mice", "ORGANISM", 303, 311], ["filarial", "ORGANISM", 361, 369], ["worms", "ORGANISM_SUBDIVISION", 370, 375], ["O. volvulus", "ORGANISM", 386, 397], ["Brugia malayi", "ORGANISM", 410, 423], ["host cells", "CELL", 452, 462], ["host cells", "CELL_TYPE", 452, 462], ["O. volvulus", "SPECIES", 214, 225], ["mice", "SPECIES", 307, 311], ["worms", "SPECIES", 370, 375], ["O. volvulus", "SPECIES", 386, 397], ["Brugia malayi", "SPECIES", 410, 423], ["O. volvulus", "SPECIES", 59, 70], ["O. volvulus", "SPECIES", 214, 225], ["mice", "SPECIES", 307, 311], ["O. volvulus", "SPECIES", 386, 397], ["Brugia malayi", "SPECIES", 410, 423], ["O. volvulus", "PROBLEM", 59, 70], ["microfilariae", "PROBLEM", 274, 287], ["vitro studies", "TEST", 325, 338], ["filarial worms", "PROBLEM", 361, 375], ["volvulus", "PROBLEM", 389, 397], ["Brugia malayi", "PROBLEM", 410, 423], ["host cells", "PROBLEM", 452, 462], ["the culture", "TEST", 477, 488], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["difference", "OBSERVATION_MODIFIER", 22, 32], ["volvulus", "OBSERVATION", 62, 70], ["size", "OBSERVATION_MODIFIER", 136, 140], ["unlikely", "UNCERTAINTY", 189, 197], ["microfilariae", "OBSERVATION", 274, 287], ["host cells", "OBSERVATION", 452, 462]]], ["Furthermore, optimal development and survival of larval T. spiralis in mice requires the presence of mouse eosinophils [33].", [["eosinophils", "ANATOMY", 107, 118], ["T. spiralis", "ORGANISM", 56, 67], ["mice", "ORGANISM", 71, 75], ["mouse", "ORGANISM", 101, 106], ["eosinophils", "CELL", 107, 118], ["mouse eosinophils", "CELL_TYPE", 101, 118], ["T. spiralis", "SPECIES", 56, 67], ["mice", "SPECIES", 71, 75], ["mouse", "SPECIES", 101, 106], ["T. spiralis", "SPECIES", 56, 67], ["mice", "SPECIES", 71, 75], ["mouse", "SPECIES", 101, 106], ["larval T. spiralis", "PROBLEM", 49, 67], ["mouse eosinophils", "PROBLEM", 101, 118]]], ["It was thus hypothesized that adding human cells to the NSG mice, from the tissues that the parasites are normally found juxtaposed in humans, might provide additional required nutritional or developmental elements found in humans required for parasite development and survival.", [["cells", "ANATOMY", 43, 48], ["tissues", "ANATOMY", 75, 82], ["human", "ORGANISM", 37, 42], ["cells", "CELL", 43, 48], ["NSG mice", "ORGANISM", 56, 64], ["tissues", "TISSUE", 75, 82], ["humans", "ORGANISM", 135, 141], ["humans", "ORGANISM", 224, 230], ["human cells", "CELL_TYPE", 37, 48], ["human", "SPECIES", 37, 42], ["mice", "SPECIES", 60, 64], ["humans", "SPECIES", 135, 141], ["humans", "SPECIES", 224, 230], ["human", "SPECIES", 37, 42], ["mice", "SPECIES", 60, 64], ["humans", "SPECIES", 135, 141], ["humans", "SPECIES", 224, 230], ["human cells", "TREATMENT", 37, 48], ["the parasites", "PROBLEM", 88, 101], ["developmental elements", "TREATMENT", 192, 214], ["parasite development", "TREATMENT", 244, 264], ["parasites", "OBSERVATION", 92, 101]]], ["Four different single cell xenografts were screened: HuSkMc, LEC, HaCaT and BESM.", [["cell xenografts", "ANATOMY", 22, 37], ["LEC", "ANATOMY", 61, 64], ["HaCaT", "ANATOMY", 66, 71], ["cell xenografts", "CANCER", 22, 37], ["HuSkMc", "CELL", 53, 59], ["LEC", "CELL", 61, 64], ["HaCaT", "CELL", 66, 71], ["BESM", "CELL", 76, 80], ["HuSkMc", "PROTEIN", 53, 59], ["LEC", "CELL_LINE", 61, 64], ["HaCaT", "CELL_LINE", 66, 71], ["BESM", "CELL_LINE", 76, 80], ["cell xenografts", "OBSERVATION", 22, 37], ["HaCaT", "ANATOMY", 66, 71]]], ["Of these four cell lines, HuSkMc was found to support the highest average percent survival of the implanted worms and consistent infection rates over a 12-week time period (Figs 1 and 2)DiscussionAs an alternative to adding single cell populations to the NSG mice, multipotential umbilical cord stem cells were transferred to the immunodeficient mice.", [["cell lines", "ANATOMY", 14, 24], ["worms", "ANATOMY", 108, 113], ["cell", "ANATOMY", 231, 235], ["multipotential umbilical cord stem cells", "ANATOMY", 265, 305], ["infection", "DISEASE", 129, 138], ["cell lines", "CELL", 14, 24], ["HuSkMc", "CELL", 26, 32], ["cell populations", "CELL", 231, 247], ["NSG mice", "ORGANISM", 255, 263], ["multipotential umbilical cord stem cells", "CELL", 265, 305], ["mice", "ORGANISM", 346, 350], ["cell lines", "CELL_LINE", 14, 24], ["HuSkMc", "PROTEIN", 26, 32], ["multipotential umbilical cord stem cells", "CELL_TYPE", 265, 305], ["worms", "SPECIES", 108, 113], ["mice", "SPECIES", 259, 263], ["mice", "SPECIES", 346, 350], ["mice", "SPECIES", 259, 263], ["mice", "SPECIES", 346, 350], ["the implanted worms", "PROBLEM", 94, 113], ["consistent infection rates", "PROBLEM", 118, 144], ["single cell populations", "TREATMENT", 224, 247], ["multipotential umbilical cord stem cells", "TREATMENT", 265, 305], ["four cell lines", "OBSERVATION", 9, 24], ["implanted worms", "OBSERVATION", 98, 113], ["infection", "OBSERVATION", 129, 138], ["umbilical cord", "ANATOMY", 280, 294], ["stem cells", "OBSERVATION", 295, 305]]], ["NSG, NSG-SGM, and NRG mice, all of which lack functional immune responses, were humanized with CD34+ umbilical cord stem cells.", [["CD34+ umbilical cord stem cells", "ANATOMY", 95, 126], ["NSG", "CELL", 0, 3], ["NSG-SGM", "CELL", 5, 12], ["NRG mice", "ORGANISM", 18, 26], ["CD34", "GENE_OR_GENE_PRODUCT", 95, 99], ["cord stem cells", "CELL", 111, 126], ["NRG", "PROTEIN", 18, 21], ["CD34", "PROTEIN", 95, 99], ["umbilical cord stem cells", "CELL_TYPE", 101, 126], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 22, 26], ["umbilical cord", "ANATOMY", 101, 115], ["stem cells", "OBSERVATION", 116, 126]]], ["The humanization of the various immunocompromised mouse strains resulted in the development of an immature human immune system.", [["immune system", "ANATOMY", 113, 126], ["mouse", "ORGANISM", 50, 55], ["human", "ORGANISM", 107, 112], ["immune system", "ANATOMICAL_SYSTEM", 113, 126], ["mouse", "SPECIES", 50, 55], ["human", "SPECIES", 107, 112], ["mouse", "SPECIES", 50, 55], ["human", "SPECIES", 107, 112], ["the various immunocompromised mouse strains", "PROBLEM", 20, 63], ["an immature human immune system", "PROBLEM", 95, 126], ["immature human immune system", "OBSERVATION", 98, 126]]], ["The developing immune system in these mice displays a T-independent response, limited antigen-specific IgM responses, and the presence of multiple innate immune cells has been noted [25].", [["immune system", "ANATOMY", 15, 28], ["immune cells", "ANATOMY", 154, 166], ["immune system", "ANATOMICAL_SYSTEM", 15, 28], ["mice", "ORGANISM", 38, 42], ["antigen", "GENE_OR_GENE_PRODUCT", 86, 93], ["IgM", "GENE_OR_GENE_PRODUCT", 103, 106], ["immune cells", "CELL", 154, 166], ["IgM", "PROTEIN", 103, 106], ["innate immune cells", "CELL_TYPE", 147, 166], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42], ["multiple innate immune cells", "PROBLEM", 138, 166], ["immune system", "OBSERVATION", 15, 28], ["immune cells", "OBSERVATION", 154, 166]]], ["When humanized NSG, NSG-SGM, and NRG mice were infected with O. volvulus L3, higher GM parasite recoveries were observed when compared to NSG mice without any human cells but these enhancements were not significant.", [["NSG", "ANATOMY", 15, 18], ["cells", "ANATOMY", 165, 170], ["GM", "CHEMICAL", 84, 86], ["NSG", "CELL", 15, 18], ["NSG-SGM", "ORGANISM", 20, 27], ["NRG mice", "ORGANISM", 33, 41], ["O. volvulus L3", "ORGANISM", 61, 75], ["NSG mice", "ORGANISM", 138, 146], ["human", "ORGANISM", 159, 164], ["cells", "CELL", 165, 170], ["NRG", "PROTEIN", 33, 36], ["human cells", "CELL_TYPE", 159, 170], ["mice", "SPECIES", 37, 41], ["O. volvulus", "SPECIES", 61, 72], ["mice", "SPECIES", 142, 146], ["human", "SPECIES", 159, 164], ["mice", "SPECIES", 37, 41], ["O. volvulus L3", "SPECIES", 61, 75], ["mice", "SPECIES", 142, 146], ["human", "SPECIES", 159, 164], ["O. volvulus L3", "PROBLEM", 61, 75], ["higher GM parasite recoveries", "PROBLEM", 77, 106], ["volvulus", "OBSERVATION", 64, 72], ["L3", "ANATOMY", 73, 75]]], ["Although NSG-SGM did have consistent infection rates with O. volvulus we had significant difficulties establishing reliable engraftment of human cells in this strain of mice.", [["cells", "ANATOMY", 145, 150], ["infection", "DISEASE", 37, 46], ["O. volvulus", "DISEASE", 58, 69], ["NSG-SGM", "ORGANISM", 9, 16], ["human", "ORGANISM", 139, 144], ["cells", "CELL", 145, 150], ["mice", "ORGANISM", 169, 173], ["human cells", "CELL_TYPE", 139, 150], ["O. volvulus", "SPECIES", 58, 69], ["human", "SPECIES", 139, 144], ["mice", "SPECIES", 169, 173], ["O. volvulus", "SPECIES", 58, 69], ["human", "SPECIES", 139, 144], ["mice", "SPECIES", 169, 173], ["consistent infection rates", "PROBLEM", 26, 52], ["O. volvulus", "PROBLEM", 58, 69], ["significant difficulties", "PROBLEM", 77, 101], ["human cells", "TREATMENT", 139, 150], ["infection", "OBSERVATION", 37, 46], ["volvulus", "OBSERVATION", 61, 69]]], ["Extending this concept further, BLT mice which contain CD34+ stem cells in addition to fetal tissue were used.", [["CD34+ stem cells", "ANATOMY", 55, 71], ["fetal tissue", "ANATOMY", 87, 99], ["BLT mice", "ORGANISM", 32, 40], ["CD34", "GENE_OR_GENE_PRODUCT", 55, 59], ["fetal tissue", "TISSUE", 87, 99], ["CD34", "PROTEIN", 55, 59], ["stem cells", "CELL_TYPE", 61, 71], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 36, 40], ["stem cells", "PROBLEM", 61, 71], ["fetal tissue", "PROBLEM", 87, 99], ["CD34+ stem cells", "OBSERVATION", 55, 71], ["fetal tissue", "ANATOMY", 87, 99]]], ["BLT mice are known to develop a more mature version of a human immune system.", [["immune system", "ANATOMY", 63, 76], ["BLT mice", "ORGANISM", 0, 8], ["human", "ORGANISM", 57, 62], ["immune system", "ANATOMICAL_SYSTEM", 63, 76], ["mice", "SPECIES", 4, 8], ["human", "SPECIES", 57, 62], ["mice", "SPECIES", 4, 8], ["human", "SPECIES", 57, 62], ["a human immune system", "TREATMENT", 55, 76]]], ["Limited T-dependent recognition is seen within these mice and better overall functionality of both the B and T-cells has been documented [36].", [["B", "ANATOMY", 103, 104], ["T-cells", "ANATOMY", 109, 116], ["T", "GENE_OR_GENE_PRODUCT", 8, 9], ["mice", "ORGANISM", 53, 57], ["B", "CELL", 103, 104], ["T-cells", "CELL", 109, 116], ["B and T-cells", "CELL_TYPE", 103, 116], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57]]], ["BLT mice supported the highest average parasite recoveries of any mouse model tested at 4-weeks, although the average fell to be in line with the HuNSG and HuSkMc models by 8-weeks post infection.", [["infection", "DISEASE", 186, 195], ["BLT mice", "ORGANISM", 0, 8], ["mouse", "ORGANISM", 66, 71], ["mice", "SPECIES", 4, 8], ["mouse", "SPECIES", 66, 71], ["mice", "SPECIES", 4, 8], ["mouse", "SPECIES", 66, 71], ["infection", "PROBLEM", 186, 195], ["infection", "OBSERVATION", 186, 195]]], ["The mean lengths of the parasites recovered from 4- and 8-week time points from the NSG mice were comparable to those recovered from BLT mice.", [["NSG", "ORGANISM", 84, 87], ["mice", "ORGANISM", 88, 92], ["BLT mice", "ORGANISM", 133, 141], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 137, 141], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 137, 141], ["the parasites", "TEST", 20, 33], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["lengths", "OBSERVATION_MODIFIER", 9, 16], ["parasites", "OBSERVATION_MODIFIER", 24, 33]]], ["This suggests a link between the enhanced survival, may be related to the presence of the human immune cells, but the growth of the parasites that survive may not be related to the human cell byproducts.", [["immune cells", "ANATOMY", 96, 108], ["cell", "ANATOMY", 187, 191], ["human", "ORGANISM", 90, 95], ["immune cells", "CELL", 96, 108], ["human", "ORGANISM", 181, 186], ["cell", "CELL", 187, 191], ["human immune cells", "CELL_TYPE", 90, 108], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 181, 186], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 181, 186], ["the human immune cells", "PROBLEM", 86, 108], ["the growth of the parasites", "PROBLEM", 114, 141], ["the human cell byproducts", "TREATMENT", 177, 202], ["enhanced", "OBSERVATION_MODIFIER", 33, 41], ["survival", "OBSERVATION", 42, 50], ["may be related to", "UNCERTAINTY", 52, 69], ["human immune cells", "OBSERVATION", 90, 108], ["growth", "OBSERVATION_MODIFIER", 118, 124], ["parasites", "OBSERVATION", 132, 141], ["may not be related to", "UNCERTAINTY", 155, 176], ["human cell byproducts", "OBSERVATION", 181, 202]]], ["Although cellular engraftments levels in BLT and HuNSG mice were not rechecked at the end of the experiment previously published data have shown that these animals reliably hold their engraftments for extended periods of time [72,73].DiscussionThe mouse models developed in this study offer a number of advantages over the models that currently exist.", [["cellular", "ANATOMY", 9, 17], ["cellular", "CELL", 9, 17], ["BLT", "CELL", 41, 44], ["HuNSG mice", "ORGANISM", 49, 59], ["mouse", "ORGANISM", 248, 253], ["mice", "SPECIES", 55, 59], ["mouse", "SPECIES", 248, 253], ["mice", "SPECIES", 55, 59], ["mouse", "SPECIES", 248, 253], ["cellular engraftments levels", "TEST", 9, 37], ["BLT", "TEST", 41, 44], ["HuNSG mice", "TEST", 49, 59], ["this study", "TEST", 274, 284]]], ["L3 implanted within diffusion chambers in both non-human primates and mice successfully molt into L4 but the lengths of the recovered parasites were significantly shorter than those recovered at 8 and 12 weeks post infection from the mice tested in this study [17].", [["L4", "ANATOMY", 98, 100], ["infection", "DISEASE", 215, 224], ["non-human", "ORGANISM", 47, 56], ["primates", "ORGANISM", 57, 65], ["mice", "ORGANISM", 70, 74], ["mice", "ORGANISM", 234, 238], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 234, 238], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 234, 238], ["infection", "PROBLEM", 215, 224], ["this study", "TEST", 249, 259], ["diffusion chambers", "OBSERVATION", 20, 38], ["both", "ANATOMY_MODIFIER", 42, 46], ["non-human", "ANATOMY_MODIFIER", 47, 56], ["L4", "ANATOMY_MODIFIER", 98, 100], ["lengths", "OBSERVATION_MODIFIER", 109, 116], ["recovered", "OBSERVATION_MODIFIER", 124, 133], ["parasites", "OBSERVATION", 134, 143], ["significantly", "OBSERVATION_MODIFIER", 149, 162], ["shorter", "OBSERVATION_MODIFIER", 163, 170], ["infection", "OBSERVATION", 215, 224]]], ["While non-human primates can support the development of the parasites from L3 to microfilariae producing adults, cost and ethical considerations limit the utility of primates for drug discovery and antigen identification [10,14].", [["non-human primates", "ORGANISM", 6, 24], ["microfilariae", "CELL", 81, 94], ["primates", "ORGANISM", 166, 174], ["the parasites", "PROBLEM", 56, 69], ["antigen identification", "TEST", 198, 220], ["parasites", "OBSERVATION", 60, 69], ["L3", "ANATOMY", 75, 77]]], ["Nodules containing adult worms recovered from humans have been implanted into SCID mice and the female worms survived and released microfilariae [15].", [["Nodules", "ANATOMY", 0, 7], ["worms", "ORGANISM", 25, 30], ["humans", "ORGANISM", 46, 52], ["SCID mice", "ORGANISM", 78, 87], ["female worms", "ORGANISM", 96, 108], ["worms", "SPECIES", 25, 30], ["humans", "SPECIES", 46, 52], ["mice", "SPECIES", 83, 87], ["worms", "SPECIES", 103, 108], ["humans", "SPECIES", 46, 52], ["mice", "SPECIES", 83, 87], ["Nodules", "PROBLEM", 0, 7], ["adult worms", "PROBLEM", 19, 30], ["adult", "OBSERVATION_MODIFIER", 19, 24], ["worms", "OBSERVATION", 25, 30]]], ["This method allows for identification of adult antigens and biomarkers, but lacks the intermediate L3 and L4 stages of development.", [["adult antigens", "PROTEIN", 41, 55], ["adult antigens", "PROBLEM", 41, 55], ["biomarkers", "TEST", 60, 70], ["L4", "ANATOMY", 106, 108]]], ["Finally, an alternative model using adult male O. ochengi implanted into SCID mice has been developed for the identifying filaricides [16], which may also be effective against O. volvulus.", [["O. volvulus", "DISEASE", 176, 187], ["filaricides", "CHEMICAL", 122, 133], ["O. ochengi", "ORGANISM", 47, 57], ["SCID mice", "ORGANISM", 73, 82], ["O. volvulus", "ORGANISM", 176, 187], ["O. ochengi", "SPECIES", 47, 57], ["mice", "SPECIES", 78, 82], ["O. ochengi", "SPECIES", 47, 57], ["mice", "SPECIES", 78, 82], ["O. volvulus", "SPECIES", 176, 187], ["volvulus", "PROBLEM", 179, 187], ["may also be", "UNCERTAINTY", 146, 157], ["volvulus", "OBSERVATION", 179, 187]]], ["The NSG models developed in this study have the critical advantage of working with O. volvulus, thereby allowing species-specific screening of filaricides and identification of biomarkers.DiscussionIt was of interest to note that the immune response found in normal mice was highly efficient at eliminating the L3 of O. volvulus, but the human immune cells in NSG mice were supportive rather than destructive of the parasites.", [["immune cells", "ANATOMY", 344, 356], ["O. volvulus", "DISEASE", 83, 94], ["O. volvulus", "DISEASE", 317, 328], ["O. volvulus", "ORGANISM", 83, 94], ["filaricides", "SIMPLE_CHEMICAL", 143, 154], ["mice", "ORGANISM", 266, 270], ["O. volvulus", "ORGANISM", 317, 328], ["human", "ORGANISM", 338, 343], ["immune cells", "CELL", 344, 356], ["NSG mice", "ORGANISM", 360, 368], ["human immune cells", "CELL_TYPE", 338, 356], ["O. volvulus", "SPECIES", 83, 94], ["mice", "SPECIES", 266, 270], ["O. volvulus", "SPECIES", 317, 328], ["human", "SPECIES", 338, 343], ["mice", "SPECIES", 364, 368], ["O. volvulus", "SPECIES", 83, 94], ["mice", "SPECIES", 266, 270], ["O. volvulus", "SPECIES", 317, 328], ["human", "SPECIES", 338, 343], ["mice", "SPECIES", 364, 368], ["this study", "TEST", 28, 38], ["volvulus", "PROBLEM", 86, 94], ["specific screening", "TEST", 121, 139], ["filaricides", "TEST", 143, 154], ["biomarkers", "TEST", 177, 187], ["O. volvulus", "PROBLEM", 317, 328], ["the human immune cells", "TREATMENT", 334, 356], ["destructive of the parasites", "PROBLEM", 397, 425], ["volvulus", "OBSERVATION", 86, 94], ["L3", "ANATOMY", 311, 313], ["volvulus", "OBSERVATION", 320, 328], ["parasites", "OBSERVATION", 416, 425]]], ["It is possible that the mouse immune cells were evolutionally adapted to eliminate the parasites, whereas the human cells were evolutionally adapted to support the parasites as observed in nature.", [["immune cells", "ANATOMY", 30, 42], ["cells", "ANATOMY", 116, 121], ["mouse", "ORGANISM", 24, 29], ["immune cells", "CELL", 30, 42], ["human", "ORGANISM", 110, 115], ["cells", "CELL", 116, 121], ["mouse immune cells", "CELL_TYPE", 24, 42], ["human cells", "CELL_TYPE", 110, 121], ["mouse", "SPECIES", 24, 29], ["human", "SPECIES", 110, 115], ["mouse", "SPECIES", 24, 29], ["human", "SPECIES", 110, 115], ["the mouse immune cells", "PROBLEM", 20, 42], ["the parasites", "PROBLEM", 83, 96], ["the human cells", "PROBLEM", 106, 121], ["the parasites", "PROBLEM", 160, 173], ["parasites", "OBSERVATION", 164, 173]]], ["A comparison between mouse and human immune reactions to the worms might yield important new insights into the etiology of resistance and susceptibility to infection with O. volvulus.DiscussionThe source of the L3 used in these studies was from parasites cryopreserved in liquid nitrogen.", [["infection", "DISEASE", 156, 165], ["O. volvulus", "DISEASE", 171, 182], ["nitrogen", "CHEMICAL", 279, 287], ["mouse", "ORGANISM", 21, 26], ["human", "ORGANISM", 31, 36], ["O. volvulus", "ORGANISM", 171, 182], ["L3", "DNA", 211, 213], ["mouse", "SPECIES", 21, 26], ["human", "SPECIES", 31, 36], ["worms", "SPECIES", 61, 66], ["O. volvulus", "SPECIES", 171, 182], ["mouse", "SPECIES", 21, 26], ["human", "SPECIES", 31, 36], ["O. volvulus", "SPECIES", 171, 182], ["human immune reactions", "TREATMENT", 31, 53], ["the worms", "PROBLEM", 57, 66], ["resistance", "PROBLEM", 123, 133], ["susceptibility to infection", "PROBLEM", 138, 165], ["volvulus", "PROBLEM", 174, 182], ["these studies", "TEST", 222, 235], ["parasites cryopreserved in liquid nitrogen", "TREATMENT", 245, 287], ["infection", "OBSERVATION", 156, 165], ["volvulus", "OBSERVATION", 174, 182], ["L3", "ANATOMY", 211, 213]]], ["After defrosting, 100 individual parasites were selected, attempting to identify only the viable/undamaged L3.", [["L3", "DNA", 107, 109], ["L3", "ANATOMY", 107, 109]]], ["It is reasonable to predict that a percentage of larvae exiting from the mouth parts of a black fly have the potential to resume development in the human host and that the cryopreservation process damaged some of those worms.", [["mouth parts", "ANATOMY", 73, 84], ["mouth", "ORGANISM_SUBDIVISION", 73, 78], ["human", "ORGANISM", 148, 153], ["human", "SPECIES", 148, 153], ["worms", "SPECIES", 219, 224], ["black fly", "SPECIES", 90, 99], ["human", "SPECIES", 148, 153], ["the cryopreservation process", "TREATMENT", 168, 196], ["mouth", "ANATOMY", 73, 78]]], ["Approximately 50 percent of the larvae recovered after cryopreservation survived in diffusion chambers implanted in mice, which may explain the overall number of worms recovered from the different mouse models in this study.", [["mice", "ORGANISM", 116, 120], ["worms", "ORGANISM", 162, 167], ["mouse", "ORGANISM", 197, 202], ["mice", "SPECIES", 116, 120], ["worms", "SPECIES", 162, 167], ["mouse", "SPECIES", 197, 202], ["mice", "SPECIES", 116, 120], ["mouse", "SPECIES", 197, 202], ["cryopreservation", "TREATMENT", 55, 71], ["diffusion chambers", "TREATMENT", 84, 102], ["this study", "TEST", 213, 223], ["chambers implanted", "OBSERVATION", 94, 112], ["may explain", "UNCERTAINTY", 128, 139], ["overall", "OBSERVATION_MODIFIER", 144, 151], ["number", "OBSERVATION_MODIFIER", 152, 158], ["worms", "OBSERVATION", 162, 167], ["different mouse models", "OBSERVATION", 187, 209]]], ["While minor differences in the overall larval recovery levels were observed between individual batches of cryopreserved larvae, multiple batches were combined before implantation to help ensure a consistent viability level going into the animal hosts.", [["cryopreserved larvae", "TREATMENT", 106, 126], ["multiple batches", "TREATMENT", 128, 144], ["implantation", "TREATMENT", 166, 178], ["a consistent viability level", "PROBLEM", 194, 222], ["minor", "OBSERVATION_MODIFIER", 6, 11], ["differences", "OBSERVATION_MODIFIER", 12, 23], ["cryopreserved larvae", "OBSERVATION", 106, 126]]], ["Even with the combination of multiple batches of larvae it cannot be ruled out that the overall viability of the injected larvae played a role in the observed recovery rates.", [["multiple batches of larvae", "TREATMENT", 29, 55]]], ["The recovery rates of O. volvulus larvae after developing in NSG mice with or without human cells was in the same order of magnitude as that reported for the recovery of adult filarial worms, where infections were initiated by larvae recovered directly from the insect vector.", [["cells", "ANATOMY", 92, 97], ["filarial worms", "DISEASE", 176, 190], ["infections", "DISEASE", 198, 208], ["O. volvulus larvae", "ORGANISM", 22, 40], ["NSG mice", "ORGANISM", 61, 69], ["human", "ORGANISM", 86, 91], ["cells", "CELL", 92, 97], ["filarial", "ORGANISM", 176, 184], ["worms", "DEVELOPING_ANATOMICAL_STRUCTURE", 185, 190], ["human cells", "CELL_TYPE", 86, 97], ["O. volvulus", "SPECIES", 22, 33], ["mice", "SPECIES", 65, 69], ["human", "SPECIES", 86, 91], ["worms", "SPECIES", 185, 190], ["O. volvulus", "SPECIES", 22, 33], ["mice", "SPECIES", 65, 69], ["human", "SPECIES", 86, 91], ["O. volvulus larvae", "PROBLEM", 22, 40], ["human cells", "PROBLEM", 86, 97], ["adult filarial worms", "PROBLEM", 170, 190], ["infections", "PROBLEM", 198, 208], ["volvulus", "OBSERVATION", 25, 33], ["filarial worms", "OBSERVATION", 176, 190]]], ["These infections included Brugia pahangi in cats [74], Brugia malayi in leaf-monkey [75], and Onchocerca ochengi in cattle [76].", [["infections", "DISEASE", 6, 16], ["Brugia pahangi", "DISEASE", 26, 40], ["Brugia malayi", "DISEASE", 55, 68], ["Onchocerca ochengi", "DISEASE", 94, 112], ["Brugia pahangi", "ORGANISM", 26, 40], ["cats [74]", "ORGANISM", 44, 53], ["Brugia malayi", "ORGANISM", 55, 68], ["leaf-monkey", "ORGANISM", 72, 83], ["Onchocerca ochengi", "ORGANISM", 94, 112], ["cattle", "ORGANISM", 116, 122], ["Brugia pahangi", "SPECIES", 26, 40], ["cats", "SPECIES", 44, 48], ["Brugia malayi", "SPECIES", 55, 68], ["leaf-monkey", "SPECIES", 72, 83], ["Onchocerca ochengi", "SPECIES", 94, 112], ["cattle", "SPECIES", 116, 122], ["Brugia pahangi", "SPECIES", 26, 40], ["Brugia malayi", "SPECIES", 55, 68], ["Onchocerca ochengi", "SPECIES", 94, 112], ["cattle", "SPECIES", 116, 122], ["These infections", "PROBLEM", 0, 16], ["Brugia pahangi in cats", "PROBLEM", 26, 48], ["Brugia malayi", "PROBLEM", 55, 68], ["Brugia pahangi", "OBSERVATION", 26, 40], ["Brugia malayi", "OBSERVATION", 55, 68]]], ["In the final analysis, optimal parasite recovery was observed in mice humanized with HuSkMc (maximum of 10 worms), HuNSG (maximum of 18 worms) and BLT mice (maximum of 10 worms).DiscussionIt was clear that worms increased in size during the infection period with individual worms achieving up to 4 times the size of the original L3.", [["infection", "DISEASE", 241, 250], ["mice", "ORGANISM", 65, 69], ["BLT mice", "ORGANISM", 147, 155], ["worms", "ORGANISM", 206, 211], ["mice", "SPECIES", 65, 69], ["worms", "SPECIES", 107, 112], ["worms", "SPECIES", 136, 141], ["mice", "SPECIES", 151, 155], ["worms", "SPECIES", 171, 176], ["worms", "SPECIES", 206, 211], ["worms", "SPECIES", 274, 279], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 151, 155], ["HuSkMc", "TEST", 85, 91], ["HuNSG", "TEST", 115, 120], ["BLT mice", "TEST", 147, 155], ["worms", "PROBLEM", 206, 211], ["the infection period", "PROBLEM", 237, 257], ["individual worms", "PROBLEM", 263, 279], ["worms", "OBSERVATION", 206, 211], ["increased", "OBSERVATION_MODIFIER", 212, 221], ["size", "OBSERVATION_MODIFIER", 225, 229], ["infection", "OBSERVATION", 241, 250], ["size", "OBSERVATION_MODIFIER", 308, 312], ["L3", "ANATOMY", 329, 331]]], ["Growth of worms within a single mouse was not consistent and suggests that there is significant variability within the infecting larval population.", [["worms", "ORGANISM", 10, 15], ["mouse", "ORGANISM", 32, 37], ["worms", "SPECIES", 10, 15], ["mouse", "SPECIES", 32, 37], ["mouse", "SPECIES", 32, 37], ["significant variability", "PROBLEM", 84, 107], ["worms", "OBSERVATION", 10, 15], ["significant", "OBSERVATION_MODIFIER", 84, 95], ["variability", "OBSERVATION", 96, 107], ["infecting", "OBSERVATION_MODIFIER", 119, 128], ["larval population", "OBSERVATION", 129, 146]]], ["It does verify, however, that humanized mice have the potential to support extended development of O. volvulus.", [["O. volvulus", "DISEASE", 99, 110], ["mice", "ORGANISM", 40, 44], ["O. volvulus", "ORGANISM", 99, 110], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 40, 44], ["O. volvulus", "SPECIES", 99, 110], ["O. volvulus", "PROBLEM", 99, 110], ["volvulus", "OBSERVATION", 102, 110]]], ["Both male and female worms grew in length and resumed their sexual development.", [["female worms", "ORGANISM", 14, 26], ["worms", "SPECIES", 21, 26]]], ["Although no cast cuticles were observed, it was evident from organ development that the parasites had molted into fourth-stage larvae.DiscussionUrine and serum was collected from humanized mice infected for 8-12-weeks with O. volvulus for the identification of biomarkers.", [["cuticles", "ANATOMY", 17, 25], ["organ", "ANATOMY", 61, 66], ["serum", "ANATOMY", 154, 159], ["organ", "ORGAN", 61, 66], ["DiscussionUrine", "SIMPLE_CHEMICAL", 134, 149], ["serum", "ORGANISM_SUBSTANCE", 154, 159], ["mice", "ORGANISM", 189, 193], ["mice", "SPECIES", 189, 193], ["mice", "SPECIES", 189, 193], ["O. volvulus", "SPECIES", 223, 234], ["cast cuticles", "PROBLEM", 12, 25], ["the parasites", "PROBLEM", 84, 97], ["serum", "TEST", 154, 159], ["O. volvulus", "PROBLEM", 223, 234], ["biomarkers", "TEST", 261, 271], ["no", "UNCERTAINTY", 9, 11], ["cast cuticles", "OBSERVATION", 12, 25], ["fourth-stage", "OBSERVATION_MODIFIER", 114, 126], ["larvae", "ANATOMY_MODIFIER", 127, 133], ["volvulus", "OBSERVATION", 226, 234]]], ["Infected HuSkMc mice or BLT mice were selected for this analysis so the biomarkers identified would develop in the presence of human cells thereby potentially enhancing their specificity.", [["cells", "ANATOMY", 133, 138], ["HuSkMc mice", "ORGANISM", 9, 20], ["BLT mice", "ORGANISM", 24, 32], ["human", "ORGANISM", 127, 132], ["cells", "CELL", 133, 138], ["human cells", "CELL_TYPE", 127, 138], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 28, 32], ["human", "SPECIES", 127, 132], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 28, 32], ["human", "SPECIES", 127, 132], ["BLT mice", "TREATMENT", 24, 32], ["this analysis", "TEST", 51, 64], ["the biomarkers", "TEST", 68, 82], ["human cells", "PROBLEM", 127, 138], ["human cells", "OBSERVATION", 127, 138]]], ["Several O. volvulus-specific peptides were identified in the serum and urine of BLT and HuSkMc mice (S3 Table), however, no O. volvulus-specific proteins were found in both urine and serum from either mouse source.", [["serum", "ANATOMY", 61, 66], ["urine", "ANATOMY", 71, 76], ["urine", "ANATOMY", 173, 178], ["serum", "ANATOMY", 183, 188], ["O. volvulus", "ORGANISM", 8, 19], ["serum", "ORGANISM_SUBSTANCE", 61, 66], ["urine", "ORGANISM_SUBSTANCE", 71, 76], ["BLT", "CELL", 80, 83], ["HuSkMc mice", "ORGANISM", 88, 99], ["O. volvulus", "ORGANISM", 124, 135], ["urine", "ORGANISM_SUBSTANCE", 173, 178], ["serum", "ORGANISM_SUBSTANCE", 183, 188], ["mouse", "ORGANISM", 201, 206], ["O. volvulus", "SPECIES", 8, 19], ["mice", "SPECIES", 95, 99], ["O. volvulus", "SPECIES", 124, 135], ["mouse", "SPECIES", 201, 206], ["mice", "SPECIES", 95, 99], ["O. volvulus", "SPECIES", 124, 135], ["mouse", "SPECIES", 201, 206], ["Several O. volvulus", "PROBLEM", 0, 19], ["specific peptides", "PROBLEM", 20, 37], ["the serum", "TEST", 57, 66], ["BLT", "TEST", 80, 83], ["O. volvulus", "PROBLEM", 124, 135], ["specific proteins", "PROBLEM", 136, 153], ["urine and serum", "TEST", 173, 188], ["volvulus", "OBSERVATION", 11, 19], ["no", "UNCERTAINTY", 121, 123], ["volvulus", "OBSERVATION", 127, 135]]], ["The most likely useful biomarkers were the proteins listed in Fig 4B.", [["most likely", "UNCERTAINTY", 4, 15]]], ["Though most of the proteins were identified by one or more unique peptide(s), among the proteins with unknown function (OVOC9087, OVOC835, OVOC224), OVOC9087 does not have orthologues in other filarial species and hence would likely be able to distinguish O. volvulus from other filarial infections.", [["O. volvulus", "DISEASE", 256, 267], ["filarial infections", "DISEASE", 279, 298], ["OVOC9087", "GENE_OR_GENE_PRODUCT", 149, 157], ["filarial", "ORGANISM", 193, 201], ["O. volvulus", "ORGANISM", 256, 267], ["filarial", "ORGANISM", 279, 287], ["OVOC9087", "PROTEIN", 149, 157], ["O. volvulus", "SPECIES", 256, 267], ["O. volvulus", "SPECIES", 256, 267], ["orthologues in other filarial species", "PROBLEM", 172, 209], ["volvulus", "PROBLEM", 259, 267], ["other filarial infections", "PROBLEM", 273, 298], ["filarial species", "OBSERVATION", 193, 209], ["volvulus", "OBSERVATION", 259, 267], ["filarial infections", "OBSERVATION", 279, 298]]], ["Because of the expected low number and abundance of O. volvulus-specific protein identification in the serum and urine from any given mouse in the current system, mass spectrometry was carried out with pooled serum and urine samples from each group of mice.DiscussionIn conclusion, novel small-animal hosts, NSG mice, have been identified that support the survival and development of O. volvulus L3 into advanced L4 mammalian stages.", [["serum", "ANATOMY", 103, 108], ["urine", "ANATOMY", 113, 118], ["serum", "ANATOMY", 209, 214], ["urine samples", "ANATOMY", 219, 232], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["urine", "ORGANISM_SUBSTANCE", 113, 118], ["mouse", "ORGANISM", 134, 139], ["serum", "ORGANISM_SUBSTANCE", 209, 214], ["urine samples", "ORGANISM_SUBSTANCE", 219, 232], ["mice", "ORGANISM", 252, 256], ["NSG mice", "ORGANISM", 308, 316], ["mouse", "SPECIES", 134, 139], ["mice", "SPECIES", 252, 256], ["mice", "SPECIES", 312, 316], ["O. volvulus", "SPECIES", 384, 395], ["O. volvulus", "SPECIES", 52, 63], ["mouse", "SPECIES", 134, 139], ["mice", "SPECIES", 252, 256], ["mice", "SPECIES", 312, 316], ["O. volvulus", "SPECIES", 384, 395], ["O. volvulus", "PROBLEM", 52, 63], ["specific protein identification", "TEST", 64, 95], ["the serum and urine", "TEST", 99, 118], ["mass spectrometry", "TEST", 163, 180], ["pooled serum", "TEST", 202, 214], ["urine samples", "TEST", 219, 232], ["the survival", "TREATMENT", 352, 364], ["O. volvulus", "PROBLEM", 384, 395], ["low number", "OBSERVATION_MODIFIER", 24, 34], ["volvulus", "OBSERVATION", 55, 63], ["small", "OBSERVATION_MODIFIER", 288, 293], ["volvulus", "OBSERVATION", 387, 395], ["L4", "ANATOMY", 413, 415]]], ["Humanized mice have also been shown to be effective at identifying biomarkers for early O. volvulus infections.", [["O. volvulus infections", "DISEASE", 88, 110], ["mice", "ORGANISM", 10, 14], ["O. volvulus", "ORGANISM", 88, 99], ["mice", "SPECIES", 10, 14], ["O. volvulus", "SPECIES", 88, 99], ["mice", "SPECIES", 10, 14], ["O. volvulus", "SPECIES", 88, 99], ["early O. volvulus infections", "PROBLEM", 82, 110], ["volvulus", "OBSERVATION", 91, 99]]], ["It is anticipated that these small-animal hosts for O. volvulus will also be useful as part of the effort to identify new anthelminthic drugs.", [["O. volvulus", "DISEASE", 52, 63], ["O. volvulus", "ORGANISM", 52, 63], ["O. volvulus", "SPECIES", 52, 63], ["O. volvulus", "SPECIES", 52, 63], ["these small-animal hosts", "PROBLEM", 23, 47], ["O. volvulus", "PROBLEM", 52, 63], ["new anthelminthic drugs", "TREATMENT", 118, 141], ["small", "OBSERVATION_MODIFIER", 29, 34], ["volvulus", "OBSERVATION", 55, 63]]], ["Finally, the fact that O. volvulus survives and develops in NSG mice humanized with human immune cells may provide the opportunity to study the human immune response to early infection with O. volvulus in a small animal model.", [["immune cells", "ANATOMY", 90, 102], ["O. volvulus", "DISEASE", 23, 34], ["infection", "DISEASE", 175, 184], ["O. volvulus", "DISEASE", 190, 201], ["O. volvulus", "ORGANISM", 23, 34], ["NSG mice", "ORGANISM", 60, 68], ["human", "ORGANISM", 84, 89], ["immune cells", "CELL", 90, 102], ["human", "ORGANISM", 144, 149], ["human immune cells", "CELL_TYPE", 84, 102], ["O. volvulus", "SPECIES", 23, 34], ["mice", "SPECIES", 64, 68], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 144, 149], ["O. volvulus", "SPECIES", 23, 34], ["mice", "SPECIES", 64, 68], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 144, 149], ["O. volvulus", "SPECIES", 190, 201], ["O. volvulus", "PROBLEM", 23, 34], ["human immune cells", "TREATMENT", 84, 102], ["early infection", "PROBLEM", 169, 184], ["O. volvulus", "PROBLEM", 190, 201], ["volvulus", "OBSERVATION", 26, 34], ["early", "OBSERVATION_MODIFIER", 169, 174], ["infection", "OBSERVATION", 175, 184], ["volvulus", "OBSERVATION", 193, 201], ["small animal model", "OBSERVATION_MODIFIER", 207, 225]]]], "PMC7250114": [["The importance of combatting fake news is starkly illustrated during the current COVID-19 pandemic.", [["pandemic", "PROBLEM", 90, 98]]], ["At the time of writing, Facebook uses machine learning algorithms to identify false or sensational claims used in advertising for alternative cures, they place potential fake news articles lower in the news feed, and they provide users with tips on how to identify fake news themselves (Sparks and Frishberg 2020).", [["alternative cures", "TREATMENT", 130, 147]]], ["Twitter ensures that searches on the virus result in credible articles and Instagram redirects anyone searching for information on the virus to a special message with credible information (Marr 2020).IntroductionThese measures are possible because different approaches exist that assist the detection of fake news.", [["the virus", "PROBLEM", 33, 42]]], ["The prevalence of fake news relates to the availability of mass media digital tools (Schade 2019).", [["mass media", "PROBLEM", 59, 69]]], ["There is no custodian of credibility standards for information on these platforms making the spread of fake news possible.", [["these platforms", "TEST", 66, 81], ["no", "UNCERTAINTY", 9, 11]]], ["Humans are manipulated through these actions to share the fake news articles (Shao et al. 2018).The Evolution of Fake News and Fake News DetectionClickbait is another tool encouraging the spread of fake news.", [["Humans", "ORGANISM", 0, 6]]], ["In order to do this, a systematic literature review was done.", [["a systematic literature review", "TEST", 21, 51]]], ["This section presents the search terms that were used, the selection criteria and the source selection.Search Terms ::: Research MethodSpecific search terms were used to enable the finding of relevant journal articles such as the following:(\u201cwhat is fake news\u201d OR \u201cnot genuine information\u201d OR \u201ccounter fit news\u201d OR \u201cinaccurate report information\u201d OR \u201cfalse store\u201d OR \u201cfalse news\u201d OR \u201cfake news\u201d OR \u201cfalse accusation\u201d OR \u201cdigital approach\u201d OR \u201cautomated tool\u201d OR \u201cprogrammed tool\u201d OR \u201cdigital device\u201d OR \u201cdigital appliance\u201d OR \u201cIS tool\u201d OR \u201cdigital gear\u201d)AND (\u201cfake news detection\u201d OR \u201capproaches to identify fake news\u201d OR \u201cmethods to identify fake news\u201d OR \u201cfinding fake news\u201d OR \u201cways to detect fake news\u201d).Inclusion Criteria. ::: Selection Criteria ::: Research MethodStudies that adhere to the following criteria: (1) studies published between 2008 and 2019; (2) studies found in English; (3) with main focus fake news on digital platforms; (4) articles that are published in IT journals or any technology related journal articles (e.g. computers in human behavior) as well as conference proceedings; (5) journal articles that are sited more than 10 times.Exclusion Criteria. ::: Selection Criteria ::: Research MethodStudies that adhered to the following criteria: (1) studies not presented in journal articles (e.g. in the form of a slide show or overhead presentation); (2) studies published, not relating to technology or IT; (3) articles on fake news but not the identification of it.Exclusion Criteria. ::: Selection Criteria ::: Research MethodThe search terms were used to find relevant articles on ProQuest, ScienceDirect, EBSCOhost and Google Scholar (seen here as \u2018other sources\u2019).Flowchart of Search Process ::: Research MethodFigure 1 below gives a flowchart of the search process: the identification of articles, the screening, the selection process and the number of the included articles.Bag of Words (BOW): ::: Language Approach ::: FindingsIn this approach, each word in a paragraph is considered of equal importance and as independent entities (Burkhardt 2017).", [["human", "ORGANISM", 1053, 1058], ["human", "SPECIES", 1053, 1058], ["human", "SPECIES", 1053, 1058], ["digital approach", "TEST", 421, 437], ["digital device", "TREATMENT", 484, 498], ["digital appliance", "TREATMENT", 504, 521], ["studies", "TEST", 866, 873], ["digital platforms", "TEST", 925, 942], ["Research MethodFigure", "TREATMENT", 1727, 1748], ["the screening", "TEST", 1830, 1843]]], ["Different compatibly scores are used in this approach.Deep Syntax: ::: Language Approach ::: FindingsThe deep syntax method is carried out through Probability Context Free Grammars (Stahl 2018).", [["Different compatibly scores", "PROBLEM", 0, 27], ["The deep syntax method", "TEST", 101, 123], ["Syntax", "OBSERVATION", 59, 65], ["deep syntax", "OBSERVATION", 105, 116]]], ["The Probability Context Free Grammars executes deep syntax tasks through parse trees that make Context Free Grammar analysis possible.", [["Free Grammar analysis", "TEST", 103, 124]]], ["Probabilistic Context Free Grammar is an extension of Context Free Grammars (Zhou and Zafarani 2018).", [["Free Grammar", "OBSERVATION", 22, 34]]], ["Sentences are converted into a set of rewritten rules and these rules are used to analyse various syntax structures.", [["rewritten rules", "TREATMENT", 38, 53]]], ["Some examples of topic-agnostic features are 1) a large number of advertisements, 2) longer headlines with eye-catching phrases, 3) different text patterns from mainstream news to induce emotive responses 4) presence of an author name (Castelo et al. 2019; Horne and Adali 2017).Machine Learning Approach ::: FindingsMachine learning algorithms can be used to identify fake news.", [["eye-catching phrases", "TREATMENT", 107, 127], ["Machine learning algorithms", "TREATMENT", 317, 344], ["large", "OBSERVATION_MODIFIER", 50, 55]]], ["This is achieved through using different types of training datasets to refine the algorithms.", [["training datasets", "TREATMENT", 50, 67], ["the algorithms", "TEST", 78, 92]]], ["One way is through crowdsourcing.", [["crowdsourcing", "OBSERVATION", 19, 32]]], ["Over 240 stories were collected and added to the fake news dataset.Machine Learning Approach ::: FindingsA machine learning approach called the rumor identification framework has been developed that legitimizes signals of ambiguous posts so that a person can easily identify fake news (Sivasangari et al. 2018).", [["person", "SPECIES", 248, 254]]], ["The framework will alert people of posts that might be fake (Sivasangari et al. 2018).", [["people", "ORGANISM", 25, 31], ["people", "SPECIES", 25, 31]]], ["Expert-oriented fact-checking requires professionals to evaluate the accuracy of the news manually through research and other studies on the specific claim.", [["other studies", "TEST", 120, 133]]], ["A recent tool called the ClaimBuster has been developed and is an example of how fact checking can automatically identify fake news (Hassan et al. 2017).", [["ClaimBuster", "DNA", 25, 36]]], ["This tool makes use of machine learning techniques combined with natural language processing and a variety of database queries.", [["machine learning techniques", "TREATMENT", 23, 50], ["natural language processing", "TREATMENT", 65, 92]]], ["It analyses context on social media, interviews and speeches in real time to determine \u2018facts\u2019 and compares it with a repository that contains verified facts and delivers it to the reader (Hassan et al. 2017).Crowd Sourcing Oriented. ::: Knowledge Based Approach ::: FindingsCrowdsourcing gives the opportunity for a group of people to make a collective decision through examining the accuracy of news (Pennycook and Rand 2019).", [["people", "ORGANISM", 326, 332], ["people", "SPECIES", 326, 332]]], ["Kiskkit is an example of a platform that can be used for crowdsourcing where the platform allows a group of people to evaluate pieces of a news article (Hassan et al. 2017).", [["people", "ORGANISM", 108, 114], ["people", "SPECIES", 108, 114]]], ["After one piece has been evaluated the crowd moves to the next piece for evaluation until the entire news article has been evaluated and the accuracy thereof has been determined by the wisdom of the crowd (Hassan et al. 2017).Hybrid Approach ::: FindingsThere are three generally agreed upon elements of fake news articles, the first element is the text of an article, second element is the response that the articles received and lastly the source used that motivate the news article (Ruchansky et al. 2017).", [["evaluation", "TEST", 73, 83]]], ["A recent study has been conducted that proposes a hybrid model which helps to identify fake news on social media through using a combination of human and machine learning to help identify fake news (Okoro et al. 2018).", [["human", "ORGANISM", 144, 149], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 144, 149], ["A recent study", "TEST", 0, 14], ["a hybrid model", "TREATMENT", 48, 62], ["human and machine learning", "TREATMENT", 144, 170]]], ["Humans only have a 4% chance of identifying fake news if they take a guess and can only identify fake news 54% of the time (Okoro et al. 2018).", [["Humans", "ORGANISM", 0, 6]]], ["The current battle against fake news on COVID-19 and the uncertainty surrounding it, shows that a hybrid approach towards fake news detection is needed.", [["COVID", "TEST", 40, 45], ["a hybrid approach", "TREATMENT", 96, 113]]], ["Human wisdom as well as digital tools need to be harnessed in this process.", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human wisdom", "TREATMENT", 0, 12], ["digital tools", "TEST", 24, 37]]]], "PMC7206633": [["Our Contributions ::: IntroductionThe contribution of this work is twofold.Our Contributions ::: IntroductionFirst, we consider upper bounds on the size of depth-two threshold circuits for", [["two threshold circuits", "TREATMENT", 162, 184], ["upper bounds", "OBSERVATION_MODIFIER", 128, 140]]]], "PMC7395832": [["IntroductionThe newly emerged SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), is a positive-sense single-stranded RNA (+ssRNA) virus that causes COVID-19 (coronavirus disease 2019), which has been getting global concern since December 2019 [[1], [2], [3], [4]].", [["acute respiratory syndrome coronavirus", "DISEASE", 49, 87], ["coronavirus disease", "DISEASE", 169, 188], ["SARS-CoV-2", "ORGANISM", 30, 40], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 42, 87], ["COVID-19", "ORGANISM", 159, 167], ["coronavirus", "ORGANISM", 169, 180], ["[2], [3], [4]", "SIMPLE_CHEMICAL", 260, 273], ["coronavirus", "SPECIES", 76, 87], ["SARS-CoV-2 (severe acute respiratory syndrome coronavirus", "SPECIES", 30, 87], ["COVID-19", "SPECIES", 159, 167], ["CoV", "TEST", 35, 38], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 42, 87], ["a positive-sense single-stranded RNA (+ssRNA) virus", "PROBLEM", 95, 146], ["COVID", "TEST", 159, 164], ["coronavirus disease", "PROBLEM", 169, 188], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["respiratory syndrome", "OBSERVATION", 55, 75]]], ["Coronaviruses belong to the subfamily Coronavirinae, in the family Coronaviridae of the order Nidovirales.", [["Coronavirinae", "GENE_OR_GENE_PRODUCT", 38, 51], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 94, 105], ["Coronaviruses", "PROBLEM", 0, 13]]], ["Like the other strains of coronavirus, SARS-CoV-2 has phospholipid bilayers envelop and the genome codes almost five types of structural proteins [[5], [6], [7], [8]] (Fig. 1).", [["SARS", "DISEASE", 39, 43], ["coronavirus", "ORGANISM", 26, 37], ["SARS-CoV-2", "ORGANISM", 39, 49], ["[6], [7], [8]]", "SIMPLE_CHEMICAL", 152, 166], ["structural proteins", "PROTEIN", 126, 145], ["coronavirus", "SPECIES", 26, 37], ["SARS-CoV", "SPECIES", 39, 47], ["coronavirus", "PROBLEM", 26, 37], ["SARS", "TEST", 39, 43], ["CoV", "TEST", 44, 47], ["phospholipid bilayers envelop", "TREATMENT", 54, 83], ["structural proteins", "TEST", 126, 145], ["Fig.", "TEST", 168, 172]]], ["The typical clinical manifestations of COVID-19 include a non-productive cough, fever, and dyspnea, while acute respiratory distress syndrome (ARDS) is the leading cause of death in COVID-19 [9,10].", [["respiratory", "ANATOMY", 112, 123], ["cough", "DISEASE", 73, 78], ["fever", "DISEASE", 80, 85], ["dyspnea", "DISEASE", 91, 98], ["acute respiratory distress syndrome", "DISEASE", 106, 141], ["ARDS", "DISEASE", 143, 147], ["death", "DISEASE", 173, 178], ["COVID-19", "CHEMICAL", 39, 47], ["COVID", "TEST", 39, 44], ["a non-productive cough", "PROBLEM", 56, 78], ["fever", "PROBLEM", 80, 85], ["dyspnea", "PROBLEM", 91, 98], ["acute respiratory distress syndrome", "PROBLEM", 106, 141], ["ARDS", "PROBLEM", 143, 147], ["death", "PROBLEM", 173, 178], ["non-productive", "OBSERVATION_MODIFIER", 58, 72], ["cough", "OBSERVATION", 73, 78], ["fever", "OBSERVATION", 80, 85], ["acute", "OBSERVATION_MODIFIER", 106, 111], ["respiratory distress", "OBSERVATION", 112, 132]]], ["Unfortunately, the outbreak is rapidly spreading worldwide.", [["rapidly", "OBSERVATION_MODIFIER", 31, 38], ["spreading", "OBSERVATION_MODIFIER", 39, 48]]], ["In the absence of effective treatments or vaccines to prevent or treat this infection, its rapid dissemination may affect public healthcare systems and severe economic and social distress worldwide [11,12].", [["infection", "DISEASE", 76, 85], ["economic and social distress", "DISEASE", 159, 187], ["effective treatments", "TREATMENT", 18, 38], ["vaccines", "TREATMENT", 42, 50], ["this infection", "PROBLEM", 71, 85], ["severe economic and social distress", "PROBLEM", 152, 187], ["infection", "OBSERVATION", 76, 85], ["severe", "OBSERVATION_MODIFIER", 152, 158], ["economic", "OBSERVATION_MODIFIER", 159, 167]]], ["Up to now, several immunotherapy strategies have been used to treat or prevent virus infection in patients with COVID-19 [13].", [["infection", "DISEASE", 85, 94], ["COVID-19", "CHEMICAL", 112, 120], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["several immunotherapy strategies", "TREATMENT", 11, 43], ["virus infection", "PROBLEM", 79, 94], ["COVID", "TEST", 112, 117]]], ["These approaches, including convalescent plasma therapy, monoclonal antibodies against IL-6 receptor and complement protein C5, cytokine therapy, mesenchymal stem cell therapy, and intravenous immunoglobulin, have been applied with varied efficiency in COVID-19 [[14], [15], [16], [17]].", [["plasma", "ANATOMY", 41, 47], ["mesenchymal stem cell", "ANATOMY", 146, 167], ["intravenous", "ANATOMY", 181, 192], ["COVID-19", "CHEMICAL", 253, 261], ["plasma", "ORGANISM_SUBSTANCE", 41, 47], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 87, 100], ["complement protein C5", "GENE_OR_GENE_PRODUCT", 105, 126], ["mesenchymal stem cell", "CELL", 146, 167], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 181, 192], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 193, 207], ["[14], [15], [16], [17]]", "SIMPLE_CHEMICAL", 263, 286], ["monoclonal antibodies", "PROTEIN", 57, 78], ["IL-6 receptor", "PROTEIN", 87, 100], ["complement protein C5", "PROTEIN", 105, 126], ["cytokine", "PROTEIN", 128, 136], ["intravenous immunoglobulin", "PROTEIN", 181, 207], ["convalescent plasma therapy", "TREATMENT", 28, 55], ["monoclonal antibodies", "TEST", 57, 78], ["IL", "TEST", 87, 89], ["complement protein C5", "TREATMENT", 105, 126], ["cytokine therapy", "TREATMENT", 128, 144], ["mesenchymal stem cell therapy", "TREATMENT", 146, 175], ["intravenous immunoglobulin", "TREATMENT", 181, 207], ["COVID", "TEST", 253, 258], ["mesenchymal stem cell therapy", "OBSERVATION", 146, 175]]], ["Interaction of the virus with the immune system mediators leads to triggering an immune response that may determine the outcome of the viral infection [18].", [["immune system", "ANATOMY", 34, 47], ["viral infection", "DISEASE", 135, 150], ["the virus", "PROBLEM", 15, 24], ["the immune system mediators", "TREATMENT", 30, 57], ["the viral infection", "PROBLEM", 131, 150], ["viral", "OBSERVATION_MODIFIER", 135, 140], ["infection", "OBSERVATION", 141, 150]]], ["Controlling viral replication in the early phase of the disease could be applied through virus recognition by Pattern recognition receptors (PRRs), including toll-like receptor (TLR), NOD-like receptor (NLR), RIG-I-like receptor (RLR), melanoma differentiation-associated gene 5 (MDA5), C-type lectin-like receptors (CLR), complement proteins, and the other unclassified receptors in the cytoplasm, like Stimulator of interferon genes (STING), DAI, and other innate immune mediators as a part of the innate immune system that may limit SARS-CoV-2 spread within the host [[19], [20], [21], [22], [23]].IntroductionAccording to the recent findings, SARS-CoV-2 replication starts when the S (Spike) proteins attach to the membrane of the lung cells via angiotensin-converting enzyme 2 (ACE2) receptor, by the clathrin-dependent and -independent endocytosis, and release their RNA that senses by endosomal TLRs (TLR3, TLR7, TLR8, and TLR9), RIG-I, MDA5 and cGAS (nucleotidyltransferase cyclic GMP-AMP synthase) in the cytoplasm [[24], [25], [26]].", [["melanoma", "ANATOMY", 236, 244], ["cytoplasm", "ANATOMY", 388, 397], ["membrane", "ANATOMY", 719, 727], ["lung cells", "ANATOMY", 735, 745], ["endosomal", "ANATOMY", 892, 901], ["cytoplasm", "ANATOMY", 1014, 1023], ["SARS", "DISEASE", 647, 651], ["angiotensin", "CHEMICAL", 750, 761], ["GMP", "CHEMICAL", 989, 992], ["AMP", "CHEMICAL", 993, 996], ["cyclic GMP-AMP", "CHEMICAL", 982, 996], ["Pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 110, 139], ["PRRs", "GENE_OR_GENE_PRODUCT", 141, 145], ["toll-like receptor", "GENE_OR_GENE_PRODUCT", 158, 176], ["TLR", "GENE_OR_GENE_PRODUCT", 178, 181], ["NOD-like receptor", "GENE_OR_GENE_PRODUCT", 184, 201], ["NLR", "GENE_OR_GENE_PRODUCT", 203, 206], ["RIG-I-like receptor", "GENE_OR_GENE_PRODUCT", 209, 228], ["RLR", "GENE_OR_GENE_PRODUCT", 230, 233], ["melanoma differentiation-associated gene 5", "GENE_OR_GENE_PRODUCT", 236, 278], ["MDA5", "GENE_OR_GENE_PRODUCT", 280, 284], ["C-type lectin-like receptors", "GENE_OR_GENE_PRODUCT", 287, 315], ["CLR", "GENE_OR_GENE_PRODUCT", 317, 320], ["complement proteins", "GENE_OR_GENE_PRODUCT", 323, 342], ["cytoplasm", "ORGANISM_SUBSTANCE", 388, 397], ["Stimulator of interferon genes", "GENE_OR_GENE_PRODUCT", 404, 434], ["STING", "GENE_OR_GENE_PRODUCT", 436, 441], ["DAI", "GENE_OR_GENE_PRODUCT", 444, 447], ["[[19], [20], [21], [22], [23]]", "SIMPLE_CHEMICAL", 570, 600], ["S (Spike) proteins", "GENE_OR_GENE_PRODUCT", 686, 704], ["membrane", "CELLULAR_COMPONENT", 719, 727], ["lung cells", "CELL", 735, 745], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 750, 781], ["ACE2", "GENE_OR_GENE_PRODUCT", 783, 787], ["clathrin", "GENE_OR_GENE_PRODUCT", 806, 814], ["endosomal", "CELLULAR_COMPONENT", 892, 901], ["TLRs", "GENE_OR_GENE_PRODUCT", 902, 906], ["TLR3", "GENE_OR_GENE_PRODUCT", 908, 912], ["TLR7", "GENE_OR_GENE_PRODUCT", 914, 918], ["TLR8", "GENE_OR_GENE_PRODUCT", 920, 924], ["TLR9", "GENE_OR_GENE_PRODUCT", 930, 934], ["RIG-I", "GENE_OR_GENE_PRODUCT", 937, 942], ["MDA5", "GENE_OR_GENE_PRODUCT", 944, 948], ["cGAS", "GENE_OR_GENE_PRODUCT", 953, 957], ["nucleotidyltransferase cyclic GMP-AMP synthase", "GENE_OR_GENE_PRODUCT", 959, 1005], ["cytoplasm", "ORGANISM_SUBSTANCE", 1014, 1023], ["[24], [25], [26]]", "SIMPLE_CHEMICAL", 1025, 1042], ["Pattern recognition receptors", "PROTEIN", 110, 139], ["PRRs", "PROTEIN", 141, 145], ["toll-like receptor", "PROTEIN", 158, 176], ["TLR", "PROTEIN", 178, 181], ["NOD-like receptor", "PROTEIN", 184, 201], ["NLR", "PROTEIN", 203, 206], ["RIG-I-like receptor", "PROTEIN", 209, 228], ["RLR", "PROTEIN", 230, 233], ["melanoma differentiation-associated gene 5 (MDA5), C-type lectin-like receptors", "PROTEIN", 236, 315], ["CLR", "PROTEIN", 317, 320], ["complement proteins", "PROTEIN", 323, 342], ["Stimulator of interferon genes", "DNA", 404, 434], ["STING", "PROTEIN", 436, 441], ["DAI", "DNA", 444, 447], ["innate immune mediators", "PROTEIN", 459, 482], ["S (Spike) proteins", "PROTEIN", 686, 704], ["lung cells", "CELL_TYPE", 735, 745], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 750, 797], ["clathrin", "PROTEIN", 806, 814], ["endosomal TLRs", "PROTEIN", 892, 906], ["TLR3", "PROTEIN", 908, 912], ["TLR7", "PROTEIN", 914, 918], ["TLR8", "PROTEIN", 920, 924], ["TLR9", "PROTEIN", 930, 934], ["RIG-I", "PROTEIN", 937, 942], ["MDA5", "PROTEIN", 944, 948], ["cGAS", "PROTEIN", 953, 957], ["nucleotidyltransferase cyclic GMP-AMP synthase", "PROTEIN", 959, 1005], ["viral replication", "TREATMENT", 12, 29], ["the disease", "PROBLEM", 52, 63], ["NOD", "TEST", 184, 187], ["melanoma differentiation", "PROBLEM", 236, 260], ["C-type lectin-like receptors", "PROBLEM", 287, 315], ["complement proteins", "PROBLEM", 323, 342], ["the other unclassified receptors in the cytoplasm", "PROBLEM", 348, 397], ["Stimulator of interferon genes", "TREATMENT", 404, 434], ["DAI", "PROBLEM", 444, 447], ["CoV", "TEST", 541, 544], ["SARS", "PROBLEM", 647, 651], ["CoV-2 replication", "TREATMENT", 652, 669], ["the S (Spike) proteins attach", "PROBLEM", 682, 711], ["angiotensin-converting enzyme 2 (ACE2) receptor", "TREATMENT", 750, 797], ["independent endocytosis", "PROBLEM", 830, 853], ["TLR3", "TEST", 908, 912], ["TLR7", "TEST", 914, 918], ["TLR8", "TEST", 920, 924], ["TLR9", "TEST", 930, 934], ["RIG", "TEST", 937, 940], ["MDA5", "TEST", 944, 948], ["cGAS", "TEST", 953, 957], ["nucleotidyltransferase cyclic GMP", "TEST", 959, 992], ["AMP synthase", "TEST", 993, 1005], ["viral replication", "OBSERVATION", 12, 29], ["early phase", "OBSERVATION_MODIFIER", 37, 48], ["melanoma", "OBSERVATION", 236, 244], ["lung", "ANATOMY", 735, 739], ["MDA5", "ANATOMY", 944, 948]]], ["Interactions between SARS-CoV-2 and alveolar cells, trigger downstream signaling pathway via TIR-domain-containing adapter-inducing interferon-\u03b2 (TRIF), and STING adaptor molecules lead to triggering MyD88 adaptor molecule, following that activation of the NF-\u03baB and interferon regulatory factor 3 (IRF3) [[27], [28], [29]].", [["alveolar cells", "ANATOMY", 36, 50], ["SARS-CoV-2", "CELL", 21, 31], ["alveolar cells", "CELL", 36, 50], ["TIR-domain-containing adapter-inducing interferon-\u03b2", "GENE_OR_GENE_PRODUCT", 93, 144], ["TRIF", "GENE_OR_GENE_PRODUCT", 146, 150], ["STING", "GENE_OR_GENE_PRODUCT", 157, 162], ["MyD88", "GENE_OR_GENE_PRODUCT", 200, 205], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 257, 262], ["interferon regulatory factor 3", "GENE_OR_GENE_PRODUCT", 267, 297], ["IRF3", "GENE_OR_GENE_PRODUCT", 299, 303], ["[27], [28], [29]]", "SIMPLE_CHEMICAL", 306, 323], ["alveolar cells", "CELL_TYPE", 36, 50], ["TIR-domain-containing adapter-inducing interferon-\u03b2", "PROTEIN", 93, 144], ["TRIF", "PROTEIN", 146, 150], ["STING adaptor molecules", "PROTEIN", 157, 180], ["MyD88 adaptor molecule", "PROTEIN", 200, 222], ["NF-\u03baB", "PROTEIN", 257, 262], ["interferon regulatory factor 3", "PROTEIN", 267, 297], ["IRF3", "PROTEIN", 299, 303], ["SARS-CoV", "SPECIES", 21, 29], ["SARS", "TEST", 21, 25], ["CoV", "TEST", 26, 29], ["alveolar cells", "PROBLEM", 36, 50], ["adapter", "TREATMENT", 115, 122], ["interferon-\u03b2 (TRIF)", "TREATMENT", 132, 151], ["STING adaptor molecules", "TREATMENT", 157, 180], ["the NF", "TEST", 253, 259], ["interferon regulatory factor", "TEST", 267, 295], ["alveolar cells", "ANATOMY", 36, 50]]], ["The result of this complex pathway is the production of IFN-\u03b1 and -\u03b2 and varied set of pro-inflammatory mediators.", [["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 56, 61], ["-\u03b2", "GENE_OR_GENE_PRODUCT", 66, 68], ["IFN", "PROTEIN", 56, 59], ["\u03b1", "PROTEIN", 60, 61], ["-\u03b2", "PROTEIN", 66, 68], ["pro-inflammatory mediators", "PROTEIN", 87, 113], ["this complex pathway", "PROBLEM", 14, 34], ["IFN", "TEST", 56, 59], ["pro-inflammatory mediators", "OBSERVATION", 87, 113]]], ["According to the recently published researches, increased levels of some plasma mediators, including IL-1, IL-2, IL-4, IL-7, IL-10, IL-12, IL-13, IL-17, TNF-\u03b1, MIP-1\u03b1, IP-10, IFN-\u03b3, GCSF, MCP-1, MCSF, and hepatocyte growth factor (HGF) lead to the lung injury in some patients with COVID-19 [[30], [31], [32], [33]].", [["plasma", "ANATOMY", 73, 79], ["lung", "ANATOMY", 248, 252], ["lung injury", "DISEASE", 248, 259], ["COVID-19", "CHEMICAL", 282, 290], ["plasma", "ORGANISM_SUBSTANCE", 73, 79], ["IL-1", "GENE_OR_GENE_PRODUCT", 101, 105], ["IL-2", "GENE_OR_GENE_PRODUCT", 107, 111], ["IL-4", "GENE_OR_GENE_PRODUCT", 113, 117], ["IL-7", "GENE_OR_GENE_PRODUCT", 119, 123], ["IL-10", "GENE_OR_GENE_PRODUCT", 125, 130], ["IL-12", "GENE_OR_GENE_PRODUCT", 132, 137], ["IL-13", "GENE_OR_GENE_PRODUCT", 139, 144], ["IL-17", "GENE_OR_GENE_PRODUCT", 146, 151], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 153, 158], ["MIP-1\u03b1", "GENE_OR_GENE_PRODUCT", 160, 166], ["IP-10", "GENE_OR_GENE_PRODUCT", 168, 173], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 175, 180], ["GCSF", "GENE_OR_GENE_PRODUCT", 182, 186], ["MCP-1", "GENE_OR_GENE_PRODUCT", 188, 193], ["MCSF", "GENE_OR_GENE_PRODUCT", 195, 199], ["hepatocyte growth factor", "GENE_OR_GENE_PRODUCT", 205, 229], ["HGF", "GENE_OR_GENE_PRODUCT", 231, 234], ["lung", "ORGAN", 248, 252], ["patients", "ORGANISM", 268, 276], ["[30], [31], [32], [33]]", "SIMPLE_CHEMICAL", 292, 315], ["plasma mediators", "PROTEIN", 73, 89], ["TNF", "PROTEIN", 153, 156], ["MIP", "PROTEIN", 160, 163], ["IFN", "PROTEIN", 175, 178], ["\u03b3", "PROTEIN", 179, 180], ["GCSF", "PROTEIN", 182, 186], ["MCP-1", "PROTEIN", 188, 193], ["MCSF", "PROTEIN", 195, 199], ["hepatocyte growth factor", "PROTEIN", 205, 229], ["HGF", "PROTEIN", 231, 234], ["patients", "SPECIES", 268, 276], ["some plasma mediators", "TEST", 68, 89], ["IL", "TEST", 101, 103], ["IL", "TEST", 107, 109], ["IL", "TEST", 113, 115], ["IL", "TEST", 119, 121], ["IL", "TEST", 125, 127], ["IL", "TEST", 132, 134], ["IL", "TEST", 139, 141], ["IL", "TEST", 146, 148], ["TNF", "TEST", 153, 156], ["MIP", "TEST", 160, 163], ["IP", "TEST", 168, 170], ["IFN", "TEST", 175, 178], ["\u03b3", "TEST", 179, 180], ["GCSF", "TEST", 182, 186], ["MCP", "TEST", 188, 191], ["MCSF", "TEST", 195, 199], ["hepatocyte growth factor", "PROBLEM", 205, 229], ["the lung injury", "PROBLEM", 244, 259], ["COVID", "TEST", 282, 287], ["GCSF", "ANATOMY", 182, 186], ["MCSF", "ANATOMY", 195, 199], ["hepatocyte", "ANATOMY", 205, 215], ["lung", "ANATOMY", 248, 252], ["injury", "OBSERVATION", 253, 259]]], ["The viral invasion occurred, when the virus particles fuse to the respiratory mucosal tissue and infect other cells, resulting in a chain of the immune system responses and cytokine storm, which may be associated with the severe condition of COVID-19 patients [[34], [35], [36]].", [["respiratory mucosal tissue", "ANATOMY", 66, 92], ["cells", "ANATOMY", 110, 115], ["immune system", "ANATOMY", 145, 158], ["COVID", "DISEASE", 242, 247], ["mucosal tissue", "TISSUE", 78, 92], ["cells", "CELL", 110, 115], ["patients", "ORGANISM", 251, 259], ["cytokine", "PROTEIN", 173, 181], ["patients", "SPECIES", 251, 259], ["The viral invasion", "PROBLEM", 0, 18], ["the virus particles", "PROBLEM", 34, 53], ["the respiratory mucosal tissue", "PROBLEM", 62, 92], ["infect other cells", "PROBLEM", 97, 115], ["the severe condition", "PROBLEM", 218, 238], ["COVID", "TEST", 242, 247], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["invasion", "OBSERVATION", 10, 18], ["respiratory mucosal tissue", "ANATOMY", 66, 92]]], ["In most studies, it was obviously proved that severe pneumonia and consequently respiratory failure and death are due to acute inflammation rather than a direct damaging effect of the virus itself [37,38].IntroductionWhile SARS-CoV-2 attaches and enters the alveolar cells, its antigen will be presented to virus-specific cytotoxic T lymphocytes (CTLs) via major histocompatibility complex (MHC) class I (and less via MHC II) existing on the surface of antigen presentation cells (APC).", [["respiratory", "ANATOMY", 80, 91], ["alveolar cells", "ANATOMY", 258, 272], ["cytotoxic T lymphocytes", "ANATOMY", 322, 345], ["CTLs", "ANATOMY", 347, 351], ["surface", "ANATOMY", 442, 449], ["antigen presentation cells", "ANATOMY", 453, 479], ["APC", "ANATOMY", 481, 484], ["pneumonia", "DISEASE", 53, 62], ["respiratory failure", "DISEASE", 80, 99], ["death", "DISEASE", 104, 109], ["inflammation", "DISEASE", 127, 139], ["SARS", "DISEASE", 223, 227], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 223, 233], ["alveolar cells", "CELL", 258, 272], ["cytotoxic T lymphocytes", "CELL", 322, 345], ["CTLs", "CELL", 347, 351], ["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 357, 389], ["MHC II", "GENE_OR_GENE_PRODUCT", 418, 424], ["surface", "CELLULAR_COMPONENT", 442, 449], ["antigen presentation cells", "CELL", 453, 479], ["APC", "GENE_OR_GENE_PRODUCT", 481, 484], ["alveolar cells", "CELL_TYPE", 258, 272], ["cytotoxic T lymphocytes", "CELL_TYPE", 322, 345], ["CTLs", "CELL_TYPE", 347, 351], ["major histocompatibility complex (MHC) class I", "PROTEIN", 357, 403], ["MHC II", "PROTEIN", 418, 424], ["antigen presentation cells", "CELL_TYPE", 453, 479], ["APC", "CELL_TYPE", 481, 484], ["SARS-CoV", "SPECIES", 223, 231], ["severe pneumonia", "PROBLEM", 46, 62], ["consequently respiratory failure", "PROBLEM", 67, 99], ["death", "PROBLEM", 104, 109], ["acute inflammation", "PROBLEM", 121, 139], ["the virus itself", "PROBLEM", 180, 196], ["SARS", "PROBLEM", 223, 227], ["virus", "TEST", 307, 312], ["APC", "TEST", 481, 484], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["pneumonia", "OBSERVATION", 53, 62], ["respiratory failure", "OBSERVATION", 80, 99], ["acute", "OBSERVATION_MODIFIER", 121, 126], ["inflammation", "OBSERVATION", 127, 139], ["alveolar cells", "ANATOMY", 258, 272]]], ["Antigen presentation subsequently stimulates the cellular and humoral immunity.", [["cellular", "ANATOMY", 49, 57], ["cellular", "CELL", 49, 57], ["Antigen presentation", "PROBLEM", 0, 20], ["humoral immunity", "OBSERVATION", 62, 78]]], ["According to the researches, multiple HLA alleles polymorphisms such as HLA-B\u22170703, HLA-B\u22174601, HLA-Cw\u22170801, HLA-DR B1\u22171202 have shown a correlation to the susceptibility of SARS-CoV-2 [39,40], while polymorphisms in the HLA-A\u22170201, HLA-DR0301, and HLA-Cw1502 are related to the protection from SARS infection [41].IntroductionAccording to Wang et al., different subsets of lymphocyte, including CD4+ and CD8+T lymphocytes, B lymphocytes as well as natural killer (NK) cells are decreased in COVID-19 patients, and this reduction is more significant in the severe cases compared to moderate ones.", [["lymphocyte", "ANATOMY", 374, 384], ["CD4+ and CD8+T lymphocytes", "ANATOMY", 396, 422], ["B lymphocytes", "ANATOMY", 424, 437], ["natural killer (NK) cells", "ANATOMY", 449, 474], ["SARS", "DISEASE", 174, 178], ["SARS infection", "DISEASE", 295, 309], ["HLA", "GENE_OR_GENE_PRODUCT", 38, 41], ["HLA-B", "GENE_OR_GENE_PRODUCT", 72, 77], ["HLA-B", "GENE_OR_GENE_PRODUCT", 84, 89], ["HLA-DR B1\u22171202", "GENE_OR_GENE_PRODUCT", 109, 123], ["SARS-CoV-2", "ORGANISM", 174, 184], ["HLA-A\u22170201", "GENE_OR_GENE_PRODUCT", 221, 231], ["HLA-DR0301", "GENE_OR_GENE_PRODUCT", 233, 243], ["HLA-Cw1502", "GENE_OR_GENE_PRODUCT", 249, 259], ["lymphocyte", "CELL", 374, 384], ["CD4", "GENE_OR_GENE_PRODUCT", 396, 399], ["CD8", "GENE_OR_GENE_PRODUCT", 405, 408], ["B lymphocytes", "CELL", 424, 437], ["natural killer (NK) cells", "CELL", 449, 474], ["patients", "ORGANISM", 501, 509], ["HLA alleles polymorphisms", "DNA", 38, 63], ["HLA-B\u22170703", "DNA", 72, 82], ["HLA-B\u22174601", "DNA", 84, 94], ["HLA-Cw\u22170801", "DNA", 96, 107], ["HLA-DR B1\u22171202", "DNA", 109, 123], ["HLA-A\u22170201", "DNA", 221, 231], ["HLA", "DNA", 233, 236], ["DR0301", "DNA", 237, 243], ["HLA-Cw1502", "DNA", 249, 259], ["lymphocyte", "CELL_TYPE", 374, 384], ["CD4+ and CD8+T lymphocytes", "CELL_TYPE", 396, 422], ["B lymphocytes", "CELL_TYPE", 424, 437], ["natural killer (NK) cells", "CELL_TYPE", 449, 474], ["patients", "SPECIES", 501, 509], ["SARS-CoV", "SPECIES", 174, 182], ["multiple HLA alleles polymorphisms", "PROBLEM", 29, 63], ["HLA", "TEST", 72, 75], ["HLA", "TEST", 84, 87], ["HLA", "TEST", 96, 99], ["HLA", "TEST", 109, 112], ["SARS", "TEST", 174, 178], ["CoV", "TEST", 179, 182], ["the HLA", "TEST", 217, 224], ["HLA", "TEST", 233, 236], ["HLA", "TEST", 249, 252], ["SARS infection", "PROBLEM", 295, 309], ["lymphocyte", "TEST", 374, 384], ["CD4", "TEST", 396, 399], ["CD8", "TEST", 405, 408], ["lymphocytes", "TEST", 411, 422], ["B lymphocytes", "TEST", 424, 437], ["COVID", "TEST", 492, 497], ["lymphocyte", "ANATOMY", 374, 384], ["lymphocytes", "ANATOMY", 411, 422], ["lymphocytes", "ANATOMY", 426, 437], ["decreased", "OBSERVATION_MODIFIER", 479, 488], ["more significant", "OBSERVATION_MODIFIER", 533, 549], ["severe", "OBSERVATION_MODIFIER", 557, 563]]], ["Peripheral lymphocyte subset alteration is associated with clinical outcome and treatment efficacy of COVID-19 [42].; the number of CD8+ T cells and CD4+/CD8+ ratio showed a significant association with inflammatory status in COVID-19; CD4+/CD8+ ratio was indicated as independent predictors of poor efficacy [41].", [["Peripheral lymphocyte", "ANATOMY", 0, 21], ["CD8+ T cells", "ANATOMY", 132, 144], ["CD4+/CD8+", "ANATOMY", 149, 158], ["CD4+/CD8+", "ANATOMY", 236, 245], ["Peripheral lymphocyte", "CELL", 0, 21], ["CD8", "GENE_OR_GENE_PRODUCT", 132, 135], ["CD4", "GENE_OR_GENE_PRODUCT", 149, 152], ["CD8", "GENE_OR_GENE_PRODUCT", 154, 157], ["CD4", "GENE_OR_GENE_PRODUCT", 236, 239], ["CD8", "GENE_OR_GENE_PRODUCT", 241, 244], ["Peripheral lymphocyte subset", "CELL_TYPE", 0, 28], ["CD8", "PROTEIN", 132, 135], ["T cells", "CELL_TYPE", 137, 144], ["CD4", "PROTEIN", 149, 152], ["CD8", "PROTEIN", 154, 157], ["CD4", "PROTEIN", 236, 239], ["CD8", "PROTEIN", 241, 244], ["Peripheral lymphocyte subset alteration", "PROBLEM", 0, 39], ["COVID", "TEST", 102, 107], ["CD8", "TEST", 132, 135], ["CD4", "TEST", 149, 152], ["CD8", "TEST", 154, 157], ["inflammatory status", "PROBLEM", 203, 222], ["COVID", "TEST", 226, 231], ["CD4", "TEST", 236, 239], ["lymphocyte subset alteration", "OBSERVATION", 11, 39], ["significant", "OBSERVATION_MODIFIER", 174, 185], ["inflammatory", "OBSERVATION_MODIFIER", 203, 215]]], ["While the virus enters the cells, its antigen will be presented to the APC.", [["cells", "ANATOMY", 27, 32], ["cells", "CELL", 27, 32], ["APC", "GENE_OR_GENE_PRODUCT", 71, 74], ["APC", "CELL_TYPE", 71, 74], ["virus", "OBSERVATION", 10, 15]]], ["According to Li et al., the number of TCD4+ and CD8+ in the peripheral blood of COVID-19 patients is significantly reduced.", [["peripheral blood", "ANATOMY", 60, 76], ["TCD4", "GENE_OR_GENE_PRODUCT", 38, 42], ["CD8", "GENE_OR_GENE_PRODUCT", 48, 51], ["peripheral blood", "ORGANISM_SUBSTANCE", 60, 76], ["patients", "ORGANISM", 89, 97], ["TCD4", "PROTEIN", 38, 42], ["CD8", "PROTEIN", 48, 51], ["patients", "SPECIES", 89, 97], ["TCD4", "TEST", 38, 42], ["CD8", "TEST", 48, 51], ["COVID", "TEST", 80, 85], ["peripheral", "ANATOMY_MODIFIER", 60, 70], ["blood", "ANATOMY", 71, 76], ["significantly", "OBSERVATION_MODIFIER", 101, 114], ["reduced", "OBSERVATION_MODIFIER", 115, 122]]], ["In contrast, they are excessively active, as evidenced by high proportions of HLA-DR (CD4 3.47%) and CD38 (CD8 39.4%) double-positive fractions [43].IntroductionAccording to the various case studies, those patients who have been infected with SARS-CoV-2 developed a protective antibody, but it is not apparent how long this protection lasts.", [["SARS", "DISEASE", 243, 247], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 78, 84], ["CD38", "GENE_OR_GENE_PRODUCT", 101, 105], ["CD8", "GENE_OR_GENE_PRODUCT", 107, 110], ["patients", "ORGANISM", 206, 214], ["SARS-CoV-2", "ORGANISM", 243, 253], ["CD4", "PROTEIN", 86, 89], ["CD38", "PROTEIN", 101, 105], ["CD8", "PROTEIN", 107, 110], ["patients", "SPECIES", 206, 214], ["SARS-CoV", "SPECIES", 243, 251], ["HLA", "TEST", 78, 81], ["CD4", "TEST", 86, 89], ["CD38", "TEST", 101, 105], ["CD8", "TEST", 107, 110], ["double-positive fractions", "PROBLEM", 118, 143], ["SARS", "PROBLEM", 243, 247], ["CoV", "TEST", 248, 251], ["a protective antibody", "PROBLEM", 264, 285], ["active", "OBSERVATION_MODIFIER", 34, 40], ["infected", "OBSERVATION", 229, 237]]], ["The quantity and quality of the antibody response may determine the fate of a viral infection [44].", [["viral infection", "DISEASE", 78, 93], ["the antibody response", "TEST", 28, 49], ["a viral infection", "PROBLEM", 76, 93], ["quantity", "OBSERVATION_MODIFIER", 4, 12], ["viral", "OBSERVATION_MODIFIER", 78, 83], ["infection", "OBSERVATION", 84, 93]]], ["High-affinity neutralizing antibodies can recognize particular viral epitopes without additional mediators via Fc regions.", [["Fc", "GENE_OR_GENE_PRODUCT", 111, 113], ["High-affinity neutralizing antibodies", "PROTEIN", 0, 37], ["viral epitopes", "PROTEIN", 63, 77], ["Fc regions", "PROTEIN", 111, 121], ["High-affinity neutralizing antibodies", "PROBLEM", 0, 37], ["particular viral epitopes", "PROBLEM", 52, 77]]], ["It seems that similar to SARS-CoV infection, in the case of SARS-CoV-2, viral fusing via ACE2 to the lung epithelia is blocked, when neutralizing antibodies recognize the particular domains on the S protein [45,46].", [["lung epithelia", "ANATOMY", 101, 115], ["SARS-CoV infection", "DISEASE", 25, 43], ["SARS", "DISEASE", 60, 64], ["SARS-CoV", "ORGANISM", 25, 33], ["SARS-CoV-2", "ORGANISM", 60, 70], ["ACE2", "GENE_OR_GENE_PRODUCT", 89, 93], ["lung epithelia", "TISSUE", 101, 115], ["ACE2", "PROTEIN", 89, 93], ["neutralizing antibodies", "PROTEIN", 133, 156], ["S protein", "PROTEIN", 197, 206], ["SARS-CoV", "SPECIES", 25, 33], ["SARS-CoV", "SPECIES", 60, 68], ["SARS", "PROBLEM", 25, 29], ["CoV infection", "PROBLEM", 30, 43], ["SARS", "PROBLEM", 60, 64], ["CoV", "TEST", 65, 68], ["viral fusing via ACE2", "TREATMENT", 72, 93], ["neutralizing antibodies", "TEST", 133, 156], ["the S protein", "TEST", 193, 206], ["CoV", "OBSERVATION_MODIFIER", 30, 33], ["infection", "OBSERVATION", 34, 43], ["lung", "ANATOMY", 101, 105], ["epithelia", "ANATOMY_MODIFIER", 106, 115]]], ["Moreover, these antibodies can also interact with the other immune cells, including NK cells, phagocytes, and complement systems, as a bridge between acquired immune responses and innate immune responses.", [["immune cells", "ANATOMY", 60, 72], ["NK cells", "ANATOMY", 84, 92], ["phagocytes", "ANATOMY", 94, 104], ["immune cells", "CELL", 60, 72], ["NK cells", "CELL", 84, 92], ["phagocytes", "CELL", 94, 104], ["antibodies", "PROTEIN", 16, 26], ["immune cells", "CELL_TYPE", 60, 72], ["NK cells", "CELL_TYPE", 84, 92], ["phagocytes", "CELL_TYPE", 94, 104], ["NK cells", "TEST", 84, 92], ["phagocytes", "TEST", 94, 104], ["NK cells", "OBSERVATION", 84, 92]]], ["After recognizing viral antigens via specific antibodies, phosphorylation of ITAMs in the cytoplasmic tail segments of the Ig\u03b1 and Ig\u03b2 in B cells occurs by SRC kinase family, lead to trigger downstream signaling to up-regulate pro-inflammatory cytokines and down-regulate anti-inflammatory cytokines [47,48].", [["cytoplasmic tail", "ANATOMY", 90, 106], ["B cells", "ANATOMY", 138, 145], ["ITAMs", "GENE_OR_GENE_PRODUCT", 77, 82], ["cytoplasmic", "ORGANISM_SUBSTANCE", 90, 101], ["Ig\u03b1", "GENE_OR_GENE_PRODUCT", 123, 126], ["Ig\u03b2", "GENE_OR_GENE_PRODUCT", 131, 134], ["B cells", "CELL", 138, 145], ["SRC kinase", "GENE_OR_GENE_PRODUCT", 156, 166], ["viral antigens", "PROTEIN", 18, 32], ["ITAMs", "PROTEIN", 77, 82], ["cytoplasmic tail segments", "PROTEIN", 90, 115], ["Ig\u03b1", "PROTEIN", 123, 126], ["Ig\u03b2", "PROTEIN", 131, 134], ["B cells", "CELL_TYPE", 138, 145], ["SRC kinase family", "PROTEIN", 156, 173], ["pro-inflammatory cytokines", "PROTEIN", 227, 253], ["anti-inflammatory cytokines", "PROTEIN", 272, 299], ["viral antigens", "PROBLEM", 18, 32], ["specific antibodies", "TEST", 37, 56], ["phosphorylation of ITAMs", "TREATMENT", 58, 82], ["the Ig\u03b1", "TEST", 119, 126], ["Ig\u03b2 in B cells", "PROBLEM", 131, 145], ["pro-inflammatory cytokines", "TEST", 227, 253], ["anti-inflammatory cytokines", "TEST", 272, 299], ["cytoplasmic", "OBSERVATION", 90, 101], ["tail segments", "ANATOMY_MODIFIER", 102, 115], ["B cells", "OBSERVATION", 138, 145]]], ["Viral components in the endosomes recognized by multiple endosomal TLRs, including TLR3, TLR7, and TLR8, resulting in immunopathology.", [["endosomes", "ANATOMY", 24, 33], ["endosomal", "ANATOMY", 57, 66], ["immunopathology", "DISEASE", 118, 133], ["endosomes", "CELLULAR_COMPONENT", 24, 33], ["endosomal", "CELLULAR_COMPONENT", 57, 66], ["TLRs", "GENE_OR_GENE_PRODUCT", 67, 71], ["TLR3", "GENE_OR_GENE_PRODUCT", 83, 87], ["TLR7", "GENE_OR_GENE_PRODUCT", 89, 93], ["TLR8", "GENE_OR_GENE_PRODUCT", 99, 103], ["endosomal TLRs", "PROTEIN", 57, 71], ["TLR3", "PROTEIN", 83, 87], ["TLR7", "PROTEIN", 89, 93], ["TLR8", "PROTEIN", 99, 103], ["Viral components", "PROBLEM", 0, 16], ["TLR3, TLR7", "TREATMENT", 83, 93], ["TLR8", "TREATMENT", 99, 103], ["immunopathology", "PROBLEM", 118, 133], ["multiple", "OBSERVATION_MODIFIER", 48, 56], ["endosomal TLRs", "OBSERVATION", 57, 71], ["immunopathology", "OBSERVATION", 118, 133]]], ["In this systematic review, we provide an update on the treatment of the COVID-19 patients with focused on the immunotherapies.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["the immunotherapies", "TREATMENT", 106, 125]]], ["Immunology knowledge along with advanced vaccine technology is expected to help us find more effective ways to cure the disease.Search strategy ::: MethodsTo identify published research trials in PubMed, Scopus, Medline, and EMBASE from Dec 1, 2019, to May 4, 2020, comprehensive search strategies were performed (Fig. 2).", [["advanced vaccine technology", "TREATMENT", 32, 59], ["the disease", "PROBLEM", 116, 127], ["comprehensive search strategies", "TEST", 266, 297], ["disease", "OBSERVATION", 120, 127]]], ["The authors recorded the reasons for excluding studies.", [["studies", "TEST", 47, 54]]], ["Disagreement was resolved through discussion with two more authors (R.N. and M.M.H.R.).Study eligibility criteria ::: MethodsTo be eligible, studies had to meet the following criteria:1)The studies included COVID-19 patients with no restrictions on patient age, sex, and ethnicity.2)Enrolled patients in the intervention group must have treated with the immunotherapy agents alone or in combination with other drugs, including anti-viral agents, corticosteroids, and antibiotics.", [["patients", "ORGANISM", 216, 224], ["patient", "ORGANISM", 249, 256], ["patients", "ORGANISM", 292, 300], ["corticosteroids", "SIMPLE_CHEMICAL", 446, 461], ["patients", "SPECIES", 216, 224], ["patient", "SPECIES", 249, 256], ["patients", "SPECIES", 292, 300], ["Methods", "TREATMENT", 118, 125], ["The studies", "TEST", 186, 197], ["COVID", "TEST", 207, 212], ["the immunotherapy agents", "TREATMENT", 350, 374], ["other drugs", "TREATMENT", 404, 415], ["anti-viral agents", "TREATMENT", 427, 444], ["corticosteroids", "TREATMENT", 446, 461], ["antibiotics", "TREATMENT", 467, 478]]]], "PMC7429089": [["IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel RNA beta coronavirus, which causes the acute respiratory disease coronavirus disease 2019 (COVID-19) [1].", [["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["RNA beta coronavirus", "DISEASE", 84, 104], ["acute respiratory disease coronavirus disease", "DISEASE", 123, 168], ["IntroductionSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 59], ["SARS-CoV-2", "ORGANISM", 61, 71], ["RNA beta coronavirus", "ORGANISM", 84, 104], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 57], ["SARS-CoV-2", "SPECIES", 61, 71], ["beta coronavirus", "SPECIES", 88, 104], ["acute respiratory disease coronavirus disease 2019 (COVID-19", "SPECIES", 123, 183], ["acute respiratory syndrome coronavirus", "PROBLEM", 19, 57], ["SARS-CoV", "TEST", 61, 69], ["a novel RNA beta coronavirus", "PROBLEM", 76, 104], ["the acute respiratory disease coronavirus disease", "PROBLEM", 119, 168], ["COVID", "TEST", 175, 180], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["respiratory disease", "OBSERVATION", 129, 148]]], ["Although COVID-19 leads to multiple organ dysfunction or failure that affects the hepatic, renal, neurological systems, the involvement of the cardiovascular and respiratory systems are the most important predictors of morbidity and mortality [2].", [["organ", "ANATOMY", 36, 41], ["hepatic", "ANATOMY", 82, 89], ["renal", "ANATOMY", 91, 96], ["cardiovascular", "ANATOMY", 143, 157], ["respiratory", "ANATOMY", 162, 173], ["COVID-19", "CHEMICAL", 9, 17], ["organ dysfunction", "DISEASE", 36, 53], ["COVID-19", "GENE_OR_GENE_PRODUCT", 9, 17], ["organ", "ORGAN", 36, 41], ["hepatic", "MULTI-TISSUE_STRUCTURE", 82, 89], ["renal", "ORGAN", 91, 96], ["cardiovascular", "ANATOMICAL_SYSTEM", 143, 157], ["COVID-19", "DNA", 9, 17], ["COVID", "TEST", 9, 14], ["multiple organ dysfunction", "PROBLEM", 27, 53], ["failure", "PROBLEM", 57, 64], ["the hepatic, renal, neurological systems", "PROBLEM", 78, 118], ["the cardiovascular and respiratory systems", "PROBLEM", 139, 181], ["multiple", "OBSERVATION_MODIFIER", 27, 35], ["organ", "ANATOMY", 36, 41], ["dysfunction", "OBSERVATION", 42, 53], ["failure", "OBSERVATION", 57, 64], ["hepatic", "ANATOMY", 82, 89], ["renal", "ANATOMY", 91, 96]]], ["Therefore, the early evaluation of whether these two systems are affected is crucial.IntroductionMany available studies have demonstrated that COVID-19 causes myocardial injury and left ventricular (LV) dysfunction.", [["myocardial", "ANATOMY", 159, 169], ["left ventricular", "ANATOMY", 181, 197], ["LV", "ANATOMY", 199, 201], ["COVID-19", "CHEMICAL", 143, 151], ["myocardial injury", "DISEASE", 159, 176], ["left ventricular (LV) dysfunction", "DISEASE", 181, 214], ["COVID-19", "CHEMICAL", 143, 151], ["COVID-19", "GENE_OR_GENE_PRODUCT", 143, 151], ["myocardial", "MULTI-TISSUE_STRUCTURE", 159, 169], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 181, 197], ["LV", "MULTI-TISSUE_STRUCTURE", 199, 201], ["the early evaluation", "TEST", 11, 31], ["COVID", "TEST", 143, 148], ["myocardial injury", "PROBLEM", 159, 176], ["left ventricular (LV) dysfunction", "PROBLEM", 181, 214], ["myocardial", "ANATOMY", 159, 169], ["injury", "OBSERVATION", 170, 176], ["left ventricular", "ANATOMY", 181, 197], ["LV", "ANATOMY", 199, 201], ["dysfunction", "OBSERVATION", 203, 214]]], ["Myocardial injury has been found to be primarily associated with mortality and has been detected using troponin levels [3, 4].", [["Myocardial", "ANATOMY", 0, 10], ["Myocardial injury", "DISEASE", 0, 17], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 0, 10], ["troponin", "GENE_OR_GENE_PRODUCT", 103, 111], ["troponin", "PROTEIN", 103, 111], ["Myocardial injury", "PROBLEM", 0, 17], ["troponin levels", "TEST", 103, 118], ["injury", "OBSERVATION", 11, 17]]], ["There is not sufficient evidence to evaluate myocardial damage more specifically.", [["myocardial", "ANATOMY", 45, 55], ["myocardial damage", "DISEASE", 45, 62], ["myocardial", "MULTI-TISSUE_STRUCTURE", 45, 55], ["myocardial damage", "PROBLEM", 45, 62], ["not sufficient evidence to", "UNCERTAINTY", 9, 35], ["myocardial", "ANATOMY", 45, 55], ["damage", "OBSERVATION", 56, 62]]], ["In any case, severe lung disease can increase the right ventricular (RV) afterload, which may lead to impaired RV functions.", [["lung", "ANATOMY", 20, 24], ["right ventricular", "ANATOMY", 50, 67], ["RV", "ANATOMY", 111, 113], ["lung disease", "DISEASE", 20, 32], ["impaired RV functions", "DISEASE", 102, 123], ["lung", "ORGAN", 20, 24], ["right ventricular", "MULTI-TISSUE_STRUCTURE", 50, 67], ["RV", "MULTI-TISSUE_STRUCTURE", 69, 71], ["RV", "MULTI-TISSUE_STRUCTURE", 111, 113], ["severe lung disease", "PROBLEM", 13, 32], ["impaired RV functions", "PROBLEM", 102, 123], ["severe", "OBSERVATION_MODIFIER", 13, 19], ["lung", "ANATOMY", 20, 24], ["disease", "OBSERVATION", 25, 32], ["right ventricular", "ANATOMY", 50, 67], ["RV", "ANATOMY", 69, 71], ["may lead to", "UNCERTAINTY", 90, 101], ["impaired", "OBSERVATION_MODIFIER", 102, 110], ["RV", "ANATOMY", 111, 113]]], ["Therefore, the evaluation of RV functions can provide information regarding the severity of the current COVID-19 [5].", [["RV", "ANATOMY", 29, 31], ["COVID-19", "CHEMICAL", 104, 112], ["RV", "MULTI-TISSUE_STRUCTURE", 29, 31], ["the evaluation of RV functions", "TEST", 11, 41], ["the current COVID", "TEST", 92, 109], ["RV", "ANATOMY", 29, 31]]], ["Cardiac structure and functions are mainly evaluated by echocardiography.", [["Cardiac", "ANATOMY", 0, 7], ["Cardiac", "ORGAN", 0, 7], ["echocardiography", "TEST", 56, 72], ["structure", "OBSERVATION", 8, 17]]], ["However, two-dimensional speckle tracking echocardiography (2D-STE) evaluates myocardial dysfunction and the subclinical impairment of myocardium earlier and more accurately than conventional echocardiography [6, 7].", [["myocardial", "ANATOMY", 78, 88], ["myocardium", "ANATOMY", 135, 145], ["myocardial dysfunction", "DISEASE", 78, 100], ["myocardial", "MULTI-TISSUE_STRUCTURE", 78, 88], ["myocardium", "ORGAN", 135, 145], ["speckle tracking echocardiography", "TEST", 25, 58], ["myocardial dysfunction", "PROBLEM", 78, 100], ["the subclinical impairment of myocardium", "PROBLEM", 105, 145], ["conventional echocardiography", "TEST", 179, 208], ["myocardial", "ANATOMY", 78, 88], ["dysfunction", "OBSERVATION", 89, 100], ["subclinical", "OBSERVATION_MODIFIER", 109, 120], ["impairment", "OBSERVATION", 121, 131], ["myocardium", "ANATOMY", 135, 145]]], ["LV global longitudinal strain (LV-GLS) has been demonstrated to estimate global LV myocardial tissue damage [8\u201310].", [["LV", "ANATOMY", 0, 2], ["LV myocardial tissue", "ANATOMY", 80, 100], ["LV", "MULTI-TISSUE_STRUCTURE", 0, 2], ["LV myocardial tissue", "TISSUE", 80, 100], ["LV global longitudinal strain", "PROBLEM", 0, 29], ["global LV myocardial tissue damage", "PROBLEM", 73, 107], ["global", "OBSERVATION_MODIFIER", 3, 9], ["longitudinal strain", "OBSERVATION", 10, 29], ["global", "OBSERVATION_MODIFIER", 73, 79], ["LV", "ANATOMY_MODIFIER", 80, 82], ["myocardial tissue", "ANATOMY", 83, 100]]], ["Additionally, RV longitudinal strain (RV-LS) viewed with 2D-STE has been shown to have a prognostic value [11].", [["RV longitudinal strain", "PROBLEM", 14, 36], ["RV", "ANATOMY", 14, 16]]], ["In the present study, we evaluate whether any cardiac functions are affected when RV-LS and LV-GLS are found in COVID-19 patients with preserved RV and LV ejection fraction, which will provide important data regarding the prognosis and severity of COVID-19 and its cardiac effects.IntroductionThe aim of this study is to evaluate the prognostic value of LV-GLS and RV-LS as they relate to in-hospital mortality and the correlation between the two in patients with COVID-19.Study population ::: MethodsA total of 100 hospitalized patients with COVID-19 with normal LV ejection fraction (\u2265 50%) between April 15 and April 30, 2020 were enrolled in this study.", [["cardiac", "ANATOMY", 46, 53], ["LV", "ANATOMY", 92, 94], ["RV", "ANATOMY", 145, 147], ["LV", "ANATOMY", 152, 154], ["cardiac", "ANATOMY", 265, 272], ["LV", "ANATOMY", 354, 356], ["LV", "ANATOMY", 564, 566], ["COVID-19", "CHEMICAL", 248, 256], ["COVID-19", "CHEMICAL", 248, 256], ["cardiac", "ORGAN", 46, 53], ["LV", "MULTI-TISSUE_STRUCTURE", 92, 94], ["patients", "ORGANISM", 121, 129], ["RV", "MULTI-TISSUE_STRUCTURE", 145, 147], ["LV", "MULTI-TISSUE_STRUCTURE", 152, 154], ["COVID-19", "GENE_OR_GENE_PRODUCT", 248, 256], ["cardiac", "ORGAN", 265, 272], ["patients", "ORGANISM", 450, 458], ["patients", "ORGANISM", 529, 537], ["LV", "MULTI-TISSUE_STRUCTURE", 564, 566], ["patients", "SPECIES", 121, 129], ["patients", "SPECIES", 450, 458], ["patients", "SPECIES", 529, 537], ["the present study", "TEST", 3, 20], ["any cardiac functions", "PROBLEM", 42, 63], ["RV", "TEST", 82, 84], ["LS", "TEST", 85, 87], ["LV", "TEST", 92, 94], ["GLS", "TEST", 95, 98], ["COVID", "TEST", 112, 117], ["LV ejection fraction", "TEST", 152, 172], ["COVID", "TEST", 248, 253], ["this study", "TEST", 304, 314], ["LV", "TEST", 354, 356], ["GLS", "TEST", 357, 360], ["RV", "TEST", 365, 367], ["COVID", "TEST", 464, 469], ["COVID", "TEST", 543, 548], ["this study", "TEST", 646, 656], ["LV", "ANATOMY", 92, 94], ["RV", "ANATOMY", 145, 147], ["LV", "ANATOMY", 152, 154], ["ejection fraction", "OBSERVATION", 155, 172], ["cardiac", "ANATOMY", 265, 272], ["RV", "ANATOMY", 365, 367], ["LV", "ANATOMY", 564, 566], ["ejection fraction", "OBSERVATION", 567, 584]]], ["A total of 45 individuals who were age- and gender-matched normative population and had no history of cardiac disease were included as the control group.", [["cardiac", "ANATOMY", 102, 109], ["cardiac disease", "DISEASE", 102, 117], ["individuals", "ORGANISM", 14, 25], ["cardiac", "ORGAN", 102, 109], ["cardiac disease", "PROBLEM", 102, 117], ["cardiac", "ANATOMY", 102, 109], ["disease", "OBSERVATION", 110, 117]]], ["According to the World Health Organization interim guidance, the diagnosis of COVID-19 must be based on real-time reverse-transcription polymerase chain reaction (RT-PCR).", [["COVID", "TEST", 78, 83], ["RT-PCR", "TEST", 163, 169]]], ["As such, SARS-CoV-2 RNA was detected by a real-time RT-PCR method at the Public Health Microbiology Reference Laboratory of the Ministry of Health.", [["SARS-CoV-2", "ORGANISM", 9, 19], ["SARS-CoV-2 RNA", "RNA", 9, 23], ["SARS", "TEST", 9, 13]]], ["Two-dimensional echocardiography (2DE) images were obtained for all patients.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["Two-dimensional echocardiography (2DE) images", "TEST", 0, 45]]], ["According to the severity of the COVID-19 infection, the patients were divided into two groups: severe and non-severe.", [["infection", "DISEASE", 42, 51], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["the COVID-19 infection", "PROBLEM", 29, 51], ["severe and non-severe", "PROBLEM", 96, 117], ["infection", "OBSERVATION", 42, 51], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["non-severe", "OBSERVATION", 107, 117]]], ["Patients younger than 18 years of age, reduced LV ejection fraction (< 50%), the presence of segmental wall-motion abnormalities of the LV, severe valvular heart disease, coronary artery disease (CAD), atrial fibrillation, pulmonary hypertension (PHT), previous or current pulmonary embolism, severe chronic obstructive pulmonary disease, malignancy, or renal failure (< 30 ml/min) were excluded from the study.", [["LV", "ANATOMY", 47, 49], ["wall", "ANATOMY", 103, 107], ["LV", "ANATOMY", 136, 138], ["valvular", "ANATOMY", 147, 155], ["heart", "ANATOMY", 156, 161], ["coronary artery", "ANATOMY", 171, 186], ["atrial", "ANATOMY", 202, 208], ["pulmonary", "ANATOMY", 223, 232], ["pulmonary", "ANATOMY", 273, 282], ["pulmonary", "ANATOMY", 320, 329], ["renal", "ANATOMY", 354, 359], ["valvular heart disease", "DISEASE", 147, 169], ["coronary artery disease", "DISEASE", 171, 194], ["CAD", "DISEASE", 196, 199], ["atrial fibrillation", "DISEASE", 202, 221], ["pulmonary hypertension", "DISEASE", 223, 245], ["PHT", "DISEASE", 247, 250], ["pulmonary embolism", "DISEASE", 273, 291], ["chronic obstructive pulmonary disease", "DISEASE", 300, 337], ["malignancy", "DISEASE", 339, 349], ["renal failure", "DISEASE", 354, 367], ["Patients", "ORGANISM", 0, 8], ["LV", "MULTI-TISSUE_STRUCTURE", 47, 49], ["LV", "MULTI-TISSUE_STRUCTURE", 136, 138], ["heart", "ORGAN", 156, 161], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 171, 186], ["atrial", "MULTI-TISSUE_STRUCTURE", 202, 208], ["pulmonary", "ORGAN", 223, 232], ["pulmonary", "ORGAN", 273, 282], ["pulmonary", "ORGAN", 320, 329], ["renal", "ORGAN", 354, 359], ["Patients", "SPECIES", 0, 8], ["reduced LV ejection fraction", "PROBLEM", 39, 67], ["segmental wall-motion abnormalities of the LV", "PROBLEM", 93, 138], ["severe valvular heart disease", "PROBLEM", 140, 169], ["coronary artery disease", "PROBLEM", 171, 194], ["CAD", "PROBLEM", 196, 199], ["atrial fibrillation", "PROBLEM", 202, 221], ["pulmonary hypertension", "PROBLEM", 223, 245], ["current pulmonary embolism", "PROBLEM", 265, 291], ["severe chronic obstructive pulmonary disease", "PROBLEM", 293, 337], ["malignancy", "PROBLEM", 339, 349], ["renal failure", "PROBLEM", 354, 367], ["the study", "TEST", 401, 410], ["LV", "ANATOMY", 47, 49], ["ejection fraction", "OBSERVATION", 50, 67], ["segmental", "ANATOMY_MODIFIER", 93, 102], ["wall", "ANATOMY_MODIFIER", 103, 107], ["motion abnormalities", "OBSERVATION", 108, 128], ["LV", "ANATOMY", 136, 138], ["severe", "OBSERVATION_MODIFIER", 140, 146], ["valvular", "OBSERVATION", 147, 155], ["heart", "ANATOMY", 156, 161], ["disease", "OBSERVATION", 162, 169], ["coronary artery", "ANATOMY", 171, 186], ["disease", "OBSERVATION", 187, 194], ["atrial", "ANATOMY", 202, 208], ["fibrillation", "OBSERVATION", 209, 221], ["pulmonary", "ANATOMY", 223, 232], ["hypertension", "OBSERVATION", 233, 245], ["pulmonary", "ANATOMY", 273, 282], ["embolism", "OBSERVATION", 283, 291], ["severe", "OBSERVATION_MODIFIER", 293, 299], ["chronic", "OBSERVATION_MODIFIER", 300, 307], ["obstructive", "OBSERVATION_MODIFIER", 308, 319], ["pulmonary", "ANATOMY", 320, 329], ["disease", "OBSERVATION", 330, 337], ["malignancy", "OBSERVATION", 339, 349], ["renal", "ANATOMY", 354, 359], ["failure", "OBSERVATION", 360, 367]]], ["This study was approved by the institutional review board and the Republic of Turkey Ministry of Health.Study population ::: MethodsDetailed data regarding patient demographics, clinical characteristics, medications, and laboratory findings were retrospectively collected from medical records.", [["patient", "ORGANISM", 156, 163], ["patient", "SPECIES", 156, 163], ["This study", "TEST", 0, 10], ["medications", "TREATMENT", 204, 215]]], ["Upon being admitted to the hospital, the performed tests included a complete blood cell analysis and test to determine blood biochemistry, kidney function, electrolytes, C-reactive protein (CRP), high-sensitive troponin I (hs-TnI), and D-dimer.", [["blood cell", "ANATOMY", 77, 87], ["blood", "ANATOMY", 119, 124], ["kidney", "ANATOMY", 139, 145], ["blood cell", "CELL", 77, 87], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["kidney", "ORGAN", 139, 145], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 170, 188], ["CRP", "GENE_OR_GENE_PRODUCT", 190, 193], ["troponin I", "GENE_OR_GENE_PRODUCT", 211, 221], ["hs-TnI", "GENE_OR_GENE_PRODUCT", 223, 229], ["D-dimer", "SIMPLE_CHEMICAL", 236, 243], ["C-reactive protein", "PROTEIN", 170, 188], ["CRP", "PROTEIN", 190, 193], ["troponin I", "PROTEIN", 211, 221], ["hs", "PROTEIN", 223, 225], ["TnI", "PROTEIN", 226, 229], ["D-dimer", "PROTEIN", 236, 243], ["tests", "TEST", 51, 56], ["a complete blood cell analysis", "TEST", 66, 96], ["test", "TEST", 101, 105], ["blood biochemistry", "TEST", 119, 137], ["kidney function", "TEST", 139, 154], ["electrolytes", "TEST", 156, 168], ["C", "TEST", 170, 171], ["CRP", "TEST", 190, 193], ["high-sensitive troponin I", "PROBLEM", 196, 221], ["TnI", "TEST", 226, 229], ["kidney", "ANATOMY", 139, 145]]], ["Computed tomography (CT) was used to confirm pneumonia.", [["pneumonia", "DISEASE", 45, 54], ["Computed tomography (CT)", "TEST", 0, 24], ["pneumonia", "PROBLEM", 45, 54], ["pneumonia", "OBSERVATION", 45, 54]]], ["The primary endpoint was in-hospital mortality due to COVID-19.Transthoracic 2DE and STE ::: MethodsStandard 2DE evaluation was performed in all patients using the X5 transducer (Philips Epiq7; Philips Healthcare, Inc., Andover, MA, USA) echocardiography device, and all measurements were conducted on the first day of admission by two experienced cardiologists who were blinded to the study design and patients\u2019 clinical data.", [["COVID-19", "CHEMICAL", 54, 62], ["patients", "ORGANISM", 145, 153], ["patients", "ORGANISM", 403, 411], ["patients", "SPECIES", 145, 153], ["patients", "SPECIES", 403, 411], ["COVID", "TEST", 54, 59], ["Transthoracic 2DE", "TEST", 63, 80], ["MethodsStandard 2DE evaluation", "TEST", 93, 123], ["the X5 transducer", "TREATMENT", 160, 177], ["echocardiography device", "TEST", 238, 261], ["all measurements", "TEST", 267, 283], ["the study", "TEST", 382, 391]]], ["Conventional echocardiographic measurements were performed according to the American Society of Echocardiography guidelines [12].", [["Conventional echocardiographic measurements", "TEST", 0, 43]]], ["Echocardiographic images were obtained in the parasternal long-axis, short-axis, apical two-chamber, apical three-chamber, and apical four-chamber views with standard transducer positions.", [["Echocardiographic images", "TEST", 0, 24], ["standard transducer positions", "TREATMENT", 158, 187], ["parasternal", "ANATOMY_MODIFIER", 46, 57], ["apical", "ANATOMY_MODIFIER", 81, 87], ["apical", "ANATOMY_MODIFIER", 101, 107], ["apical", "ANATOMY_MODIFIER", 127, 133]]], ["LV end-diastole diameter (LVEDD) and end-systole diameter (LVESD) and interventricular septal and posterior wall thicknesses were expressed in millimeters with M-mode echocardiography.", [["LV", "ANATOMY", 0, 2], ["interventricular septal", "ANATOMY", 70, 93], ["posterior wall", "ANATOMY", 98, 112], ["LV", "MULTI-TISSUE_STRUCTURE", 0, 2], ["interventricular septal", "MULTI-TISSUE_STRUCTURE", 70, 93], ["posterior wall", "TISSUE", 98, 112], ["LV end-diastole diameter", "TEST", 0, 24], ["LVEDD", "TEST", 26, 31], ["end-systole diameter", "TEST", 37, 57], ["LVESD", "TEST", 59, 64], ["interventricular septal and posterior wall thicknesses", "PROBLEM", 70, 124], ["M-mode echocardiography", "TEST", 160, 183], ["diastole diameter", "OBSERVATION", 7, 24], ["systole diameter", "OBSERVATION", 41, 57], ["interventricular septal", "ANATOMY", 70, 93], ["posterior", "ANATOMY_MODIFIER", 98, 107], ["wall", "ANATOMY_MODIFIER", 108, 112], ["thicknesses", "ANATOMY_MODIFIER", 113, 124]]], ["LV ejection fraction (LVEF) was calculated using the modified Simpson\u2019s biplane method [13].", [["LV", "ANATOMY", 0, 2], ["LV", "MULTI-TISSUE_STRUCTURE", 0, 2], ["LV ejection fraction", "TEST", 0, 20], ["LVEF", "TEST", 22, 26], ["the modified Simpson\u2019s biplane method", "TREATMENT", 49, 86], ["ejection fraction", "OBSERVATION", 3, 20]]], ["The left atrial (LA) diameter was measured from the parasternal long-axis view at end-systole, and the RV diameter was measured from the apical four-chamber view at the tricuspid annulus [14].", [["left atrial", "ANATOMY", 4, 15], ["LA", "ANATOMY", 17, 19], ["RV", "ANATOMY", 103, 105], ["tricuspid annulus", "ANATOMY", 169, 186], ["left atrial", "MULTI-TISSUE_STRUCTURE", 4, 15], ["LA", "MULTI-TISSUE_STRUCTURE", 17, 19], ["RV", "ORGAN", 103, 105], ["The left atrial (LA) diameter", "TEST", 0, 29], ["the RV diameter", "TEST", 99, 114], ["left atrial", "ANATOMY", 4, 15], ["LA", "ANATOMY_MODIFIER", 17, 19], ["diameter", "OBSERVATION_MODIFIER", 21, 29], ["parasternal", "ANATOMY_MODIFIER", 52, 63], ["RV", "OBSERVATION_MODIFIER", 103, 105], ["diameter", "OBSERVATION_MODIFIER", 106, 114], ["apical", "ANATOMY_MODIFIER", 137, 143], ["tricuspid annulus", "ANATOMY", 169, 186]]], ["Pulsed wave Doppler velocity recordings were performed in the apical four-chamber views by placing the sample at the ends of the volume mitral valve.", [["sample", "ANATOMY", 103, 109], ["mitral valve", "ANATOMY", 136, 148], ["mitral valve", "MULTI-TISSUE_STRUCTURE", 136, 148], ["Pulsed wave Doppler velocity recordings", "TEST", 0, 39], ["apical", "ANATOMY_MODIFIER", 62, 68], ["volume mitral valve", "OBSERVATION", 129, 148]]], ["Mitral early peak velocity (E) and mitral late peak velocity (A) were recorded, and the E/A ratio was calculated.", [["Mitral", "ANATOMY", 0, 6], ["mitral", "ANATOMY", 35, 41], ["Mitral", "MULTI-TISSUE_STRUCTURE", 0, 6], ["Mitral early peak velocity", "TEST", 0, 26], ["mitral late peak velocity", "TEST", 35, 60], ["the E/A ratio", "TEST", 84, 97], ["early", "OBSERVATION_MODIFIER", 7, 12], ["peak velocity", "OBSERVATION", 13, 26], ["mitral", "ANATOMY_MODIFIER", 35, 41], ["late", "OBSERVATION_MODIFIER", 42, 46], ["peak", "OBSERVATION_MODIFIER", 47, 51], ["velocity", "OBSERVATION_MODIFIER", 52, 60]]], ["LV end-diastolic volume (LV EDV, ml) and end-systolic volume (LV ESV, ml) were calculated and stroke volume (EDV\u2014ESV, ml) and cardiac output (stroke volume x heart rate, l/m) derived.", [["LV", "ANATOMY", 0, 2], ["LV", "ANATOMY", 25, 27], ["cardiac", "ANATOMY", 126, 133], ["heart", "ANATOMY", 158, 163], ["stroke", "DISEASE", 94, 100], ["stroke", "DISEASE", 142, 148], ["LV", "MULTI-TISSUE_STRUCTURE", 0, 2], ["LV", "MULTI-TISSUE_STRUCTURE", 25, 27], ["cardiac", "ORGAN", 126, 133], ["heart", "ORGAN", 158, 163], ["LV end-diastolic volume", "TEST", 0, 23], ["EDV", "TEST", 28, 31], ["end-systolic volume", "TEST", 41, 60], ["LV ESV", "TEST", 62, 68], ["stroke volume", "TEST", 94, 107], ["EDV", "TEST", 109, 112], ["ESV", "TEST", 113, 116], ["ml", "TEST", 118, 120], ["cardiac output", "TEST", 126, 140], ["stroke volume", "TEST", 142, 155], ["heart rate", "TEST", 158, 168], ["diastolic volume", "OBSERVATION", 7, 23], ["systolic volume", "OBSERVATION", 45, 60], ["cardiac", "ANATOMY", 126, 133], ["output", "OBSERVATION_MODIFIER", 134, 140]]], ["Tricuspid annulus plane systolic excursion was conducted by the M-Mode, which was placed across the lateral tricuspid valve annulus on a four-chamber view.", [["Tricuspid annulus plane", "ANATOMY", 0, 23], ["lateral tricuspid valve annulus", "ANATOMY", 100, 131], ["Tricuspid annulus plane systolic excursion", "TEST", 0, 42], ["annulus", "ANATOMY_MODIFIER", 10, 17], ["excursion", "OBSERVATION_MODIFIER", 33, 42], ["lateral", "ANATOMY_MODIFIER", 100, 107], ["tricuspid valve", "ANATOMY", 108, 123], ["annulus", "ANATOMY_MODIFIER", 124, 131]]], ["Systolic pulmonary artery pressure (sPAP) was measured by tricuspid regurgitation peak velocity.", [["pulmonary artery", "ANATOMY", 9, 25], ["tricuspid", "ANATOMY", 58, 67], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 9, 25], ["Systolic pulmonary artery pressure", "TEST", 0, 34], ["sPAP", "TEST", 36, 40], ["tricuspid regurgitation peak velocity", "PROBLEM", 58, 95], ["pulmonary artery", "ANATOMY", 9, 25], ["pressure", "OBSERVATION_MODIFIER", 26, 34], ["tricuspid", "ANATOMY", 58, 67], ["regurgitation", "OBSERVATION", 68, 81], ["peak velocity", "OBSERVATION", 82, 95]]], ["2DE RV fractional area change was calculated on a four-chamber view by tracing the end-diastolic and end-systolic cavity and calculating the percentage change in area.", [["2DE RV fractional area change", "PROBLEM", 0, 29], ["tracing", "TEST", 71, 78], ["RV", "ANATOMY_MODIFIER", 4, 6], ["fractional area", "OBSERVATION", 7, 22], ["diastolic", "ANATOMY_MODIFIER", 87, 96], ["systolic cavity", "OBSERVATION", 105, 120], ["percentage change", "OBSERVATION", 141, 158]]], ["The LV mass was calculated using the Devereux formula [15].", [["LV mass", "ANATOMY", 4, 11], ["LV", "MULTI-TISSUE_STRUCTURE", 4, 6], ["The LV mass", "PROBLEM", 0, 11], ["the Devereux formula", "TREATMENT", 33, 53], ["LV", "ANATOMY", 4, 6], ["mass", "OBSERVATION", 7, 11]]], ["All measurements were corrected according to the body mass index (BMI).Transthoracic 2DE and STE ::: MethodsMyocardial function was evaluated by 2D-STE with a quantitative analysis function of myocardial deformation.", [["body", "ANATOMY", 49, 53], ["Myocardial", "ANATOMY", 108, 118], ["myocardial", "ANATOMY", 193, 203], ["myocardial deformation", "DISEASE", 193, 215], ["body", "ORGANISM_SUBDIVISION", 49, 53], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 108, 118], ["myocardial", "MULTI-TISSUE_STRUCTURE", 193, 203], ["All measurements", "TEST", 0, 16], ["the body mass index", "TEST", 45, 64], ["Transthoracic 2DE", "TEST", 71, 88], ["myocardial deformation", "PROBLEM", 193, 215], ["myocardial deformation", "OBSERVATION", 193, 215]]], ["The end of diastole was defined as the peak R wave of the electrocardiogram, while the end of systole was defined as the time at which the aortic valve closed.", [["aortic valve", "ANATOMY", 139, 151], ["aortic valve", "MULTI-TISSUE_STRUCTURE", 139, 151], ["the electrocardiogram", "TEST", 54, 75], ["diastole", "OBSERVATION", 11, 19], ["aortic valve", "ANATOMY", 139, 151]]], ["Endocardial borders were monitored within the frame of 2D images at the end of systole.", [["Endocardial", "ANATOMY", 0, 11], ["2D images", "TEST", 55, 64], ["borders", "ANATOMY_MODIFIER", 12, 19]]], ["The epicardial border was determined by adjusting a wide myocardial width.", [["epicardial border", "ANATOMY", 4, 21], ["myocardial", "ANATOMY", 57, 67], ["epicardial border", "TISSUE", 4, 21], ["myocardial", "MULTI-TISSUE_STRUCTURE", 57, 67], ["a wide myocardial width", "PROBLEM", 50, 73], ["epicardial", "ANATOMY", 4, 14], ["border", "ANATOMY_MODIFIER", 15, 21], ["wide", "OBSERVATION_MODIFIER", 52, 56], ["myocardial", "OBSERVATION", 57, 67], ["width", "OBSERVATION_MODIFIER", 68, 73]]], ["The midpoints between the endocardial and epicardial borders and the middle myocardial border were determined automatically.", [["endocardial", "ANATOMY", 26, 37], ["epicardial borders", "ANATOMY", 42, 60], ["middle myocardial border", "ANATOMY", 69, 93], ["endocardial", "MULTI-TISSUE_STRUCTURE", 26, 37], ["epicardial borders", "TISSUE", 42, 60], ["myocardial border", "MULTI-TISSUE_STRUCTURE", 76, 93], ["endocardial", "ANATOMY_MODIFIER", 26, 37], ["epicardial", "ANATOMY", 42, 52], ["borders", "ANATOMY_MODIFIER", 53, 60], ["middle myocardial", "ANATOMY", 69, 86], ["border", "ANATOMY_MODIFIER", 87, 93]]], ["If necessary, manual adjustments were made to ensure correct tracking and to involve all LV wall thickness for 2D speckle viewing width.", [["LV wall", "ANATOMY", 89, 96], ["LV wall", "TISSUE", 89, 96], ["manual adjustments", "TREATMENT", 14, 32], ["2D speckle viewing width", "TEST", 111, 135], ["LV", "ANATOMY", 89, 91], ["wall", "ANATOMY_MODIFIER", 92, 96]]], ["The analysis of LV-GLS was performed from the apical four-, three-, and two- chamber images.", [["LV", "ANATOMY", 16, 18], ["LV", "MULTI-TISSUE_STRUCTURE", 16, 18], ["The analysis", "TEST", 0, 12], ["LV-GLS", "TEST", 16, 22], ["LV", "ANATOMY", 16, 18], ["apical", "ANATOMY_MODIFIER", 46, 52]]], ["In the analysis, the QLAB-CMQ software program Philips Epiq 7C was used.", [["QLAB", "DNA", 21, 25], ["the analysis", "TEST", 3, 15], ["the QLAB", "TEST", 17, 25], ["Philips Epiq 7C", "TREATMENT", 47, 62]]], ["Peak systolic strain measurements of each segment were automatically taken by a software (analysis) program.", [["Peak systolic strain measurements", "TEST", 0, 33], ["systolic strain", "OBSERVATION", 5, 20]]], ["Longitudinal strain values of a total of 18 segments were obtained, and the mean value was determined as the global strain [16].", [["Longitudinal strain values", "TEST", 0, 26], ["the mean value", "TEST", 72, 86], ["the global strain", "PROBLEM", 105, 122]]], ["The analysis of RV-LS was performed from the apical four-chamber view.", [["The analysis of RV-LS", "TEST", 0, 21], ["RV", "ANATOMY", 16, 18], ["apical", "ANATOMY_MODIFIER", 45, 51]]], ["After tracing the RV endocardial border, the region of interest was automatically generated, and manual corrections were subsequently performed to fit the thickness of the RV myocardial wall.", [["RV endocardial border", "ANATOMY", 18, 39], ["RV myocardial wall", "ANATOMY", 172, 190], ["RV myocardial wall", "TISSUE", 172, 190], ["RV endocardial", "ANATOMY", 18, 32], ["border", "ANATOMY_MODIFIER", 33, 39], ["RV myocardial", "ANATOMY", 172, 185], ["wall", "ANATOMY_MODIFIER", 186, 190]]], ["The RV free wall was automatically divided into three segments: basal, mid, and apical.", [["RV free wall", "ANATOMY", 4, 16], ["RV free wall", "MULTI-TISSUE_STRUCTURE", 4, 16], ["basal, mid, and apical", "PROBLEM", 64, 86], ["RV", "ANATOMY_MODIFIER", 4, 6], ["free wall", "ANATOMY", 7, 16], ["three segments", "ANATOMY_MODIFIER", 48, 62], ["basal", "ANATOMY_MODIFIER", 64, 69], ["mid", "ANATOMY_MODIFIER", 71, 74], ["apical", "ANATOMY_MODIFIER", 80, 86]]], ["RV-LS was calculated as the mean of the strain values of the three segments of the RV free wall.", [["RV free wall", "ANATOMY", 83, 95], ["RV", "TEST", 0, 2], ["LS", "ANATOMY_MODIFIER", 3, 5], ["three", "ANATOMY_MODIFIER", 61, 66], ["segments", "ANATOMY_MODIFIER", 67, 75], ["RV", "ANATOMY", 83, 85], ["free", "ANATOMY_MODIFIER", 86, 90], ["wall", "ANATOMY_MODIFIER", 91, 95]]], ["Segments that could not be tracked after manual adjustment by the operator were excluded.Transthoracic 2DE and STE ::: MethodsThe wall motion of each LV segment was visually evaluated on the basis of motion and systolic thickening in a 16-segment model (three segments per wall).", [["wall", "ANATOMY", 130, 134], ["LV", "ANATOMY", 150, 152], ["wall", "ANATOMY", 273, 277], ["Segments", "MULTI-TISSUE_STRUCTURE", 0, 8], ["wall", "MULTI-TISSUE_STRUCTURE", 130, 134], ["LV segment", "MULTI-TISSUE_STRUCTURE", 150, 160], ["wall", "TISSUE", 273, 277], ["manual adjustment", "TREATMENT", 41, 58], ["Transthoracic 2DE", "TEST", 89, 106], ["systolic thickening", "PROBLEM", 211, 230], ["could not be", "UNCERTAINTY", 14, 26], ["wall", "ANATOMY_MODIFIER", 130, 134], ["motion", "OBSERVATION", 135, 141], ["LV", "ANATOMY", 150, 152], ["segment", "ANATOMY_MODIFIER", 153, 160], ["systolic", "OBSERVATION_MODIFIER", 211, 219], ["thickening", "OBSERVATION", 220, 230], ["wall", "ANATOMY_MODIFIER", 273, 277]]], ["Each segment was classified according to a conventional four-point scale (1, normokinesis; 2, hypokinesis; 3 akinesis; 4; dyskinesia).", [["normokinesis", "DISEASE", 77, 89], ["hypokinesis", "DISEASE", 94, 105], ["akinesis", "DISEASE", 109, 117], ["dyskinesia", "DISEASE", 122, 132], ["normokinesis", "TEST", 77, 89], ["hypokinesis", "PROBLEM", 94, 105], ["3 akinesis", "PROBLEM", 107, 117], ["dyskinesia", "PROBLEM", 122, 132], ["hypokinesis", "OBSERVATION", 94, 105]]], ["The wall motion score index (WMSI) was calculated by obtaining the average value of all segments of each location [14].Definitions ::: MethodsThe severe group consisted of patients with any of the following: (i) respiratory distress (respiratory rate: \u2265 30 breaths per min), (ii) an oxygen saturation of \u2264 93% at rest, (iii) a ratio of the partial pressure of arterial oxygen to the fractional concentration of oxygen inspired air of \u2264 300 mmHg, or (iv) a critical complication (septic shock, multiple organ dysfunction/failure that required admission to an intensive care unit (ICU), and/or any type of respiratory failure that required mechanical ventilation) [17].", [["wall", "ANATOMY", 4, 8], ["respiratory", "ANATOMY", 212, 223], ["respiratory", "ANATOMY", 234, 245], ["arterial", "ANATOMY", 360, 368], ["organ", "ANATOMY", 502, 507], ["respiratory", "ANATOMY", 604, 615], ["respiratory distress", "DISEASE", 212, 232], ["oxygen", "CHEMICAL", 283, 289], ["oxygen", "CHEMICAL", 369, 375], ["oxygen", "CHEMICAL", 411, 417], ["shock", "DISEASE", 486, 491], ["organ dysfunction", "DISEASE", 502, 519], ["respiratory failure", "DISEASE", 604, 623], ["oxygen", "CHEMICAL", 283, 289], ["oxygen", "CHEMICAL", 369, 375], ["oxygen", "CHEMICAL", 411, 417], ["wall", "TISSUE", 4, 8], ["patients", "ORGANISM", 172, 180], ["oxygen", "SIMPLE_CHEMICAL", 283, 289], ["arterial", "MULTI-TISSUE_STRUCTURE", 360, 368], ["oxygen", "SIMPLE_CHEMICAL", 369, 375], ["oxygen", "SIMPLE_CHEMICAL", 411, 417], ["organ", "ORGAN", 502, 507], ["patients", "SPECIES", 172, 180], ["The wall motion score index", "TEST", 0, 27], ["WMSI", "TEST", 29, 33], ["respiratory distress", "PROBLEM", 212, 232], ["respiratory rate", "TEST", 234, 250], ["an oxygen saturation", "TEST", 280, 300], ["arterial oxygen", "TREATMENT", 360, 375], ["oxygen inspired air", "TEST", 411, 430], ["a critical complication", "PROBLEM", 454, 477], ["septic shock", "PROBLEM", 479, 491], ["multiple organ dysfunction", "PROBLEM", 493, 519], ["failure", "PROBLEM", 520, 527], ["respiratory failure", "PROBLEM", 604, 623], ["mechanical ventilation", "TREATMENT", 638, 660], ["wall", "ANATOMY_MODIFIER", 4, 8], ["motion", "OBSERVATION_MODIFIER", 9, 15], ["respiratory", "ANATOMY", 212, 223], ["distress", "OBSERVATION", 224, 232], ["arterial", "ANATOMY", 360, 368], ["complication", "OBSERVATION", 465, 477], ["septic shock", "OBSERVATION", 479, 491], ["multiple", "OBSERVATION_MODIFIER", 493, 501], ["organ dysfunction", "OBSERVATION", 502, 519], ["failure", "OBSERVATION", 520, 527], ["respiratory failure", "OBSERVATION", 604, 623]]], ["Patients with clinical symptoms who were hospitalized but did not meet severe criteria were included in the non-severe group.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["clinical symptoms", "PROBLEM", 14, 31], ["severe criteria", "PROBLEM", 71, 86]]], ["Acute cardiac injury was defined as hs-TnI serum levels above the 99th percentile upper reference limit [18].Statistical analyses ::: MethodsAll statistical tests were conducted using the Statistical Package for the Social Sciences 21.0 for Windows (SPSS Inc., Chicago, IL, USA).", [["cardiac", "ANATOMY", 6, 13], ["serum", "ANATOMY", 43, 48], ["cardiac injury", "DISEASE", 6, 20], ["cardiac", "ORGAN", 6, 13], ["hs-TnI", "GENE_OR_GENE_PRODUCT", 36, 42], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["TnI", "PROTEIN", 39, 42], ["Acute cardiac injury", "PROBLEM", 0, 20], ["TnI serum levels", "TEST", 39, 55], ["Methods", "TREATMENT", 134, 141], ["All statistical tests", "TEST", 141, 162], ["cardiac", "ANATOMY", 6, 13], ["injury", "OBSERVATION", 14, 20]]], ["The Kolmogorov\u2013Smirnov test was used to analyze the normality of the data.", [["The Kolmogorov\u2013Smirnov test", "TEST", 0, 27]]], ["Continuous data are expressed as mean \u00b1 standard deviation (SD), and categorical data are expressed as percentages.", [["mean \u00b1 standard deviation (SD), and categorical data", "PROBLEM", 33, 85]]], ["A chi-square test was used to assess the differences in categorical variables between the groups.", [["A chi-square test", "TEST", 0, 17]]], ["A Student\u2019s t-test or the Mann\u2013Whitney U test was used to compare unpaired samples as needed.", [["samples", "ANATOMY", 75, 82], ["A Student\u2019s t-test", "TEST", 0, 18], ["the Mann\u2013Whitney U test", "TEST", 22, 45]]], ["The relationships among the parameters were assessed using Pearson\u2019s or Spearman\u2019s correlation analysis according to the normality of the data.", [["correlation analysis", "TEST", 83, 103]]], ["Primary analysis used ANOVA to compare all reported data for parametric variables, whereas the Kruskal\u2013Wallis test was used for comparison among non-parametric variables between the severe subjects, non-severe subjects, and controls.", [["Primary analysis", "TEST", 0, 16], ["parametric variables", "TEST", 61, 81], ["the Kruskal\u2013Wallis test", "TEST", 91, 114], ["the severe subjects", "PROBLEM", 178, 197], ["severe", "OBSERVATION_MODIFIER", 182, 188]]], ["Univariate and multivariate logistic regression analyses were used to identify the independent variables of mortality.", [["Univariate", "TREATMENT", 0, 10], ["multivariate logistic regression analyses", "TREATMENT", 15, 56]]], ["After performing univariate analysis, the stepwise method was used to select significant obtained variables for use in the multivariate logistic regression analysis.", [["univariate analysis", "TEST", 17, 36], ["the stepwise method", "TEST", 38, 57], ["the multivariate logistic regression analysis", "TEST", 119, 164]]], ["The results of the univariate and multivariate regression analyses are presented as odds ratios with 95% confidence intervals (CIs).", [["multivariate regression analyses", "TEST", 34, 66]]], ["For the echocardiographic parameter of strain including LV-GLS and RV-LS, receiver operating characteristic (ROC) curves were obtained, and the optimal values with the greatest total sensitivity and specificity in the prediction of mortality were selected.", [["LV", "ANATOMY", 56, 58], ["LV", "MULTI-TISSUE_STRUCTURE", 56, 58], ["the echocardiographic parameter", "TEST", 4, 35], ["strain", "PROBLEM", 39, 45], ["LV", "TEST", 56, 58], ["GLS", "TEST", 59, 62], ["RV", "TEST", 67, 69], ["ROC) curves", "TEST", 109, 120], ["RV", "ANATOMY", 67, 69]]], ["Cumulative survival curves were derived according to the Kaplan\u2013Meier method.", [["Cumulative survival curves", "TEST", 0, 26]]], ["Reproducibility was assessed by reanalyzing 20 randomly selected patients (reported as intra-observer reliability) and calculating from a second independent observer (reported as inter-observer reproducibility).", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["intra-observer reliability", "TEST", 87, 113]]], ["Significance was assumed at a two-sided p < 0.05.Clinical characteristics ::: ResultsA total of 145 patients were included in the present study.", [["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["the present study", "TEST", 126, 143]]], ["Of these, 100 had tested positive for COVID-19; their clinical and demographic characteristics are shown in Table 1.", [["COVID", "TEST", 38, 43]]], ["There was no statistically significant difference between the groups in terms of gender, age, BMI, heart rate (HR), systolic arterial pressure, diastolic arterial pressure, or smoking.", [["heart", "ANATOMY", 99, 104], ["arterial", "ANATOMY", 125, 133], ["arterial", "ANATOMY", 154, 162], ["heart", "ORGAN", 99, 104], ["arterial", "MULTI-TISSUE_STRUCTURE", 125, 133], ["arterial", "MULTI-TISSUE_STRUCTURE", 154, 162], ["BMI", "TEST", 94, 97], ["heart rate", "TEST", 99, 109], ["HR", "TEST", 111, 113], ["systolic arterial pressure", "TEST", 116, 142], ["diastolic arterial pressure", "TEST", 144, 171], ["no", "UNCERTAINTY", 10, 12], ["statistically", "OBSERVATION_MODIFIER", 13, 26], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["difference", "OBSERVATION", 39, 49], ["heart", "ANATOMY", 99, 104], ["systolic arterial", "ANATOMY", 116, 133], ["pressure", "OBSERVATION_MODIFIER", 134, 142], ["diastolic arterial pressure", "OBSERVATION", 144, 171]]], ["The number of respiratory rate (RR) was significantly higher in the severe group compared to the control and non-severe groups (p < 0.001).", [["respiratory", "ANATOMY", 14, 25], ["respiratory rate", "TEST", 14, 30], ["RR", "TEST", 32, 34], ["number", "OBSERVATION_MODIFIER", 4, 10], ["respiratory rate", "OBSERVATION", 14, 30], ["higher", "OBSERVATION_MODIFIER", 54, 60], ["severe", "OBSERVATION_MODIFIER", 68, 74]]], ["Similarly, lung involvement was detected in all patients of the severe group by CT imaging; 55% of the non-severe group demonstrated lung involvement, and the difference was statistically significant (p < 0.001).", [["lung", "ANATOMY", 11, 15], ["lung", "ANATOMY", 133, 137], ["lung", "ORGAN", 11, 15], ["patients", "ORGANISM", 48, 56], ["lung", "ORGAN", 133, 137], ["patients", "SPECIES", 48, 56], ["lung involvement", "PROBLEM", 11, 27], ["CT imaging", "TEST", 80, 90], ["lung involvement", "PROBLEM", 133, 149], ["lung", "ANATOMY", 11, 15], ["involvement", "OBSERVATION", 16, 27], ["lung", "ANATOMY", 133, 137], ["involvement", "OBSERVATION", 138, 149], ["significant", "OBSERVATION_MODIFIER", 188, 199]]], ["When the groups were compared in terms of the presence of chronic illness (hypertension [HTN], diabetes mellitus [DM], hyperlipidemia), there was no statistically significant difference among them.", [["chronic illness", "DISEASE", 58, 73], ["hypertension", "DISEASE", 75, 87], ["HTN", "DISEASE", 89, 92], ["diabetes mellitus", "DISEASE", 95, 112], ["DM", "DISEASE", 114, 116], ["hyperlipidemia", "DISEASE", 119, 133], ["chronic illness", "PROBLEM", 58, 73], ["hypertension", "PROBLEM", 75, 87], ["HTN", "PROBLEM", 89, 92], ["diabetes mellitus", "PROBLEM", 95, 112], ["DM", "PROBLEM", 114, 116], ["hyperlipidemia", "PROBLEM", 119, 133], ["chronic", "OBSERVATION_MODIFIER", 58, 65], ["illness", "OBSERVATION", 66, 73], ["hypertension", "OBSERVATION", 75, 87], ["hyperlipidemia", "OBSERVATION", 119, 133], ["no", "UNCERTAINTY", 146, 148]]], ["While there was no statistical difference between the laboratory findings in terms of white blood cell, creatinine, sodium, potassium, or creatine kinase-MB levels, the levels of glucose, CRP, hs-TnI and D-dimer were statistically significantly higher than in the non-severe group.", [["white blood cell", "ANATOMY", 86, 102], ["creatinine", "CHEMICAL", 104, 114], ["sodium", "CHEMICAL", 116, 122], ["potassium", "CHEMICAL", 124, 133], ["creatine", "CHEMICAL", 138, 146], ["glucose", "CHEMICAL", 179, 186], ["creatinine", "CHEMICAL", 104, 114], ["sodium", "CHEMICAL", 116, 122], ["potassium", "CHEMICAL", 124, 133], ["creatine", "CHEMICAL", 138, 146], ["glucose", "CHEMICAL", 179, 186], ["blood cell", "CELL", 92, 102], ["creatinine", "SIMPLE_CHEMICAL", 104, 114], ["sodium", "SIMPLE_CHEMICAL", 116, 122], ["potassium", "SIMPLE_CHEMICAL", 124, 133], ["creatine kinase-MB", "SIMPLE_CHEMICAL", 138, 156], ["glucose", "SIMPLE_CHEMICAL", 179, 186], ["CRP", "GENE_OR_GENE_PRODUCT", 188, 191], ["hs-TnI", "GENE_OR_GENE_PRODUCT", 193, 199], ["D-dimer", "SIMPLE_CHEMICAL", 204, 211], ["creatine kinase", "PROTEIN", 138, 153], ["CRP", "PROTEIN", 188, 191], ["TnI", "PROTEIN", 196, 199], ["D-dimer", "PROTEIN", 204, 211], ["white blood cell", "TEST", 86, 102], ["creatinine", "TEST", 104, 114], ["sodium", "TEST", 116, 122], ["potassium", "TEST", 124, 133], ["creatine kinase", "TEST", 138, 153], ["MB levels", "TEST", 154, 163], ["the levels", "TEST", 165, 175], ["glucose", "TEST", 179, 186], ["CRP", "TEST", 188, 191], ["hs", "TEST", 193, 195], ["TnI", "TEST", 196, 199], ["D-dimer", "TEST", 204, 211], ["no", "UNCERTAINTY", 16, 18], ["higher", "OBSERVATION_MODIFIER", 245, 251]]], ["Likewise, hemoglobin (Hgb) and arterial oxygen saturation (SaO2) levels were also statistically significantly lower in the severe group compared to the non-severe and control groups.", [["arterial", "ANATOMY", 31, 39], ["oxygen", "CHEMICAL", 40, 46], ["oxygen", "CHEMICAL", 40, 46], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 10, 20], ["Hgb", "GENE_OR_GENE_PRODUCT", 22, 25], ["arterial", "MULTI-TISSUE_STRUCTURE", 31, 39], ["oxygen", "SIMPLE_CHEMICAL", 40, 46], ["hemoglobin", "PROTEIN", 10, 20], ["Hgb", "PROTEIN", 22, 25], ["hemoglobin", "TEST", 10, 20], ["Hgb", "TEST", 22, 25], ["arterial oxygen saturation", "TEST", 31, 57], ["SaO2) levels", "TEST", 59, 71], ["hemoglobin", "OBSERVATION_MODIFIER", 10, 20], ["arterial", "ANATOMY", 31, 39], ["significantly", "OBSERVATION_MODIFIER", 96, 109], ["lower", "OBSERVATION_MODIFIER", 110, 115], ["severe", "OBSERVATION_MODIFIER", 123, 129]]], ["When the patients in the severe and non-severe groups were compared in terms of the treatment they received, there was no statistically significant difference between the groups in terms of antiviral and antibiotic treatment, while the oxygen therapy, high flow oxygen therapy, and non-invasive ventilation rates were statistically significantly higher in the severe group.", [["oxygen", "CHEMICAL", 236, 242], ["oxygen", "CHEMICAL", 262, 268], ["oxygen", "CHEMICAL", 236, 242], ["oxygen", "CHEMICAL", 262, 268], ["patients", "ORGANISM", 9, 17], ["oxygen", "SIMPLE_CHEMICAL", 236, 242], ["oxygen", "SIMPLE_CHEMICAL", 262, 268], ["patients", "SPECIES", 9, 17], ["the severe and non-severe groups", "PROBLEM", 21, 53], ["the treatment", "TREATMENT", 80, 93], ["antiviral", "TREATMENT", 190, 199], ["antibiotic treatment", "TREATMENT", 204, 224], ["the oxygen therapy", "TREATMENT", 232, 250], ["high flow oxygen therapy", "TREATMENT", 252, 276], ["non-invasive ventilation rates", "TEST", 282, 312], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["significant", "OBSERVATION_MODIFIER", 136, 147], ["difference", "OBSERVATION", 148, 158], ["oxygen therapy", "OBSERVATION", 236, 250], ["oxygen therapy", "OBSERVATION", 262, 276], ["severe", "OBSERVATION_MODIFIER", 360, 366]]], ["Similarly, ICU admission, acute cardiac injury, and acute kidney injury rates were found to be statistically significantly higher in the severe group than in the non-severe group.", [["cardiac", "ANATOMY", 32, 39], ["kidney", "ANATOMY", 58, 64], ["acute cardiac injury", "DISEASE", 26, 46], ["acute kidney injury", "DISEASE", 52, 71], ["cardiac", "ORGAN", 32, 39], ["kidney", "ORGAN", 58, 64], ["acute cardiac injury", "PROBLEM", 26, 46], ["acute kidney injury rates", "PROBLEM", 52, 77], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["cardiac", "ANATOMY", 32, 39], ["injury", "OBSERVATION", 40, 46], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["kidney", "ANATOMY", 58, 64], ["injury", "OBSERVATION", 65, 71], ["significantly", "OBSERVATION_MODIFIER", 109, 122], ["higher", "OBSERVATION_MODIFIER", 123, 129], ["severe", "OBSERVATION_MODIFIER", 137, 143], ["non-severe", "OBSERVATION", 162, 172]]], ["Finally, discharge and mortality rates were compared between the severe and non-severe groups.", [["mortality rates", "TEST", 23, 38], ["the severe and non-severe groups", "PROBLEM", 61, 93], ["non-severe", "OBSERVATION", 76, 86]]], ["The discharge rates were high in the non-severe group; no mortality was observed in this group.", [["The discharge rates", "TEST", 0, 19], ["mortality", "PROBLEM", 58, 67]]], ["However, in the severe group, the discharge rate was low, and 22 deaths were observed.", [["deaths", "DISEASE", 65, 71], ["the discharge rate", "TEST", 30, 48], ["severe", "OBSERVATION_MODIFIER", 16, 22]]], ["There was a statistically significant difference between the groups in terms of discharge and death.", [["death", "DISEASE", 94, 99], ["death", "PROBLEM", 94, 99], ["statistically", "OBSERVATION_MODIFIER", 12, 25], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["difference", "OBSERVATION", 38, 48]]], ["The median hospital stay was six days in the non-severe group and 13 days in the severe group, and there was a statistically significant difference between the two groups (p < 0.001) (Table 2).Echocardiographic characteristics ::: ResultsUsing 2D-STE, the conventional echocardiography parameters and GLS parameters of the three groups were compared.", [["the conventional echocardiography parameters", "TEST", 252, 296], ["GLS parameters", "TEST", 301, 315], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["significant", "OBSERVATION_MODIFIER", 125, 136], ["difference", "OBSERVATION_MODIFIER", 137, 147]]], ["A comparison of the LVEF, stroke volume (SV), cardiac output (CO), LVEDD, LVESD, LV mass, WMSI, left atrium (LA), the E/A ratio, and the E/e\u2019 ratio of the three groups revealed no statistically significant difference.", [["cardiac", "ANATOMY", 46, 53], ["LV", "ANATOMY", 81, 83], ["left atrium", "ANATOMY", 96, 107], ["stroke", "DISEASE", 26, 32], ["cardiac", "ORGAN", 46, 53], ["LV", "MULTI-TISSUE_STRUCTURE", 81, 83], ["left atrium", "MULTI-TISSUE_STRUCTURE", 96, 107], ["LA", "MULTI-TISSUE_STRUCTURE", 109, 111], ["the LVEF", "TEST", 16, 24], ["stroke volume", "TEST", 26, 39], ["cardiac output", "TEST", 46, 60], ["CO", "TEST", 62, 64], ["LVEDD", "TEST", 67, 72], ["LVESD", "TEST", 74, 79], ["LV mass", "PROBLEM", 81, 88], ["WMSI", "TEST", 90, 94], ["the E/A ratio", "TEST", 114, 127], ["the E/e\u2019 ratio", "TEST", 133, 147], ["statistically significant difference", "PROBLEM", 180, 216], ["stroke", "OBSERVATION", 26, 32], ["cardiac", "ANATOMY", 46, 53], ["LV", "ANATOMY", 81, 83], ["mass", "OBSERVATION", 84, 88], ["left atrium", "ANATOMY", 96, 107], ["LA", "ANATOMY_MODIFIER", 109, 111], ["no", "UNCERTAINTY", 177, 179], ["statistically", "OBSERVATION_MODIFIER", 180, 193], ["significant", "OBSERVATION_MODIFIER", 194, 205], ["difference", "OBSERVATION", 206, 216]]], ["The LV-GLS values of the control, non-severe, and severe groups were \u2212 19.4 \u00b1 1.6%, \u2212 16.7 \u00b1 1.3%, and \u2212 14.5 \u00b1 1.8%, respectively, and there was a statistically significant difference among the three groups (p < 0.001).", [["LV", "ANATOMY", 4, 6], ["LV", "MULTI-TISSUE_STRUCTURE", 4, 6], ["The LV", "TEST", 0, 6], ["GLS values", "TEST", 7, 17], ["non-severe, and severe groups", "PROBLEM", 34, 63], ["\u2212", "TEST", 69, 70], ["\u2212", "TEST", 84, 85], ["\u2212", "TEST", 103, 104], ["LV", "ANATOMY", 4, 6], ["non-severe", "OBSERVATION_MODIFIER", 34, 44], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["statistically", "OBSERVATION_MODIFIER", 148, 161], ["significant", "OBSERVATION_MODIFIER", 162, 173], ["difference", "OBSERVATION_MODIFIER", 174, 184]]], ["It was observed that the sPAP value, which is one of the conventional parameters, was statistically significantly higher in the severe group compared to the other groups.", [["sPAP", "SIMPLE_CHEMICAL", 25, 29], ["sPAP", "PROTEIN", 25, 29], ["the sPAP value", "TEST", 21, 35], ["significantly", "OBSERVATION_MODIFIER", 100, 113], ["higher", "OBSERVATION_MODIFIER", 114, 120], ["severe", "OBSERVATION_MODIFIER", 128, 134]]], ["In addition, the RV diameter was found to be higher in the severe group compared to the other groups, The RV-LS values of the control, non-severe, and severe groups were \u2212 27.3 \u00b1 3.1%, \u2212 20.5 \u00b1 3.2%, and \u2212 17.2 \u00b1 2.3%, respectively, indicating a statistically significant difference among the groups (p < 0.001) (Fig. 1).Echocardiographic characteristics ::: ResultsThe relationships of the LV-GLS and RV-LS values with age, hs-TnI, D-dimer, CRP, Hgb, sPAP, SaO2, RR, and HR were evaluated via Spearman\u2019s or Pearson\u2019s correlation analyses.", [["RV", "ANATOMY", 17, 19], ["LV", "ANATOMY", 391, 393], ["RV", "ORGAN", 17, 19], ["LV", "MULTI-TISSUE_STRUCTURE", 391, 393], ["hs-TnI", "GENE_OR_GENE_PRODUCT", 425, 431], ["D-dimer", "GENE_OR_GENE_PRODUCT", 433, 440], ["CRP", "GENE_OR_GENE_PRODUCT", 442, 445], ["Hgb", "GENE_OR_GENE_PRODUCT", 447, 450], ["sPAP", "GENE_OR_GENE_PRODUCT", 452, 456], ["TnI", "PROTEIN", 428, 431], ["D-dimer", "PROTEIN", 433, 440], ["CRP", "PROTEIN", 442, 445], ["Hgb", "PROTEIN", 447, 450], ["sPAP", "PROTEIN", 452, 456], ["the RV diameter", "TEST", 13, 28], ["The RV", "TEST", 102, 108], ["non-severe", "PROBLEM", 135, 145], ["severe groups", "PROBLEM", 151, 164], ["\u2212", "TEST", 185, 186], ["\u2212", "TEST", 204, 205], ["Echocardiographic characteristics", "TEST", 321, 354], ["the LV", "TEST", 387, 393], ["GLS", "TEST", 394, 397], ["RV", "TEST", 402, 404], ["LS values", "TEST", 405, 414], ["age", "TEST", 420, 423], ["hs", "TEST", 425, 427], ["TnI", "TEST", 428, 431], ["D", "TEST", 433, 434], ["CRP", "TEST", 442, 445], ["Hgb", "TEST", 447, 450], ["sPAP", "TEST", 452, 456], ["SaO2", "TEST", 458, 462], ["RR", "TEST", 464, 466], ["HR", "TEST", 472, 474], ["RV", "ANATOMY", 17, 19], ["diameter", "OBSERVATION_MODIFIER", 20, 28], ["higher", "OBSERVATION_MODIFIER", 45, 51], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["RV", "ANATOMY", 106, 108], ["non-severe", "OBSERVATION_MODIFIER", 135, 145], ["severe", "OBSERVATION_MODIFIER", 151, 157], ["statistically", "OBSERVATION_MODIFIER", 246, 259], ["significant", "OBSERVATION_MODIFIER", 260, 271], ["difference", "OBSERVATION_MODIFIER", 272, 282], ["LV", "ANATOMY", 391, 393], ["RV", "ANATOMY", 402, 404]]], ["A statistically significant relationship was detected between the LV-GLS value and hs-TnI, D-dimer, and sO2, as seen in Table 3.Predictors of mortality ::: ResultsOf the patients in this study, 22 died in the hospital (Fig. 2).", [["LV", "ANATOMY", 66, 68], ["hs-TnI", "GENE_OR_GENE_PRODUCT", 83, 89], ["D-dimer", "GENE_OR_GENE_PRODUCT", 91, 98], ["sO2", "SIMPLE_CHEMICAL", 104, 107], ["patients", "ORGANISM", 170, 178], ["GLS", "PROTEIN", 69, 72], ["TnI", "PROTEIN", 86, 89], ["D-dimer", "PROTEIN", 91, 98], ["sO2", "PROTEIN", 104, 107], ["patients", "SPECIES", 170, 178], ["the LV", "TEST", 62, 68], ["hs", "TEST", 83, 85], ["TnI", "TEST", 86, 89], ["sO2", "TEST", 104, 107], ["this study", "TEST", 182, 192], ["LV", "ANATOMY", 66, 68], ["TnI", "ANATOMY", 86, 89]]], ["The parameters affecting mortality were evaluated by including LV-GLS and RV-LS in the two models separately using logistic regression analysis with univariate and multivariate analysis.", [["LV", "TEST", 63, 65], ["GLS", "TEST", 66, 69], ["RV", "TEST", 74, 76], ["logistic regression analysis", "TEST", 115, 143], ["univariate", "TEST", 149, 159], ["multivariate analysis", "TEST", 164, 185], ["RV", "ANATOMY", 74, 76]]], ["Age, gender, HT, DM, CRP, cardiac injury, D-dimer, LV-GLS, RV-LS, RR, SaO2, and sPAP were first evaluated using univariate analysis.", [["cardiac", "ANATOMY", 26, 33], ["LV", "ANATOMY", 51, 53], ["HT", "DISEASE", 13, 15], ["DM", "DISEASE", 17, 19], ["cardiac injury", "DISEASE", 26, 40], ["CRP", "GENE_OR_GENE_PRODUCT", 21, 24], ["cardiac", "ORGAN", 26, 33], ["D-dimer", "SIMPLE_CHEMICAL", 42, 49], ["LV", "MULTI-TISSUE_STRUCTURE", 51, 53], ["CRP", "PROTEIN", 21, 24], ["HT", "PROBLEM", 13, 15], ["DM", "PROBLEM", 17, 19], ["CRP", "TEST", 21, 24], ["cardiac injury", "PROBLEM", 26, 40], ["D-dimer", "PROBLEM", 42, 49], ["LV", "TEST", 51, 53], ["GLS", "TEST", 54, 57], ["RV", "TEST", 59, 61], ["LS", "TEST", 62, 64], ["RR", "TEST", 66, 68], ["SaO2", "TEST", 70, 74], ["sPAP", "TEST", 80, 84], ["univariate analysis", "TEST", 112, 131], ["cardiac", "ANATOMY", 26, 33], ["injury", "OBSERVATION", 34, 40], ["LV", "ANATOMY", 51, 53], ["RV", "ANATOMY", 59, 61], ["LS", "ANATOMY", 62, 64]]], ["Age, gender, cardiac injury, D-dimer, SaO2, LV-GLS, and RV-LS, which were statistically significant in the univariate analysis, were then reevaluated in a multivariate analysis.", [["cardiac", "ANATOMY", 13, 20], ["LV", "ANATOMY", 44, 46], ["cardiac injury", "DISEASE", 13, 27], ["cardiac", "ORGAN", 13, 20], ["D-dimer", "GENE_OR_GENE_PRODUCT", 29, 36], ["LV", "MULTI-TISSUE_STRUCTURE", 44, 46], ["cardiac injury", "PROBLEM", 13, 27], ["D-dimer", "TEST", 29, 36], ["SaO2", "TEST", 38, 42], ["LV", "TEST", 44, 46], ["GLS", "TEST", 47, 50], ["RV", "TEST", 56, 58], ["the univariate analysis", "TEST", 103, 126], ["a multivariate analysis", "TEST", 153, 176], ["cardiac", "ANATOMY", 13, 20], ["injury", "OBSERVATION", 21, 27], ["LV", "ANATOMY", 44, 46], ["RV", "ANATOMY", 56, 58], ["LS", "ANATOMY", 59, 61], ["significant", "OBSERVATION_MODIFIER", 88, 99]]], ["In the first model of Table 4, cardiac injury (OR 5.125, p = 0.027), SaO2 (OR 0.842, p = 0.025), LV-GLS (OR 1.635, p = 0.010), and LV-GLS > \u2212 15.20% (OR 8.342, p < 0.001) were thus determined to be independent predictors of mortality.", [["cardiac", "ANATOMY", 31, 38], ["LV", "ANATOMY", 97, 99], ["LV", "ANATOMY", 131, 133], ["cardiac injury", "DISEASE", 31, 45], ["cardiac", "ORGAN", 31, 38], ["cardiac injury", "PROBLEM", 31, 45], ["p", "TEST", 57, 58], ["SaO2", "TEST", 69, 73], ["p", "TEST", 85, 86], ["LV", "TEST", 97, 99], ["GLS", "TEST", 100, 103], ["p", "TEST", 115, 116], ["LV", "TEST", 131, 133], ["GLS", "TEST", 134, 137], ["p", "TEST", 160, 161], ["cardiac", "ANATOMY", 31, 38], ["injury", "OBSERVATION", 39, 45], ["LV", "ANATOMY", 131, 133]]], ["The second model of Table 4 was created by removing the LV-GLS and adding the RV-LS to predict mortality development.", [["the LV", "TEST", 52, 58], ["the RV", "TEST", 74, 80], ["LV", "ANATOMY", 56, 58], ["RV", "ANATOMY", 78, 80]]], ["In this second model, cardiac injury (OR 1.417, p = 0.031), D-dimer (OR 4.250, p = 0.021), SaO2 (OR 0.830, p = 0.012), RV-LS (OR 1.557, p = 0.019), and RV-LS > \u2212 18.45% (OR 6.229, p = 0.011) were thus determined to be independent predictors of mortality (Table 4).Predictors of mortality ::: ResultsWe evaluated the specificity and sensitivity of the LV-GLS and RV-LS values that were significant in the multivariate analysis with ROC analysis to predict mortality development in patients.", [["cardiac", "ANATOMY", 22, 29], ["LV", "ANATOMY", 351, 353], ["cardiac injury", "DISEASE", 22, 36], ["cardiac", "ORGAN", 22, 29], ["D-dimer", "GENE_OR_GENE_PRODUCT", 60, 67], ["patients", "ORGANISM", 480, 488], ["patients", "SPECIES", 480, 488], ["cardiac injury", "PROBLEM", 22, 36], ["D-dimer", "TEST", 60, 67], ["p", "TEST", 79, 80], ["SaO2", "TEST", 91, 95], ["p", "TEST", 107, 108], ["RV", "TEST", 119, 121], ["LS", "TEST", 122, 124], ["p", "TEST", 136, 137], ["RV", "TEST", 152, 154], ["LS", "TEST", 155, 157], ["p", "TEST", 180, 181], ["the specificity", "TEST", 312, 327], ["the LV", "TEST", 347, 353], ["GLS", "TEST", 354, 357], ["RV", "TEST", 362, 364], ["LS values", "TEST", 365, 374], ["the multivariate analysis", "TEST", 400, 425], ["ROC analysis", "TEST", 431, 443], ["cardiac", "ANATOMY", 22, 29], ["injury", "OBSERVATION", 30, 36], ["RV", "ANATOMY", 119, 121], ["RV", "ANATOMY", 152, 154], ["LV", "ANATOMY", 351, 353], ["RV", "ANATOMY", 362, 364]]], ["The blue line represents LV-GLS, and the green line represents RV-LS; the area under the curve (AUC) of each was 0.83 (0.74\u20130.92) and 0.77 (0.66\u20130.88), respectively.", [["LV", "ANATOMY", 25, 27], ["blue line", "CELL", 4, 13], ["LV", "CELL", 25, 27], ["The blue line", "TREATMENT", 0, 13], ["LV", "TEST", 25, 27], ["GLS", "TEST", 28, 31], ["the green line", "PROBLEM", 37, 51], ["the curve", "TEST", 85, 94], ["AUC", "TEST", 96, 99], ["blue line", "OBSERVATION", 4, 13], ["LV", "ANATOMY", 25, 27], ["GLS", "OBSERVATION_MODIFIER", 28, 31], ["green line", "OBSERVATION", 41, 51], ["RV", "ANATOMY", 63, 65], ["LS", "ANATOMY_MODIFIER", 66, 68], ["curve", "OBSERVATION_MODIFIER", 89, 94]]], ["The LV-GLS value predicts mortality development with 77% sensitivity and 75% specificity with a \u2212 15.20 cutoff value, and the RV-LS value predicts mortality development with 72% sensitivity and 66% specificity with a \u2212 18.45 cutoff value (Fig. 3).Reproducibility ::: ResultsA total of 20 patients were randomly selected for intra- and interobserver variability analysis.", [["LV", "ANATOMY", 4, 6], ["LV", "MULTI-TISSUE_STRUCTURE", 4, 6], ["patients", "ORGANISM", 288, 296], ["patients", "SPECIES", 288, 296], ["The LV", "TEST", 0, 6], ["GLS value", "TEST", 7, 16], ["mortality development", "TEST", 26, 47], ["sensitivity", "TEST", 57, 68], ["specificity", "TEST", 77, 88], ["the RV", "TEST", 122, 128], ["LS value", "TEST", 129, 137], ["sensitivity", "TEST", 178, 189], ["intra- and interobserver variability analysis", "TEST", 324, 369], ["LV", "ANATOMY", 4, 6], ["RV", "ANATOMY", 126, 128]]], ["The compatibility of intra- and interobserver LV-GLS, RV-LS, and WMSI values were calculated.", [["LV", "ANATOMY", 46, 48], ["GLS", "TEST", 49, 52], ["RV", "TEST", 54, 56], ["WMSI values", "TEST", 65, 76], ["intra", "ANATOMY_MODIFIER", 21, 26], ["LV", "ANATOMY", 46, 48], ["RV", "ANATOMY", 54, 56], ["LS", "ANATOMY", 57, 59]]], ["The correlation coefficient for intra- and interobserver variability was evaluated, and the following results were obtained\u2014intraobserver: 0.94 (95% CI, 0.91\u20130.96), interobserver: 0.90 (95% CI 0.84\u20130.95) for LV-GLS; intraobserver: 0.92 (95% CI 0.88\u20130.94), interobserver: 0.89 (95% CI 0.82\u20130.94) for RV-LS; intraobserver: 0.89 (95% CI 0.84\u20130.94), and interobserver:0.86 (95% CI 0.77\u20130.94) for WMSI.DiscussionWe evaluate the prognostic value of LV-GLS and RV-LS in patients with COVID-19.", [["LV", "ANATOMY", 443, 445], ["LV", "MULTI-TISSUE_STRUCTURE", 443, 445], ["patients", "ORGANISM", 463, 471], ["patients", "SPECIES", 463, 471], ["intraobserver", "TEST", 124, 137], ["CI", "TEST", 149, 151], ["interobserver", "TEST", 165, 178], ["CI", "TEST", 190, 192], ["LV", "TEST", 208, 210], ["GLS", "TEST", 211, 214], ["intraobserver", "TEST", 216, 229], ["CI", "TEST", 241, 243], ["interobserver", "TEST", 256, 269], ["CI", "TEST", 281, 283], ["RV", "TEST", 299, 301], ["LS", "TEST", 302, 304], ["intraobserver", "TEST", 306, 319], ["CI", "TEST", 331, 333], ["interobserver", "TEST", 350, 363], ["CI", "TEST", 374, 376], ["WMSI", "TEST", 392, 396], ["LV", "TEST", 443, 445], ["GLS", "TEST", 446, 449], ["RV", "TEST", 454, 456], ["COVID", "TEST", 477, 482], ["RV", "ANATOMY", 299, 301], ["RV", "ANATOMY", 454, 456]]], ["The principal findings of our study are as follows: (i) LV-GLS and RV-LS were lower in the severe group compared to the non-severe group; (ii) cardiac injury, D-dimer, SaO2, LV-GLS, and RV-LS were found to be independent predictors of mortality through multivariate analysis.DiscussionThe structure and function of the LV are commonly assessed by echocardiography.", [["LV", "ANATOMY", 56, 58], ["cardiac", "ANATOMY", 143, 150], ["LV", "ANATOMY", 174, 176], ["LV", "ANATOMY", 319, 321], ["cardiac injury", "DISEASE", 143, 157], ["cardiac", "ORGAN", 143, 150], ["D-dimer", "SIMPLE_CHEMICAL", 159, 166], ["LV", "MULTI-TISSUE_STRUCTURE", 174, 176], ["RV-LS", "GENE_OR_GENE_PRODUCT", 186, 191], ["LV", "MULTI-TISSUE_STRUCTURE", 319, 321], ["our study", "TEST", 26, 35], ["LV", "TEST", 56, 58], ["GLS", "TEST", 59, 62], ["RV", "TEST", 67, 69], ["LS", "TEST", 70, 72], ["cardiac injury", "PROBLEM", 143, 157], ["D-dimer", "TEST", 159, 166], ["SaO2", "TEST", 168, 172], ["LV", "TEST", 174, 176], ["GLS", "TEST", 177, 180], ["RV", "TEST", 186, 188], ["multivariate analysis", "TEST", 253, 274], ["echocardiography", "TEST", 347, 363], ["LV", "ANATOMY", 56, 58], ["RV", "ANATOMY", 67, 69], ["lower", "OBSERVATION_MODIFIER", 78, 83], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["cardiac", "ANATOMY", 143, 150], ["injury", "OBSERVATION", 151, 157], ["LV", "ANATOMY", 174, 176], ["RV", "ANATOMY", 186, 188], ["LV", "ANATOMY", 319, 321]]], ["STE quantifies myocardial deformation globally and regionally, regardless of the insonation angle or cardiac translational movements.", [["myocardial", "ANATOMY", 15, 25], ["cardiac", "ANATOMY", 101, 108], ["myocardial", "MULTI-TISSUE_STRUCTURE", 15, 25], ["cardiac", "ORGAN", 101, 108], ["myocardial deformation globally", "PROBLEM", 15, 46], ["myocardial", "ANATOMY", 15, 25], ["deformation", "OBSERVATION", 26, 37], ["cardiac", "ANATOMY", 101, 108], ["translational movements", "OBSERVATION", 109, 132]]], ["Direct strain measurement from 2D grayscale images makes STE a better tool than 2DE for the evaluation of cardiac mechanics.", [["cardiac", "ANATOMY", 106, 113], ["cardiac", "ORGAN", 106, 113], ["Direct strain measurement", "TEST", 0, 25], ["2D grayscale images", "TEST", 31, 50], ["the evaluation", "TEST", 88, 102], ["cardiac mechanics", "TEST", 106, 123], ["cardiac", "ANATOMY", 106, 113], ["mechanics", "OBSERVATION", 114, 123]]], ["Furthermore, STE is a more useful method for evaluating global and regional myocardial deformations compared to tissue Doppler imaging as it is accurate, highly reproducible, angle-independent, and does not require a fixed angle of insonation [21, 22].DiscussionDue to the fact that subendocardial cardiac fibers are particularly and primarily sensitive to the deleterious effects of fibrosis; diseases such as HTN, CAD, DM, and obesity may induce fibrotic processes of the LV with preserved EF by affecting the subendocardial fibers which provide longitudinal systolic functions in the beginning [23, 24].", [["myocardial", "ANATOMY", 76, 86], ["tissue", "ANATOMY", 112, 118], ["subendocardial cardiac fibers", "ANATOMY", 283, 312], ["LV", "ANATOMY", 474, 476], ["subendocardial fibers", "ANATOMY", 512, 533], ["myocardial deformations", "DISEASE", 76, 99], ["fibrosis", "DISEASE", 384, 392], ["HTN", "DISEASE", 411, 414], ["CAD", "DISEASE", 416, 419], ["DM", "DISEASE", 421, 423], ["obesity", "DISEASE", 429, 436], ["myocardial", "MULTI-TISSUE_STRUCTURE", 76, 86], ["tissue", "TISSUE", 112, 118], ["subendocardial cardiac fibers", "CELL", 283, 312], ["LV", "MULTI-TISSUE_STRUCTURE", 474, 476], ["subendocardial fibers", "TISSUE", 512, 533], ["EF", "PROTEIN", 492, 494], ["global and regional myocardial deformations", "PROBLEM", 56, 99], ["tissue Doppler imaging", "TEST", 112, 134], ["a fixed angle of insonation", "TEST", 215, 242], ["subendocardial cardiac fibers", "PROBLEM", 283, 312], ["fibrosis", "PROBLEM", 384, 392], ["diseases", "PROBLEM", 394, 402], ["HTN", "PROBLEM", 411, 414], ["CAD", "PROBLEM", 416, 419], ["DM", "PROBLEM", 421, 423], ["obesity", "PROBLEM", 429, 436], ["fibrotic processes of the LV", "PROBLEM", 448, 476], ["longitudinal systolic functions", "TEST", 548, 579], ["regional myocardial", "ANATOMY", 67, 86], ["deformations", "OBSERVATION", 87, 99], ["subendocardial", "ANATOMY_MODIFIER", 283, 297], ["cardiac", "ANATOMY", 298, 305], ["fibers", "OBSERVATION", 306, 312], ["fibrosis", "OBSERVATION", 384, 392], ["HTN", "OBSERVATION", 411, 414], ["obesity", "OBSERVATION", 429, 436], ["fibrotic", "OBSERVATION", 448, 456], ["LV", "ANATOMY", 474, 476], ["preserved", "OBSERVATION", 482, 491], ["subendocardial fibers", "OBSERVATION", 512, 533]]], ["Shah et al. and Donal et al. designed multicentric studies and enrolled a large number of patients.", [["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["multicentric studies", "TEST", 38, 58], ["large", "OBSERVATION_MODIFIER", 74, 79]]], ["These two studies have assessed the association of LV-GLS with poor cardiovascular outcomes in patients with heart failure with preserved EF [25, 26].", [["LV", "ANATOMY", 51, 53], ["cardiovascular", "ANATOMY", 68, 82], ["heart", "ANATOMY", 109, 114], ["heart failure", "DISEASE", 109, 122], ["LV", "MULTI-TISSUE_STRUCTURE", 51, 53], ["cardiovascular", "ANATOMICAL_SYSTEM", 68, 82], ["patients", "ORGANISM", 95, 103], ["heart", "ORGAN", 109, 114], ["patients", "SPECIES", 95, 103], ["These two studies", "TEST", 0, 17], ["LV", "TEST", 51, 53], ["poor cardiovascular outcomes", "PROBLEM", 63, 91], ["heart failure", "PROBLEM", 109, 122], ["LV", "ANATOMY", 51, 53], ["heart", "ANATOMY", 109, 114], ["failure", "OBSERVATION", 115, 122]]], ["A meta-analysis including 794 patients with severe sepsis and/or septic shock showed that LV-GLS measurements were strongly associated with survival (standard mean difference, \u2212 0.26; 95% CI \u2212 0.47, \u2212 0.04; p = 0.02), while LV ejection fraction was not found to be a predictor of mortality [27].", [["LV", "ANATOMY", 90, 92], ["LV", "ANATOMY", 224, 226], ["sepsis", "DISEASE", 51, 57], ["septic shock", "DISEASE", 65, 77], ["patients", "ORGANISM", 30, 38], ["LV", "MULTI-TISSUE_STRUCTURE", 224, 226], ["patients", "SPECIES", 30, 38], ["A meta-analysis", "TEST", 0, 15], ["severe sepsis", "PROBLEM", 44, 57], ["septic shock", "PROBLEM", 65, 77], ["LV", "TEST", 90, 92], ["GLS measurements", "TEST", 93, 109], ["CI", "TEST", 188, 190], ["p", "TEST", 207, 208], ["LV ejection fraction", "TEST", 224, 244], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["sepsis", "OBSERVATION", 51, 57], ["septic shock", "OBSERVATION", 65, 77], ["LV", "ANATOMY", 90, 92]]], ["In our study, although there was no statistically significant difference among the three groups in terms of the conventional echocardiography parameters of LV, there was a statistically significant difference among the LV-GLS values of the patients in the three groups.DiscussionZhaohai Zheng et al. analyzed 13 meta-analyses and examined 3027 patients with COVID-19; they found that elevated troponin and D-dimer levels were related to the severity of the disease and mortality.", [["LV", "ANATOMY", 156, 158], ["LV", "ANATOMY", 219, 221], ["LV", "MULTI-TISSUE_STRUCTURE", 156, 158], ["patients", "ORGANISM", 240, 248], ["patients", "ORGANISM", 344, 352], ["troponin", "GENE_OR_GENE_PRODUCT", 393, 401], ["D-dimer", "GENE_OR_GENE_PRODUCT", 406, 413], ["troponin", "PROTEIN", 393, 401], ["patients", "SPECIES", 240, 248], ["patients", "SPECIES", 344, 352], ["our study", "TEST", 3, 12], ["the conventional echocardiography parameters", "TEST", 108, 152], ["COVID", "TEST", 358, 363], ["elevated troponin", "PROBLEM", 384, 401], ["D-dimer levels", "TEST", 406, 420], ["the disease", "PROBLEM", 453, 464], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["difference", "OBSERVATION", 62, 72], ["LV", "ANATOMY", 156, 158], ["significant", "OBSERVATION_MODIFIER", 186, 197], ["difference", "OBSERVATION", 198, 208], ["elevated", "OBSERVATION", 384, 392], ["disease", "OBSERVATION", 457, 464]]], ["Elevated troponin levels are frequently present in patients with COVID-19 and are significantly associated with myocardial injury and fatal outcomes [28, 29].", [["myocardial", "ANATOMY", 112, 122], ["myocardial injury", "DISEASE", 112, 129], ["troponin", "GENE_OR_GENE_PRODUCT", 9, 17], ["patients", "ORGANISM", 51, 59], ["myocardial", "MULTI-TISSUE_STRUCTURE", 112, 122], ["troponin", "PROTEIN", 9, 17], ["patients", "SPECIES", 51, 59], ["Elevated troponin levels", "PROBLEM", 0, 24], ["COVID", "TEST", 65, 70], ["myocardial injury", "PROBLEM", 112, 129], ["fatal outcomes", "PROBLEM", 134, 148], ["myocardial", "ANATOMY", 112, 122], ["injury", "OBSERVATION", 123, 129], ["fatal", "OBSERVATION_MODIFIER", 134, 139]]], ["As expected, increased troponin levels showing myocardial damage were also associated with the disruption in the LV-GLS, which is evidence of myocardial tissue impairment.", [["myocardial", "ANATOMY", 47, 57], ["LV", "ANATOMY", 113, 115], ["myocardial tissue", "ANATOMY", 142, 159], ["myocardial damage", "DISEASE", 47, 64], ["myocardial tissue impairment", "DISEASE", 142, 170], ["troponin", "GENE_OR_GENE_PRODUCT", 23, 31], ["myocardial", "MULTI-TISSUE_STRUCTURE", 47, 57], ["myocardial tissue", "TISSUE", 142, 159], ["troponin", "PROTEIN", 23, 31], ["increased troponin levels", "PROBLEM", 13, 38], ["myocardial damage", "PROBLEM", 47, 64], ["the disruption in the LV", "PROBLEM", 91, 115], ["myocardial tissue impairment", "PROBLEM", 142, 170], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["myocardial", "ANATOMY", 47, 57], ["damage", "OBSERVATION", 58, 64], ["disruption", "OBSERVATION", 95, 105], ["LV", "ANATOMY", 113, 115], ["evidence of", "UNCERTAINTY", 130, 141], ["myocardial tissue", "OBSERVATION", 142, 159]]], ["In our study, there was a statistically significant relationship between the LV-GLS value, hs-TnI, and D-dimer levels.", [["LV", "ANATOMY", 77, 79], ["hs-TnI", "GENE_OR_GENE_PRODUCT", 91, 97], ["D-dimer", "GENE_OR_GENE_PRODUCT", 103, 110], ["GLS", "PROTEIN", 80, 83], ["TnI", "PROTEIN", 94, 97], ["our study", "TEST", 3, 12], ["the LV", "TEST", 73, 79], ["hs", "TEST", 91, 93], ["TnI", "TEST", 94, 97], ["D-dimer levels", "TEST", 103, 117], ["LV", "ANATOMY", 77, 79]]], ["In a study of 61 unstable patients with angina, the LV-GLS value was found to be better in 48 patients who underwent invasive coronary angiography (ICA) and did not have significant coronary artery stenosis (\u2212 19.4 vs. \u2212 15.9%, p < 0.001).", [["LV", "ANATOMY", 52, 54], ["coronary", "ANATOMY", 126, 134], ["coronary artery", "ANATOMY", 182, 197], ["angina", "DISEASE", 40, 46], ["coronary artery stenosis", "DISEASE", 182, 206], ["patients", "ORGANISM", 26, 34], ["LV", "MULTI-TISSUE_STRUCTURE", 52, 54], ["patients", "ORGANISM", 94, 102], ["coronary", "MULTI-TISSUE_STRUCTURE", 126, 134], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 182, 197], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 94, 102], ["a study", "TEST", 3, 10], ["angina", "PROBLEM", 40, 46], ["the LV", "TEST", 48, 54], ["GLS value", "TEST", 55, 64], ["invasive coronary angiography", "TEST", 117, 146], ["significant coronary artery stenosis", "PROBLEM", 170, 206], ["\u2212", "TEST", 219, 220], ["p", "TEST", 228, 229], ["LV", "ANATOMY", 52, 54], ["coronary artery", "ANATOMY", 182, 197], ["stenosis", "OBSERVATION", 198, 206]]], ["Patients who did not undergo ICA had a better LV-GLS value (\u2212 20.2 vs. \u2212 17.7%, p = 0.017) [30].", [["LV", "ANATOMY", 46, 48], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["ICA", "TEST", 29, 32], ["GLS value", "TEST", 49, 58], ["p", "TEST", 80, 81]]], ["In our study, LV-GLS was also impaired in patients in the non-severe COVID-19 group with relatively low troponin levels.", [["LV", "ANATOMY", 14, 16], ["COVID", "DISEASE", 69, 74], ["LV", "MULTI-TISSUE_STRUCTURE", 14, 16], ["patients", "ORGANISM", 42, 50], ["troponin", "GENE_OR_GENE_PRODUCT", 104, 112], ["troponin", "PROTEIN", 104, 112], ["patients", "SPECIES", 42, 50], ["our study", "TEST", 3, 12], ["LV-GLS", "TEST", 14, 20], ["the non-severe COVID", "TEST", 54, 74], ["relatively low troponin levels", "PROBLEM", 89, 119], ["LV", "ANATOMY", 14, 16], ["impaired", "OBSERVATION", 30, 38]]], ["In patients with normal EF who have an underlying cardiac disease, LV-GLS might be impaired even if hs-TnI is negative.", [["cardiac", "ANATOMY", 50, 57], ["LV", "ANATOMY", 67, 69], ["cardiac disease", "DISEASE", 50, 65], ["patients", "ORGANISM", 3, 11], ["cardiac", "ORGAN", 50, 57], ["LV", "MULTI-TISSUE_STRUCTURE", 67, 69], ["hs-TnI", "GENE_OR_GENE_PRODUCT", 100, 106], ["TnI", "PROTEIN", 103, 106], ["patients", "SPECIES", 3, 11], ["an underlying cardiac disease", "PROBLEM", 36, 65], ["LV-GLS", "TEST", 67, 73], ["hs", "TEST", 100, 102], ["TnI", "TEST", 103, 106], ["cardiac", "ANATOMY", 50, 57], ["disease", "OBSERVATION", 58, 65], ["LV", "ANATOMY", 67, 69], ["negative", "OBSERVATION", 110, 118]]], ["In a case report, it was determined that the RV was affected as well as the LV in the patient with COVID-19 [31].", [["RV", "ANATOMY", 45, 47], ["LV", "ANATOMY", 76, 78], ["COVID-19", "CHEMICAL", 99, 107], ["RV", "ORGAN", 45, 47], ["LV", "MULTI-TISSUE_STRUCTURE", 76, 78], ["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 86, 93], ["COVID", "TEST", 99, 104], ["RV", "ANATOMY", 45, 47], ["LV", "ANATOMY", 76, 78]]], ["Cardiac chambers with greater volumes are interdependent on prolonged exposure to higher pressures.", [["Cardiac", "ANATOMY", 0, 7], ["chambers", "OBSERVATION", 8, 16], ["greater", "OBSERVATION_MODIFIER", 22, 29], ["volumes", "OBSERVATION_MODIFIER", 30, 37], ["higher", "OBSERVATION_MODIFIER", 82, 88], ["pressures", "OBSERVATION_MODIFIER", 89, 98]]], ["When chamber pressures increase, cardiac troponin is released, and the increased wall strain may lead to subendocardial ischemia and injury [32, 33].", [["cardiac", "ANATOMY", 33, 40], ["wall", "ANATOMY", 81, 85], ["subendocardial", "ANATOMY", 105, 119], ["subendocardial ischemia", "DISEASE", 105, 128], ["cardiac", "ORGAN", 33, 40], ["troponin", "GENE_OR_GENE_PRODUCT", 41, 49], ["subendocardial", "MULTI-TISSUE_STRUCTURE", 105, 119], ["troponin", "PROTEIN", 41, 49], ["chamber pressures", "TEST", 5, 22], ["cardiac troponin", "TEST", 33, 49], ["the increased wall strain", "PROBLEM", 67, 92], ["subendocardial ischemia", "PROBLEM", 105, 128], ["injury", "PROBLEM", 133, 139], ["pressures", "OBSERVATION_MODIFIER", 13, 22], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["wall strain", "OBSERVATION", 81, 92], ["subendocardial", "ANATOMY", 105, 119], ["ischemia", "OBSERVATION", 120, 128]]], ["In our study, there was a statistically significant relationship between RV-LS values and both hs-TnI and D-dimer levels.DiscussionIn a recent study by Li et al. involving 120 patients with COVID-19, RV-LS was identified as an independent predictor of mortality [34].", [["Li", "CHEMICAL", 152, 154], ["hs-TnI", "GENE_OR_GENE_PRODUCT", 95, 101], ["D-dimer", "GENE_OR_GENE_PRODUCT", 106, 113], ["patients", "ORGANISM", 176, 184], ["TnI", "PROTEIN", 98, 101], ["patients", "SPECIES", 176, 184], ["our study", "TEST", 3, 12], ["RV", "TEST", 73, 75], ["LS values", "TEST", 76, 85], ["TnI and D-dimer levels", "TEST", 98, 120], ["a recent study", "TEST", 134, 148], ["COVID", "TEST", 190, 195], ["RV", "TEST", 200, 202], ["RV", "ANATOMY", 73, 75], ["RV", "ANATOMY", 200, 202]]], ["In this study, the best cutoff value of RV-LS for outcome prediction was \u2212 23% (AUC, 0.87; P < 0.001; sensitivity, 94.4%; specificity, 64.7%).", [["this study", "TEST", 3, 13], ["RV", "TEST", 40, 42], ["outcome prediction", "TEST", 50, 68], ["\u2212", "TEST", 73, 74], ["AUC", "TEST", 80, 83], ["P", "TEST", 91, 92], ["sensitivity", "TEST", 102, 113], ["specificity", "TEST", 122, 133], ["RV", "ANATOMY", 40, 42]]], ["In this study, only RV-LS was evaluated, and no examination was conducted regarding how LV-GLS is affected by COVID-19 and its prognosis.", [["LV", "ANATOMY", 88, 90], ["this study", "TEST", 3, 13], ["RV", "TEST", 20, 22], ["examination", "TEST", 48, 59], ["GLS", "TEST", 91, 94], ["COVID", "TEST", 110, 115], ["RV", "ANATOMY", 20, 22]]], ["In this study, patients with low ejection fraction were also included.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["this study", "TEST", 3, 13], ["low ejection fraction", "PROBLEM", 29, 50]]], ["In our study, the prognostic significance of LV-GLS in relation to RV-LS was investigated.", [["LV", "ANATOMY", 45, 47], ["LV", "MULTI-TISSUE_STRUCTURE", 45, 47], ["our study", "TEST", 3, 12], ["LV", "TEST", 45, 47], ["RV", "TEST", 67, 69], ["RV", "ANATOMY", 67, 69]]], ["Patients with a low ejection fraction were excluded, and the biventricular function was evaluated by STE in patients with COVID-19 with preserved ejection fraction.", [["biventricular", "ANATOMY", 61, 74], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 108, 116], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 108, 116], ["a low ejection fraction", "PROBLEM", 14, 37], ["COVID", "TEST", 122, 127], ["biventricular", "ANATOMY", 61, 74], ["ejection fraction", "OBSERVATION", 146, 163]]], ["To our knowledge, no study has evaluated the prognostic value of the LV function with LV-GLS or the relationship between RV-LS and LV-GLS using 2D-STE in patients with COVID-19.", [["LV", "ANATOMY", 69, 71], ["LV", "ANATOMY", 86, 88], ["LV", "ANATOMY", 131, 133], ["LV", "MULTI-TISSUE_STRUCTURE", 69, 71], ["LV", "MULTI-TISSUE_STRUCTURE", 131, 133], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["LV", "TEST", 86, 88], ["RV", "TEST", 121, 123], ["LS", "TEST", 124, 126], ["LV", "TEST", 131, 133], ["GLS", "TEST", 134, 137], ["COVID", "TEST", 168, 173], ["LV", "ANATOMY", 69, 71], ["RV", "ANATOMY", 121, 123], ["LV", "ANATOMY", 131, 133]]], ["We also found that a correlation between LV-GLS and RV-LS and that the values decrease as the severity of the COVID-19 infection increases.DiscussionIn the recent times, studies showed the presence of myocardial dysfunction using echocardiography in intensive care patients diagnosed with sepsis who are receiving mechanical ventilation [35, 36].", [["LV", "ANATOMY", 41, 43], ["myocardial", "ANATOMY", 201, 211], ["infection", "DISEASE", 119, 128], ["myocardial dysfunction", "DISEASE", 201, 223], ["sepsis", "DISEASE", 289, 295], ["myocardial", "MULTI-TISSUE_STRUCTURE", 201, 211], ["patients", "ORGANISM", 265, 273], ["patients", "SPECIES", 265, 273], ["LV", "TEST", 41, 43], ["GLS", "TEST", 44, 47], ["RV", "TEST", 52, 54], ["the COVID", "TEST", 106, 115], ["infection", "PROBLEM", 119, 128], ["studies", "TEST", 170, 177], ["myocardial dysfunction", "PROBLEM", 201, 223], ["echocardiography", "TEST", 230, 246], ["sepsis", "PROBLEM", 289, 295], ["mechanical ventilation", "TREATMENT", 314, 336], ["RV", "ANATOMY", 52, 54], ["infection", "OBSERVATION", 119, 128], ["myocardial", "ANATOMY", 201, 211], ["dysfunction", "OBSERVATION", 212, 223], ["sepsis", "OBSERVATION", 289, 295]]], ["In these studies, it was observed that almost 30\u201340% of sepsis patients developed a decrease in LVEF and diastolic dysfunction.", [["sepsis", "DISEASE", 56, 62], ["diastolic dysfunction", "DISEASE", 105, 126], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["these studies", "TEST", 3, 16], ["sepsis", "PROBLEM", 56, 62], ["a decrease in LVEF", "PROBLEM", 82, 100], ["diastolic dysfunction", "PROBLEM", 105, 126], ["sepsis", "OBSERVATION", 56, 62], ["decrease", "OBSERVATION_MODIFIER", 84, 92], ["LVEF", "OBSERVATION", 96, 100], ["diastolic dysfunction", "OBSERVATION", 105, 126]]], ["Hyperdynamic heart functions because of systemic inflammatory response, increase of cardiac output (CO) and LVEF are observed in the early period in these sepsis patients.", [["heart", "ANATOMY", 13, 18], ["cardiac", "ANATOMY", 84, 91], ["increase of cardiac output", "DISEASE", 72, 98], ["sepsis", "DISEASE", 155, 161], ["heart", "ORGAN", 13, 18], ["cardiac", "ORGAN", 84, 91], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["Hyperdynamic heart functions", "PROBLEM", 0, 28], ["systemic inflammatory response", "PROBLEM", 40, 70], ["cardiac output", "TEST", 84, 98], ["LVEF", "TEST", 108, 112], ["these sepsis patients", "PROBLEM", 149, 170], ["heart", "ANATOMY", 13, 18], ["systemic", "OBSERVATION_MODIFIER", 40, 48], ["inflammatory", "OBSERVATION", 49, 61], ["increase", "OBSERVATION_MODIFIER", 72, 80], ["cardiac", "ANATOMY", 84, 91], ["output", "OBSERVATION_MODIFIER", 92, 98], ["early", "OBSERVATION_MODIFIER", 133, 138], ["period", "OBSERVATION_MODIFIER", 139, 145], ["sepsis", "OBSERVATION", 155, 161]]], ["In the late period, extensive myocardial injury occurs due to severe hypoxia and inflammation [37].", [["myocardial", "ANATOMY", 30, 40], ["myocardial injury", "DISEASE", 30, 47], ["hypoxia", "DISEASE", 69, 76], ["inflammation", "DISEASE", 81, 93], ["myocardial", "MULTI-TISSUE_STRUCTURE", 30, 40], ["extensive myocardial injury", "PROBLEM", 20, 47], ["severe hypoxia", "PROBLEM", 62, 76], ["inflammation", "PROBLEM", 81, 93], ["extensive", "OBSERVATION_MODIFIER", 20, 29], ["myocardial", "ANATOMY", 30, 40], ["injury", "OBSERVATION", 41, 47], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["hypoxia", "OBSERVATION", 69, 76], ["inflammation", "OBSERVATION", 81, 93]]], ["Previous studies have shown right heart function impairment in patients with acute respiratory distress syndrome (ARDS) [38, 39].", [["right heart", "ANATOMY", 28, 39], ["respiratory", "ANATOMY", 83, 94], ["heart function impairment", "DISEASE", 34, 59], ["acute respiratory distress syndrome", "DISEASE", 77, 112], ["ARDS", "DISEASE", 114, 118], ["heart", "ORGAN", 34, 39], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["Previous studies", "TEST", 0, 16], ["right heart function impairment", "PROBLEM", 28, 59], ["acute respiratory distress syndrome", "PROBLEM", 77, 112], ["ARDS", "PROBLEM", 114, 118], ["right", "ANATOMY_MODIFIER", 28, 33], ["heart", "ANATOMY", 34, 39], ["function", "OBSERVATION_MODIFIER", 40, 48], ["impairment", "OBSERVATION", 49, 59], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["respiratory distress", "OBSERVATION", 83, 103]]], ["The extent of RV dysfunction has been shown to be an important predictor of mortality in different patient groups.", [["RV", "ANATOMY", 14, 16], ["RV dysfunction", "DISEASE", 14, 28], ["RV", "MULTI-TISSUE_STRUCTURE", 14, 16], ["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["RV dysfunction", "PROBLEM", 14, 28], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["RV", "ANATOMY", 14, 16], ["dysfunction", "OBSERVATION", 17, 28]]], ["Right heart dysfunction come into prominence in determining circulation and respiratory management strategies, especially in patients with COVID-19 with lung involvement.", [["heart", "ANATOMY", 6, 11], ["respiratory", "ANATOMY", 76, 87], ["lung", "ANATOMY", 153, 157], ["Right heart dysfunction", "DISEASE", 0, 23], ["heart", "ORGAN", 6, 11], ["patients", "ORGANISM", 125, 133], ["lung", "ORGAN", 153, 157], ["patients", "SPECIES", 125, 133], ["Right heart dysfunction", "PROBLEM", 0, 23], ["respiratory management strategies", "TREATMENT", 76, 109], ["COVID", "TEST", 139, 144], ["lung involvement", "PROBLEM", 153, 169], ["heart", "ANATOMY", 6, 11], ["dysfunction", "OBSERVATION", 12, 23], ["prominence", "OBSERVATION", 34, 44], ["circulation", "OBSERVATION_MODIFIER", 60, 71], ["respiratory management", "OBSERVATION", 76, 98], ["lung", "ANATOMY", 153, 157], ["involvement", "OBSERVATION", 158, 169]]], ["Our results showed that patients with a more severe clinical state present more severe cardiac dysfunction; but it is not clear whether this can be imputable to COVID-19 or this is a general outcome that can be expected in non-COVID-19 patients with similarly severe clinical conditions (respiratory disease).DiscussionThere are several publications regarding the possible mechanisms of cardiac damage observed in patients with COVID-19 [1\u20134].", [["cardiac", "ANATOMY", 87, 94], ["respiratory", "ANATOMY", 288, 299], ["cardiac", "ANATOMY", 387, 394], ["cardiac dysfunction", "DISEASE", 87, 106], ["respiratory disease", "DISEASE", 288, 307], ["cardiac damage", "DISEASE", 387, 401], ["COVID-19", "CHEMICAL", 161, 169], ["COVID-19", "CHEMICAL", 428, 436], ["patients", "ORGANISM", 24, 32], ["cardiac", "ORGAN", 87, 94], ["patients", "ORGANISM", 236, 244], ["cardiac", "ORGAN", 387, 394], ["patients", "ORGANISM", 414, 422], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 236, 244], ["patients", "SPECIES", 414, 422], ["a more severe clinical state", "PROBLEM", 38, 66], ["severe cardiac dysfunction", "PROBLEM", 80, 106], ["similarly severe clinical conditions", "PROBLEM", 250, 286], ["respiratory disease)", "PROBLEM", 288, 308], ["cardiac damage", "PROBLEM", 387, 401], ["COVID", "TEST", 428, 433], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["cardiac", "ANATOMY", 87, 94], ["dysfunction", "OBSERVATION", 95, 106], ["severe", "OBSERVATION_MODIFIER", 260, 266], ["respiratory disease", "OBSERVATION", 288, 307], ["cardiac", "ANATOMY", 387, 394], ["damage", "OBSERVATION", 395, 401]]], ["Myocardial injury detected with increased troponin levels was found to be related to both the severity of the disease and mortality.", [["Myocardial", "ANATOMY", 0, 10], ["Myocardial injury", "DISEASE", 0, 17], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 0, 10], ["troponin", "GENE_OR_GENE_PRODUCT", 42, 50], ["troponin", "PROTEIN", 42, 50], ["Myocardial injury", "PROBLEM", 0, 17], ["increased troponin levels", "PROBLEM", 32, 57], ["the disease", "PROBLEM", 106, 117], ["injury", "OBSERVATION", 11, 17], ["disease", "OBSERVATION", 110, 117]]], ["Moreover, patients with cardiovascular diseases appear to have a potentially fatal with different mechanisms including myocardial damage, cytokine storm, myocarditis, and microembolism.", [["cardiovascular", "ANATOMY", 24, 38], ["myocardial", "ANATOMY", 119, 129], ["cardiovascular diseases", "DISEASE", 24, 47], ["myocardial damage", "DISEASE", 119, 136], ["myocarditis", "DISEASE", 154, 165], ["microembolism", "DISEASE", 171, 184], ["patients", "ORGANISM", 10, 18], ["myocardial", "MULTI-TISSUE_STRUCTURE", 119, 129], ["cytokine", "PROTEIN", 138, 146], ["patients", "SPECIES", 10, 18], ["cardiovascular diseases", "PROBLEM", 24, 47], ["myocardial damage", "PROBLEM", 119, 136], ["cytokine storm", "PROBLEM", 138, 152], ["myocarditis", "PROBLEM", 154, 165], ["microembolism", "PROBLEM", 171, 184], ["myocardial", "ANATOMY", 119, 129], ["damage", "OBSERVATION", 130, 136], ["cytokine storm", "OBSERVATION", 138, 152], ["myocarditis", "OBSERVATION", 154, 165], ["microembolism", "OBSERVATION", 171, 184]]], ["The related mechanisms are summarized as follows: (i) Cytokine storm and multiple organ failure due to acute systemic inflammatory response; (ii) an imbalance between the oxygen supply and demand of the myocardium secondary to severe hypoxia resulting from acute respiratory failure; (iii) cardiotoxicity that may develop due to the agents used in the treatment; (iv) coronary thrombosis caused by plaque rupture as a result of shear stress caused by increased coronary circulation with systemic inflammation; (v) a tendency to arrhythmia that occurs due to an electrolyte imbalance in the renin-angiotensin aldosterone system in relation to the ACE-2 signaling system of the virus; (vi) embolic complications caused by the tendency to thrombosis due to systemic inflammation; and vii) myocarditis possibly caused by the direct entry of the virus (although not yet proven for myocardium) into the cell by binding to the ACE-2 receptor, which is predominantly expressed in lung and heart tissue, and causing changes in the ACE2 signaling system.", [["organ", "ANATOMY", 82, 87], ["myocardium", "ANATOMY", 203, 213], ["respiratory", "ANATOMY", 263, 274], ["coronary", "ANATOMY", 368, 376], ["plaque", "ANATOMY", 398, 404], ["coronary", "ANATOMY", 461, 469], ["myocardium", "ANATOMY", 876, 886], ["cell", "ANATOMY", 897, 901], ["lung", "ANATOMY", 972, 976], ["heart tissue", "ANATOMY", 981, 993], ["organ failure", "DISEASE", 82, 95], ["oxygen", "CHEMICAL", 171, 177], ["hypoxia", "DISEASE", 234, 241], ["acute respiratory failure", "DISEASE", 257, 282], ["cardiotoxicity", "DISEASE", 290, 304], ["coronary thrombosis", "DISEASE", 368, 387], ["plaque rupture", "DISEASE", 398, 412], ["inflammation", "DISEASE", 496, 508], ["arrhythmia", "DISEASE", 528, 538], ["angiotensin", "CHEMICAL", 596, 607], ["aldosterone", "CHEMICAL", 608, 619], ["embolic complications", "DISEASE", 688, 709], ["thrombosis", "DISEASE", 736, 746], ["inflammation", "DISEASE", 763, 775], ["myocarditis", "DISEASE", 786, 797], ["oxygen", "CHEMICAL", 171, 177], ["aldosterone", "CHEMICAL", 608, 619], ["Cytokine", "GENE_OR_GENE_PRODUCT", 54, 62], ["organ", "ORGAN", 82, 87], ["oxygen", "SIMPLE_CHEMICAL", 171, 177], ["myocardium", "ORGAN", 203, 213], ["coronary", "MULTI-TISSUE_STRUCTURE", 368, 376], ["coronary", "MULTI-TISSUE_STRUCTURE", 461, 469], ["renin-angiotensin aldosterone", "GENE_OR_GENE_PRODUCT", 590, 619], ["ACE-2", "GENE_OR_GENE_PRODUCT", 646, 651], ["myocardium", "ORGAN", 876, 886], ["cell", "CELL", 897, 901], ["ACE-2 receptor", "GENE_OR_GENE_PRODUCT", 920, 934], ["lung", "ORGAN", 972, 976], ["heart tissue", "TISSUE", 981, 993], ["ACE2", "GENE_OR_GENE_PRODUCT", 1022, 1026], ["Cytokine", "PROTEIN", 54, 62], ["renin", "PROTEIN", 590, 595], ["ACE-2 receptor", "PROTEIN", 920, 934], ["ACE2", "PROTEIN", 1022, 1026], ["Cytokine storm", "PROBLEM", 54, 68], ["multiple organ failure", "PROBLEM", 73, 95], ["acute systemic inflammatory response", "PROBLEM", 103, 139], ["an imbalance", "PROBLEM", 146, 158], ["the oxygen supply", "TREATMENT", 167, 184], ["severe hypoxia", "PROBLEM", 227, 241], ["acute respiratory failure", "PROBLEM", 257, 282], ["iii) cardiotoxicity", "PROBLEM", 285, 304], ["the agents", "TREATMENT", 329, 339], ["the treatment", "TREATMENT", 348, 361], ["coronary thrombosis", "PROBLEM", 368, 387], ["plaque rupture", "PROBLEM", 398, 412], ["shear stress", "PROBLEM", 428, 440], ["increased coronary circulation", "PROBLEM", 451, 481], ["systemic inflammation", "PROBLEM", 487, 508], ["a tendency to arrhythmia", "PROBLEM", 514, 538], ["an electrolyte imbalance", "PROBLEM", 558, 582], ["the renin", "TEST", 586, 595], ["angiotensin aldosterone system", "TREATMENT", 596, 626], ["the ACE", "TEST", 642, 649], ["the virus", "PROBLEM", 672, 681], ["embolic complications", "PROBLEM", 688, 709], ["the tendency to thrombosis", "PROBLEM", 720, 746], ["systemic inflammation", "PROBLEM", 754, 775], ["myocarditis", "PROBLEM", 786, 797], ["the virus", "PROBLEM", 837, 846], ["changes in the ACE2 signaling system", "PROBLEM", 1007, 1043], ["organ", "ANATOMY", 82, 87], ["failure", "OBSERVATION", 88, 95], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["systemic", "OBSERVATION_MODIFIER", 109, 117], ["inflammatory", "OBSERVATION", 118, 130], ["imbalance", "OBSERVATION", 149, 158], ["oxygen supply", "OBSERVATION", 171, 184], ["myocardium", "ANATOMY", 203, 213], ["severe", "OBSERVATION_MODIFIER", 227, 233], ["hypoxia", "OBSERVATION", 234, 241], ["acute", "OBSERVATION_MODIFIER", 257, 262], ["respiratory failure", "OBSERVATION", 263, 282], ["coronary", "ANATOMY", 368, 376], ["thrombosis", "OBSERVATION", 377, 387], ["plaque", "OBSERVATION", 398, 404], ["shear stress", "OBSERVATION", 428, 440], ["increased", "OBSERVATION_MODIFIER", 451, 460], ["coronary circulation", "ANATOMY", 461, 481], ["systemic", "OBSERVATION_MODIFIER", 487, 495], ["inflammation", "OBSERVATION", 496, 508], ["arrhythmia", "OBSERVATION", 528, 538], ["electrolyte imbalance", "OBSERVATION", 561, 582], ["virus", "OBSERVATION", 676, 681], ["embolic complications", "OBSERVATION", 688, 709], ["thrombosis", "OBSERVATION", 736, 746], ["systemic", "OBSERVATION_MODIFIER", 754, 762], ["inflammation", "OBSERVATION", 763, 775], ["myocarditis", "OBSERVATION", 786, 797], ["predominantly", "OBSERVATION_MODIFIER", 945, 958], ["lung", "ANATOMY", 972, 976], ["heart", "ANATOMY", 981, 986], ["tissue", "ANATOMY_MODIFIER", 987, 993]]], ["Considering this mechanisms, the myocardial tissue of a RV affected by the current respiratory condition may be affected in the early stages of the disease process, and RV-LS decreases in patients with COVID-19.", [["myocardial tissue", "ANATOMY", 33, 50], ["RV", "ANATOMY", 56, 58], ["respiratory", "ANATOMY", 83, 94], ["COVID-19", "CHEMICAL", 202, 210], ["myocardial tissue", "TISSUE", 33, 50], ["RV", "MULTI-TISSUE_STRUCTURE", 56, 58], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 188, 196], ["the current respiratory condition", "PROBLEM", 71, 104], ["the disease process", "PROBLEM", 144, 163], ["RV", "TEST", 169, 171], ["COVID", "TEST", 202, 207], ["myocardial tissue", "ANATOMY", 33, 50], ["RV", "OBSERVATION", 56, 58], ["respiratory condition", "OBSERVATION", 83, 104], ["disease", "OBSERVATION", 148, 155], ["RV", "ANATOMY", 169, 171], ["decreases", "OBSERVATION_MODIFIER", 175, 184]]], ["One of the mechanisms of cardiac effects causing mortality in patients with COVID-19 has been identified as myocardial disruption at the tissue level.", [["cardiac", "ANATOMY", 25, 32], ["myocardial", "ANATOMY", 108, 118], ["tissue", "ANATOMY", 137, 143], ["COVID-19", "CHEMICAL", 76, 84], ["myocardial disruption", "DISEASE", 108, 129], ["COVID-19", "CHEMICAL", 76, 84], ["cardiac", "ANATOMICAL_SYSTEM", 25, 32], ["patients", "ORGANISM", 62, 70], ["COVID-19", "GENE_OR_GENE_PRODUCT", 76, 84], ["myocardial", "MULTI-TISSUE_STRUCTURE", 108, 118], ["tissue", "TISSUE", 137, 143], ["patients", "SPECIES", 62, 70], ["cardiac effects", "PROBLEM", 25, 40], ["COVID", "TEST", 76, 81], ["myocardial disruption at the tissue level", "PROBLEM", 108, 149], ["cardiac", "ANATOMY", 25, 32], ["myocardial", "ANATOMY", 108, 118], ["disruption", "OBSERVATION", 119, 129], ["tissue", "ANATOMY", 137, 143]]], ["For this reason, LV and RV longitudinal strain are the main factors of prognosis due to COVID-19 early and more pronounced effect compared to other conventional echocardiography parameters.DiscussionOur study is limited in several ways.", [["LV", "ANATOMY", 17, 19], ["LV", "MULTI-TISSUE_STRUCTURE", 17, 19], ["LV and RV longitudinal strain", "PROBLEM", 17, 46], ["COVID", "TEST", 88, 93], ["other conventional echocardiography parameters", "TEST", 142, 188], ["Our study", "TEST", 199, 208], ["LV", "ANATOMY", 17, 19], ["RV", "ANATOMY", 24, 26], ["longitudinal strain", "OBSERVATION", 27, 46], ["more pronounced", "OBSERVATION_MODIFIER", 107, 122]]], ["First, the data was derived from a single center, and the sample size was relatively small.", [["the sample size", "TEST", 54, 69], ["size", "OBSERVATION_MODIFIER", 65, 69], ["relatively", "OBSERVATION_MODIFIER", 74, 84], ["small", "OBSERVATION_MODIFIER", 85, 90]]], ["Second, there was a lack of measurement of the strain on the left atrium.", [["left atrium", "ANATOMY", 61, 72], ["left atrium", "MULTI-TISSUE_STRUCTURE", 61, 72], ["the strain on the left atrium", "PROBLEM", 43, 72], ["strain", "OBSERVATION", 47, 53], ["left atrium", "ANATOMY", 61, 72]]], ["Third, no 2DE data was obtained from patients prior to COVID-19 infection.", [["infection", "DISEASE", 64, 73], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["2DE data", "TEST", 10, 18], ["COVID-19 infection", "PROBLEM", 55, 73], ["infection", "OBSERVATION", 64, 73]]], ["Fourth, echocardiography images were recorded by one person due to the risk of infection but evaluated by two physicians.DiscussionIn conclusion, we have determined that both RV-LS and LV-GLS were affected by COVID-19 and are parameters of independent predictors of mortality in patients with COVID-19.", [["LV", "ANATOMY", 185, 187], ["infection", "DISEASE", 79, 88], ["patients", "ORGANISM", 279, 287], ["person", "SPECIES", 53, 59], ["patients", "SPECIES", 279, 287], ["echocardiography images", "TEST", 8, 31], ["infection", "PROBLEM", 79, 88], ["RV", "TEST", 175, 177], ["LS", "TEST", 178, 180], ["LV", "TEST", 185, 187], ["GLS", "TEST", 188, 191], ["COVID", "TEST", 209, 214], ["COVID", "TEST", 293, 298], ["infection", "OBSERVATION", 79, 88], ["RV", "ANATOMY", 175, 177], ["LV", "ANATOMY", 185, 187]]], ["RV dysfunction can be detected using echocardiography, which can provide early information regarding the severity of the COVID-19 infection, which may in turn help to guide the treatment of this group of patients.", [["RV", "ANATOMY", 0, 2], ["RV dysfunction", "DISEASE", 0, 14], ["infection", "DISEASE", 130, 139], ["RV", "MULTI-TISSUE_STRUCTURE", 0, 2], ["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 204, 212], ["RV dysfunction", "PROBLEM", 0, 14], ["echocardiography", "TEST", 37, 53], ["the COVID-19 infection", "PROBLEM", 117, 139], ["dysfunction", "OBSERVATION", 3, 14], ["infection", "OBSERVATION", 130, 139]]]], "0b82d75437611047e46c37729000c5cfd201ab47": [["IntroductionFeline infectious peritonitis (FIP) is caused by internally arising 3c and S gene mutants of a ubiquitous and largely non-pathogenic feline enteric coronavirus (FECV) (Chang et al., 2012; Pedersen et al., 2012) .", [["infectious peritonitis", "DISEASE", 19, 41], ["FIP", "DISEASE", 43, 46], ["feline enteric coronavirus", "DISEASE", 145, 171], ["feline enteric coronavirus", "ORGANISM", 145, 171], ["feline enteric coronavirus", "SPECIES", 145, 171], ["feline enteric coronavirus", "SPECIES", 145, 171], ["FECV", "SPECIES", 173, 177], ["IntroductionFeline infectious peritonitis", "PROBLEM", 0, 41], ["internally arising 3c", "PROBLEM", 61, 82], ["largely non-pathogenic feline enteric coronavirus", "PROBLEM", 122, 171], ["infectious", "OBSERVATION_MODIFIER", 19, 29], ["peritonitis", "OBSERVATION", 30, 41], ["non-pathogenic feline", "OBSERVATION", 130, 151], ["enteric coronavirus", "ANATOMY", 152, 171]]], ["The resultant FIP viruses (FIPVs) cause disease mainly among young cats from pedigreed catteries, shelters, and other dense multi-cat environments.", [["FIP viruses", "ORGANISM", 14, 25], ["cats", "ORGANISM", 67, 71], ["cats", "SPECIES", 67, 71], ["FIP viruses", "SPECIES", 14, 25], ["The resultant FIP viruses", "PROBLEM", 0, 25], ["disease", "PROBLEM", 40, 47], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["FIP viruses", "OBSERVATION", 14, 25], ["dense", "OBSERVATION_MODIFIER", 118, 123], ["multi-cat environments", "OBSERVATION", 124, 146]]], ["FIP prevalence is around 1-5% in these populations, but mortality among affected cats is virtually 100% once clinical signs appear (Pedersen, 2009 ).", [["FIP", "DISEASE", 0, 3], ["cats", "ORGANISM", 81, 85], ["cats", "SPECIES", 81, 85], ["FIP prevalence", "TEST", 0, 14], ["clinical signs", "TEST", 109, 123]]], ["This suggests that either the FECV-to-FIPV mutation rate is very low or that most infections are abortive.", [["infections", "DISEASE", 82, 92], ["FECV", "GENE_OR_GENE_PRODUCT", 30, 34], ["FIPV", "GENE_OR_GENE_PRODUCT", 38, 42], ["the FECV", "TEST", 26, 34], ["FIPV mutation rate", "TEST", 38, 56], ["most infections", "PROBLEM", 77, 92]]], ["The first scenario is unlikely based on two different studies.", [["two different studies", "TEST", 40, 61]]], ["Chang et al. (2012) calculated that thousands of FECV progeny carrying the S protein mutation occur during any single infection.", [["infection", "DISEASE", 118, 127], ["FECV progeny", "CELL", 49, 61], ["FECV progeny", "CELL_LINE", 49, 61], ["S protein", "PROTEIN", 75, 84], ["the S protein mutation", "PROBLEM", 71, 93], ["any single infection", "PROBLEM", 107, 127], ["infection", "OBSERVATION", 118, 127]]], ["Another study indicated that the FECV-to-FIPV mutation and FIP occurs in at least 20% of older cats following FECV exposure, but only in individuals that were immunocompromised (Poland et al., 1996) .", [["FIP", "DISEASE", 59, 62], ["FECV", "CHEMICAL", 110, 114], ["FECV", "GENE_OR_GENE_PRODUCT", 33, 37], ["FIPV", "GENE_OR_GENE_PRODUCT", 41, 45], ["cats", "ORGANISM", 95, 99], ["cats", "SPECIES", 95, 99], ["Another study", "TEST", 0, 13], ["the FECV", "TEST", 29, 37], ["FIPV mutation", "PROBLEM", 41, 54], ["FIP", "PROBLEM", 59, 62], ["FECV exposure", "PROBLEM", 110, 123], ["immunocompromised", "PROBLEM", 159, 176]]], ["Therefore, additional extrinsic (environment) or intrinsic (host) factors must play an important role in actual disease occurrence.", [["intrinsic (host) factors", "PROBLEM", 49, 73], ["actual disease occurrence", "PROBLEM", 105, 130], ["extrinsic", "OBSERVATION_MODIFIER", 22, 31]]], ["Extrinsic factors that increase the level of exposure to FECV (Foley et al., 1997) or that depress the immune system at the time of initial FECV infection (reviewed Pedersen, 2009; Poland et al., 1996) affect FIP prevalence.", [["immune system", "ANATOMY", 103, 116], ["infection", "DISEASE", 145, 154], ["FIP", "DISEASE", 209, 212], ["FECV", "SPECIES", 140, 144], ["Extrinsic factors", "PROBLEM", 0, 17], ["Foley", "TREATMENT", 63, 68], ["depress the immune system", "PROBLEM", 91, 116], ["initial FECV infection", "PROBLEM", 132, 154], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["infection", "OBSERVATION", 145, 154]]], ["Age at the time of initial FECV exposure, which usually occurs around 9 weeks of age (Pedersen et al., 2008) , may also be a critical factor, because the adaptive immune system of kittens is still maturing during this period (Pedersen, 1987) .", [["FECV", "CHEMICAL", 27, 31], ["kittens", "ORGANISM", 180, 187]]], ["Kittens from dense multi-cat environments such as catteries and shelters are often under heavy stress due to the effects of overpopulation, diet changes, early weaning and exposure to a myriad of other common kitten-hood infections (Pedersen, 2009) .IntroductionSusceptibility to FIPV is also affected by factors that are intrinsic to the host.", [["infections", "DISEASE", 221, 231], ["FIPV", "CHEMICAL", 280, 284], ["FIPV", "PROTEIN", 280, 284], ["FIPV", "SPECIES", 280, 284], ["early weaning", "TREATMENT", 154, 167], ["hood infections", "PROBLEM", 216, 231], ["IntroductionSusceptibility to FIPV", "PROBLEM", 250, 284], ["dense", "OBSERVATION_MODIFIER", 13, 18], ["multi-", "OBSERVATION_MODIFIER", 19, 25], ["cat environments", "OBSERVATION", 25, 41], ["hood", "OBSERVATION_MODIFIER", 216, 220], ["infections", "OBSERVATION", 221, 231], ["FIPV", "OBSERVATION", 280, 284]]], ["Confirmed cases of FIP did not exist before the 1950s (reviewed Pedersen, 2009 ).", [["FIP", "DISEASE", 19, 22], ["FIP", "OBSERVATION", 19, 22]]], ["As such, cats have not had a long period of time to evolve significant immunity to the virus.", [["cats", "ORGANISM", 9, 13], ["cats", "SPECIES", 9, 13], ["the virus", "PROBLEM", 83, 92]]], ["Pedigreed cats are more likely to develop FIP than random-bred cats and certain breeds are more likely to succumb to FIP than others (Pesteanu-Somogyi et al., 2006; Rohrbach et al., 2001; Worthing et al., 2012) .", [["FIP", "DISEASE", 42, 45], ["FIP", "DISEASE", 117, 120], ["cats", "ORGANISM", 10, 14], ["cats", "ORGANISM", 63, 67], ["cats", "SPECIES", 10, 14], ["cats", "SPECIES", 63, 67], ["FIP", "PROBLEM", 42, 45], ["certain breeds", "PROBLEM", 72, 86], ["more likely to", "UNCERTAINTY", 19, 33], ["FIP", "OBSERVATION", 42, 45], ["more likely", "UNCERTAINTY", 91, 102]]], ["One study of Persian catteries and pedigrees indicated that susceptibility to FIP was at least 50% heritable .", [["FIP", "DISEASE", 78, 81], ["One study", "TEST", 0, 9], ["FIP", "TEST", 78, 81]]], ["Identifying a genetic association with FIP susceptibility may be possible using a newly available moderate density feline SNP array with Ostrander, 2012) .", [["FIP", "DISEASE", 39, 42], ["SNP", "CHEMICAL", 122, 125], ["feline", "ORGANISM", 115, 121], ["FIP susceptibility", "PROBLEM", 39, 57]]], ["There has been much less experience with GWAS in cats than dogs, although many phenotypic and disease traits of cats have been identified by candidate gene approaches (Bighignoli et al., 2007; Filler et al., 2012; Gandolfi et al., 2010; Grahn et al., 2012 ) and a recent GWAS study discovered the causative mutation for hypokalemia in Burmese using just 35 cases and 25 controls .", [["hypokalemia", "DISEASE", 320, 331], ["cats", "ORGANISM", 49, 53], ["cats", "ORGANISM", 112, 116], ["cats", "SPECIES", 49, 53], ["dogs", "SPECIES", 59, 63], ["cats", "SPECIES", 112, 116], ["GWAS in cats than dogs", "PROBLEM", 41, 63], ["many phenotypic and disease traits of cats", "PROBLEM", 74, 116], ["a recent GWAS study", "TEST", 262, 281], ["the causative mutation", "PROBLEM", 293, 315], ["hypokalemia", "PROBLEM", 320, 331], ["much less", "OBSERVATION_MODIFIER", 15, 24], ["disease", "OBSERVATION", 94, 101]]], ["This was the first attempt to elucidate genes associated with a complex disease susceptibility trait in cats using GWAS, which is a far more difficult task than identifying causative genes for simple Mendelian traits.", [["cats", "ORGANISM", 104, 108], ["a complex disease susceptibility trait in cats", "PROBLEM", 62, 108], ["GWAS", "TEST", 115, 119], ["simple Mendelian traits", "PROBLEM", 193, 216], ["complex", "OBSERVATION_MODIFIER", 64, 71], ["disease", "OBSERVATION", 72, 79]]], ["However, given sufficient numbers of cases and controls, it may be possible to identify regions of the genome containing relevant candidate genes.", [["candidate genes", "DNA", 130, 145]]], ["The Birman breed is ideal for such a study, given its high incidence of FIP (Pesteanu-Somogyi et al., 2006) , relatively small population size and high linkage disequilibrium (Alhaddad et al., 2013) .Cats used in studyBuccal swabs of 199 Birman cats were submitted by breeders, veterinarians and owners from Denmark and USA (Table 1) , along with three generation pedigrees.", [["studyBuccal swabs", "ANATOMY", 213, 230], ["FIP", "DISEASE", 72, 75], ["cats", "ORGANISM", 245, 249], ["cats", "SPECIES", 245, 249], ["a study", "TEST", 35, 42], ["FIP", "PROBLEM", 72, 75], ["relatively small population size", "PROBLEM", 110, 142], ["high linkage disequilibrium", "PROBLEM", 147, 174], ["studyBuccal swabs", "TEST", 213, 230], ["FIP", "OBSERVATION", 72, 75], ["small", "OBSERVATION_MODIFIER", 121, 126], ["population", "OBSERVATION_MODIFIER", 127, 137], ["size", "OBSERVATION_MODIFIER", 138, 142], ["high", "OBSERVATION_MODIFIER", 147, 151], ["linkage disequilibrium", "OBSERVATION", 152, 174]]], ["The diagnosis of FIP was confirmed by attending veterinarians based on clinical signs, blood tests, analysis of ascites or pleural fluids, and in some cases by gross or complete necropsies.", [["blood", "ANATOMY", 87, 92], ["ascites", "ANATOMY", 112, 119], ["pleural fluids", "ANATOMY", 123, 137], ["FIP", "DISEASE", 17, 20], ["ascites", "DISEASE", 112, 119], ["FIP", "ORGANISM", 17, 20], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["FIP", "PROBLEM", 17, 20], ["clinical signs", "TEST", 71, 85], ["blood tests", "TEST", 87, 98], ["ascites", "PROBLEM", 112, 119], ["pleural fluids", "PROBLEM", 123, 137], ["FIP", "OBSERVATION", 17, 20], ["ascites", "OBSERVATION", 112, 119], ["pleural", "ANATOMY", 123, 130], ["fluids", "OBSERVATION", 131, 137]]], ["The male to female ratio of cats in the study was 1.3:1 and \u223c70% of cats dying of FIP were 1\u00bd years of age or younger (Fig. 1) .", [["FIP", "DISEASE", 82, 85], ["female", "ORGANISM", 12, 18], ["cats", "ORGANISM", 28, 32], ["cats", "ORGANISM", 68, 72], ["cats", "SPECIES", 28, 32], ["cats", "SPECIES", 68, 72], ["the study", "TEST", 36, 45]]], ["No cats greater than 5\u00bd years of age in this study developed FIP.", [["FIP", "DISEASE", 61, 64], ["cats", "ORGANISM", 3, 7], ["cats", "SPECIES", 3, 7], ["this study", "TEST", 40, 50], ["FIP", "PROBLEM", 61, 64], ["cats", "OBSERVATION_MODIFIER", 3, 7], ["greater", "OBSERVATION_MODIFIER", 8, 15], ["FIP", "OBSERVATION", 61, 64]]], ["Sixty four percent of cats died with the non-effusive form of FIP and 36% with effusive disease.", [["FIP", "DISEASE", 62, 65], ["effusive disease", "DISEASE", 79, 95], ["cats", "ORGANISM", 22, 26], ["cats", "SPECIES", 22, 26], ["FIP", "PROBLEM", 62, 65], ["effusive disease", "PROBLEM", 79, 95], ["FIP", "OBSERVATION", 62, 65], ["effusive disease", "OBSERVATION", 79, 95]]], ["The gender and age distribution was typical for FIP, while the predominance of non-effusive over effusive FIP was atypical (Pedersen, 2009 ).DNA extraction and genotypingDNA from buccal swabs was extracted following the manufacturer's recommendations (Puregene DNA buccal cell kit; Gentra Systems, Inc., Minneapolis, MN).", [["buccal swabs", "ANATOMY", 179, 191], ["buccal cell", "ANATOMY", 265, 276], ["FIP", "DISEASE", 48, 51], ["FIP", "DISEASE", 106, 109], ["DNA", "CELLULAR_COMPONENT", 141, 144], ["buccal swabs", "MULTI-TISSUE_STRUCTURE", 179, 191], ["FIP", "PROBLEM", 48, 51], ["non-effusive over effusive FIP", "PROBLEM", 79, 109], ["DNA extraction", "TREATMENT", 141, 155], ["genotypingDNA", "PROBLEM", 160, 173], ["buccal swabs", "PROBLEM", 179, 191], ["the manufacturer's recommendations", "TREATMENT", 216, 250], ["Puregene DNA buccal cell kit", "TREATMENT", 252, 280], ["Gentra Systems", "TREATMENT", 282, 296]]], ["DNA samples were genotyped with the Illumina Infinium HD feline 63K single nucleotide polymorphism (SNP) BeadChip \u00ae Array (Illumina Inc., San Diego, CA) by GeneSeek Inc., Lincoln, NE.", [["samples", "ANATOMY", 4, 11], ["SNP", "CHEMICAL", 100, 103], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["NE", "DNA", 180, 182], ["DNA samples", "TEST", 0, 11], ["the Illumina Infinium HD feline", "TREATMENT", 32, 63], ["single nucleotide polymorphism (SNP)", "TREATMENT", 68, 104]]], ["A large number of SNPs (n = 6890) were not assigned to a chromosome or position at the time the array was developed and were therefore packaged on an artificial chromosome i.e., \"chr.Un.\".", [["chromosome", "ANATOMY", 57, 67], ["chromosome", "ANATOMY", 161, 171], ["chromosome", "CELLULAR_COMPONENT", 57, 67], ["chromosome", "CELLULAR_COMPONENT", 161, 171], ["artificial chromosome", "DNA", 150, 171], ["chr.Un", "DNA", 179, 185], ["SNPs", "TEST", 18, 22], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["The correct chromosome and position assignments for the 63K SNPs for this study was based upon the ICGSC Felis catus 6.2/felCat5 (September 2011) assembly on the UCSC genome browser.Association analysisThe 199 Birman DNA samples were genotyped and genomewide association (GWAS) studies were performed with PLINK (Purcell et al., 2007) .", [["chromosome", "ANATOMY", 12, 22], ["samples", "ANATOMY", 221, 228], ["K", "CHEMICAL", 58, 59], ["chromosome", "CELLULAR_COMPONENT", 12, 22], ["63K SNPs", "DNA", 56, 64], ["UCSC genome browser", "DNA", 162, 181], ["ICGSC Felis catus", "SPECIES", 99, 116], ["this study", "TEST", 69, 79], ["Association analysis", "TEST", 182, 202], ["Birman DNA samples", "TEST", 210, 228], ["GWAS) studies", "TEST", 272, 285]]], ["All markers were subject to stringent qualitycontrol criteria to assure high-quality data.", [["stringent qualitycontrol criteria", "TEST", 28, 61]]], ["Fourteen samples were excluded due to low genotyping (MIND > 0.1, which excluded individuals with more than 10% missing genotype).", [["samples", "ANATOMY", 9, 16], ["Fourteen samples", "TEST", 0, 16], ["low genotyping", "PROBLEM", 38, 52]]], ["The total genotyping rate in remaining individuals was 0.99.", [["The total genotyping rate", "TEST", 0, 25], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["Some SNPs (n = 811) failed missingness test (GENO > 0.1, which excluded SNPs with 10% missing genotyping rate).", [["Some SNPs", "PROBLEM", 0, 9], ["missingness test", "TEST", 27, 43], ["GENO", "TEST", 45, 49], ["SNPs", "TEST", 72, 76], ["genotyping rate", "TEST", 94, 109]]], ["Some SNPs (n = 25,484) failed the frequency test (MAF < 0.05, exclusion of SNPs with less than 5% minor allele frequency).", [["Some SNPs", "PROBLEM", 0, 9], ["the frequency test", "TEST", 30, 48], ["MAF", "TEST", 50, 53], ["SNPs", "TEST", 75, 79]]], ["After frequency and genotyping pruning, 36,862 SNPs remained for analysis.", [["genotyping pruning", "TEST", 20, 38], ["SNPs", "TEST", 47, 51], ["analysis", "TEST", 65, 73]]], ["Population stratification in case and control populations from each region were assessed by multidimensional scaling (MDS) and relatedness was confirmed by Pi-Hat test using the PLINK whole genome association analysis toolset (Purcell et al., 2007) .", [["Pi", "CHEMICAL", 156, 158], ["Hat test", "TEST", 159, 167]]], ["After filtering, GWAS data from 185 cats (cases = 34, controls = 151) remained for further analysis (Table 1) .", [["cats", "ORGANISM", 36, 40], ["cats", "SPECIES", 36, 40], ["GWAS data", "TEST", 17, 26], ["cats", "TEST", 36, 40], ["cases", "TEST", 42, 47], ["further analysis", "TEST", 83, 99]]], ["Allele frequencies were compared between the cases and controls, and the strength of associations between specific SNPs and disease was shown in terms of P(raw).ResultsThe first step in this study was to select case and control populations for GWAS based on available information.", [["P", "DNA", 154, 155], ["Allele frequencies", "PROBLEM", 0, 18], ["disease", "PROBLEM", 124, 131], ["this study", "TEST", 186, 196], ["GWAS", "PROBLEM", 244, 248]]], ["Multidimensional scaling of case and control cats from both the USA and Denmark indicated that the two populations were closely related but geographically distinguishable, but with no stratification between cases and controls within the same countries (Fig. 2 ).", [["cats", "ORGANISM", 45, 49], ["the two populations", "PROBLEM", 95, 114], ["stratification between cases and controls", "PROBLEM", 184, 225]]], ["Given these facts, and assuming that FIP susceptibility traits have been under neutral selection since 1925 when the breed was formally recognized, a decision was made to first compare all case and control cats regardless of country of origin (Table 1) .", [["cats", "ORGANISM", 206, 210], ["FIP susceptibility traits", "PROBLEM", 37, 62]]], ["A second analysis involved stratifying cases and controls by limiting cases to cats 1\u00bd years of age or younger (the most susceptible) and the controls to cats 2 years of age or older (the most resistant) ( Fig. 1 and Table 1 ).", [["cats", "ORGANISM", 79, 83], ["cats", "ORGANISM", 154, 158], ["cats", "SPECIES", 79, 83], ["A second analysis", "TEST", 0, 17]]], ["Genomic inflation factor (GIF) values for both analysis groups were 1.35 and 1.43, respectively.", [["GIF", "GENE_OR_GENE_PRODUCT", 26, 29], ["Genomic inflation factor", "PROTEIN", 0, 24], ["GIF", "PROTEIN", 26, 29], ["Genomic inflation factor", "PROBLEM", 0, 24], ["GIF) values", "TEST", 26, 37], ["both analysis groups", "TEST", 42, 62]]], ["The highest ranking SNPs in both analyses are shown in Table 2 .", [["highest", "OBSERVATION_MODIFIER", 4, 11], ["ranking SNPs", "OBSERVATION", 12, 24]]], ["All potential candidate genes involved with immune responses within 500 kb of each SNP were identified, Table 2 Highest ranking SNPs from analysis-1 (34 cases vs. 151 controls) and analysis-2 (20 cases vs. 88 controls) based on unadjusted P(raw) and corrected P(Bonf) probabilities, and candidate genes known to be strongly involved in immune responses. and if no candidate genes were identified the search was extended to a distance of 1 Mb.", [["SNP", "CHEMICAL", 83, 86], ["P", "DNA", 239, 240], ["P", "DNA", 260, 261], ["candidate genes", "DNA", 287, 302], ["candidate genes", "DNA", 364, 379], ["each SNP", "TREATMENT", 78, 86], ["analysis", "TEST", 138, 146], ["analysis", "TEST", 181, 189]]], ["When the 34 FIP cases and 151 controls were analyzed (analysis-1), the strongest associations (\u2212log 10 P(raw) \u2265 5.0) were found on chr.A2, chr.C2 and chr.D4 (Table 2, Fig. 3a) .", [["A2", "GENE_OR_GENE_PRODUCT", 135, 137], ["chr.C2", "GENE_OR_GENE_PRODUCT", 139, 145], ["chr", "GENE_OR_GENE_PRODUCT", 150, 153], ["chr", "DNA", 131, 134], ["A2", "PROTEIN", 135, 137], ["chr.C2", "DNA", 139, 145], ["chr", "DNA", 150, 153], ["analysis", "TEST", 54, 62], ["A2", "PROBLEM", 135, 137]]], ["Given a Bonferroni correction of \u2212log 10 P(raw) \u2265 5.8 for genome-wide significance, only the highest ranked SNP on chr.A2 attained significance (p = 0.048) ( Table 2 ).", [["SNP", "CHEMICAL", 108, 111], ["chr", "CELLULAR_COMPONENT", 115, 118], ["A2", "GENE_OR_GENE_PRODUCT", 119, 121], ["P", "DNA", 41, 42], ["chr", "DNA", 115, 118], ["A2", "PROTEIN", 119, 121], ["a Bonferroni correction of \u2212log", "TREATMENT", 6, 37]]], ["The Manhattan plot of analysis-2 cats demonstrated 3 peaks with 6 SNPs having \u2212log 10 P(raw) \u2265 5.0 on chr.A1, chr.A3, and chr.E2 (Table 2, Fig. 3b ).", [["E2", "CHEMICAL", 126, 128], ["cats", "ORGANISM", 33, 37], ["A1", "GENE_OR_GENE_PRODUCT", 106, 108], ["chr.A3", "GENE_OR_GENE_PRODUCT", 110, 116], ["chr", "GENE_OR_GENE_PRODUCT", 122, 125], ["chr", "DNA", 102, 105], ["A1", "DNA", 106, 108], ["chr.A3", "PROTEIN", 110, 116], ["chr", "DNA", 122, 125], ["The Manhattan plot of analysis", "TEST", 0, 30], ["\u2212log", "TEST", 78, 82]]], ["Only the three highest ranking SNPs on chr.A1 and highest ranked SNP on chr.E2 had genome-wide significance after Bonferroni correction (p = 0.009-0.043) ( Table 2) .", [["SNP", "CHEMICAL", 65, 68], ["E2", "CHEMICAL", 76, 78], ["SNP", "CHEMICAL", 65, 68], ["chr", "CELLULAR_COMPONENT", 39, 42], ["A1", "GENE_OR_GENE_PRODUCT", 43, 45], ["chr", "CELLULAR_COMPONENT", 72, 75], ["E2", "GENE_OR_GENE_PRODUCT", 76, 78], ["chr", "DNA", 39, 42], ["A1", "DNA", 43, 45], ["chr", "DNA", 72, 75], ["A1", "PROBLEM", 43, 45], ["Bonferroni correction", "TREATMENT", 114, 135], ["highest", "OBSERVATION_MODIFIER", 50, 57], ["wide", "OBSERVATION_MODIFIER", 90, 94]]], ["Two SNPs on chr.A2 (log 10 P(raw) = 4.86) and chr.C2 (\u2212log 10 P(raw) = 4.93) were just below the cutoff at \u2212log 10 P(raw) \u2265 5.0 ( Table 2 ).", [["chr", "CELLULAR_COMPONENT", 12, 15], ["A2", "GENE_OR_GENE_PRODUCT", 16, 18], ["chr", "DNA", 12, 15], ["A2", "PROTEIN", 16, 18], ["A2", "TEST", 16, 18], ["C2 (\u2212log 10 P(raw)", "TEST", 50, 68]]], ["The SNP on chr.A2 was identical to the highest ranking SNP identified in analysis-1, further bolstering its significance.", [["SNP", "CHEMICAL", 4, 7], ["SNP", "CHEMICAL", 55, 58], ["chr", "CELLULAR_COMPONENT", 11, 14], ["A2", "GENE_OR_GENE_PRODUCT", 15, 17], ["chr", "DNA", 11, 14], ["A2", "PROTEIN", 15, 17], ["The SNP on chr", "TREATMENT", 0, 14], ["analysis", "TEST", 73, 81]]], ["The chr.C2 SNP identified in analysis-2 was separated by only 300 kb from the second ranking SNP on analysis-1.", [["SNP", "CHEMICAL", 11, 14], ["SNP", "CHEMICAL", 93, 96], ["chr.C2", "GENE_OR_GENE_PRODUCT", 4, 10], ["chr.C2 SNP", "DNA", 4, 14], ["The chr.C2 SNP", "TEST", 0, 14], ["analysis", "TEST", 29, 37], ["analysis", "TEST", 100, 108]]], ["Although neither SNP was significant upon Bonferroni correction, their proximity and high ranking by both analyses was taken as reason to also interrogate this chr.C2 region for candidate genes.", [["SNP", "CHEMICAL", 17, 20], ["chr", "CELLULAR_COMPONENT", 160, 163], ["chr", "DNA", 160, 163], ["C2 region", "DNA", 164, 173], ["candidate genes", "DNA", 178, 193], ["Bonferroni correction", "TREATMENT", 42, 63], ["significant", "OBSERVATION_MODIFIER", 25, 36]]], ["GWAS of analysis-1 and -2 cats identified five potential candidate genes on four different chromosomes: engulfment and cell motility protein 1 (ELMO1), Ras-related GTP binding A (RRAGA), tumor necrosis factor superfamily 10 (TNFSF10), and endoplasmic reticulum aminopeptidase 1 and 2 (ERAP1 and ERAP2) ( Table 2) .", [["chromosomes", "ANATOMY", 91, 102], ["cell", "ANATOMY", 119, 123], ["tumor necrosis", "DISEASE", 187, 201], ["cats", "ORGANISM", 26, 30], ["chromosomes", "CELLULAR_COMPONENT", 91, 102], ["cell motility protein 1", "GENE_OR_GENE_PRODUCT", 119, 142], ["ELMO1", "GENE_OR_GENE_PRODUCT", 144, 149], ["Ras-related GTP binding A", "GENE_OR_GENE_PRODUCT", 152, 177], ["RRAGA", "GENE_OR_GENE_PRODUCT", 179, 184], ["tumor necrosis factor superfamily 10", "GENE_OR_GENE_PRODUCT", 187, 223], ["TNFSF10", "GENE_OR_GENE_PRODUCT", 225, 232], ["endoplasmic reticulum aminopeptidase 1", "GENE_OR_GENE_PRODUCT", 239, 277], ["2", "GENE_OR_GENE_PRODUCT", 282, 283], ["ERAP1", "GENE_OR_GENE_PRODUCT", 285, 290], ["ERAP2", "GENE_OR_GENE_PRODUCT", 295, 300], ["Table 2", "GENE_OR_GENE_PRODUCT", 304, 311], ["candidate genes", "DNA", 57, 72], ["chromosomes", "DNA", 91, 102], ["engulfment and cell motility protein 1", "PROTEIN", 104, 142], ["ELMO1", "PROTEIN", 144, 149], ["Ras-related GTP binding A", "PROTEIN", 152, 177], ["RRAGA", "PROTEIN", 179, 184], ["tumor necrosis factor superfamily 10", "PROTEIN", 187, 223], ["TNFSF10", "PROTEIN", 225, 232], ["endoplasmic reticulum aminopeptidase 1 and 2", "PROTEIN", 239, 283], ["ERAP1", "PROTEIN", 285, 290], ["ERAP2", "PROTEIN", 295, 300], ["Table 2", "PROTEIN", 304, 311], ["analysis", "TEST", 8, 16], ["cell motility protein", "TEST", 119, 140], ["ELMO1", "TEST", 144, 149], ["Ras-related GTP binding A (RRAGA)", "PROBLEM", 152, 185], ["tumor necrosis factor superfamily", "PROBLEM", 187, 220], ["endoplasmic reticulum aminopeptidase", "TEST", 239, 275], ["tumor", "OBSERVATION_MODIFIER", 187, 192], ["necrosis", "OBSERVATION", 193, 201]]], ["No candidate genes were identified on chr.A3 and chr.E2, both of which demonstrated strong associations in analysis-2.", [["E2", "CHEMICAL", 53, 55], ["chr", "CELLULAR_COMPONENT", 38, 41], ["A3", "GENE_OR_GENE_PRODUCT", 42, 44], ["chr", "GENE_OR_GENE_PRODUCT", 49, 52], ["E2", "GENE_OR_GENE_PRODUCT", 53, 55], ["candidate genes", "DNA", 3, 18], ["chr", "DNA", 38, 41], ["A3", "DNA", 42, 44], ["chr", "DNA", 49, 52], ["analysis", "TEST", 107, 115], ["strong", "OBSERVATION_MODIFIER", 84, 90]]], ["Only a single high ranking SNP was associated with ELMO1 ( Fig. 4) and RRAGA (Fig. 5) , while several high ranking SNPs were associated with TNFSF10 (Fig. 6) .", [["SNP", "CHEMICAL", 27, 30], ["TNFSF10", "GENE_OR_GENE_PRODUCT", 141, 148], ["ELMO1", "PROTEIN", 51, 56], ["RRAGA", "PROTEIN", 71, 76], ["TNFSF10", "PROTEIN", 141, 148], ["a single high ranking SNP", "PROBLEM", 5, 30], ["ELMO1", "TEST", 51, 56], ["RRAGA", "TEST", 71, 76], ["several high ranking SNPs", "PROBLEM", 94, 119]]], ["Nineteen of 30 highest ranking SNPs in analysis-2, including the top three ranked SNPs, were on chr.A1 (data not shown).", [["A1", "GENE_OR_GENE_PRODUCT", 100, 102], ["chr", "DNA", 96, 99], ["A1", "PROTEIN", 100, 102], ["A1 (data", "TEST", 100, 108]]], ["Seventeen of the 19 SNPs formed a 10.5 Mb region flanked by the three highest ranking SNPs (Fig. 7) .", [["10.5 Mb region", "DNA", 34, 48], ["a 10.5 Mb region flanked", "PROBLEM", 32, 56], ["10.5 Mb", "OBSERVATION_MODIFIER", 34, 41]]], ["This region contained 31 or more genes, two of which (ERAP1 and ERAP2) were strong candidates at positions chr.A1.158,772,633 and chr.A1.158,978,956 bp, respectively.", [["ERAP1", "GENE_OR_GENE_PRODUCT", 54, 59], ["ERAP2", "GENE_OR_GENE_PRODUCT", 64, 69], ["chr", "CELLULAR_COMPONENT", 107, 110], ["chr", "CELLULAR_COMPONENT", 130, 133], ["ERAP1", "DNA", 54, 59], ["ERAP2", "DNA", 64, 69], ["positions chr", "DNA", 97, 110], ["chr", "TEST", 130, 133], ["bp", "TEST", 149, 151], ["more genes", "OBSERVATION_MODIFIER", 28, 38]]], ["These two genes were near the center of the 10.5 Mb region. (b) analysis-2 containing 20 cases (1\u00bd years and younger) and 88 controls (2 years or older).", [["10.5 Mb region", "DNA", 44, 58], ["two", "OBSERVATION_MODIFIER", 6, 9], ["genes", "OBSERVATION_MODIFIER", 10, 15], ["10.5 Mb", "OBSERVATION_MODIFIER", 44, 51]]], ["Bonferonni correction significant at \u2212log10 P (raw) = 5.8.", [["Bonferonni", "CHEMICAL", 0, 10], ["Bonferonni", "SIMPLE_CHEMICAL", 0, 10]]], ["\"Chromosome Un\" contains a small number of unmapped SNPs.", [["Chromosome", "CELLULAR_COMPONENT", 1, 11], ["Chromosome Un", "DNA", 1, 14], ["unmapped SNPs", "DNA", 43, 56], ["small", "OBSERVATION_MODIFIER", 27, 32], ["number", "OBSERVATION_MODIFIER", 33, 39], ["unmapped SNPs", "OBSERVATION", 43, 56]]], ["Peaks > 5.0 \u2212 log10 P (raw) were investigated for candidate genes.DiscussionThis was the first attempt to identify genes associated with FIP susceptibility; a trait presumed to be genetically complex.", [["FIP", "DISEASE", 137, 140], ["candidate genes", "DNA", 50, 65], ["Peaks", "TEST", 0, 5], ["FIP susceptibility", "PROBLEM", 137, 155]]], ["Its complexity was confirmed by the multiplicity of strong associations between case and control cats observed in GWAS.", [["cats", "ORGANISM", 97, 101]]], ["However, none of these associations was totally concordant with the FIP susceptibility phenotype.", [["FIP", "DISEASE", 68, 71], ["the FIP susceptibility phenotype", "PROBLEM", 64, 96], ["FIP susceptibility phenotype", "OBSERVATION", 68, 96]]], ["Therefore, the associations need to be further confirmed with GWAS of additional case and control cats and sequencing of candidate genes for polymorphisms.DiscussionThere are findings in studies of this type that either diminish or increase confidence in a particular candidate gene.", [["cats", "ORGANISM", 98, 102], ["candidate genes", "DNA", 121, 136], ["candidate gene", "DNA", 268, 282], ["control cats", "TREATMENT", 90, 102], ["polymorphisms", "PROBLEM", 141, 154]]], ["Candidate genes on chr.A2 (ELMO1) and chr.C2 (TNFSF10) were identified by two different GWAS configurations.", [["chr", "GENE_OR_GENE_PRODUCT", 19, 22], ["A2", "GENE_OR_GENE_PRODUCT", 23, 25], ["ELMO1", "GENE_OR_GENE_PRODUCT", 27, 32], ["chr.C2", "GENE_OR_GENE_PRODUCT", 38, 44], ["TNFSF10", "GENE_OR_GENE_PRODUCT", 46, 53], ["chr", "DNA", 19, 22], ["A2", "PROTEIN", 23, 25], ["ELMO1", "PROTEIN", 27, 32], ["chr.C2", "DNA", 38, 44], ["TNFSF10", "DNA", 46, 53], ["A2 (ELMO1)", "TEST", 23, 33], ["two", "OBSERVATION_MODIFIER", 74, 77], ["different", "OBSERVATION_MODIFIER", 78, 87], ["GWAS configurations", "OBSERVATION", 88, 107]]], ["However, only a single high ranking SNP was associated with RRAGA and ELMO1, which was somewhat discomforting.", [["SNP", "CHEMICAL", 36, 39], ["ELMO1", "GENE_OR_GENE_PRODUCT", 70, 75], ["ELMO1", "PROTEIN", 70, 75], ["a single high ranking SNP", "PROBLEM", 14, 39], ["ELMO1", "TREATMENT", 70, 75], ["somewhat discomforting", "PROBLEM", 87, 109]]], ["In contrast, a number of adjacent high ranking SNPs were associated with TNFSF10, ERAP1 and ERAP2, giving more confidence to these associations.", [["TNFSF10", "GENE_OR_GENE_PRODUCT", 73, 80], ["ERAP1", "GENE_OR_GENE_PRODUCT", 82, 87], ["ERAP2", "GENE_OR_GENE_PRODUCT", 92, 97], ["TNFSF10", "PROTEIN", 73, 80], ["ERAP1", "PROTEIN", 82, 87], ["ERAP2", "PROTEIN", 92, 97], ["adjacent high ranking SNPs", "PROBLEM", 25, 51], ["TNFSF10", "TREATMENT", 73, 80], ["ERAP1", "TEST", 82, 87], ["ERAP2", "TEST", 92, 97], ["high", "OBSERVATION_MODIFIER", 34, 38], ["ranking SNPs", "OBSERVATION", 39, 51]]], ["The distance between high ranking SNPs and potential candidate genes was another consideration, and the preference is for high ranking SNPs to lie within a candidate gene's coding region.", [["candidate gene's coding region", "DNA", 156, 186], ["high ranking SNPs", "PROBLEM", 122, 139], ["distance", "OBSERVATION_MODIFIER", 4, 12], ["high", "OBSERVATION_MODIFIER", 21, 25], ["ranking SNPs", "OBSERVATION", 26, 38]]], ["However, confirmed candidate genes for cat phenotypic and disease traits are often found 1 Mb or more distant from their identifying SNPs .", [["cat", "ORGANISM", 39, 42], ["candidate genes", "DNA", 19, 34], ["SNPs", "DNA", 133, 137], ["cat phenotypic and disease traits", "PROBLEM", 39, 72]]], ["Candidate genes TNFSF10 and RRAGA were 69-359 kb away from their respective highest ranking SNPs on chr.C2 and chr.D4, while ELMO1 was 814 kb from the highest ranking SNP on chr.A2.", [["SNP", "CHEMICAL", 167, 170], ["TNFSF10", "GENE_OR_GENE_PRODUCT", 16, 23], ["RRAGA", "GENE_OR_GENE_PRODUCT", 28, 33], ["chr", "CELLULAR_COMPONENT", 100, 103], ["C2", "GENE_OR_GENE_PRODUCT", 104, 106], ["chr", "GENE_OR_GENE_PRODUCT", 111, 114], ["D4", "GENE_OR_GENE_PRODUCT", 115, 117], ["ELMO1", "GENE_OR_GENE_PRODUCT", 125, 130], ["A2", "GENE_OR_GENE_PRODUCT", 178, 180], ["Candidate genes", "DNA", 0, 15], ["TNFSF10", "DNA", 16, 23], ["RRAGA", "DNA", 28, 33], ["chr", "DNA", 100, 103], ["C2", "DNA", 104, 106], ["chr", "DNA", 111, 114], ["D4", "DNA", 115, 117], ["ELMO1", "DNA", 125, 130], ["chr", "DNA", 174, 177], ["A2", "PROTEIN", 178, 180], ["RRAGA", "TEST", 28, 33], ["A2", "PROBLEM", 178, 180], ["chr", "OBSERVATION", 111, 114]]], ["ERAP1 and ERAP2, highly relevant candidate genes, were situated in the center of a 10.5 Mb region flanked by the three highest ranking SNPs and strongly associated with the disease phenotype.", [["ERAP1", "GENE_OR_GENE_PRODUCT", 0, 5], ["ERAP2", "GENE_OR_GENE_PRODUCT", 10, 15], ["ERAP1", "DNA", 0, 5], ["ERAP2", "DNA", 10, 15], ["10.5 Mb region", "DNA", 83, 97], ["ERAP1", "TEST", 0, 5], ["ERAP2", "TEST", 10, 15], ["a 10.5 Mb region flanked", "PROBLEM", 81, 105], ["the disease phenotype", "PROBLEM", 169, 190], ["10.5 Mb", "OBSERVATION_MODIFIER", 83, 90], ["disease", "OBSERVATION", 173, 180]]], ["Although distant, the SNP structure of this region and the relevance of these two genes to FIP immunopathogenesis made them obvious candidates for further study.DiscussionAnalysis of GWAS data was also complicated by case/control numbers and population substructure apparent in MDS and from GIF values.", [["SNP", "CHEMICAL", 22, 25], ["FIP", "DISEASE", 91, 94], ["MDS", "DISEASE", 278, 281], ["GIF", "GENE_OR_GENE_PRODUCT", 291, 294], ["GIF", "PROTEIN", 291, 294], ["further study", "TEST", 147, 160], ["GWAS data", "TEST", 183, 192], ["case/control numbers", "PROBLEM", 217, 237], ["population substructure", "PROBLEM", 242, 265], ["MDS", "PROBLEM", 278, 281], ["GIF values", "TEST", 291, 301], ["distant", "OBSERVATION_MODIFIER", 9, 16]]], ["Population substructure exists in all breeds of cats because of their short generation time, large numbers of offspring, and intense selection pressures applied by individual breeders.", [["cats", "ORGANISM", 48, 52], ["cats", "SPECIES", 48, 52], ["Population substructure", "PROBLEM", 0, 23], ["intense selection pressures", "TREATMENT", 125, 152], ["large", "OBSERVATION_MODIFIER", 93, 98], ["numbers", "OBSERVATION_MODIFIER", 99, 106], ["pressures", "OBSERVATION_MODIFIER", 143, 152]]], ["These factors were highlighted by genetic comparisons of Danish and American Birman cats, which evolved from a common gene pool and were segregated for only a few decades by geography.", [["Birman cats", "ORGANISM", 77, 88], ["cats", "SPECIES", 84, 88], ["American Birman cats", "SPECIES", 68, 88]]], ["Although highly related as a breed, Danish and American cats were distinguishable by MDS, with the latter being more homogenous than the former.", [["MDS", "DISEASE", 85, 88], ["cats", "ORGANISM", 56, 60], ["cats", "SPECIES", 56, 60], ["MDS", "PROBLEM", 85, 88], ["more homogenous", "OBSERVATION_MODIFIER", 112, 127]]], ["This could only have resulted from subtle phenotypic preferences among breeders in the two countries.DiscussionNumbers of cases and controls is another confounding factor in identifying complex genetic traits, even within relatively inbred populations.", [["subtle phenotypic preferences", "PROBLEM", 35, 64], ["another confounding factor", "PROBLEM", 144, 170], ["subtle", "OBSERVATION_MODIFIER", 35, 41], ["phenotypic", "OBSERVATION", 42, 52]]], ["The removal or addition of relatively few animals in the current study caused strong peaks of association to lose significance or disappear altogether, weaker peaks to gain significance, and new peaks to appear.", [["The removal", "TREATMENT", 0, 11], ["the current study", "TEST", 53, 70], ["relatively", "OBSERVATION_MODIFIER", 27, 37], ["few", "OBSERVATION_MODIFIER", 38, 41]]], ["This effect was evident between GWAS of analysis-1 (all cases vs. all controls, regardless of age or geography) and analysis-2 (young cats with FIP vs. older healthy cats, regardless of geography).DiscussionThe actual disease and exposure status of case and control is another covariate in a study of this type.", [["FIP", "DISEASE", 144, 147], ["cats", "ORGANISM", 134, 138], ["cats", "ORGANISM", 166, 170], ["cats", "SPECIES", 134, 138], ["analysis", "TEST", 40, 48], ["analysis", "TEST", 116, 124], ["FIP", "PROBLEM", 144, 147], ["older healthy cats", "TREATMENT", 152, 170], ["The actual disease", "PROBLEM", 207, 225], ["a study", "TEST", 290, 297]]], ["There was a high degree of confidence in the FIP diagnoses, because they were made by veterinarians knowledgeable about FIP and who often worked closely with breeders on the problem.", [["FIP", "DISEASE", 45, 48], ["FIP", "DISEASE", 120, 123], ["high degree", "OBSERVATION_MODIFIER", 12, 23], ["FIP", "OBSERVATION", 45, 48]]], ["The exposure status of control cats was much more difficult to determine, even though FECV is enzootic in virtually all catteries (Pedersen, 2009) and the FECV to FIPV mutation rate is relatively high (Poland et al., 1996) .", [["cats", "ORGANISM", 31, 35], ["cats", "SPECIES", 31, 35], ["FECV", "SPECIES", 86, 90], ["enzootic", "PROBLEM", 94, 102], ["the FECV to FIPV mutation rate", "TEST", 151, 181], ["enzootic", "OBSERVATION", 94, 102]]], ["The logic of stratifying the larger combined American and Danish populations into a smaller analysis group according to age was based on a single fact-exposure and susceptibility to FIPV was only certain for those cats that died of FIP.", [["FIP", "DISEASE", 232, 235], ["cats", "ORGANISM", 214, 218], ["FIPV", "SPECIES", 182, 186], ["susceptibility to FIPV", "PROBLEM", 164, 186], ["FIP", "PROBLEM", 232, 235], ["larger", "OBSERVATION_MODIFIER", 29, 35], ["FIP", "OBSERVATION", 232, 235]]], ["Extending the age for control cats enhanced the chance for FIPV exposure and therefore increased the odds that healthy cats surviving beyond this time were resistant.", [["FIPV", "CHEMICAL", 59, 63], ["cats", "ORGANISM", 30, 34], ["cats", "ORGANISM", 119, 123], ["cats", "SPECIES", 30, 34], ["FIPV exposure", "PROBLEM", 59, 72], ["healthy cats", "PROBLEM", 111, 123], ["FIPV exposure", "OBSERVATION", 59, 72], ["increased", "OBSERVATION_MODIFIER", 87, 96]]], ["Stratifying the GWAS population in this manner did produce stronger associations, bolstered confidence in candidate genes such as ELMO1 and TNFSF10 and identified promising new candidate genes ERAP1 and ERAP2.DiscussionThe potential candidate genes identified in this study have been strongly implicated in immune pathways concerning cellular migration, phagocytosis, programmed cell death (apoptosis), and virus/host cell interactions.", [["cellular", "ANATOMY", 334, 342], ["cell", "ANATOMY", 379, 383], ["cell", "ANATOMY", 418, 422], ["ELMO1", "GENE_OR_GENE_PRODUCT", 130, 135], ["TNFSF10", "GENE_OR_GENE_PRODUCT", 140, 147], ["ERAP1", "GENE_OR_GENE_PRODUCT", 193, 198], ["ERAP2", "GENE_OR_GENE_PRODUCT", 203, 208], ["cellular", "CELL", 334, 342], ["cell", "CELL", 379, 383], ["host cell", "CELL", 413, 422], ["candidate genes", "DNA", 106, 121], ["ELMO1", "DNA", 130, 135], ["TNFSF10", "DNA", 140, 147], ["candidate genes", "DNA", 177, 192], ["ERAP1", "DNA", 193, 198], ["ERAP2", "DNA", 203, 208], ["TNFSF10", "TREATMENT", 140, 147], ["ERAP2", "TEST", 203, 208], ["this study", "TEST", 263, 273], ["cellular migration", "PROBLEM", 334, 352], ["phagocytosis", "PROBLEM", 354, 366], ["programmed cell death", "PROBLEM", 368, 389], ["apoptosis", "PROBLEM", 391, 400], ["virus", "PROBLEM", 407, 412], ["host cell interactions", "PROBLEM", 413, 435], ["cellular migration", "OBSERVATION", 334, 352], ["host cell interactions", "OBSERVATION", 413, 435]]], ["ELMO1 (engulfment and cell motility 1) is involved in cytoskeletal rearrangements required for cell motility and phagocytosis of apoptotic cells (Gumienny et al., 2001) .", [["cell", "ANATOMY", 22, 26], ["cytoskeletal", "ANATOMY", 54, 66], ["cell", "ANATOMY", 95, 99], ["cells", "ANATOMY", 139, 144], ["ELMO1", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell motility 1", "GENE_OR_GENE_PRODUCT", 22, 37], ["cytoskeletal", "CELLULAR_COMPONENT", 54, 66], ["cell", "CELL", 95, 99], ["cells", "CELL", 139, 144], ["ELMO1", "PROTEIN", 0, 5], ["apoptotic cells", "CELL_TYPE", 129, 144], ["cell motility", "TEST", 95, 108], ["apoptotic cells", "PROBLEM", 129, 144], ["engulfment", "OBSERVATION_MODIFIER", 7, 17], ["cytoskeletal rearrangements", "OBSERVATION", 54, 81], ["apoptotic cells", "OBSERVATION", 129, 144]]], ["ELMO1 has been associated with the inhibition of HIV-1 transcription in monocyte/macrophages in the face of apoptotic events occurring in the T cell compartment (Gekonge et al., 2006) .", [["monocyte", "ANATOMY", 72, 80], ["macrophages", "ANATOMY", 81, 92], ["T cell compartment", "ANATOMY", 142, 160], ["ELMO1", "CHEMICAL", 0, 5], ["ELMO1", "GENE_OR_GENE_PRODUCT", 0, 5], ["HIV-1", "GENE_OR_GENE_PRODUCT", 49, 54], ["monocyte", "CELL", 72, 80], ["macrophages", "CELL", 81, 92], ["T cell", "CELL", 142, 148], ["ELMO1", "PROTEIN", 0, 5], ["monocyte", "CELL_TYPE", 72, 80], ["macrophages", "CELL_TYPE", 81, 92], ["HIV-1", "SPECIES", 49, 54], ["HIV-1", "SPECIES", 49, 54], ["HIV", "PROBLEM", 49, 52], ["monocyte/macrophages", "TREATMENT", 72, 92], ["apoptotic events", "PROBLEM", 108, 124], ["monocyte", "ANATOMY", 72, 80], ["macrophages", "OBSERVATION", 81, 92], ["apoptotic events", "OBSERVATION", 108, 124]]], ["TNFSF10, also known as TNF-related apoptosis-inducing ligand (TRAIL), plays an important role in induction of cell death by apoptosis and is indispensable for a normal functioning immune system (Falschlehner et al., 2009) .", [["cell", "ANATOMY", 110, 114], ["death", "DISEASE", 115, 120], ["TNFSF10", "GENE_OR_GENE_PRODUCT", 0, 7], ["TNF-related apoptosis-inducing ligand", "GENE_OR_GENE_PRODUCT", 23, 60], ["TRAIL", "GENE_OR_GENE_PRODUCT", 62, 67], ["cell", "CELL", 110, 114], ["TNFSF10", "PROTEIN", 0, 7], ["TNF-related apoptosis-inducing ligand", "PROTEIN", 23, 60], ["TRAIL", "PROTEIN", 62, 67], ["cell death", "PROBLEM", 110, 120], ["apoptosis", "PROBLEM", 124, 133]]], ["TRAIL can be expressed by various cells of the immune system, including T cells, natural killer (NK) cells, natural killer T cells, dendritic cells and macrophages.", [["cells", "ANATOMY", 34, 39], ["immune system", "ANATOMY", 47, 60], ["T cells", "ANATOMY", 72, 79], ["natural killer (NK) cells", "ANATOMY", 81, 106], ["natural killer T cells", "ANATOMY", 108, 130], ["dendritic cells", "ANATOMY", 132, 147], ["macrophages", "ANATOMY", 152, 163], ["TRAIL", "CHEMICAL", 0, 5], ["TRAIL", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 34, 39], ["immune system", "ANATOMICAL_SYSTEM", 47, 60], ["T cells", "CELL", 72, 79], ["natural killer (NK) cells", "CELL", 81, 106], ["natural killer T cells", "CELL", 108, 130], ["dendritic cells", "CELL", 132, 147], ["macrophages", "CELL", 152, 163], ["TRAIL", "PROTEIN", 0, 5], ["T cells", "CELL_TYPE", 72, 79], ["natural killer (NK) cells", "CELL_TYPE", 81, 106], ["natural killer T cells", "CELL_TYPE", 108, 130], ["dendritic cells", "CELL_TYPE", 132, 147], ["macrophages", "CELL_TYPE", 152, 163], ["TRAIL", "TREATMENT", 0, 5], ["dendritic cells and macrophages", "PROBLEM", 132, 163], ["natural killer T cells", "OBSERVATION", 108, 130], ["dendritic cells", "OBSERVATION", 132, 147], ["macrophages", "ANATOMY", 152, 163]]], ["Type I interferon and interferon regulatory factors also regulate TNF-related apoptosisinducing ligand (TRAIL) in HIV-1-infected macrophages (Herold et al., 2009) .", [["macrophages", "ANATOMY", 129, 140], ["Type I interferon", "GENE_OR_GENE_PRODUCT", 0, 17], ["interferon regulatory factors", "GENE_OR_GENE_PRODUCT", 22, 51], ["TNF-related apoptosisinducing ligand", "GENE_OR_GENE_PRODUCT", 66, 102], ["TRAIL", "GENE_OR_GENE_PRODUCT", 104, 109], ["HIV-1", "ORGANISM", 114, 119], ["macrophages", "CELL", 129, 140], ["Type I interferon", "PROTEIN", 0, 17], ["interferon regulatory factors", "PROTEIN", 22, 51], ["TNF-related apoptosisinducing ligand", "PROTEIN", 66, 102], ["TRAIL", "PROTEIN", 104, 109], ["infected macrophages", "CELL_TYPE", 120, 140], ["HIV-1", "SPECIES", 114, 119], ["HIV-1", "SPECIES", 114, 119], ["Type I interferon", "TREATMENT", 0, 17], ["interferon regulatory factors", "TREATMENT", 22, 51], ["TNF", "TEST", 66, 69], ["HIV", "PROBLEM", 114, 117], ["infected macrophages", "PROBLEM", 120, 140], ["macrophages", "ANATOMY", 129, 140]]], ["Highly virulent strains of avian influenza virus induce high levels of TRAIL in macrophages, which in turn may contribute to the disease pathogenesis (Zhou et al., 2006) .", [["macrophages", "ANATOMY", 80, 91], ["influenza virus", "DISEASE", 33, 48], ["avian influenza virus", "ORGANISM", 27, 48], ["TRAIL", "GENE_OR_GENE_PRODUCT", 71, 76], ["macrophages", "CELL", 80, 91], ["TRAIL", "PROTEIN", 71, 76], ["macrophages", "CELL_TYPE", 80, 91], ["avian influenza virus", "SPECIES", 27, 48], ["avian influenza virus", "SPECIES", 27, 48], ["Highly virulent strains of avian influenza virus", "PROBLEM", 0, 48], ["high levels of TRAIL in macrophages", "PROBLEM", 56, 91], ["the disease pathogenesis", "PROBLEM", 125, 149], ["may contribute to", "UNCERTAINTY", 107, 124], ["disease", "OBSERVATION", 129, 136]]], ["Ebola virus infection is known to greatly disrupt immunity by infecting phagocytic cells and releasing cytokines that induce apoptosis in bystander lymphocytes (Hensley et al., 2002) .", [["phagocytic cells", "ANATOMY", 72, 88], ["bystander lymphocytes", "ANATOMY", 138, 159], ["Ebola virus infection", "DISEASE", 0, 21], ["Ebola virus", "ORGANISM", 0, 11], ["phagocytic cells", "CELL", 72, 88], ["bystander lymphocytes", "CELL", 138, 159], ["phagocytic cells", "CELL_TYPE", 72, 88], ["cytokines", "PROTEIN", 103, 112], ["bystander lymphocytes", "CELL_TYPE", 138, 159], ["Ebola virus", "SPECIES", 0, 11], ["Ebola virus", "SPECIES", 0, 11], ["Ebola virus infection", "PROBLEM", 0, 21], ["infecting phagocytic cells", "PROBLEM", 62, 88], ["releasing cytokines", "PROBLEM", 93, 112], ["apoptosis", "PROBLEM", 125, 134], ["infection", "OBSERVATION", 12, 21], ["infecting phagocytic cells", "OBSERVATION", 62, 88], ["apoptosis", "OBSERVATION_MODIFIER", 125, 134]]], ["RRAGA encodes a protein involved in the RCC1/Ran-GTPase pathway, which plays a direct role in a TNF-alpha signaling pathway leading to apoptosis.", [["RRAGA", "GENE_OR_GENE_PRODUCT", 0, 5], ["RCC1", "GENE_OR_GENE_PRODUCT", 40, 44], ["Ran", "GENE_OR_GENE_PRODUCT", 45, 48], ["GTPase", "GENE_OR_GENE_PRODUCT", 49, 55], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 96, 105], ["RRAGA", "PROTEIN", 0, 5], ["RCC1", "PROTEIN", 40, 44], ["Ran", "PROTEIN", 45, 48], ["GTPase", "PROTEIN", 49, 55], ["TNF", "PROTEIN", 96, 99], ["a protein", "TEST", 14, 23], ["the RCC1", "TEST", 36, 44], ["a TNF", "TEST", 94, 99], ["apoptosis", "PROBLEM", 135, 144]]], ["RRAGA may also cause cell death by acting as a cellular target for adenovirus E3-14.7K, an inhibitor of TNF-alpha functions (Li et al., 1997) .", [["cell", "ANATOMY", 21, 25], ["cellular", "ANATOMY", 47, 55], ["RRAGA", "CHEMICAL", 0, 5], ["death", "DISEASE", 26, 31], ["adenovirus E3-14.7K", "CHEMICAL", 67, 86], ["RRAGA", "SIMPLE_CHEMICAL", 0, 5], ["cell", "CELL", 21, 25], ["cellular", "CELL", 47, 55], ["adenovirus", "ORGANISM", 67, 77], ["E3-14.7K", "GENE_OR_GENE_PRODUCT", 78, 86], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 104, 113], ["RRAGA", "PROTEIN", 0, 5], ["E3", "PROTEIN", 78, 80], ["TNF", "PROTEIN", 104, 107], ["cell death", "PROBLEM", 21, 31], ["a cellular target", "TEST", 45, 62], ["adenovirus E3", "TEST", 67, 80], ["an inhibitor", "TEST", 88, 100], ["TNF", "TEST", 104, 107]]], ["ERAP1 and ERAP2 (endoplasmic reticulum aminopeptidase 1 and 2) encode aminopeptidases involved with cleavage of viral and bacterial proteins into smaller fragments within the endoplasmic reticulum and transport to the cell surface (Falk and R\u00f6tzschke, 2002) .", [["fragments", "ANATOMY", 154, 163], ["endoplasmic reticulum", "ANATOMY", 175, 196], ["cell surface", "ANATOMY", 218, 230], ["ERAP1", "GENE_OR_GENE_PRODUCT", 0, 5], ["ERAP2", "GENE_OR_GENE_PRODUCT", 10, 15], ["endoplasmic reticulum aminopeptidase 1", "GENE_OR_GENE_PRODUCT", 17, 55], ["2", "GENE_OR_GENE_PRODUCT", 60, 61], ["aminopeptidases", "GENE_OR_GENE_PRODUCT", 70, 85], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 175, 196], ["cell surface", "CELLULAR_COMPONENT", 218, 230], ["ERAP1", "PROTEIN", 0, 5], ["ERAP2", "PROTEIN", 10, 15], ["endoplasmic reticulum aminopeptidase 1 and 2", "PROTEIN", 17, 61], ["aminopeptidases", "PROTEIN", 70, 85], ["viral and bacterial proteins", "PROTEIN", 112, 140], ["ERAP1", "TEST", 0, 5], ["ERAP2", "TEST", 10, 15], ["endoplasmic reticulum aminopeptidase", "TEST", 17, 53], ["encode aminopeptidases", "PROBLEM", 63, 85], ["viral and bacterial proteins into smaller fragments", "PROBLEM", 112, 163], ["bacterial proteins", "OBSERVATION", 122, 140], ["smaller", "OBSERVATION_MODIFIER", 146, 153], ["fragments", "OBSERVATION", 154, 163], ["endoplasmic reticulum", "OBSERVATION", 175, 196]]], ["At the surface, these proteins can then cleave cytokine receptors and reduce their ability to transmit signals into the cell, thus affecting inflammatory responses.", [["surface", "ANATOMY", 7, 14], ["cell", "ANATOMY", 120, 124], ["surface", "CELLULAR_COMPONENT", 7, 14], ["cell", "CELL", 120, 124], ["cytokine receptors", "PROTEIN", 47, 65], ["cytokine receptors", "TREATMENT", 47, 65], ["surface", "ANATOMY_MODIFIER", 7, 14], ["cell", "ANATOMY", 120, 124], ["inflammatory", "OBSERVATION_MODIFIER", 141, 153]]], ["Small peptides produced by cleavage of bacterial or viral proteins can also attach to MHC class I molecules in the endoplasmic reticulum and be exported to the cell surface and displayed to the immune system.", [["endoplasmic reticulum", "ANATOMY", 115, 136], ["cell surface", "ANATOMY", 160, 172], ["immune system", "ANATOMY", 194, 207], ["MHC class I molecules", "GENE_OR_GENE_PRODUCT", 86, 107], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 115, 136], ["cell surface", "CELLULAR_COMPONENT", 160, 172], ["bacterial or viral proteins", "PROTEIN", 39, 66], ["MHC class I molecules", "PROTEIN", 86, 107], ["Small peptides", "PROBLEM", 0, 14], ["bacterial or viral proteins", "PROBLEM", 39, 66], ["peptides", "OBSERVATION", 6, 14], ["bacterial", "OBSERVATION_MODIFIER", 39, 48], ["viral proteins", "OBSERVATION", 52, 66], ["endoplasmic reticulum", "ANATOMY", 115, 136]]], ["If the MHC class I/peptide complex is recognized as foreign by the immune system, the infected cell will undergo apoptosis.", [["immune system", "ANATOMY", 67, 80], ["cell", "ANATOMY", 95, 99], ["MHC class I", "GENE_OR_GENE_PRODUCT", 7, 18], ["cell", "CELL", 95, 99], ["MHC class I/peptide complex", "PROTEIN", 7, 34], ["the MHC class I/peptide complex", "PROBLEM", 3, 34], ["the infected cell", "PROBLEM", 82, 99], ["apoptosis", "PROBLEM", 113, 122], ["infected cell", "OBSERVATION", 86, 99], ["apoptosis", "OBSERVATION", 113, 122]]], ["Polymorphisms in ERAP1, 2 as well as MHC class I have been associated with natural selection among human populations for resistance to intracellular pathogens such as HIV-1 (Cagliani et al., 2010) .DiscussionThe fact that these potential candidate genes were involved in some manner with processes such as immune regulation and apoptosis makes them highly relevant to what is known about FIPV pathogenesis (reviewed Pedersen, 2009 ).", [["intracellular", "ANATOMY", 135, 148], ["ERAP1", "GENE_OR_GENE_PRODUCT", 17, 22], ["2", "GENE_OR_GENE_PRODUCT", 24, 25], ["MHC class I", "GENE_OR_GENE_PRODUCT", 37, 48], ["human", "ORGANISM", 99, 104], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 135, 148], ["HIV-1", "ORGANISM", 167, 172], ["FIPV", "GENE_OR_GENE_PRODUCT", 388, 392], ["ERAP1", "PROTEIN", 17, 22], ["MHC class I", "PROTEIN", 37, 48], ["candidate genes", "DNA", 238, 253], ["human", "SPECIES", 99, 104], ["HIV-1", "SPECIES", 167, 172], ["human", "SPECIES", 99, 104], ["HIV-1", "SPECIES", 167, 172], ["Polymorphisms in ERAP1", "PROBLEM", 0, 22], ["human populations", "TREATMENT", 99, 116], ["intracellular pathogens", "PROBLEM", 135, 158], ["HIV", "PROBLEM", 167, 170], ["apoptosis", "PROBLEM", 328, 337], ["FIPV pathogenesis", "PROBLEM", 388, 405]]], ["However, two crucial questions regarding FIP pathogenesis remain to be explained:Discussion(1) why does FIPV target a type of macrophage that has a peculiar tropism for venules in the omentum, serosal surfaces, meninges, and uveal tract, and (2) why do these macrophages fail to undergo pathogen-induced apoptosis either by intracellular or extracellular signaling?", [["macrophage", "ANATOMY", 126, 136], ["venules", "ANATOMY", 169, 176], ["omentum", "ANATOMY", 184, 191], ["serosal surfaces", "ANATOMY", 193, 209], ["meninges", "ANATOMY", 211, 219], ["uveal tract", "ANATOMY", 225, 236], ["macrophages", "ANATOMY", 259, 270], ["intracellular", "ANATOMY", 324, 337], ["extracellular", "ANATOMY", 341, 354], ["FIP", "DISEASE", 41, 44], ["FIPV", "CHEMICAL", 104, 108], ["FIP", "ORGANISM", 41, 44], ["FIPV", "GENE_OR_GENE_PRODUCT", 104, 108], ["macrophage", "CELL", 126, 136], ["venules", "MULTI-TISSUE_STRUCTURE", 169, 176], ["omentum", "TISSUE", 184, 191], ["serosal surfaces", "MULTI-TISSUE_STRUCTURE", 193, 209], ["meninges", "MULTI-TISSUE_STRUCTURE", 211, 219], ["uveal tract", "MULTI-TISSUE_STRUCTURE", 225, 236], ["macrophages", "CELL", 259, 270], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 324, 337], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 341, 354], ["macrophage", "CELL_TYPE", 126, 136], ["macrophages", "CELL_TYPE", 259, 270], ["FIPV", "PROBLEM", 104, 108], ["venules in the omentum", "PROBLEM", 169, 191], ["uveal tract", "PROBLEM", 225, 236], ["these macrophages", "PROBLEM", 253, 270], ["pathogen", "PROBLEM", 287, 295], ["apoptosis", "PROBLEM", 304, 313], ["macrophage", "OBSERVATION", 126, 136], ["omentum", "ANATOMY", 184, 191], ["serosal surfaces", "ANATOMY", 193, 209], ["meninges", "ANATOMY", 211, 219], ["uveal tract", "ANATOMY", 225, 236]]], ["Targeting of a specific macrophage subset is most likely associated with the way the virus and host cell membrane interact, while polymorphisms within any or all of the five candidate genes identified in the present study are more likely to be associated with why infected macrophages remain persistently infected.", [["macrophage", "ANATOMY", 24, 34], ["cell membrane", "ANATOMY", 100, 113], ["macrophages", "ANATOMY", 273, 284], ["macrophage", "CELL", 24, 34], ["cell membrane", "CELLULAR_COMPONENT", 100, 113], ["macrophages", "CELL", 273, 284], ["macrophage subset", "CELL_TYPE", 24, 41], ["infected macrophages", "CELL_TYPE", 264, 284], ["a specific macrophage subset", "PROBLEM", 13, 41], ["the virus", "PROBLEM", 81, 90], ["polymorphisms", "PROBLEM", 130, 143], ["infected macrophages", "PROBLEM", 264, 284], ["persistently infected", "PROBLEM", 292, 313], ["macrophage subset", "OBSERVATION", 24, 41], ["most likely", "UNCERTAINTY", 45, 56], ["virus", "OBSERVATION", 85, 90], ["host cell membrane", "OBSERVATION", 95, 113], ["more likely", "UNCERTAINTY", 226, 237], ["infected", "OBSERVATION_MODIFIER", 264, 272], ["macrophages", "OBSERVATION", 273, 284], ["persistently", "OBSERVATION_MODIFIER", 292, 304], ["infected", "OBSERVATION", 305, 313]]], ["All five genes relate to a programmed cell death in the face of viral infection through inhibition of viral replication, cytokine interactions, or MHC class I/peptide complex induced apoptosis.DiscussionAlthough there were several moderately strong SNP/genome regions associated with FIP susceptibility, 100% concordance with the FIP phenotype was not detected for any individual SNP or region.", [["cell", "ANATOMY", 38, 42], ["death", "DISEASE", 43, 48], ["viral infection", "DISEASE", 64, 79], ["SNP", "CHEMICAL", 249, 252], ["FIP", "DISEASE", 284, 287], ["SNP", "CHEMICAL", 380, 383], ["cell", "CELL", 38, 42], ["cytokine", "PROTEIN", 121, 129], ["MHC class I", "PROTEIN", 147, 158], ["SNP/genome regions", "DNA", 249, 267], ["a programmed cell death", "PROBLEM", 25, 48], ["viral infection", "PROBLEM", 64, 79], ["viral replication", "TREATMENT", 102, 119], ["cytokine interactions", "PROBLEM", 121, 142], ["apoptosis", "PROBLEM", 183, 192], ["several moderately strong SNP/genome regions", "PROBLEM", 223, 267], ["FIP susceptibility", "TEST", 284, 302], ["the FIP phenotype", "TEST", 326, 343], ["programmed cell death", "OBSERVATION", 27, 48], ["viral infection", "OBSERVATION", 64, 79], ["viral replication", "OBSERVATION", 102, 119], ["apoptosis", "OBSERVATION", 183, 192], ["moderately", "OBSERVATION_MODIFIER", 231, 241], ["strong", "OBSERVATION_MODIFIER", 242, 248], ["FIP susceptibility", "OBSERVATION", 284, 302]]], ["This could be expected in situations where multiple genes contribute only small to moderate degrees of risk either independently or collectively (epistasis) and are not inherited uniformly by every individual.", [["epistasis", "PROBLEM", 146, 155], ["small to moderate degrees", "OBSERVATION_MODIFIER", 74, 99]]], ["Complex traits must be also interpreted with clear guidelines in mind.", [["Complex traits", "PROBLEM", 0, 14]]], ["Three such guidelines for dissecting complex genetic traits have been advocated by Lander and Kruglyak (1995) and include: (1) scan entire genomes with a dense collection of markers, (2) calculate a linkage statistic at each marker position, and (3) identify regions where the association deviates significantly from what would be expected from random assortment.", [["dissecting complex genetic traits", "PROBLEM", 26, 59], ["dense", "OBSERVATION_MODIFIER", 154, 159], ["collection", "OBSERVATION", 160, 170]]], ["However, this recipe does not take into account population size, degree of heritability, and numerous non-genetic covariates (Thornton-Wells et al., 2004) .", [["heritability", "PROBLEM", 75, 87], ["numerous non-genetic covariates", "PROBLEM", 93, 124], ["size", "OBSERVATION_MODIFIER", 59, 63], ["heritability", "OBSERVATION", 75, 87], ["numerous", "OBSERVATION_MODIFIER", 93, 101]]], ["Lander and Kruglyak (1995) also stressed the importance of reporting negative or weak findings when the evidence clearly supports a negative or weak association, while confirmatory linkage requires the same result to be found in a second study, preferably done by an independent group of investigators and at an adjusted probability of \u22640.01.DiscussionIt is hoped that the present study can be expanded to the point where genotypes linked to FIP susceptibility can be confirmed.", [["FIP", "DISEASE", 442, 445], ["a second study", "TEST", 229, 243], ["the present study", "TEST", 369, 386], ["FIP susceptibility", "TEST", 442, 460]]], ["Confirmatory studies may require greater numbers of case and control cats, much denser SNP arrays, and even whole genome sequencing.", [["SNP", "CHEMICAL", 87, 90], ["Confirmatory studies", "TEST", 0, 20], ["control cats", "TREATMENT", 61, 73], ["much denser SNP arrays", "TREATMENT", 75, 97]]], ["Confirmed FIP susceptibility genotypes could be used to breed cats more resistant to FIP.", [["FIP", "DISEASE", 10, 13], ["FIP", "DISEASE", 85, 88], ["cats", "ORGANISM", 62, 66], ["FIP susceptibility genotypes", "PROBLEM", 10, 38], ["FIP", "OBSERVATION", 10, 13]]], ["Until this time is reached, the best genetic advice that can be given to pedigreed cat breeders is not to breed healthy toms and queens that produce offspring dying from FIP, or to breed offspring of parents that died subsequently of FIP.", [["FIP", "DISEASE", 170, 173], ["FIP", "DISEASE", 234, 237], ["cat", "ORGANISM", 83, 86], ["FIP", "PROBLEM", 234, 237], ["FIP", "OBSERVATION", 234, 237]]]], "5a5dfc4052225fa9ad9bf955ff32d6ab62be2a4d": [["As a prime example of panic-driven, reasonably unreasonable conduct, civilian hoarding may indeed be counteracted to some important extent by repeatedly invoking \"positive peer pressure\" through various social awareness campaigns, but uniform enactment is all but guaranteed, and significant social impunity looms.", [["panic", "DISEASE", 22, 27], ["hoarding", "DISEASE", 78, 86], ["panic", "PROBLEM", 22, 27]]]], "PMC7503962": []}